0001055726-23-000010.txt : 20230301 0001055726-23-000010.hdr.sgml : 20230301 20230301163533 ACCESSION NUMBER: 0001055726-23-000010 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INOVIO PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001055726 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330969592 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14888 FILM NUMBER: 23694199 BUSINESS ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584103134 MAIL ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: INOVIO BIOMEDICAL CORP DATE OF NAME CHANGE: 20050404 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL CORP DATE OF NAME CHANGE: 20011116 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL LTD DATE OF NAME CHANGE: 19980213 10-K 1 ino-20221231.htm 10-K ino-20221231
false2022FY0001055726http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006MemberP3YP2Y0.18580455000010557262022-01-012022-12-3100010557262022-06-30iso4217:USD00010557262023-02-24xbrli:shares00010557262022-12-3100010557262021-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Member2022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Member2021-12-31iso4217:USDxbrli:shares00010557262021-01-012021-12-3100010557262020-01-012020-12-310001055726ino:ConvertibleBondsMember2022-01-012022-12-310001055726ino:ConvertibleBondsMember2021-01-012021-12-310001055726ino:ConvertibleBondsMember2020-01-012020-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Member2022-01-012022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Member2021-01-012021-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Member2020-01-012020-12-310001055726us-gaap:PreferredStockMember2019-12-310001055726us-gaap:CommonStockMember2019-12-310001055726us-gaap:AdditionalPaidInCapitalMember2019-12-310001055726us-gaap:RetainedEarningsMember2019-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001055726us-gaap:NoncontrollingInterestMember2019-12-3100010557262019-12-310001055726us-gaap:CommonStockMember2020-01-012020-12-310001055726us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001055726us-gaap:PreferredStockMember2020-01-012020-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:CommonStockMember2020-01-012020-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001055726us-gaap:CommonStockMemberino:August2019ConvertibleBondsMember2020-01-012020-12-310001055726ino:August2019ConvertibleBondsMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001055726ino:August2019ConvertibleBondsMember2020-01-012020-12-310001055726us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001055726us-gaap:RetainedEarningsMember2020-01-012020-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001055726us-gaap:PreferredStockMember2020-12-310001055726us-gaap:CommonStockMember2020-12-310001055726us-gaap:AdditionalPaidInCapitalMember2020-12-310001055726us-gaap:RetainedEarningsMember2020-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001055726us-gaap:NoncontrollingInterestMember2020-12-3100010557262020-12-310001055726us-gaap:CommonStockMember2021-01-012021-12-310001055726us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001055726us-gaap:RetainedEarningsMember2021-01-012021-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001055726us-gaap:PreferredStockMember2021-12-310001055726us-gaap:CommonStockMember2021-12-310001055726us-gaap:AdditionalPaidInCapitalMember2021-12-310001055726us-gaap:RetainedEarningsMember2021-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001055726us-gaap:NoncontrollingInterestMember2021-12-310001055726us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001055726us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001055726srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001055726us-gaap:CommonStockMember2022-01-012022-12-310001055726us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001055726us-gaap:RetainedEarningsMember2022-01-012022-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001055726us-gaap:PreferredStockMember2022-12-310001055726us-gaap:CommonStockMember2022-12-310001055726us-gaap:AdditionalPaidInCapitalMember2022-12-310001055726us-gaap:RetainedEarningsMember2022-12-310001055726us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001055726us-gaap:NoncontrollingInterestMember2022-12-310001055726ino:August2019ConvertibleBondsMember2022-01-012022-12-310001055726ino:August2019ConvertibleBondsMember2021-01-012021-12-310001055726us-gaap:CommonStockMemberino:SalesAgreementMember2022-01-012022-12-310001055726us-gaap:CommonStockMemberino:SalesAgreementMember2021-01-012021-12-310001055726us-gaap:CommonStockMemberino:SalesAgreementMember2020-01-012020-12-310001055726us-gaap:CommonStockMemberino:UnderwrittenPublicOfferingMember2021-01-012021-12-31ino:segment0001055726srt:MinimumMember2022-01-012022-12-310001055726srt:MaximumMember2022-01-012022-12-310001055726us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001055726us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001055726us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001055726ino:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001055726ino:ServiceBasedRestrictedStockUnitsMember2021-01-012021-12-310001055726ino:ServiceBasedRestrictedStockUnitsMember2020-01-012020-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001055726us-gaap:ConvertiblePreferredStockMember2022-01-012022-12-310001055726us-gaap:ConvertiblePreferredStockMember2021-01-012021-12-310001055726us-gaap:ConvertiblePreferredStockMember2020-01-012020-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-12-310001055726us-gaap:ConvertibleDebtSecuritiesMemberino:December2019ConvertibleBondsMember2022-01-012022-12-310001055726us-gaap:ConvertibleDebtSecuritiesMemberino:December2019ConvertibleBondsMember2021-01-012021-12-310001055726us-gaap:ConvertibleDebtSecuritiesMemberino:December2019ConvertibleBondsMember2020-01-012020-12-310001055726ino:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-31xbrli:pure0001055726ino:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001055726ino:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001055726ino:NonEmployeeMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001055726ino:NonEmployeeMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001055726ino:NonEmployeeMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001055726us-gaap:AccountingStandardsUpdate202006Member2022-01-010001055726us-gaap:AccountingStandardsUpdate202006Member2022-12-310001055726ino:AdvaccineMember2022-01-012022-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AdvaccineMember2022-01-012022-12-310001055726ino:AdvaccineMember2021-01-012021-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AdvaccineMember2021-01-012021-12-310001055726ino:AdvaccineMember2020-01-012020-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AdvaccineMember2020-01-012020-12-310001055726ino:PlumblineLifeSciencesIncMember2022-01-012022-12-310001055726ino:PlumblineLifeSciencesIncMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001055726ino:PlumblineLifeSciencesIncMember2021-01-012021-12-310001055726ino:PlumblineLifeSciencesIncMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001055726ino:PlumblineLifeSciencesIncMember2020-01-012020-12-310001055726ino:PlumblineLifeSciencesIncMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001055726ino:DoDMember2022-01-012022-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberino:DoDMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001055726ino:DoDMember2021-01-012021-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberino:DoDMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001055726ino:DoDMember2020-01-012020-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberino:DoDMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001055726ino:AllOtherCustomersMember2022-01-012022-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AllOtherCustomersMember2022-01-012022-12-310001055726ino:AllOtherCustomersMember2021-01-012021-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AllOtherCustomersMember2021-01-012021-12-310001055726ino:AllOtherCustomersMember2020-01-012020-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberino:AllOtherCustomersMember2020-01-012020-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001055726us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001055726ino:DoDMemberus-gaap:CustomerConcentrationRiskMember2021-12-310001055726us-gaap:AccountsReceivableMemberino:DoDMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001055726us-gaap:CustomerConcentrationRiskMemberino:CEPIMERSMember2021-12-310001055726us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberino:CEPIMERSMember2021-01-012021-12-310001055726ino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2021-01-012021-01-310001055726ino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310001055726ino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310001055726us-gaap:LicenseMemberino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310001055726us-gaap:LicenseMemberino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310001055726us-gaap:LicenseMemberino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310001055726ino:AdvaccineMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310001055726ino:ApolloBioMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310001055726us-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2018-04-112018-04-110001055726us-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2022-01-012022-12-310001055726us-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2021-01-012021-12-310001055726us-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-01-012020-12-310001055726us-gaap:CollaborativeArrangementMemberino:LassaFeverAndMERSVaccineMemberino:CoalitionforEpidemicPreparednessInnovationsMember2022-12-310001055726us-gaap:CollaborativeArrangementMemberino:LassaFeverAndMERSVaccineMemberino:CoalitionforEpidemicPreparednessInnovationsMember2021-12-310001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-01-012020-01-310001055726us-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-04-012020-04-300001055726ino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-04-012020-04-300001055726ino:INO4800Memberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-04-012020-04-300001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2022-01-012022-12-310001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2021-01-012021-12-310001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2020-01-012020-12-310001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2022-12-310001055726ino:SARSCoV2COVID19VaccineMemberus-gaap:CollaborativeArrangementMemberino:CoalitionforEpidemicPreparednessInnovationsMember2021-12-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2018-10-012018-10-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2019-08-012019-08-300001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2022-01-012022-12-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2021-01-012021-12-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2020-01-012020-12-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2022-12-310001055726us-gaap:CollaborativeArrangementMemberino:DNAEncodedMonoclonalAntibodyTechnologyMemberino:BillAndMelindaGatesFoundationMember2021-12-310001055726ino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMemberino:BillAndMelindaGatesFoundationMember2020-03-012020-03-310001055726ino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMemberino:BillAndMelindaGatesFoundationMember2022-01-012022-12-310001055726ino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMemberino:BillAndMelindaGatesFoundationMember2021-01-012021-12-310001055726ino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMemberino:BillAndMelindaGatesFoundationMember2020-01-012020-12-310001055726ino:DepartmentOfDefenceMemberino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMember2020-06-012020-06-300001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310001055726ino:DepartmentOfDefenceMemberino:CELLECTRA3PSPProprietarySmartDeviceMemberus-gaap:CollaborativeArrangementMember2022-01-012022-01-310001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2022-12-310001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2021-12-310001055726ino:DepartmentOfDefenceMemberus-gaap:CollaborativeArrangementMember2020-12-310001055726ino:MutualFundsMember2022-12-310001055726us-gaap:USTreasuryBillSecuritiesMember2022-01-012022-12-310001055726us-gaap:USTreasuryBillSecuritiesMember2022-12-310001055726us-gaap:CertificatesOfDepositMembersrt:MaximumMember2022-01-012022-12-310001055726us-gaap:CertificatesOfDepositMember2022-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2022-12-310001055726ino:MutualFundsMember2021-12-310001055726us-gaap:CertificatesOfDepositMembersrt:MaximumMember2021-01-012021-12-310001055726us-gaap:USTreasuryBillSecuritiesMember2021-12-310001055726us-gaap:CommercialPaperMember2021-12-310001055726us-gaap:CertificatesOfDepositMember2021-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-12-31ino:position0001055726ino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueInputsLevel1Memberino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueInputsLevel2Memberino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726ino:MutualFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001055726ino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueInputsLevel1Memberino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueInputsLevel2Memberino:MutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726ino:MutualFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001055726us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel1Member2022-12-310001055726ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember2022-07-310001055726ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember2022-01-012022-12-310001055726us-gaap:LeaseholdImprovementsMember2022-12-310001055726us-gaap:OfficeEquipmentMember2022-12-310001055726us-gaap:FurnitureAndFixturesMember2022-12-310001055726us-gaap:PropertyPlantAndEquipmentOtherTypesMember2022-12-310001055726us-gaap:LeaseholdImprovementsMember2021-12-310001055726us-gaap:OfficeEquipmentMember2021-12-310001055726us-gaap:FurnitureAndFixturesMember2021-12-310001055726us-gaap:PropertyPlantAndEquipmentOtherTypesMember2021-12-310001055726us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310001055726us-gaap:LicensingAgreementsMembersrt:WeightedAverageMember2022-01-012022-12-310001055726us-gaap:LicensingAgreementsMember2022-12-310001055726us-gaap:LicensingAgreementsMember2021-12-310001055726ino:BiojectMembersrt:WeightedAverageMember2022-01-012022-12-310001055726ino:BiojectMember2022-12-310001055726ino:BiojectMember2021-12-310001055726srt:WeightedAverageMemberus-gaap:OtherIntangibleAssetsMember2022-01-012022-12-310001055726us-gaap:OtherIntangibleAssetsMember2022-12-310001055726us-gaap:OtherIntangibleAssetsMember2021-12-310001055726srt:WeightedAverageMember2022-01-012022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2019-03-010001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2019-02-192019-02-280001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2019-02-192019-03-01ino:day0001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2022-12-310001055726us-gaap:ConvertibleDebtMember2022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2022-01-012022-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2021-01-012021-12-310001055726ino:A6.50ConvertibleSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2020-01-012020-12-310001055726us-gaap:ConvertibleDebtMemberino:December2019ConvertibleBondsMember2019-12-26iso4217:KRW0001055726us-gaap:ConvertibleDebtMemberino:December2019ConvertibleBondsMember2019-12-262019-12-260001055726us-gaap:ConvertibleDebtMemberino:December2019ConvertibleBondsMember2021-03-172021-03-170001055726us-gaap:ConvertibleDebtMemberino:December2019ConvertibleBondsMember2022-01-012022-12-310001055726us-gaap:ConvertibleDebtMemberino:December2019ConvertibleBondsMember2021-12-310001055726us-gaap:SeriesCPreferredStockMember2022-12-310001055726us-gaap:SeriesCPreferredStockMember2021-12-310001055726us-gaap:CommonStockMemberino:SalesAgreementMember2021-11-092021-11-090001055726us-gaap:CommonStockMemberino:SalesAgreementMember2022-12-310001055726us-gaap:CommonStockMemberino:UnderwrittenPublicOfferingMember2021-01-252021-01-250001055726us-gaap:CommonStockMemberino:UnderwrittenPublicOfferingMember2021-01-250001055726ino:A2016IncentivePlanMember2016-05-130001055726ino:A2016IncentivePlanMember2022-01-010001055726ino:A2016IncentivePlanMember2022-12-310001055726ino:A2016IncentivePlanMember2022-01-012022-12-310001055726ino:A2016IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-12-310001055726ino:A2022InducementPlanMember2022-06-240001055726ino:A2022InducementPlanMember2022-12-310001055726ino:A2007IncentivePlanMember2022-12-310001055726ino:A2007IncentivePlanMember2022-01-012022-12-310001055726us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001055726us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001055726us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001055726us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001055726us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001055726us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001055726ino:FormerPresidentAndChiefExecutiveOfficerMember2022-01-012022-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2022-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2021-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001055726us-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-12-310001055726us-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-12-310001055726us-gaap:ShareBasedPaymentArrangementNonemployeeMember2020-01-012020-12-310001055726us-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-12-310001055726ino:RangeOfExercisePricesOneMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesOneMember2022-12-310001055726ino:RangeOfExercisePricesTwoMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesTwoMember2022-12-310001055726ino:RangeOfExercisePricesThreeMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesThreeMember2022-12-310001055726ino:RangeOfExercisePricesFourMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesFourMember2022-12-310001055726ino:RangeOfExercisePricesFiveMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesFiveMember2022-12-310001055726ino:RangeOfExercisePricesSixMember2022-01-012022-12-310001055726ino:RangeOfExercisePricesSixMember2022-12-310001055726us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001055726ino:FormerPresidentAndChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001055726ino:SanDiegoCaliforniaMember2022-01-012022-12-31utr:sqft0001055726ino:PlymouthMeetingPennsylvaniaMember2022-01-012022-12-310001055726srt:MinimumMember2022-12-310001055726srt:MaximumMember2022-12-3100010557262019-10-012019-12-31ino:agreement0001055726ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember2021-03-090001055726us-gaap:InternalRevenueServiceIRSMember2022-12-310001055726ino:CaliforniaIncomeTaxAuthorityMember2022-12-310001055726ino:PennsylvaniaStateIncomeTaxAuthorityMember2022-12-310001055726us-gaap:InternalRevenueServiceIRSMember2018-12-310001055726ino:KoreanStateIncomeTaxAuthorityMember2022-12-310001055726us-gaap:InternalRevenueServiceIRSMemberus-gaap:ResearchMember2022-12-310001055726us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2022-12-310001055726us-gaap:DomesticCountryMember2022-12-310001055726us-gaap:StateAndLocalJurisdictionMember2022-12-310001055726us-gaap:ForeignCountryMember2022-12-310001055726us-gaap:DomesticCountryMemberus-gaap:ResearchMember2022-12-310001055726ino:PlumblineLifeSciencesMember2021-12-310001055726ino:PlumblineLifeSciencesMember2022-12-310001055726ino:PLSaffiliatedentityMember2022-01-012022-12-310001055726ino:PLSaffiliatedentityMember2021-01-012021-12-310001055726ino:PLSaffiliatedentityMember2020-01-012020-12-310001055726ino:PLSaffiliatedentityMember2022-12-310001055726ino:PLSaffiliatedentityMember2021-12-310001055726ino:TheWistarInstituteMember2016-03-012016-03-310001055726srt:DirectorMember2021-01-012021-12-310001055726srt:DirectorMember2016-11-012016-11-300001055726ino:TheWistarInstituteMember2020-01-012020-12-310001055726ino:TheWistarInstituteMember2022-01-012022-12-310001055726srt:DirectorMember2022-01-012022-12-310001055726ino:TheWistarInstituteMember2021-01-012021-12-310001055726ino:TheWistarInstituteMember2022-12-310001055726ino:TheWistarInstituteMember2021-12-310001055726ino:GeneosTherapeuticsInc.Member2019-02-012019-02-280001055726ino:GeneosTherapeuticsInc.Member2019-02-280001055726ino:GeneosTherapeuticsInc.Member2020-01-310001055726ino:GeneosTherapeuticsInc.Member2020-01-310001055726ino:GeneosTherapeuticsInc.Member2020-06-300001055726ino:GeneosTherapeuticsInc.Member2020-06-300001055726ino:GeneosTherapeuticsInc.Member2020-06-012020-06-010001055726ino:GeneosTherapeuticsInc.Member2020-11-012020-11-300001055726ino:GeneosTherapeuticsInc.Member2020-11-300001055726ino:GeneosTherapeuticsInc.Member2021-01-012021-03-310001055726ino:GeneosTherapeuticsInc.Member2021-03-310001055726us-gaap:CommonStockMemberino:GeneosTherapeuticsInc.Member2021-01-012021-03-310001055726us-gaap:CommonStockMemberino:GeneosTherapeuticsInc.Member2021-03-310001055726ino:GeneosTherapeuticsInc.Memberino:SeriesAOnePreferredStockMember2021-01-012021-03-310001055726ino:GeneosTherapeuticsInc.Memberino:SeriesAOnePreferredStockMember2021-03-310001055726ino:GeneosTherapeuticsInc.Member2021-02-280001055726ino:GeneosTherapeuticsInc.Memberus-gaap:PreferredStockMember2022-03-012022-03-310001055726ino:GeneosTherapeuticsInc.Member2022-03-310001055726ino:SeriesA2OnePreferredStockMember2022-03-012022-03-310001055726ino:SeriesA2OnePreferredStockMember2022-03-310001055726ino:SeriesA2OnePreferredStockMember2021-12-310001055726ino:SeriesA2OnePreferredStockMember2022-01-012022-12-310001055726ino:SeriesA2OnePreferredStockMember2022-12-310001055726us-gaap:SubsequentEventMember2023-01-312023-01-31ino:employee0001055726srt:ScenarioForecastMember2023-03-310001055726ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMemberus-gaap:SubsequentEventMember2023-02-280001055726ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMemberus-gaap:SubsequentEventMember2023-02-012023-02-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM                     TO                     
COMMISSION FILE NO. 001-14888
ino-20221231_g1.jpg
 INOVIO PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 33-0969592
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania
 19462
(Address of principal executive offices) (Zip Code)
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (267) 440-4200
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
COMMON STOCK, $0.001 PAR VALUEINONasdaq Global Select Market
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨   No  x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x  No    ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer¨Accelerated filer¨
Non-accelerated filerxSmaller reporting companyx
Emerging growth company¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  x
The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June 30, 2022 was approximately $425.5 million based on $1.73 per share, the closing price on that date of the Registrant’s Common Stock on the Nasdaq Global Select Market.
The number of shares outstanding of the Registrant’s Common Stock, $0.001 par value, was 260,131,986 as of February 24, 2023.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be filed with the Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement’) are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2022.


TABLE OF CONTENTS
 
73
F-1



1

PART I
 
ITEM 1.    BUSINESS
This Annual Report on Form 10-K (including the following section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.
Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.
This Annual Report includes trademarks and registered trademarks of INOVIO Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to “we,” “our,” “us,” “INOVIO” or the “Company” refer to INOVIO Pharmaceuticals, Inc. and its subsidiaries. References herein to “DNA medicines” refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Summary Risk Factors
Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Part I, Item 1A., Risk Factors herein. These risk factors include, but are not limited to, the following:
•We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.
•We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.
•We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.
•None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.
•We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are currently pursuing third-party sponsored and funded development of this candidate, but there can be no assurance that it will ever receive regulatory approval as a vaccine booster in any country, whether by Emergency Use Authorization or otherwise.
•DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.
•If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart devices and DNA medicine candidates.
•If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.
•We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates.
2

•Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.
•We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.
•We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines, if approved.
•We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.
•It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
•If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.

Company Overview
We are a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.
In clinical trials, our DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into cells using our investigational proprietary smart device, CELLECTRA.
Many of our lead candidates are focused on diseases associated with HPV. In 2022, we announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces our belief that DNA medicines may play a key role in the treatment of HPV-related diseases.

Characteristics of DNA Medicines
DNA medicines are optimized DNA plasmids containing a gene encoding for a target protein which is expressed once DNA medicines are delivered into cells. Characteristics of our DNA medicines include:
a.T Cell Responses: DNA medicines have demonstrated the ability to generate high levels of T cell (CD4+, CD8+, and memory) response along with antibody response. CD8+ T cell responses are thought to play an important role in clearing tumors or infected cells.
b.Tolerability: DNA medicines appear to be well-tolerated when evaluated against multiple disease targets. Our DNA medicines have been administered over 15,000 times across more than 5,000 participants to date.
c.Ability to Readminister: DNA medicines have been used in clinical trials to boost immune response via repeat administration, offering the possibility for boosting without any concerns of generating an anti-vector response.
d.Versatility: Our gene encoding technology can target any disease or condition that is strongly associated with an antigen or protein.
e.Stability of Product: DNA medicines have been shown to be stable at room temperature for extended periods and do not require frozen storage or shipping. Certain of our DNA plasmids under development have been room temperature stable for over 6 months.
f.Design and Manufacture: DNA medicines can be rapidly designed and scaled. Ease of manufacture may provide a cost advantage.
g.Delivery Mechanism: Cell membranes can hinder the entry of large molecules such as DNA plasmids. To overcome this barrier, delivery mechanisms such as electroporation are used to increase cellular uptake.




3

Overview of Our DNA Medicines Platform
Our DNA medicines platform consists of DNA plasmids and our investigational proprietary smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. These two components combine to create a versatile platform that has the potential to target any disease or condition that is associated with a specific antigen or protein.
SynCon® - DNA Plasmid Design Technology
Our precisely designed DNA plasmids are circular double-stranded DNA that have been optimized using our proprietary SynCon technology to express the target antigen or protein. In the areas of HPV-related diseases, cancer, and infectious diseases, the expressed proteins are the antigens that are strongly associated with the target disease. The expressed antigens, in turn, elicit antigen-specific antibody and T cell responses. We first identify one or more antigens that we believe are the best targets for directing the immune system toward a particular tumor or infectious disease. We then apply our SynCon design process, which analyzes the genetic make-up of the selected antigens from multiple variants of a tumor or strains of a virus.
For each antigen, SynCon technology creates a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen. In doing so, we believe we can create a differentiated SynCon sequence to help the immune system better recognize the target antigen and potentially variations of the target antigen. We have generated immune responses, including CD4+, CD8+, and memory T cells, with SynCon-designed DNA medicines against various tumor-associated antigens, as well as against different strains of certain infectious diseases in human clinical trials. Because the engineered SynCon sequences are substantially similar to the original sequences, without matching them exactly, we believe they are patentable.
Once a SynCon sequence is engineered, it is then inserted into a circular DNA plasmid with its own promoter. Promoters serve a vital role in “promoting” the expression of the target antigen once the DNA medicine has entered the cell. Through our SynCon technology, our DNA plasmids have been optimized to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of antigen expression compared to traditional approaches, potentially enhancing the overall ability to induce the desired immune response.
The plasmids are then manufactured in a bacterial fermentation process using scalable manufacturing technology. We have recently developed a high-yield manufacturing process which we anticipate using to manufacture our DNA medicines. The manufactured DNA medicines are designed to be stable under normal environmental conditions for extended periods of time.
CELLECTRA® Delivery Technology
Large molecules, like DNA plasmids, tend to be hindered by the cell membrane from entering the cell. To overcome this hurdle and allow for an efficient cellular uptake of our DNA plasmids, we have developed the CELLECTRA delivery technology, which delivers the DNA medicines directly into cells either intramuscularly (IM) or intradermally (ID). CELLECTRA devices use brief electrical pulses to reversibly open small pores in the cell membrane, allowing DNA plasmids to enter. Through this process, the cellular uptake of the DNA plasmids can be substantially increased compared to the injection of DNA plasmids alone. This improved cellular uptake has enabled the immune responses and efficacy results observed in our clinical trials to date.
Our CELLECTRA device portfolio currently consists of three models. CELLECTRA 2000 can perform both IM and ID injections and has been used in numerous clinical trials to date. CELLECTRA 5PSP is our new IM device utilizing a prefilled drug cartridge. CELLECTRA 5PSP has been used in our Phase 3 trials (REVEAL1/REVEAL2) for cervical high-grade squamous intraepithelial lesions (HSIL). We are also planning to use CELLECTRA 5PSP for the planned Phase 3 trial for INO-3107, our DNA medicines candidate for RRP. Finally, CELLECTRA 3PSP is our next-generation ID delivery device developed with support from the U.S. Department of Defense, which is ready for large volume production and application submission to regulatory agencies for review and approval.
CELLECTRA devices are validated and manufactured under Current Good Manufacturing Practices (cGMP). We have filed device master files with the U.S. Food and Drug Administration (FDA) covering the use of CELLECTRA smart devices in human clinical trials. CELLECTRA 2000 and 5PSP models have received CE mark certification in the EU.
The process for administration of our DNA medicines is illustrated in the following graphic.

4

ino-20221231_g2.jpg

DNA Medicines and HPV-related Diseases
Human papillomavirus (HPV) is a sexually-transmitted, persistent viral infection with one or more high-risk genotypes that can lead to warts, precancerous lesions and cancers, such as RRP, cervical, head and neck, anal and vulvar dysplasias, which are abnormal precancerous cells, and cancers. Approximately 90% of all HPV infections clear naturally and do not result in disease. However, for those not able to clear the virus naturally, persistent infection can lead to cancer and other debilitating, life-threatening diseases affecting quality of life.
HPV types fall into two groups. Low-risk HPV (e.g., HPV 6 and HPV 11) may lead to benign growths (warts or papillomas) that can develop into conditions such as RRP. High-risk (HR) HPV (e.g., HPV 16 and HPV 18) may lead to cell changes and lesions (i.e., precancerous dysplasia) that can become malignant and lead to cervical cancer. HPV causes nearly all cervical cancers and many cancers of the vagina, vulva, penis, anus, rectum, and oropharynx.
While there are currently vaccines available to prevent HPV infection, challenges with acceptance, accessibility, and patient compliance have resulted in many vaccine-eligible people remaining unvaccinated and at risk. It is estimated that even in the United States, only 50-60% of the eligible population has been vaccinated against HPV. In addition, current preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes. As a result, there is still an urgent need for the development of HPV therapies that can treat existing infections and prevent the development of HPV-related diseases. The current standard of care for many HPV-related diseases, including cervical dysplasia, cancer, and RRP, is surgery. These surgeries can be invasive and may be needed repeatedly because the underlying HPV infection is not eliminated. This is especially true for chronic diseases such as RRP and anal dysplasia. In addition to surgery, other options are being explored to treat HPV-related diseases, including the usage of checkpoint inhibitors and other immunotherapies.
A summary of the key characteristics of DNA medicines that we believe are important for the treatment of HPV-related diseases are listed in the following graphic:

ino-20221231_g3.jpg
5

Our DNA Medicines in Development
The chart below provides an overview of our DNA medicines pipeline. Each of the programs identified are described in more detail below.
ino-20221231_g4.jpg
INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP)
RRP is a life-long, rare disease characterized by the growth of tumors in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, such papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of RRP is the tendency for the papilloma to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases, RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include a hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults.
Incidence and prevalence of RRP is variable and depends on several factors that vary based on geographic location. There are estimated to be approximately 14,000 active cases and approximately 1.8 new cases per 100,000 adults in the United States each year. Global data for RRP is even more scarce, but available studies show a burden of disease in almost every country studied, ranging from an incidence of 0.18 cases per 100,000 adults in Lesotho to 0.54 per 100,000 adults in Norway and 0.02 cases per 100,000 children in Australia to 2.8 per 100,000 children in Thailand. The average yearly cost of treatment for RRP is estimated to be approximately $72,000.
In October 2022, we announced preliminary results from an open-label, multicenter Phase 1/2 trial evaluating the efficacy, safety, tolerability and immunogenicity of INO-3107, a DNA medicine candidate targeting HPV-6 and HPV-11 associated RRP. For this trial, adult patients first underwent surgical removal of their papilloma(s) and then received up to four doses of INO-3107, once every three weeks. The study protocol also included the administration of INO-9112, which encodes for human interleukin-12 (IL-12) to help enhance the immune response. The primary endpoint of this trial was safety and tolerability. Interim results from the trial showed INO-3107 to be well-tolerated with all patients completing the trial follow-up. Treatment-emergent adverse events (TEAEs) observed in the trial were generally low-grade, with 86% of patients experiencing at least one TEAE, most of which were Grade 1. Three patients (14%) experienced a Grade 3 TEAE, but none were deemed related to treatment with INO-3107. The most commonly reported TEAEs were injection site pain (38%) and fatigue (19%). While two serious adverse events were reported, these were also deemed unrelated to INO-3107.
The trial also assessed the efficacy of INO-3107. Preliminary results from the initial cohort of 21 patients showed a statistically significant reduction in the number of RRP surgical interventions in the year following the administration of INO-3107 compared with the year prior to treatment, which was the clinical endpoint of the trial. Of the 21 patients, 16 (76%) had a decrease in surgical interventions in the year following the administration of INO-3107 relative to the number of surgeries in the year prior to the trial. Of those 16 patients, six required no surgical intervention during the trial period. There was a median decrease of three surgical interventions (95% CI 1, 3) across the initial cohort.
6

In the trial, INO-3107 generated cellular responses against both HPV 6 and HPV 11, spanning both CD4 and CD8 T cells, including killer T cells. T-cell activity against HPV 6 and HPV 11 was present at the study end, which was 43 weeks after completion of treatment, and is indicative of a persistent cellular memory response.
INO-3107 was granted Orphan Drug Designation (ODD) by the FDA in July 2020.
In February 2023, we announced positive preliminary results from the second cohort of our Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated RRP in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 patients (91%) had a reduction in surgical interventions in the year following initial treatment, with measurement beginning at Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior. In the year prior to treatment, the number of surgical interventions for these 11 patients ranged between 2 and 8, and the median was 5.
Treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing both activated CD4 and activated lytic CD8 T cells. T cell responses were also observed at Week 52, which was 43 weeks after final treatment with INO-3107, indicating a persistent cellular memory response.
INO-3107 was well-tolerated in the trial, with all 11 patients completing the trial follow-up. Treatment-emergent adverse events (TEAE) observed in the trial were generally low-grade, with five patients (46%) experiencing at least one TEAE; four patients (36%) reported at least one related TEAE, all of which were Grade 1 or 2. The only adverse events reported by more than one patient were injection site pain (two patients) and headache (two patients). The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022.

VGX-3100 for the Treatment of HPV-related Cervical HSIL
Cervical HSIL is a pre-cancerous condition caused by HPV infection. While most genital HPV infections are cleared naturally by the body's own immune system, persistent cervical infection with one or more HR-HPV genotypes can eventually lead to cervical high-grade dysplasia (HSIL) and eventually to cervical cancer.
Current management options for cervical HSIL are limited and are associated with potential unwanted side effects. The “watch-and-wait” process associated with low-grade squamous intraepithelial lesions (LSIL, formerly called low-grade dysplasia or CIN 1), and in some young women with CIN2, can be a stressful approach. The current standard of care for cervical HSIL is surgery, which involves ablating or cutting into a women’s cervix to remove the pre-cancerous lesions. These treatments may lead to short-term adverse effects including excess bleeding, and infection, or to longer-term reproductive risks such as pre-term birth, miscarriage, and perhaps infertility. Recurrence of high-grade precancerous lesions can occur after surgery because surgery does not clear the underlying HPV infection.
Currently, there is no approved immunotherapy or drug available to treat persistent HPV infection or cervical HSIL.
VGX-3100 is designed to generate T cell immune responses against the E6 and E7 oncogenic proteins of high-risk HPV types 16 and 18 that can be present in both precancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into precancerous and cancerous cells, thus making them appealing targets for T cell-directed immunotherapy. The goal of VGX-3100 is to stimulate the body's immune system to generate a T cell response to kill the cells producing the E6/E7 protein. The potential of such immunotherapy would be to treat HSIL caused by these HPV types.
We have completed randomized, blinded, placebo-controlled Phase 2b and Phase 3 clinical trials of VGX-3100 compared to placebo, in women with HPV-16 and HPV-18 cervical HSIL. In the Phase 2b trial, women treated with VGX-3100 were more likely to demonstrate resolution of cervical HSIL and HPV clearance from cervical lesions than those women receiving placebo. In addition, antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated with placebo. All women were monitored for an additional 52 weeks following the primary endpoint to assess for safety; VGX-3100 was well-tolerated and there were no safety concerns observed. Immune endpoints were also assessed and women whose lesions regressed also had higher frequencies of HPV-specific CD8+ T cells which co-expressed key molecules important in the T cell killing cascade and directly correlated with clinical efficacy. To our knowledge, this Phase 2b trial was the first study from which data was published indicating a direct correlation between antigen-specific CD8+ T cells generated in vivo and clinical efficacy.
VGX-3100 Immune Correlates and Biomarker Signatures
We are pursuing a biomarker signature for our VGX-3100 program. In May 2019, we entered into a collaboration with QIAGEN N.V. to co-develop a liquid biopsy-based diagnostic for this biomarker signature to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. In February 2021, we announced an extension of our partnership with QIAGEN with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on
7

next-generation sequencing technology to complement our therapies. QIAGEN is utilizing the Illumina NextSeq™ 550Dx platform for this biomarker, the first development based on a partnership QIAGEN and Illumina entered into in October 2019.
In December 2021, we announced that we and QIAGEN had identified candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature of a pre-treatment in vitro diagnostic to meet the specific characteristics desired to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. This biomarker, if validated, may have the potential to identify those women who are more likely to have a favorable treatment outcome, specifically the regression of cervical HSIL and viral clearance.
Phase 3 Trials (REVEAL1 and REVEAL2)
Our Phase 3 program, named REVEAL, consists of a primary trial (REVEAL1; HPV-301) and confirmatory trial (REVEAL2; HPV-303). The REVEAL trials are prospective, randomized (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical HSIL (CIN 2/3). The primary endpoint is regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix, which was a secondary endpoint that was achieved in our Phase 2b trial. Overall, the Phase 3 trials are evaluating cervical tissue changes at approximately 9 months after beginning a three-dose regimen of VGX-3100 administered at months 0, 1 and 3.
In March 2021, we announced the results of the REVEAL1 trial of VGX-3100. The trial protocol-defined intention to treat (ITT) population (N=201) included all randomized participants regardless of availability of endpoint data and defines those without endpoint data as non-responders. There were eight such participants (seven in the treatment group, one in the placebo group) in the ITT population. Including participants with missing endpoint data, the percentage of participants meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 95%CI: -0.4,21.2), which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (95%CI: -0.6,24.5).
For the protocol-defined mITT population (N=193), which included all participants with endpoint data, VGX-3100 achieved the primary and secondary endpoints among all evaluable participants. For the primary endpoint of histopathological regression of HSIL and virologic clearance of HPV-16 and/or HPV-18 at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 95%CI: 0.4,22.5), which was statistically significant. All secondary efficacy endpoints were achieved in this population. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. There were no treatment-related serious adverse events (SAEs) and most adverse events (AEs) were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials. The data from REVEAL1 was presented at the 2021 American Society for Colposcopy and Cervical (ASCCP) annual scientific meeting, and at the 34th International Papillomavirus Conference (IPVC) in November 2021.
We completed the 52-week safety follow-up of participants in REVEAL1 and showed that VGX-3100 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88.
REVEAL2 is our second Phase 3 trial with VGX-3100. In April 2022, the trial protocol was amended to utilize a biomarker-selected population as the primary population, based on prior analysis of REVEAL1 results suggesting that this investigational biomarker had the potential to identify women more likely to respond to treatment with VGX-3100. We announced that this trial would no longer be considered to be a pivotal trial and would not lead to a BLA filing for a biomarker-selected population, as the FDA advised us that the biomarker-positive population would not be sufficient to support approval of a potential marketing application for VGX-3100. The FDA recommended using REVEAL2 as an exploratory trial and that conducting one or two additional well-controlled trials in the biomarker-selected population would be more likely to provide evidence to support approval of a marketing application.
Trial participants in REVEAL2 included 203 women, 18 years of age or older, who had histologically-confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. Participants received either VGX-3100 or placebo at 0, 4 and 12 weeks (randomized 2:1). The primary endpoint, as amended, was the percentage of biomarker-selected participants with regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix. A secondary endpoint was the percentage of all participants with regression and virologic clearance.
In March 2023, we announced data from our REVEAL2 trial. Statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance.
The percentage of participants in the investigational biomarker-selected population meeting the endpoint was 28.6% (6/21) in the treatment group, versus 0% (0/4) in the placebo group (p=0.115; difference in percentage 28.6, 95%CI: -24.6, 50.4), which was not statistically significant.
8

The result of the all-participants population of 203 participants (134 participants in the treatment group, 69 in the placebo group) was statistically significant, with 27.6% (37/134) of the participants meeting the endpoint in the treatment group, versus 8.7% (6/69) in the placebo group (p=0.001; difference in percentage 18.9, 95%CI: 7.8, 28.6).
In particular, in the all-participants population of REVEAL2, viral clearance was observed in 37.3% (50/134) in the treatment group versus 8.7% (6/69) in the placebo group. Given the importance of viral clearance in removing the underlying cause of the HPV-related diseases, this data may have positive implications in our other HPV-related programs.
An ad hoc integrated efficacy analysis of the results for both REVEAL1 and REVEAL2 shows statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. For the combined biomarker-selected population of 92 participants (68 participants in the treatment group, 24 in the placebo group), the percentage of participants meeting the primary endpoint was 54.4% (37/68 in the treatment group, versus 12.5% (3/24) in the placebo group (p=<0.001; difference in percentage 41.9, 95%CI: 20.4, 57.0). For the combined all-participants population of 404 participants (272 participants in the treatment group, 132 in the placebo group), the percentage of participants meeting the primary endpoint was 25.0% (68/272 in the treatment group, versus 9.8% (13/132) in the placebo group (p=<0.001; difference in percentage 15.2, 95%CI: 7.4, 22.1).
In both REVEAL1 and REVEAL2, VGX-3100 was well-tolerated. There were no treatment-related serious adverse events and most adverse events were considered to be mild to moderate.
This combined data set will be used as supportive data in any future regulatory interactions involving VGX-3100. We will continue to evaluate the results to determine next steps for VGX-3100 in our HPV programs. We plan to submit the data for publication in a peer-reviewed journal later this year.
VGX-3100 for the Treatment of Anal or Perianal HSIL
HPV-16 and HPV-18 can also cause precancerous lesions of the anus (anal HSIL). Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL is observed in approximately 20% of patients. Persistent infection with one or more high-risk HPV genotypes is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically.
There are no validated screening tests or a general consensus for screening recommendations for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, recurrence rates are high, up to 49% one year after treatment, as ablation does not clear the underlying HPV infection, resulting in an unmet medical need.
We have completed a Phase 2 clinical trial (HPV-203) to evaluate VGX-3100 in participants who are HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. This open-label trial enrolled 24 participants who received three doses of VGX-3100 delivered by our CELLECTRA-5PSP device. The primary endpoint of the trial was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples. In December 2020, we announced Phase 2 efficacy results from this trial. One-half of participants treated with VGX-3100 (11/22) showed resolution of HPV-16/18-associated anal HSIL at six months following the start of treatment. VGX-3100 was well-tolerated in the trial.
In addition to the Phase 2 anal HSIL trial described above, a separate ongoing Phase 2 trial sponsored by the AIDS Malignancy Consortium (AMC-103) is evaluating VGX-3100 in participants with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18 who are HIV-positive. This open-label single-arm trial plans to enroll approximately 90 participants who will receive up to four doses of VGX-3100 delivered by CELLECTRA-5PSP smart device. The primary endpoint of the trial is histological regression of high-grade anal lesions to low-grade SIL or normal histology.
VGX-3100 for the Treatment of Vulvar HSIL
HPV-16 and HPV-18 can also cause precancerous and cancerous lesions of the vulva. These precancerous lesions, or vulvar HSIL, have less than a 5% rate of spontaneous or natural regression and there are no FDA-approved treatments. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term pain, and psychological distress for women who undergo the procedure. Non-surgical options such as the off-label use of topical imiquimod are also available.
We have completed a Phase 2 trial (HPV-201) to evaluate the efficacy of VGX-3100 in participants with vulvar HSIL. This randomized, open-label Phase 2 clinical trial assessed the efficacy of VGX-3100 in 33 women with vulvar HSIL. VGX-3100 was administered with our CELLECTRA -5PSP smart device. The primary endpoint of the trial was histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The trial also evaluated the safety and tolerability of VGX-3100. In January 2021, we announced efficacy results from this trial. A 25% or more reduction in HPV-16/18-associated vulvar HSIL was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six
9

months post-treatment. Three of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. VGX-3100 was well-tolerated in the Phase 2 trial.

INO-5401 for the Treatment of Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common aggressive type of brain cancer. In the United States, the median age at diagnosis is 65 years, and the incidence rate increases thereafter. Prognosis is extremely poor, and a limited number of new therapies have been approved over the last 10 years; median overall survival for U.S. patients receiving standard of care therapy is approximately 10 months and the five-year survival is 6.8% for all ages combined. The annual incidence of GBM is estimated to be approximately 12,000 cases per year and increasing.
Our product candidate INO-5401 is an immunotherapy consisting of three DNA plasmids encoding for three tumor-associated antigens: human Telomerase Reverse Transcriptase (hTERT), Wilms Tumor gene-1 (WT1) and Prostate-Specific Membrane Antigen (PSMA).
We have completed a Phase 1/2 immuno-oncology trial of INO-5401 and INO-9012 (IL-12 plasmid) in participants with newly diagnosed GBM, in combination with cemiplimab (Libtayo®), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. This open-label trial began in 2018 and enrolled 52 newly diagnosed GBM participants. The primary endpoint was safety and tolerability, and the trial also evaluated immunogenicity and efficacy (Overall Survival, or OS).
In May 2022, we presented OS data at the 2022 American Society of Clinical Oncology (ASCO) from GBM-001 Phase 2 trial. Median OS duration in patients with an unmethylated MGMT promoter (Cohort A) was 17.9 months, which compares favorably to historical comparisons (14.6-16 months). Median OS data in patients with a MGMT methylated promoter (Cohort B), was 32.5 months, which compares favorably to historical comparisons (23.2-25 months). Overall, INO-5401 + INO-9012 demonstrated tolerability and immunogenicity when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors.

INO-5151 (INO-5150 + INO-9012) for the Treatment of Prostate Cancer
INO-5151 consists of DNA plasmids targeting Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSMA), combined with INO-9112, the IL-12 plasmid, for the treatment of prostate cancer.
In 2019, we announced a clinical collaboration with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) as part of which INO-5151 is being combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 immune checkpoint inhibitor (nivolumab) in participants with metastatic castration-resistant prostate cancer (mCRPC), in a PICI-sponsored platform trial (PORTER). This combination trial is an open-label, non-randomized, exploratory platform trial designed to assess the safety and antitumor activity of multiple immunotherapy-based combinations in participants with mCRPC who have received prior secondary androgen inhibition. The trial evaluated biomarkers of immune activity and clinical outcomes using a multi-omic, multi-parameter approach. Under the agreement, PICI designed and conducted the clinical trial, working in collaboration with its established network of clinical academic and industry cancer centers, with funding support from CRI.
In November 2022, at the Society for Immunotherapy of Cancer (SITC) 2022 annual meeting, PICI announced that while the treatment with INO-5151 induced antigen-specific T cell responses, the combination therapy of INO-5151 + nivolumab + CDX-301 was not deemed to have sufficient clinical activity by the study sponsors and will not be expanded for further study.

Infectious Disease Product Candidates
INO-4800 for COVID-19
Phase 2/3 Clinical Trial – INNOVATE
In 2022, we announced the discontinuance of all internally funded COVID-19 vaccine programs for INO-4800. The decision followed a comprehensive review of market conditions and global demand for COVID-19 vaccines. In May 2022, we announced the discontinuance of our INNOVATE program, which was focused on developing INO-4800 as a primary vaccine candidate against COVID-19. At that time, our intention was to continue our efforts to develop INO-4800 as a heterologous booster vaccine. However, in October 2022, we announced the discontinuance of these heterologous booster vaccine efforts for INO-4800 as market conditions continued to shift. While we believe that INO-4800 has attributes that could be beneficial as a potential vaccine and/or booster vaccine against COVID-19, such as its ability to elicit immune responses at the humoral and cellular level, including driving cross-reactive T cell responses against multiple variants of concern, our decision was driven by external factors. These included epidemiological trends, including reduced number of severe COVID-19 cases, difficulty in conducting heterologous booster trials in highly vaccinated populations, market conditions such as vaccine oversupply, lower
10

forecast projections for vaccine doses in the future, and vaccine fatigue, and changes in regulatory timelines and requirements, as well as diminishing government financial support.
Phase 2/3 Clinical Trial – SOLIDARITY TRIAL VACCINES (STV)
INO-4800 is one of two initial COVID-19 vaccine candidates included in the World Health Organization (WHO) sponsored Solidarity Trial Vaccines, which is designed to evaluate the efficacy and safety of promising new candidate vaccines selected by an independent vaccine prioritization advisory group composed of leading scientists and experts. Our decision to discontinue our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine does not affect the evaluation of INO-4800 in this trial.
INO-4800 in China
Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. The trials are designed to evaluate safety, tolerability and immunogenicity of INO-4800 as a homologous booster where INO-4800 was administered as the primary vaccine and as a heterologous booster where an inactivated vaccine was administered as the primary vaccine.
COVID-19 dMAb®
Using our SynCon technology, we are able to create a precisely designed DNA plasmid that encodes for a specific monoclonal antibody (mAb). We refer to these DNA plasmids as our dMAb product candidates. We deliver the plasmid directly into cells of the body using our CELLECTRA smart delivery system, enabling the electroporated cells to manufacture those mAbs in vivo (i.e. by the body itself), unlike conventional mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs. We expect to design dMAb product candidates not only for new disease targets that are not currently addressable with conventional recombinant mAbs, but also targets of existing, commercially available mAb products.
In December 2020, we, along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our dMAb technology to develop anti-SARS-CoV-2-specific dMAbs that function as both a therapeutic and preventive treatment for COVID-19.
As part of DARPA's two-year grant, the consortium constructed COVID-19 dMAb candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19.
In July 2022, Wistar announced the dosing of the first participant in a Phase 1, open-label, single-center, 24-person dose escalation trial to evaluate the safety, tolerability and pharmacokinetic profile of two of our mAb product candidates , administered IM followed immediately by electroporation using our CELLECTRA 2000 device in a 1- and 2-dose regimen (Days 0 and 3) in healthy adults (NCT05293249).

INO-4201 for Ebola Virus Disease
The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging approximately 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within 2 to 21 days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola virus. This approval was from the European Medicines Agency (EMA) for the vaccine ERVEBO®. That same month, the WHO pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, there are no proven effective therapeutic treatments for Ebola. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing.
In December 2021, we announced complete enrollment of a 46-participant Phase 1b trial in which our DNA medicine candidate INO-4201 was assessed as a heterologous booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (ERVEBO®), an FDA- and EMA- approved viral vector-based Ebola vaccine (NCT04906629). To date, INO-4201 has been well-tolerated and has not demonstrated systemic SAEs, such as fever, joint pain, and low white blood cell counts, that have been reported in association with some viral vector-based Ebola vaccines currently in development.
In February 2022, we announced results from the Phase 1b trial. INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. We and our collaborators plan to publish the data in a peer-reviewed journal and provide updates on the next steps for INO-4201.

INO-4700 for Middle East Respiratory Syndrome (MERS)
11

The Middle East Respiratory Syndrome (MERS) is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an animal reservoir to humans, but human to human transmission has been confirmed. In 2018, we announced a collaboration with CEPI under which CEPI would fund up to $56 million of costs to support our pre-clinical and clinical advancement through Phase 2 of our vaccine candidate INO-4700.
We dosed and completed enrollment for the first part (dose finding stage) of the Phase 2 trial (192 participants) of INO-4700. The multi-center Phase 2 trial was a randomized, double-blinded, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of INO-4700 administered with CELLECTRA 2000 in approximately 500 healthy adult participants (NCT04588428). The trial was conducted at sites in Jordan, Lebanon, and Kenya.
Based on initial analysis of data from the studies, we and CEPI agreed to discontinue development of INO-4700 for MERS in November 2022. Although INO-4700 was well-tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development.

INO-4500 for Lassa Fever
Lassa fever, also known as Lassa hemorrhagic fever, is an acute viral disease which occurs mostly in West Africa.
In October 2021, we completed enrollment of a 220 participant Phase 1b trial for our vaccine candidate INO-4500 in Accra, Ghana, which was the first vaccine clinical trial for Lassa Fever conducted in West Africa, where the viral illness is endemic. The trial was funded by CEPI. The dosing regimen involved two intradermal vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg doses.
In November 2022, we announced that we and CEPI agreed to discontinue development of INO-4500 for Lassa Fever, following initial analyses of data from studies. Although INO-4500 was well tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development.

Collaboration and Alliances
Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
Our most material collaboration arrangements are summarized below.
Advaccine
On December 31, 2020, we entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), which was amended and restated on June 7, 2021 (as amended and restated, the “Advaccine Agreement”). Under the terms of the Advaccine Agreement, we granted to Advaccine the exclusive right to develop, manufacture and commercialize our vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as “Greater China”) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without our express prior written consent. As part of the collaboration, Advaccine also granted to us a non-exclusive license to certain DNA vaccine manufacturing processes.
In certain instances, we will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay us its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China.
Under the Agreement, Advaccine made an upfront payment to us of $3.0 million in January 2021. In addition to the upfront payment, we are entitled to receive up to an aggregate of $200.0 million, payable upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. In December 2020 we earned a $2.0 million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. We are also entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine’s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region
12

within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.
Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay us an annual maintenance fee of $1.5 million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.
Under the Advaccine Agreement, we will supply Advaccine’s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine’s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.
The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, we may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by us to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months’ written notice to us, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months’ written notice thereafter; provided that we may accelerate the effectiveness of such termination to the extent permitted by law.
ApolloBio

In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio. Under the terms of this License and Collaboration Agreement, which became effective in March 2018, we granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, our DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories - Greater China (defined as China, Hong Kong, Macao and Taiwan). As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory.
In addition to the upfront payment that we received in 2018, we are entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the Amended and Restated License and Collaboration Agreement. In the event that VGX-3100 is approved for marketing in these territories, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio’s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory. The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations. In December 2021, ApolloBio dosed its first participant in a separate Phase 3 trial in China (HPV-303CHN).
Competition
As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include AbbVie, AstraZeneca, BioNTech, Bristol-Myers Squibb, GlaxoSmithKline plc, Janssen Pharmaceuticals (part of J&J), Merck, Moderna, Novartis, Pfizer, Roche, and Sanofi-Aventis. There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, including but not limited to CureVac, Dynavax, GeneOne, Genexine, Hookipa, Imunon, Iovance, Nektar, Nykode, Precigen, Translate Bio, Vir Biotechnology, and Zydus. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects.
Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is working to develop a treatment based on a Gorilla adenovirus vector. Genexine and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.
We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen
13

production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their unique obstacles to overcome.
Viral Vaccine Delivery
This technology utilizes a virus as a carrier, or vector, to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. The potential limitation of the technology stems from problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration difficult. In addition, complexity and safety concerns increase their cost and complicate regulatory approval.
Lipid DNA/RNA Delivery
A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system. While there has been significant progress in this field, including emergency use authorization of COVID-19 mRNA vaccines in 2020, lipid nanoparticle delivery of mRNA may have thermal stability issues as well as the potential of adverse events from the lipid nanoparticle formulations.
DNA Immunotherapy Delivery with Electroporation
There are other companies with electroporation intellectual property and devices. We believe we have competitive advantages over other companies focused on electroporation for multiple reasons:
•We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA-based agents. This experience has been validated with multiple sets of interim data from clinical trials assessing DNA-based immunotherapies and vaccines against cancers and infectious disease.
•We have a broad product line of electroporation instruments designed to enable DNA delivery, including our intradermal and intramuscular devices.
•We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate.
If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours.
Our competitive position will be affected by the disease indications addressed by our product candidates and those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales.
The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications.
Commercialization and Manufacturing
Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as HPV-related diseases, infectious diseases, and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances.
We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.
Intellectual Property
14

Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information.
As of December 31, 2022, our patent portfolio included approximately 100 issued U.S. patents and approximately 80 U.S. patent applications as well as approximately 800 issued foreign counterpart patents and approximately 700 counterpart foreign patent applications. These are comprised, in part, of:
•two U.S. patent applications and approximately 40 counterpart foreign patent applications, directed to treatment of RRP;
•seven issued U.S. patents and five U.S. patent applications, as well as approximately 80 issued foreign counterpart patents and approximately 50 counterpart foreign patent applications, directed to treatment of GBM;
•approximately 70 issued U.S. patents and approximately 50 U.S. patent applications, as well as approximately 400 issued foreign counterpart patents and approximately 500 counterpart foreign patent applications, directed to our other earlier-stage product candidates; and
•approximately 30 issued U.S. patents and approximately 20 U.S. patent applications, as well as approximately 30 issued foreign counterpart patents and approximately 125 counterpart foreign patent applications, directed to our device delivery systems.
Our pending patent applications directed to treatment of RRP, if issued, would expire between about 2040 and 2043. Our issued patents directed to treatment of GBM expire between about 2027 and 2037 and our pending patent applications, if issued, would expire between about 2027 and 2040. Our issued patents directed to our other product candidates expire between about 2023 and 2036 and our pending patent applications, if issued, would expire between about 2027 and 2042. Our issued patents directed to our device delivery systems expire between about 2023 and 2036 and our pending patent applications, if issued, would expire between about 2023 and 2042.
Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries in which we file patent applications, including the United States, the patent term is 20 years from the date of filing of the first non-provisional patent application to which priority is claimed. In some instances, a patent term can be extended under certain circumstances, such as patent term extension or patent term adjustment; alternatively, a patent term may be shortened, for example in the United States, if a patent is terminally disclaimed over an earlier-filed patent. Protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.
If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel.
There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic
15

drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.
Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others’ proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.
We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection.
Government Regulation
Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.
Review and Approval of Combination Products in the United States
Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:
•a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
•two or more separate products packaged together in a single package or as a unit and comprised of drug and device products;
•a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or
•any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.
Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the “primary mode of action” of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action, with the device component reviewed under a Device Master File.
U.S. Biological Product Development
16

In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.
Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:
•completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA’s Good Laboratory Practice, or GLP, regulations;
•submission to the FDA of an IND, which must become effective before human clinical trials may begin;
•performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;
•submission to the FDA of a BLA;
•satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA’s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality, purity and potency;
•potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and
•FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States.
The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.
The clinical stage of development involves the administration of the product candidate to healthy participants under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor’s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant selection and exclusion criteria, and the parameters to be used to monitor participant safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial participant or his or her legal representative and must monitor the clinical trial until completed.
There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and
17

disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion.
Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand participants) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.
Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor’s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic’s safety and effectiveness after BLA approval.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.
BLA and FDA Review Process
Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.
Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.
Once a BLA has been accepted for filing, which occurs, if at all, 60 days after the BLA’s submission, the FDA’s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for
18

additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA’s review process again, including the initial 60-day review to determine if the application is sufficiently complete to permit substantive review.
After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate’s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.
Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.
There is no assurance that the FDA will ultimately approve a product for marketing in the United States and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product’s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.
Post-Marketing Requirements
Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product’s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.
19

In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.
The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of our products under development.
Coverage and Reimbursement
Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and vaccines. Accordingly, a pharmaceutical company’s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.
Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.
Coverage and reimbursement policies for drug products and vaccines can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.
A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.
Healthcare Reform
20

In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably. In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA’s provisions of importance to the pharmaceutical industry are that it:
•Created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;
•Increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;
•Created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;
•Expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
•Expanded the entities eligible for discounts under the Public Health program;
•Created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;
•Established a Center for Medicare & Medicaid Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and
•Created a licensure framework for follow on biologic products.

There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA’s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and by creating a newly established manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted.
On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, in July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of
21

potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Healthcare Laws
Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company’s ability to operate include:
•the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid;
•Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;
•the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities;
•the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
•the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples;
•the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; and
•state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and
•additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians.
A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company’s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be
22

subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations.
Other Regulations
We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.
Significant Customers and Research and Development
During the year ended December 31, 2022, we derived 94% of our revenue from the procurement contract with the DoD that we entered into in June 2020. During the year ended December 31, 2021, we derived 43% of our revenue from the procurement contract with the DoD and 14% of our revenue from our collaborator Plumbline Life Sciences, a company of which we are an approximately 19% stockholder. During the year ended December 31, 2020, we derived 68% of our revenue from Advaccine and 18% of our revenue from Plumbline Life Sciences.
Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $187.7 million in 2022, $249.2 million in 2021 and $94.2 million in 2020.
Geographic Information
All of our revenue for the years ended December 31, 2022, 2021 and 2020 was earned in the United States. All of our long-lived assets are located in the United States.
Corporate Information
Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200.
Available Information
Our Internet website address is www.inovio.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.
We make our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.
Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, and information for contacting our board of directors is available on our website.
Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law.
Employees and Human Capital Resources
As of February 14, 2023, we employed 184 people on a full-time basis. Of the total, 136 were in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, and 48 were in general and administrative functions, which includes corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. Approximately one-half of our workforce is comprised of women and approximately one-half is comprised of individuals with ethnically diverse backgrounds. In addition, four of the eight members of our board of directors are women. None of our employees are subject to collective bargaining agreements. We consider our relationship with our employees to be good.
We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our
23

ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice.
Employee Engagement
As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and acknowledge individual contributions to INOVIO through several rewards and recognition initiatives. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work.
Health, Safety and Wellness
The physical health, financial well-being, life balance and mental health of our employees is vital to our success. In 2021, we launched a Company-wide comprehensive wellness program inclusive of financial, physical, and mental well-being.
The environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at the workplace are extremely low and are always investigated to determine if any environmental or other changes need to be implemented.
24

ITEM 1A.    RISK FACTORS
You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.

Risks Related to Our Financial Position and Need for Additional Capital

We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.
We have experienced significant operating losses over the last several years. As of December 31, 2022 our accumulated deficit was $1.5 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary smart device technology and thus may never have any significant future revenues or achieve and sustain profitability.
We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.
We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in:
•developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates;
•developing our proprietary smart device technology; and
•commercializing any products for which we receive approval from the FDA and foreign regulatory authorities.
Our proprietary smart device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary smart device and DNA medicine candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary smart device and DNA medicine products, and we may not be able to continue our operations.
A small number of licensing partners and government contracts currently account for a substantial portion of our revenue.
We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected.
We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.
Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary smart device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:
•the progress of our current and new product development programs;
•the progress, scope and results of our pre-clinical and clinical testing;
•the time and cost involved in obtaining regulatory approvals;
•the cost of manufacturing our DNA medicine candidates;
•the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights;
•debt service obligations;
•competing technological and market developments; and
25

•our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market.
Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.
Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations.
Risks Related to Product Development, Manufacturing and Regulatory Approval
If we are unable to obtain FDA approval of our product candidates, we will not be able to commercialize them in the United States.
We need FDA approval prior to marketing our proprietary smart device and DNA medicine candidates in the United States. If we fail to obtain FDA approval to market our proprietary smart device and DNA medicine candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.
This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary smart device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary smart device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.
The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary smart device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.
It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability.
Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.
26

In order to market any proprietary smart device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies.
Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.
Our product candidates could fail to complete the clinical trial process for many reasons, including the following:
•we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary smart device or product candidate is safe and effective for any indication;
•the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
•the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
•we may not be successful in enrolling a sufficient number of participants in clinical trials;
•we may be unable to demonstrate that our proprietary smart device or DNA medicine candidates' clinical and other benefits outweigh their safety risks;
•we may be unable to demonstrate that our proprietary smart device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial;
•the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
•the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere;
•the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and
•the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.
Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:
•obtaining regulatory approval to commence a clinical trial;
27

•adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;
•reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•future bans or stricter standards imposed on clinical trials of gene-based therapy;
•manufacturing sufficient quantities of our proprietary smart device and DNA medicine candidates for use in clinical trials;
•obtaining Internal Review Board, or IRB, approval to conduct a clinical trial at a prospective site;
•slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;
•conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;
•retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;
•collecting, reviewing and analyzing our clinical trial data; and
•global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors beyond our control.
With respect to clinical trials of product candidates for rare diseases, such as our clinical trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of respiratory distress, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment.
Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:
•failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
•inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
•unforeseen safety issues; and
•lack of adequate funding to continue the clinical trial.
If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary smart device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. For example, in November 2022 we announced the discontinuation of the development programs for our product candidates INO-4700 for MERS and INO-4500 for Lassa Fever. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.
None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.
Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products.
In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.
28

We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.
Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine.
We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator, Advaccine, is continuing the clinical development of INO-4800 in a Phase 2 clinical trial in China and may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought.
Our COVID-19 vaccine candidate continues to be evaluated as part of the World Health Organization’s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine’s ability to market and sell our COVID-19 vaccine.
DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.
No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.
If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart device and DNA medicine candidates.
We manufacture some components of our proprietary smart devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and
29

process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations.
If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary smart device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.
Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely.
In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.
Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA’s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates.
We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates and investigational medicines.
We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our product candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.
If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the
30

replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.
Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:
•delays to the development timelines for our development candidates or investigational medicines;
•interruption of supply resulting from modifications to or discontinuation of a supplier’s operations;
•delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier’s variation in a component;
•a lack of long-term supply arrangements for key components with our suppliers;
•inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;
•difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;
•production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;
•delay in delivery due to our suppliers’ prioritizing other customer orders over ours;
•damage to our reputation caused by defective components produced by our suppliers; and
•fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.
If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.
Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.
Even if United States regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product’s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may:
•issue Warning Letters or untitled letters;
•impose civil or criminal penalties;
•suspend regulatory approvals;
•suspend any ongoing clinical trials;
•refuse to approve pending applications or supplements to applications filed by us;
•impose restrictions on operations, including costly new manufacturing requirements; or
•seize or detain products or require us to initiate a product recall.
We are developing some of our investigational DNA medicines and sometimes using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.
31

There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. In particular, there are challenges associated with agreeing to a primary endpoint with the FDA for the treatment of RRP where no precedent exists.
Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.
We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.
We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances.
Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations.
A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.
32

We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.
Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.
Risks Related to Reliance on Third Parties
If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.
We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control.
If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.
We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business.
Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator.
We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates.
We have entered into agreements with government agencies, such as the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, DARPA, Medical CBRN Defense Consortium and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, or DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued
33

performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that it discontinued funding for the Phase 3 segment of our INNOVATE trial, which resulted in increased expenditures by us.
Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements.
We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.
We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary smart device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications.
If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.
We enter into various contracts in the normal course of our business in which we agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.
In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees’ exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.
Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.
Risks Related to Commercialization of Our DNA Medicine Candidates
We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.
We currently have only a small commercial organization to support pre-commercial activities for our proprietary smart device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to
34

commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues.
If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.
The commercial success of our proprietary smart device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including:
•our ability to provide acceptable evidence of safety and efficacy;
•the relative convenience and ease of administration, including the acceptance and usage of our proprietary smart device by the medical community;
•the prevalence and severity of any actual or perceived adverse side effects;
•limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential “black box” warnings;
•availability of alternative treatments;
•pricing and cost effectiveness;
•the effectiveness of our or any future collaborators' sales and marketing strategies;
•the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement;
•our ability to obtain sufficient third-party coverage and adequate reimbursement; and
•the willingness of patients to pay out of pocket in the absence of third-party coverage.
If our proprietary smart device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful.
We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success.
Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary smart device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA.
Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.
Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the
35

product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.
Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.
A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.
Risks Related to Employee and Operational Matters
Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.
In July 2022 and again in January 2023, we undertook restructuring plans that resulted in a total reduction in headcount of approximately 79 employees and a significant majority of our contractors. Restructuring plans may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. During the second half of 2022, we experienced increased attrition after conducting the first reduction in force. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation.
Furthermore, employees whose positions have been or will be eliminated in connection with these restructuring plans may seek future employment with our competitors. Although all our employees are required to sign a confidentiality agreement with us at the time of hire, we cannot be certain that the confidential nature of our proprietary information will be maintained in the course of such future employment. We cannot be certain that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from our current or any future restructuring plans. In addition, if we continue to reduce our workforce, it may adversely impact our ability to respond rapidly to any new growth or revenue opportunities. Any restructuring activities we undertake may take longer than expected and may require changes to our business that we are unable to implement. If we are unsuccessful in implementing our cost saving initiatives and restructuring plans or if we do not achieve our expected results, our results of operations and cash flows could be adversely affected.
We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.
We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of INO-4800 in violation of certain federal securities laws. Although we have settled the current class action securities litigation, there can be no guarantee that we will not become subject to similar claims in the future. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.
We have experienced changes to our senior leadership team, which creates uncertainty and could harm our business.
36

We have experienced changes to our senior leadership team over the past year. Our former President and Chief Executive Officer, Dr. J. Joseph Kim, who served in those roles since 2009, resigned in May 2022, and Dr. Jacqueline Shea, previously our Chief Operating Officer, was appointed to those roles. Although Dr. Shea has served with our Company since 2019, the management transition had the potential to create uncertainty and disrupt our operations and relationships with employees, suppliers and partners and result in operational inefficiencies, decreased employee morale and productivity and increased turnover. Any departure at a senior level could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. In addition, our competitors may seek to use this management transition and the related potential disruptions to gain a competitive advantage over us. If we are unable to successfully navigate the transition of our chief executive officer, our business could suffer.
We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates.
The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates.
Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.
In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. These or similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.
The spread of COVID-19, which caused a broad impact globally, could also affect us economically. While the potential economic impact brought by COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negatively affect our future liquidity.
Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us.
We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines, if approved.
If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to commercialize our products, if approved, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or noncompetitive, or result in treatments or cures superior to ours.
37

Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&J), Sanofi-Aventis, GlaxoSmithKline plc, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Translate Bio, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development.
Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is working to develop a treatment based on a gorilla adenovirus vector. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.
We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases.
Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. See “Business—Competition” for additional information on our competitive landscape.
Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.
We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products.
The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.
In addition, future acquisitions may entail numerous operational and financial risks, including:
•exposure to unknown liabilities;
•disruption of our business and diversion of our management's time and attention to develop acquired products or technologies;
•incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;
•higher than expected acquisition and integration costs;
•increased amortization expenses;
•difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
•impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and
•inability to retain key employees of any acquired businesses.
Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities.
38

Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.
We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.
We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.
The use of our proprietary smart device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in:
•decreased demand for our DNA medicine candidates;
•impairment of our business reputation;
•withdrawal of clinical trial participants;
•costs of related litigation;
•distraction of management's attention from our primary business;
•substantial monetary awards to patients or other claimants;
•loss of revenues; and
•inability to commercialize our products.
39

We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business.
Healthcare reform measures could hinder or prevent our products' commercial success.
In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA’s provisions of importance to the pharmaceutical industry are that it:
•imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;
•created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;
•increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;
•created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;
•expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
•expanded the entities eligible for discounts under the Public Health program;
•created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;
•established a Center for Medicare & Medicaid Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and
•created a licensure framework for follow on biologic products.
There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA’s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage was eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2031, unless Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals,
40

and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, in July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect:
•our ability to set a price we believe is fair for our products;
•our ability to generate revenues and achieve or maintain profitability;
•the availability of capital; and
•our ability to obtain timely approval of our products.
If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:
•the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
•federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;
•HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities;
•the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and
41

chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
•the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples;
•the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business;
•state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and
•additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians.
The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.
We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business.
Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected.
We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.
We are party to a license and collaboration agreement with a China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems.
Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy has caused delays in Advaccine’s conduct of clinical trials for INO-4800 in China under our collaboration with them, which has in turn resulted in delays in obtaining clinical data to evaluate the
42

safety and potential efficacy of INO-4800. Further, the threat of a trade war between the United States and China could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. These interruptions or failures could then impede commercialization of our DNA medicine candidates and impair our competitive position. We may also be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.
Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.
Employee litigation and unfavorable publicity could negatively affect our future business.
Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.
Risks Related to Our Intellectual Property
It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary smart device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges.
The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge.
The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example:
•we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents;
•the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges;
43

•others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds;
•pending patent applications may not result in issued patents;
•the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value;
•the issued patents may be challenged and invalidated, or rendered unenforceable;
•governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;
•the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable;
•we may not develop or acquire additional proprietary technologies that are patentable;
•our trademarks may be invalid or subject to a third party's prior use; or
•our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling.
We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly.
We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.
If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability.
From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current “first-to-invent” system to a system that awards a patent to the “first-inventor-to-file” for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention.
If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights.
Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications.
If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including:
44

•we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed;
•we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent;
•we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and
•we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time.
If any of these events occur, our business could suffer and the market price of our common stock may decline.
We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.
Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.
Risks Related to an Investment in Our Common Stock
An active trading market for our common stock may not be sustained.
Although our common stock is listed on the Nasdaq Global Select Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.
The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value.
In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control:
•developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;
•fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;
•our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments;
•fluctuations in our operating results;
•announcements of technological innovations;
•new products or services that we or our competitors offer;
•changes in the structure of healthcare payment systems;
•the initiation, conduct and/or outcome of intellectual property and/or litigation matters;
•changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business;
•conditions or trends in bio-pharmaceutical or other healthcare industries;
•regulatory developments in the United States and other countries;
•perceptions of gene-based therapy;
•changes in the economic performance and/or market valuations of other biotechnology and medical device companies;
•additions or departures of key personnel;
•sales or other transactions involving our common stock;
•changes in our capital structure;
45

•sales or other transactions by executive officers or directors involving our common stock;
•changes in accounting principles;
•global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, and economic and other external factors; and
•catastrophic weather and/or global disease pandemics, including COVID-19.
The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.
We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.
Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses during the period from 2020 to 2022 significantly increased due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.
Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock.
Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:
•the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval;
•all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and
•the elimination of cumulative voting.
In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.
We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future.
We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation’s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use
46

of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.
General Risk Factors
Our quarterly operating results may fluctuate significantly.
We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:
•variations in the level of expenses related to our proprietary smart device, DNA medicine candidates or future development programs;
•expenses related to corporate transactions, including ones not fully completed;
•addition or termination of clinical trials or funding support;
•any intellectual property infringement lawsuit in which we may become involved;
•any legal claims that may be asserted against us or any of our officers;
•regulatory developments affecting our proprietary smart device and DNA medicine candidates or those of our competitors;
•debt service obligations;
•changes in the fair value of our investments, including investments in affiliated entities;
•our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and
•if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products.
If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.
Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions.
Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits.
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.
The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.
Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or
47

otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.
We incur significant costs and demands upon management as a result of being a public company.
As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.
Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.
Changes in tax laws could adversely affect our business and financial condition.
The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In December 2017, tax legislation commonly known as the Tax Cuts and Jobs Act was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or changes proposed or implemented by the current U.S. presidential administration or otherwise, could materially affect our tax obligations and effective tax rate.
The increasing use of social media platforms presents new risks and challenges.
Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public’s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.

48

ITEM 1B.    UNRESOLVED STAFF COMMENTS
None.
 
ITEM 2.    PROPERTIES
We own no real property and have no plans to acquire any real property in the future.
San Diego Leases
In April 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The term of the First San Diego Lease commenced on December 1, 2013. The initial term of the First San Diego Lease is ten years, with an option to extend the term by five years, subject to specified conditions. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. The commencement of the amended First San Diego Lease was in January 2016. As of December 31, 2022, rent payments under the First San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. We had an option to terminate the First San Diego Lease on December 1, 2019, which we did not exercise.
In October 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced on June 1, 2017. The initial term of the Second San Diego Lease is ten years, with a right to terminate on November 30, 2023, subject to specified conditions.
The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, 2022, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000.
Plymouth Meeting Lease
In March 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We occupied the space in June 2014. The initial term of the Plymouth Meeting Lease was 11.5 years, with a right to extend the term by five years, subject to specified conditions. We use the space for office purposes.
The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, 2022, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately 2 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $49,000. In July 2015, we amended the Plymouth Meeting Lease to increase the total leased space to 27,583 square feet.
In June 2017, we entered into another amendment to the Plymouth Meeting Lease to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029. In connection with this amendment, we paid the landlord an additional security deposit of $75,000.
In the fourth quarter of 2019, we entered into two agreements to sublease a total of approximately 13,500 square feet in our Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.
We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.

ITEM 3.    LEGAL PROCEEDINGS
Securities Litigation
Securities Class Action Litigation
On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our former President and Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants.
49

On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff’s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants’ motion to dismiss. The court granted Defendants’ motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants’ motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, we will pay $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers have paid the $30.0 million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement, and on January 18, 2023, the court entered an order granting final approval of the settlement, as set forth in a stipulation of settlement.
In February 2023, pursuant to the securities class action settlement, we issued 7,000,000 shares of common stock. Following the expiration of the appeal period or resolution of an appeal if one is filed, we will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. The number of shares will be calculated based on the average trading price of our common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.
Shareholder Derivative Litigation
On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v. Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.
On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.
On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.
VGXI Litigation
On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.
On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI’s counterclaims, disputing the allegations and the claims raised in VGXI’s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.
We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI’s counterclaims.
GeneOne Litigation
50

On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys’ fees, interest, and other relief from us. On January 29, 2021, we filed preliminary objections to the complaint. On August 23, 2021, the Court overruled our preliminary objections to the complaint. On September 13, 2021, we filed an answer to the complaint, new matter, and counterclaims. The Company’s counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney’s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne’s new matter. A trial date for this litigation has not been set.
We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne’s complaint.
ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.
51

PART II
 
ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange.
As of February 24, 2023, we had approximately 100 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
The closing price per share of our common stock on February 24, 2023 was $1.28, as reported on the Nasdaq Global Select Market.
Dividends
The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.
Performance Graph
The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2022. The graph assumes a $100 investment on December 31, 2017 in our common stock and in each index, with the reinvestment of all dividends, if any.
ino-20221231_g5.jpg
*$100 invested on 12/31/17 in stock or index, including reinvestment of dividends.
Fiscal year ended December 31.
52

12/1712/1812/1912/2012/2112/22
Inovio Pharmaceuticals, Inc.  100.00 96.85 79.90 214.29 120.82 37.77 
NYSE American100.00 82.80 91.24 86.80 111.40 107.09 
Nasdaq Composite100.00 97.16 132.81 192.47 235.15 158.65 
S&P SuperCap Biotechnology Index100.00 94.71 110.80 121.76 134.95 153.42 
The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Parties
None.

ITEM 6.    RESERVED
    


 


53

ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This report contains forward-looking statements, as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.
Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.
The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item 1A of Part I of this Annual Report under the caption “Risk Factors.”
Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary smart device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.

Overview
We are a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.
In clinical trials, our DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into cells using our investigational proprietary smart device, CELLECTRA.
Many of our lead candidates are focused on diseases associated with HPV. In 2022, we announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces our belief that DNA medicines may play a key role in the treatment of HPV-related diseases.
Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
54

We or our collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, our DNA medicines for Ebola HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head & neck, cervical, anal, penile, vulvar, and vaginal; other HPV-related disorders, such as RRP; and GBM.
All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.
As of December 31, 2022, we had an accumulated deficit of $1.5 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.
VGX-3100 Update
REVEAL2 is our second Phase 3 trial with VGX-3100. In April 2022, the trial protocol was amended to utilize a biomarker-selected population as the primary population, based on prior analysis of REVEAL1 results suggesting that this investigational biomarker had the potential to identify women more likely to respond to treatment with VGX-3100. We announced that this trial would no longer be considered to be a pivotal trial and would not lead to a BLA filing for a biomarker-selected population, as the FDA advised us that the biomarker-positive population would not be sufficient to support approval of a potential marketing application for VGX-3100. The FDA recommended using REVEAL2 as an exploratory trial and that conducting one or two additional well-controlled trials in the biomarker-selected population would be more likely to provide evidence to support approval of a marketing application.
Trial participants in REVEAL2 included 203 women, 18 years of age or older, who had histologically-confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. Participants received either VGX-3100 or placebo at 0, 4 and 12 weeks (randomized 2:1). The primary endpoint, as amended, was the percentage of biomarker-selected participants with regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix. A secondary endpoint was the percentage of all participants with regression and virologic clearance.
In March 2023, we announced data from our REVEAL2 trial. Statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance.
The percentage of participants in the investigational biomarker-selected population meeting the primary endpoint was 28.6% (6/21) in the treatment group, versus 0% (0/4) in the placebo group (p=0.115; difference in percentage 28.6, 95%CI: -24.6, 50.4), which was not statistically significant.
The result of the all-participants population of 203 participants (134 participants in the treatment group, 69 in the placebo group) was statistically significant, with 27.6% (37/134) of the participants meeting the endpoint in the treatment group, versus 8.7% (6/69) in the placebo group (p=0.001; difference in percentage 18.9, 95%CI: 7.8, 28.6).
In particular, in the all-participants population of REVEAL2, viral clearance was observed in 37.3% (50/134) in the treatment group versus 8.7% (6/69) in the placebo group. Given the importance of viral clearance in removing the underlying cause of the HPV-related diseases, this data may have positive implications in our other HPV-related programs.
An ad-hoc integrated efficacy analysis of the results for both REVEAL1 and REVEAL2 achieved statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. For the combined biomarker-selected population of 92 participants (68 participants in the treatment group, 24 in the placebo group), the percentage of participants meeting the primary endpoint was 54.4% (37/68 in the treatment group, versus 12.5% (3/24) in the placebo group (p=<0.001; difference in percentage 41.9, 95%CI: 20.4, 57.0). For the combined all-participants population of 404 participants (272 participants in the treatment group, 132 in the placebo group), the percentage of participants meeting the primary endpoint was 25.0% (68/272 in the treatment group, versus 9.8% (13/132) in the placebo group (p=<0.001; difference in percentage 15.2, 95%CI: 7.4, 22.1).
In both REVEAL1 and REVEAL2, VGX-3100 was well-tolerated. There were no treatment-related serious adverse events and most adverse events were considered to be mild to moderate.
This combined data set will be used as supportive data in future regulatory interactions involving VGX-3100. We will continue to evaluate the results to determine next steps for VGX-3100 in our HPV programs. We plan to submit the data for publication in a peer-reviewed journal later this year.
INO-4800 Update
55

On October 27, 2022, we announced that we have discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision was based on our assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines.
INO-4800 continues to be evaluated as part of the World Health Organization’s Solidarity Trial Vaccines and we continue preclinical development of a potential pan-COVID-19 vaccine candidate. In addition, our clinical collaborator Advaccine is continuing to develop INO-4800 as a potential COVID-19 heterologous booster vaccine in Greater China using its own resources.
Reductions in Force
On January 31, 2023, we committed to and communicated a corporate reorganization plan, including a reduction in force, or the Reduction. The purpose of the Reduction was to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, we reduced overall headcount by approximately 24 employees, which represented 11% of our full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. We expect to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services.
In the third quarter of 2022, we undertook a separate reorganization and reduced overall headcount by approximately 55 employees, which represented 18% of our full-time employees. We also terminated agreements with approximately 86% of our contractors. We incurred a one-time pre-tax charge of $1.6 million in the third quarter of 2022 related to these actions, consisting primarily of one-time severance payments upon termination, continued benefits and outplacement services.
Securities Class Action Settlement
In January 2023, the United States District Court for the Eastern District of Pennsylvania, or the Court, entered an order, or the Order, granting final approval for the settlement of the class action securities litigation described in this report under “Legal Proceedings.” The settlement includes $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers have paid the cash component of the settlement and we will therefore not incur any material cash expenses associated with the litigation, other than legal fees and related expenses, which were approximately $11.0 million through December 31, 2022.
In February 2023, pursuant to the securities class action settlement, we issued 7,000,000 shares of common stock. Following the expiration of the appeal period or resolution of an appeal if one is filed, we will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million.

Critical Accounting Policies and Estimates
The SEC defines critical accounting policies as those that are, in management’s view, important to the portrayal of our financial condition and results of operations and require management’s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S. GAAP. Our significant accounting policies are outlined in Note 2 to the consolidated financial statements included in this report.
The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements:
Collaboration Agreements and Revenue Recognition
We assess whether our collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and we conclude that our collaboration partner is not a customer, we present such payments as a reduction of research and development expense. If payments from our collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”).
We enter into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or
56

commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, we assess the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.
For collaboration arrangements that include license fees, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
For collaboration arrangements that include milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on our past experience with our collaboration partner, market insight and partner communication. Milestone payments that are not within our or our collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.
For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue in the period the underlying sales occur. To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.
Research and Development Expenses - Clinical Trial Accruals
Our activities have largely consisted of research and development efforts related to developing proprietary smart device technologies, DNA medicine candidates and dMABs. For clinical trial expenses, judgments used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations.

Recent Accounting Pronouncements
Information regarding recent accounting pronouncements is contained in Note 2 to the consolidated financial statements, included elsewhere in this report.

Results of Operations
The consolidated financial data for the years ended December 31, 2022, 2021 and 2020 is presented in the following table and the results of these periods are used in the discussion thereafter.
57

Year Ended December 31, Increase/(Decrease) 2022 vs. 2021Increase/(Decrease) 2021 vs. 2020
202220212020$%$%
Revenue from collaborative arrangements and other contracts, including affiliated entity
$10,262,268 $1,774,758 $7,411,220 $8,487,510 478 %$(5,636,462)(76)%
Operating expenses:
Research and development187,650,503 249,240,324 94,245,436 (61,589,821)(25)154,994,888 164 
General and administrative90,185,285 53,752,353 37,247,828 36,432,932 68 16,504,525 44 
Total operating expenses277,835,788 302,992,677 131,493,264 (25,156,889)(8)171,499,413 130 
Loss from operations(267,573,520)(301,217,919)(124,082,044)33,644,399 11 (177,135,875)(143)
Interest income4,782,030 3,363,080 3,311,846 1,418,950 42 51,234 2 
Interest expense(1,253,952)(1,936,447)(8,702,450)682,495 (35)6,766,003 (78)
Change in fair value of derivative liability— — (75,670,977)— *75,670,977 *
(Loss) gain on investment in affiliated entity(1,899,654)(553,570)36,556,658 (1,346,084)*(37,110,228)*
Net unrealized (loss) gain on available-for-sale equity securities(7,846,172)(3,222,838)1,695,497 (4,623,334)*(4,918,335)*
Other (expense) income, net(3,861,584)343,371 (704,896)(4,204,955)*1,048,267 *
Gain on deconsolidation of Geneos— — 4,121,075 — *(4,121,075)*
Loss on extinguishment of convertible bonds— — (8,177,043)— *8,177,043 *
Gain on extinguishment of convertible senior notes— — 8,762,030 — *(8,762,030)*
Net loss before share in net loss of Geneos(277,652,852)(303,224,323)(162,890,304)25,571,471 8 (140,334,019)(86)
Share in net loss of Geneos(2,165,213)(434,387)(4,584,610)(1,730,826)*4,150,223 *
Net loss(279,818,065)(303,658,710)(167,474,914)23,840,645 (8)(136,183,796)81 
Net loss attributable to non-controlling interest— — 1,063,757 — *(1,063,757)(100)
Net loss attributed to Inovio Pharmaceuticals, Inc.$(279,818,065)$(303,658,710)$(166,411,157)$23,840,645 8 %$(137,247,553)(82)%

*Not meaningful
Comparison of Years Ended December 31, 2022 and 2021
Revenue
Revenue was primarily derived under collaborative arrangements and contracts, including arrangements with affiliated entities, for the years ended December 31, 2022 and 2021. The $8.5 million increase in revenue was primarily due to higher revenue earned from our Procurement Contract with the DoD.
Research and Development Expenses
Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.
Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
58

The following tables summarize our research and development expense by product candidate for the years ended December 31, 2022 and 2021:
 Years Ended December 31,Increase (Decrease)
(dollars in thousands)20222021$%
INO-4800 and other Covid-19$93,464 $109,587 $(16,123)(15)%
VGX-310015,989 30,873 (14,884)(48)
INO-31078,133 9,109 (976)(11)
INO-5401 and other Immuno-oncology2,775 2,404 371 15 
Other research and development programs6,227 4,442 1,785 40 
Engineering and device-related 25,187 47,889 (22,702)(47)
Stock-based compensation9,059 13,378 (4,319)(32)
Other unallocated expenses26,817 31,558 (4,741)(15)
Research and development expense$187,651 $249,240 $(61,589)(25)%

The $61.6 million overall decrease in research and development expenses year over year was primarily the result of:
•$45.9 million in lower drug manufacturing and outside services related to INO-4800;
•$21.9 million of costs related to the acquisition and installation of manufacturing equipment for INO-4800 during 2021 that did not recur in 2022;
•$15.6 million in lower engineering services and expensed equipment related to our CELLECTRA 3PSP device and array automation project;
•$11.8 million in lower clinical study, outside services and immunology expenses related to VGX-3100;
•$4.9 million in lower expensed inventory related to the CELLECTRA 2000 device; and
•$4.6 million in lower employee stock-based compensation primarily from lower weighted average grant date fair values for the awards granted during 2022.
These decreases were partially offset by:
•$29.2 million of lower contra-research and development expense recorded from grant agreements; and
•$14.4 million of increased drug manufacturing costs related to our COVID-19 variant studies and DARPA COVID-19 dMAb grant.
Contributions received from current grant agreements and recorded as contra-research and development expense were $24.5 million and $53.7 million for the years ended December 31, 2022 and 2021, respectively. The decrease year over year was primarily due to decreases of $21.0 million, $5.8 million, $3.3 million and $3.2 million earned under the DoD 3PSP device development grant, CEPI grants related to INO-4800 and device development activities, reimbursements from Advaccine and the CEPI Lassa and MERS grant, respectively. These decreases were offset by an increase of $5.3 million, earned primarily under the sub-grant through Wistar for DARPA COVID-19 dMAb.
General and Administrative Expenses
General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $90.2 million for the year ended December 31, 2022 as compared to $53.8 million in 2021. The $36.4 overall increase year over year was primarily the result of:
•$44.0 million related to the class action securities litigation settlement, which was reduced by $30.0 million of insurance recoveries, resulting in a net $14.0 million expense, which is the value of our common stock to be issued in connection with the settlement;
•$14.3 million in higher legal expenses, primarily related to litigation matters;
•$6.9 million in severance expenses related to the separation of our former President and Chief Executive Officer in May 2022, including $4.2 million of stock-based compensation expense related to equity award modifications (see Note 10 to our consolidated financial statements included in this report for additional information); and
•$1.6 million in overall higher employee compensation.
Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period. Total employee stock-based compensation cost for the
59

years ended December 31, 2022 and 2021 was $22.2 million and $25.0 million, of which $8.8 million and $13.4 million was included in research and development expenses and $13.4 million and $11.6 million was included in general and administrative expenses, respectively.
Interest Income
The $1.4 million increase in interest income for the year ended December 31, 2022 as compared to 2021 was primarily due to higher interest rates.
Interest Expense
The $682,000 decrease in interest expense for the year ended December 31, 2022 as compared to 2021 was primarily due to lower non-cash interest expense related to the $78.5 million aggregate principal amount of our 6.50% convertible senior notes due 2024 as a result of the adoption of ASU‑2020-06, and no interest expense recorded on the convertible promissory notes issued in December 2019 due to their full conversion into shares of our common stock in March 2021.
Loss on Investment in Affiliated Entity
The loss on investment in affiliated entity resulted from the declines in the fair market value of our investment in PLS of $1.9 million and $554,000 for the years ended December 31, 2022 and 2021, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.
Net Unrealized Loss on Available-for-Sale Equity Securities
The net unrealized loss on available-for-sale equity securities for the years ended December 31, 2022 and 2021 was $7.8 million and $3.2 million, respectively, which resulted from a change in the fair market value of the investments.
Share in Net Loss of Geneos
The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020.
Income Taxes
Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December 31, 2022, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. We also had U.S. federal and state research and development tax credits of $40.5 million and $4.7 million, respectively, net of the federal research and development credits that will expire due to IRC Section 383 limitations. The net operating losses and credits began to expire during 2022.

Comparison of Years Ended December 31, 2021 and 2020
For a comparison of the years ended December 31, 2021 and 2020, you may refer to Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.

Liquidity and Capital Resources
Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities for the advancement of DNA medicine candidates. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.
Working Capital and Liquidity
As of December 31, 2022, we had cash and short-term investments of $253.0 million and working capital of $218.4 million, as compared to $401.3 million and $382.7 million as of December 31, 2021, respectively.
Cash Flows
Operating Activities
Net cash used in operating activities was $216.2 million and $215.7 million for the years ended December 31, 2022 and 2021, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.
Investing Activities
60

Net cash provided by (used in) investing activities was $109.6 million and $(175.3) million for the years ended December 31, 2022 and 2021, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.
Financing Activities
Net cash provided by financing activities was $81.8 million and $211.5 million for the years ended December 31, 2022 and 2021, respectively. The variance was primarily due to the proceeds from the January 2021 underwritten public offering, partially offset by an increase in the proceeds from the sale of common stock under the Sales Agreement (defined below) in 2022 compared to 2021.
Issuances of Common Stock
On November 9, 2021, we entered into an ATM Equity OfferingSM Sales Agreement (the “Sales Agreement”) with outside sales agents (collectively, the “Sales Agents”) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.
Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an “at the market offering”. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During the year ended December 31, 2022, we sold 34,445,743 shares of common stock under the Sales Agreement for aggregate net proceeds of $83.0 million. During the year ended December 31, 2021, we sold 6,955,341 shares of common stock under the Sales Agreement for aggregate net proceeds of $47.7 million.
During the year ended December 31, 2020, we sold 66,064,887 shares of common stock for aggregate net proceeds of $454.5 million under previous ATM sales agreements.
On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1 million.
During the year ended December 31, 2022, stock options to purchase 118,694 shares of common stock were exercised for aggregate net proceeds of $283,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $1.4 million. During the year ended December 31, 2021, stock options to purchase 1,310,263 shares of common stock were exercised for aggregate net proceeds of $6.7 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.6 million. During the year ended December 31, 2020, stock options to purchase 2,178,252 shares of common stock were exercised for aggregate net proceeds of $12.3 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.0 million.
Funding Requirements
As of December 31, 2022, we had an accumulated deficit of $1.5 billion and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources, including amounts that we may be able to obtain through sales of common stock under our “at the market” equity facility, will not be sufficient to complete the clinical development of any of our product candidates, and we anticipate that additional financing will be required in order to commercialize and generate revenues from the sale of any product candidates that receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report.
As described above, in January 2023 and July 2022, we undertook corporate reorganization plans to decrease our expenses, extend our cash runway, and maintain a streamlined organization to support key clinical programs that we expect to drive our long-term growth. Also, in October 2022, we announced that we have discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. We expect these actions to reduce our operating expenses incrementally and extend our cash runway into the first quarter of 2025, without giving effect to any further capital raising activities, whether under the Sales Agreement or otherwise.
Contractual Obligations
61

As of December 31, 2022, future minimum payments due under our contractual obligations are set forth in the table below. We expect to be able to satisfy these obligations, both in the short-term and in the longer-term, with cash on hand and proceeds from sales of our common stock under the Sales Agreement.
Payments Due by Period
TotalLess than
1 year		1 – 3 years3 – 5 yearsMore than
5 years
Convertible senior notes (1)$18,015,000 $1,067,000 $16,948,000 $— $— 
Operating lease obligations (2)$20,090,000 $4,089,000 $6,113,000 $5,665,000 $4,223,000 
Manufacturing commitments (3)$11,515,000 $11,515,000 $— $— $— 

(1) Amounts represent remaining contractual amounts due under our Notes, including interest based on the fixed rate of 6.5% per year. Although these Notes mature in March 2024, they may be converted into shares of our common stock prior to maturity if certain conditions are met. We may also redeem the Notes prior to their maturity if certain conditions are met. Any redemption prior to maturity would result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See Note 9, Convertible Debt, to the consolidated financial statements in this report for additional information.
(2) We have entered into operating leases for our facilities, which expire from 2023 to 2029, and operating leases for office equipment, which expire in 2024. In the fourth quarter of 2019, we entered into two subleases for a portion of our Plymouth Meeting corporate headquarters facility with one period through March 31, 2025 and the other month-to-month after December 31, 2022. As of December 31, 2022, we expect to receive aggregate future minimum lease payments totaling $434,000 (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above. 
(3) Remaining purchase obligations from supply agreements with contract manufacturers.
In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.
 

ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During the year ended December 31, 2022, there was a pronounced increase in prevailing interest rates in the United States, which contributed to a loss of $7.8 million in the market value of our investment portfolio during the period.
The interest rate on our indebtedness is fixed and not subject to fluctuations in interest rates.
Foreign Currency Risk
We have operated primarily in the United States and most transactions during the year ended December 31, 2022 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars.
Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.
We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes.
62

Inflation Risk
Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent months, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the year ended December 31, 2022.

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this Item 8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page F-1 of this report.
 
ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
 
ITEM 9A.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures.
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) were effective as of December 31, 2022 at the reasonable assurance level.
Internal Control Over Financial Reporting
Management’s Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.
As of December 31, 2022, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in “Internal Control—Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December 31, 2022.
This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit smaller reporting companies to provide only management’s report in this Annual Report.
Changes in Internal Control over Financial Reporting
63

There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December 31, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
64

ITEM 9B.     OTHER INFORMATION
Not applicable.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
PART III
 
ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item 10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation 14A within 120 days after the end of our 2022 fiscal year, under the captions “Election of Directors” and “Executive Officers and Other Information.”
 
ITEM 11.    EXECUTIVE COMPENSATION
The information required by this Item 11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation 14A within 120 days after the end of our 2022 fiscal year, under the captions “Compensation Discussion and Analysis,” “Executive Compensation,” “Compensation of Directors” and “Director Compensation Table.”
 
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item 12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation 14A within 120 days after the end of our 2022 fiscal year, under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information.”
 
ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Director independence and other information required by this Item 13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation 14A within 120 days after the end of our 2022 fiscal year, under the captions “Certain Relationships and Related Party Transactions” and “Election of Directors.”
 
ITEM 14.    PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this Item 14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation 14A within 120 days after the end of our 2022 fiscal year, under the caption “Ratification of Appointment of Registered Public Accounting Firm.”


65

PART IV
 
ITEM 15.    EXHIBITS, FINANCIAL STATEMENT SCHEDULES
1.Financial Statements
Consolidated financial statements required to be filed hereunder are indexed on Page F-1 hereof.
2.Financial Statement Schedules 
Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.
3.Exhibits
The following exhibits are filed as part of this annual report on Form 10-K:
Exhibit
Number
Description of Document
66

67

68

101.INS
XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Designates management contract, compensatory plan or arrangement.
†Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.
††
Certain confidential portions of this exhibit (indicated by asterisks) were omitted because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential.
^These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

ITEM 16.    FORM 10-K SUMMARY

Not applicable.


69

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 1, 2023.
 
Inovio Pharmaceuticals, Inc.
By:/s/ JACQUELINE E. SHEA
Jacqueline E. Shea
President, Chief Executive Officer and Director (On Behalf of the Registrant)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline E. Shea and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form 10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
SignatureTitleDate
/s/ JACQUELINE E. SHEAPresident, Chief Executive Officer and Director (Principal Executive Officer)March 1, 2023
Jacqueline E. Shea
/s/    SIMON X. BENITOChairman of the Board of DirectorsMarch 1, 2023
Simon X. Benito
/s/    PETER KIESChief Financial Officer (Principal Accounting Officer and Principal Financial Officer)March 1, 2023
Peter Kies
/s/ ROGER D. DANSEYDirectorMarch 1, 2023
Roger D. Dansey
/s/ ANN C. MILLERDirectorMarch 1, 2023
Ann C. Miller
/s/    JAY SHEPARDDirectorMarch 1, 2023
Jay Shepard
/s/    DAVID B. WEINERDirectorMarch 1, 2023
David B. Weiner
/s/    WENDY L. YARNODirectorMarch 1, 2023
Wendy L. Yarno
/s/    LOTA S. ZOTHDirectorMarch 1, 2023
Lota S. Zoth

70

INOVIO PHARMACEUTICALS, INC.
Index to Consolidated Financial Statements
 

F-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Inovio Pharmaceuticals, Inc.
Opinion on the Financial Statements
We have audited the consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

F-2

Accrual of Clinical Trial Expenses
Description of the Matter
During 2022, the Company incurred $187.7 million for research and development expenses and as of December 31, 2022 accrued $10.6 million for clinical study costs. A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (“CROs”). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements.

Auditing management’s accounting for accrued clinical study costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.


How We Addressed the Matter in our Audit
We obtained an understanding of the accounting for accrued clinical trial expenses including management’s process for measuring estimated accrued clinical study costs such as patient enrollment and total cost incurred to date from third-parties.

To test the completeness of the Company’s accrued clinical trial expenses, we obtained from third-parties confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management’s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.


/s/ Ernst & Young LLP
We have served as the Company's auditor since 2002.
San Diego, California
March 1, 2023



F-3


Inovio Pharmaceuticals, Inc.
CONSOLIDATED BALANCE SHEETS
 December 31,
 20222021
ASSETS
Current assets:
Cash and cash equivalents$46,329,359 $71,143,778 
Short-term investments206,669,397 330,170,940 
Accounts receivable1,701,726 5,466,850 
Accounts receivable from affiliated entities10,036,490 2,565,194 
Prepaid expenses and other current assets50,130,481 38,836,991 
Prepaid expenses and other current assets from affiliated entities375,227 261,192 
Total current assets315,242,680 448,444,945 
Fixed assets, net7,727,997 17,453,206 
Investments in affiliated entity 2,007,142 3,906,796 
Intangible assets, net2,129,861 2,626,355 
Goodwill10,513,371 10,513,371 
Operating lease right-of-use assets10,228,207 11,571,026 
Other assets684,044 1,425,794 
Total assets$348,533,302 $495,941,493 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses$79,686,885 $47,644,530 
Accounts payable and accrued expenses due to affiliated entities1,220,439 548,032 
Accrued clinical trial expenses10,594,073 10,326,266 
Deferred revenue— 21,628 
Operating lease liability2,803,973 2,603,956 
Grant funding liability2,475,031 4,559,721 
Grant funding liability from affiliated entities87,673 37,500 
Total current liabilities96,868,074 65,741,633 
Deferred revenue, net of current portion— 64,361 
Convertible senior notes16,614,840 14,959,647 
Operating lease liability, net of current portion12,655,586 15,459,559 
Deferred tax liabilities32,046 32,046 
Other liabilities— 14,826 
Total liabilities126,170,546 96,272,072 
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021
— — 
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021
253,090 217,382 
Additional paid-in capital1,710,656,191 1,609,589,797 
Accumulated deficit(1,487,847,784)(1,209,855,522)
Accumulated other comprehensive loss(698,741)(282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity222,362,756 399,669,421 
Total liabilities and stockholders’ equity$348,533,302 $495,941,493 
The accompanying notes are an integral part of these consolidated financial statements.
F-4

Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS 
 For the Year ended December 31,
 202220212020
Revenue from collaborative arrangements and other contracts, including affiliated entity$10,262,268 $1,774,758 $7,411,220 
Operating expenses:
Research and development187,650,503 249,240,324 94,245,436 
General and administrative90,185,285 53,752,353 37,247,828 
Total operating expenses277,835,788 302,992,677 131,493,264 
Loss from operations(267,573,520)(301,217,919)(124,082,044)
Other income (expense):
Interest income4,782,030 3,363,080 3,311,846 
Interest expense(1,253,952)(1,936,447)(8,702,450)
Change in fair value of derivative liability— — (75,670,977)
(Loss) gain on investment in affiliated entities(1,899,654)(553,570)36,556,658 
Net unrealized (loss) gain on available-for-sale equity securities(7,846,172)(3,222,838)1,695,497 
Other (expense) income, net(3,861,584)343,371 (704,896)
Gain on deconsolidation of Geneos— — 4,121,075 
Loss on extinguishment of convertible bonds— — (8,177,043)
Gain on extinguishment of convertible senior notes— — 8,762,030 
Net loss before share in net loss of Geneos(277,652,852)(303,224,323)(162,890,304)
Share in net loss of Geneos(2,165,213)(434,387)(4,584,610)
Net loss(279,818,065)(303,658,710)(167,474,914)
Net loss attributable to non-controlling interest— — 1,063,757 
Net loss attributable to Inovio Pharmaceuticals, Inc.$(279,818,065)$(303,658,710)$(166,411,157)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
      Basic and diluted$(1.17)$(1.45)$(1.07)
Weighted average number of common shares outstanding
      Basic and diluted238,622,188 208,829,801 155,126,857 
The accompanying notes are an integral part of these consolidated financial statements.

F-5


Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 
 For the Year ended December 31,
 202220212020
Net loss$(279,818,065)$(303,658,710)$(167,474,914)
Other comprehensive (loss) income:
     Foreign currency translation(25,556)(30,134)27,205 
    Unrealized (loss) gain on short-term investments, net of tax(390,949)4,048 (755,963)
Comprehensive loss$(280,234,570)$(303,684,796)$(168,203,672)
      Comprehensive loss attributable to non-controlling interest— — 1,063,757 
Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.$(280,234,570)$(303,684,796)$(167,139,915)

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
 Preferred stockCommon stockAdditional
paid-in
capital		Accumulated
deficit		Accumulated
other
comprehensive
income (loss)		Non-
controlling
interest		Total
stockholders’
equity
 Number
of shares		AmountNumber
of shares		Amount
Balance at December 31, 201923 — 101,361,034 $101,361 $742,646,785 $(739,785,655)$472,608 $1,969,759 $5,404,858 
Issuance of common stock for cash, net of financing costs— — 66,064,886 66,065 454,420,335 — — — 454,486,400 
Conversion of preferred stock to common stock(14)— 5,147 5 (5)— — — — 
Conversion of senior notes to common stock— — 11,535,660 11,536 43,682,850 — — — 43,694,386 
Conversion of August 2019 Bonds to common stock— — 4,962,364 4,961 102,666,349 — — — 102,671,310 
Exercise of stock options for cash and vesting of RSUs, net of tax payments— — 2,922,402 2,923 8,238,701 — — — 8,241,624 
Stock-based compensation— — — — 15,655,585 — — (8,062)15,647,523 
Acquisition of non-controlling interest in Geneos, net— — — — — — — 2,379,969 2,379,969 
Deconsolidation of Geneos— — — — — — — (3,181,640)(3,181,640)
Net loss attributable to common stockholders— — — — — (166,411,157)— (1,063,757)(167,474,914)
Dissolution of majority-owned subsidiary VGX Animal Health, Inc.— — — — 96,269 — — (96,269)— 
Unrealized loss on short-term investments, net of tax— — — — — — (755,963)— (755,963)
Foreign currency translation— — — — — — 27,205 — 27,205 
Balance at December 31, 20209 — 186,851,493 $186,851 $1,367,406,869 $(906,196,812)$(256,150)$— $461,140,758 
Issuance of common stock for cash, net of financing costs— — 27,310,341 27,310 209,414,100 — — — 209,441,410 
Conversion of December 2019 Bonds to common stock— — 1,009,450 1,009 4,376,883 — — — 4,377,892 
Exercise of stock options for cash and vesting of RSUs, net of tax payments— — 2,211,603 2,212 2,055,181 — — — 2,057,393 
Stock-based compensation— — — — 26,336,764 — — — 26,336,764 
Net loss — — — — — (303,658,710)— — (303,658,710)
Unrealized gain on short-term investments, net of tax— — — — — — 4,048 — 4,048 
Foreign currency translation— — — — — — (30,134)— (30,134)
Balance at December 31, 20219 — 217,382,887 $217,382 $1,609,589,797 $(1,209,855,522)$(282,236)$— $399,669,421 
Cumulative adjustment from adoption of ASU 2020-06— — — — (3,294,019)1,825,803 — — (1,468,216)
Issuance of common stock for cash, net of financing costs— — 34,445,743 34,447 82,920,864 — — — 82,955,311 
Exercise of stock options for cash and vesting of RSUs, net of tax payments— — 1,262,689 1,261 (1,115,870)— — — (1,114,609)
Stock-based compensation— — — — 22,555,419 — — — 22,555,419 
Net loss— — — — — (279,818,065)— — (279,818,065)
Unrealized loss on short-term investments, net of tax— — — — — — (390,949)— (390,949)
Foreign currency translation— — — — — — (25,556)— (25,556)
Balance at December 31, 20229 $— 253,091,319 $253,090 $1,710,656,191 $(1,487,847,784)$(698,741)$— $222,362,756 

The accompanying notes are an integral part of these consolidated financial statements.
F-7
Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS

 For the Year ended December 31,
 202220212020
Cash flows from operating activities:
Net loss$(279,818,065)$(303,658,710)$(167,474,914)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation3,656,713 3,040,096 3,038,996 
Amortization of intangible assets496,494 520,415 547,081 
Amortization of operating lease right-of-use assets1,342,819 1,170,270 1,041,713 
Change in fair value of derivative liability— — 75,670,977 
Non-cash stock-based compensation22,555,419 26,336,764 15,647,523 
Non-cash interest expense186,977 858,644 4,077,686 
Amortization of (discounts) premiums on investments(1,320,546)1,633,286 — 
Loss on short-term investments4,029,961 5,397 588,270 
Settlement of receivable with shares of common stock from affiliated entity (PLS)— — (1,713,770)
Gain on deconsolidation of Geneos— — (4,121,075)
Gain on remeasurement of investment in Geneos(165,215)— — 
Loss on disposal of fixed assets1,074,830 — 26,913 
Loss (gain) on equity investment in affiliated entities1,899,654 553,570 (36,556,658)
Share of net loss in Geneos2,165,213 434,387 4,584,610 
Loss on extinguishment of convertible August 2019 bonds— — 8,177,043 
Gain on extinguishment of convertible senior notes— — (8,762,030)
Net unrealized loss (gain) on available-for-sale equity securities7,846,172 3,222,838 (1,695,497)
Unrealized transaction (gain) loss on foreign-currency denominated debt— (176,927)15,902 
Changes in operating assets and liabilities:
Accounts receivable, including from affiliated entities(3,706,172)11,031,705 (17,015,471)
Prepaid expenses and other current assets, including from affiliated entities(5,336,525)(6,343,632)(38,475,465)
Other assets741,750 24,531,654 (23,285,424)
Accounts payable and accrued expenses, including from affiliated entities32,606,581 26,140,970 3,251,478 
Accrued clinical trial expenses267,807 375,921 5,962,381 
Deferred revenue, including from affiliated entity(85,989)(39,853)(62,353)
Operating lease right-of-use assets and liabilities, net(2,603,956)(2,329,394)(2,091,855)
Grant funding liability, including from affiliated entity(2,034,517)(2,973,089)624,173 
Other liabilities(14,826)(42,837)20,720 
Net cash used in operating activities(216,215,421)(215,708,525)(177,979,046)
Cash flows from investing activities:
Purchases of investments(248,528,843)(348,953,236)(156,216,677)
Proceeds from sale of or maturity of investments361,083,850 174,839,758 62,991,023 
Purchases of capital assets(969,153)(1,231,006)(1,520,665)
Proceeds from sale of investment of GeneOne— — 40,125,418 
Decrease in cash resulting from the deconsolidation of Geneos— — (2,774,851)
Investment in Geneos(1,999,998)— (1,399,999)
Net cash provided by (used in) investing activities109,585,856 (175,344,484)(58,795,751)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs82,955,311 209,441,410 454,486,400 
Proceeds from stock option exercises283,022 6,668,741 12,269,801 
Taxes paid related to net share settlement of equity awards(1,397,631)(4,611,348)(4,028,177)
Acquisition of non-controlling interest— — 2,379,969 
Proceeds from Geneos issuance of note payable— — 171,620 
Net cash provided by financing activities81,840,702 211,498,803 465,279,613 
       Effect of exchange rate changes on cash and cash equivalents(25,556)(30,134)27,205 
(Decrease) increase in cash and cash equivalents(24,814,419)(179,584,340)228,532,021 
Cash and cash equivalents, beginning of period71,143,778 250,728,118 22,196,097 
Cash and cash equivalents, end of period$46,329,359 $71,143,778 $250,728,118 
Supplemental disclosure:
Amounts accrued for purchases of property and equipment$108,181 $204,815 $136,711 
Interest paid$1,066,975 $1,077,803 $4,624,764 
Change in prepaid expenses and other current assets related to fixed assets$6,071,000 $7,709,337 $— 

The accompanying notes are an integral part of these consolidated financial statements.
F-8

Inovio Pharmaceuticals, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. The Company
Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company’s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.
In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA.
INOVIO's lead candidates are focused on diseases associated with HPV. In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases.
The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head & neck; other HPV-related disorders, such as RRP; and GBM.
INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.

2. Summary of Significant Accounting Policies

Basis of Presentation and Liquidity
The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December 31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December 31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company’s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.
In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0 million, $47.7 million and $454.5 million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1 million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Company also issued convertible notes and bonds in a series of private placement transactions. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.
The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of
F-9

liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.
The Company is and, from time to time, may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition.
Consolidation
The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.
The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.
Fair Value of Financial Instruments
The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company’s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.
Cash and Cash Equivalents
Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December 31, 2022 and 2021.
Short-term Investments
The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company’s affiliated entity, PLS, at December 31, 2022 and 2021.
F-10

Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.
Accounts Receivable
Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December 31, 2022 and 2021.
Fixed Assets
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.
Long-Lived Assets
All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December 31, 2022.
Valuation of Intangible Assets and Goodwill
Intangible assets are amortized over their estimated useful lives ranging from two to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.
License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2022 and 2021, the Company’s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1 million and $2.6 million, respectively.
The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2022.
Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.
Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company
F-11

cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. See Note 8 for further discussion of the Company’s goodwill and intangible assets.
Income Taxes
The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
Valuation allowances against the Company’s deferred tax assets were $299.1 million and $237.2 million at December 31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.
Revenue Recognition
The Company recognizes revenue, in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Collaborative Arrangements
The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.
The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.
As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
License Fees
If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
F-12

Product Supply Services
Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer.
Milestone Payments
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.
Grants
The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.
Foreign Currency Transactions
The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.
Variable Interest Entities (VIE)
The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.
Equity Investments
Under ASC Topic 321, Investments - Equity Securities, the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, Fair Value Measurement, to estimate fair value using the net asset value per share (or its equivalent). The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. 
F-13

Research and Development Expenses
The Company’s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.
Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.
Net Loss Per Share
Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.
The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:
Year Ended December 31,
202220212020
Options to purchase common stock12,221,548 10,488,993 8,906,624 
Service-based restricted stock units2,556,257 2,448,868 2,558,052 
Performance-based restricted stock units111,941 663,353 663,353 
Convertible preferred stock3,309 3,309 3,309 
Convertible notes3,049,980 3,049,980 3,049,980 
December 2019 Bonds— — 1,009,450 
Total17,943,035 16,654,503 16,190,768 

Leases
For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.
Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.
Stock-Based Compensation
The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the
F-14

date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.
The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate2.05%0.91%0.63%
Expected volatility94%93%78%
Expected life in years5.766
Dividend yield———

The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate1.96%1.45%0.82%
Expected volatility87%87%76%
Expected life in years101010
Dividend yield———

Recent Accounting Pronouncements
The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
ASU No. 2020-06. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8 million, a decrease in additional paid-in capital of $3.3 million, and an increase in convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5 million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).

3. Revenue Recognition and Concentration of Credit Risk
During the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:

F-15

Customer2022 Revenue% of Total
Revenue		2021 Revenue% of Total
Revenue		2020 Revenue% of Total
Revenue
Advaccine$— — %$— — %$5,000,000 68 %
Plumbline Life Sciences, Inc. (affiliated entity)33,596 — 245,310 14 1,370,396 18 
U.S. Department of Defense9,591,778 94 754,853 43 — — 
All other, including affiliated entities636,894 6 774,595 43 1,040,824 14 
Total revenue$10,262,268 100 %1$1,774,758 100 %1$7,411,220 100 %

Of the total revenue recognized during the year ended December 31, 2022, $14,000 was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $46,000 that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date.
As of December 31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December 31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

4. Collaborative Agreements
Advaccine Biopharmaceuticals Suzhou Co., Ltd.
On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), which was amended and restated on June 7, 2021 (as amended and restated, the “Advaccine Agreement”). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company’s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as “Greater China”) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company’s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.
The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company’s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company’s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.
Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0 million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0 million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine’s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.
Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5 million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.
Under the Advaccine Agreement, the Company will supply Advaccine’s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine’s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.
F-16

The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months’ written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months’ written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.
The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0 million upfront payment received in January 2021 plus a $2.0 million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.
Under Topic 606, the entire transaction price of $5.0 million was allocated to the license performance obligation. The Company recognized $0, $0 and $5.0 million of revenue for the years ended December 31, 2022, 2021, and 2020, respectively, under the Advaccine Agreement.
In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured. During the years ended December 31, 2022, 2021 and 2020 the Company received funding of $1.2 million, $4.5 million and $0, respectively, from Advaccine that was recorded as contra-research and development expense.
ApolloBio Corporation
On December 29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"), with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, its DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories.
The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the ApolloBio Agreement. In the event that VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio’s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory.
The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.
For the years ended December 31, 2022, 2021 and 2020, there has been no significant reimbursable program costs under the ApolloBio Agreement.
Coalition for Epidemic Preparedness Innovations
F-17

The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December 31, 2022, 2021 and 2020, the Company received funding of $6.7 million, $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December 31, 2022 and 2021, the Company had an accounts receivable balance of $1.7 million and $1.9 million, respectively, on the consolidated balance sheet related to these CEPI grants.
In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.
In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the years ended December 31, 2022, 2021 and 2020, the Company received funding of $1.1 million, $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December 31, 2022 and 2021, the Company had $2.3 million and $1.8 million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively
Bill & Melinda Gates Foundation
In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $233,000, $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December 31, 2022 and 2021, the Company had $153,000 and $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.
In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $0, $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant.
Department of Defense (DoD)
In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the “OTA Agreement”) with the DoD to fund the Company’s efforts in developing the CELLECTRA® 3PSP device and associated arrays to be used for delivery of INO-4800 against COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5 million. The Company determined that the OTA Agreement should be considered under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $6.1 million, $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement
Additionally, in June 2020, the Company was awarded a fixed-price contract (the “Procurement Contract”) from the DoD for the purchase of the Company’s intradermal CELLECTRA® 2000 device and accessories. The total purchase price under the Procurement Contract was $16.8 million. The Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA® 2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7 million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended December 31, 2022, 2021
F-18

and 2020, the Company recorded revenue of $9.6 million, $755,000 and $0, respectively, from the Procurement Contract.

5. Short-term Investments and Fair Value Measurements
The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:
 
 As of December 31, 2022
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$117,036,232 $— $(9,373,514)$107,662,718 
U.S. treasury securities
Less than 1
95,001,209 7,567 (44,266)94,964,510 
Certificates of deposit
Less than 1
2,977,564 13,664 (320)2,990,908 
U.S. agency mortgage-backed securities*1,435,592 — (384,331)1,051,261 
$216,450,597 $21,231 $(9,802,431)$206,669,397 
 As of December 31, 2021
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$192,966,772 $87,069 $(1,614,411)$191,439,430 
U.S. treasury securities
Less than 1
94,193,441 — (9,921)94,183,520 
Commercial paper
Less than 1
39,967,853 — — 39,967,853 
Certificates of deposit
Less than 1
2,976,210 15,618 (338)2,991,490 
U.S. agency mortgage-backed securities*1,608,137 4,508 (23,998)1,588,647 
$331,712,413 $107,195 $(1,648,668)$330,170,940 

*No single maturity date.

During the years ended December 31, 2022 and 2021, the Company recorded gross realized gain on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8 million and $3.2 million, respectively. No material balances were reclassified out of accumulated other comprehensive loss for the years ended December 31, 2022, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December 31, 2022, the Company had 29 available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months.
The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were primarily due to changes in interest rates, and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December 31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.
The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:
 
F-19

Fair Value Measurements at
 December 31, 2022
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
    Mutual funds$107,662,718 $107,662,718 $— $— 
    U.S. treasury securities94,964,510 94,964,510 — — 
    Certificates of deposit2,990,908 — 2,990,908 — 
    U.S. agency mortgage-backed securities1,051,261 — 1,051,261 — 
Total short-term investments206,669,397 202,627,228 4,042,169 — 
Investment in affiliated entity2,007,142 2,007,142 — — 
Total assets measured at fair value$208,676,539 $204,634,370 $4,042,169 $— 

The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:
 
Fair Value Measurements at
 December 31, 2021
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
     Mutual funds$191,439,430 $191,439,430 $— $— 
     U.S. treasury securities94,183,520 94,183,520 — — 
     Commercial paper39,967,853 — 39,967,853 — 
     Certificates of deposit2,991,490 — 2,991,490 — 
     U.S. agency mortgage-backed securities1,588,647 — 1,588,647 — 
Total short-term investments330,170,940 285,622,950 44,547,990 — 
Investments in affiliated entity3,906,796 3,906,796 — — 
Total assets measured at fair value$334,077,736 $289,529,746 $44,547,990 $— 

Level 1 assets at December 31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company’s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain or loss on available-for-sale equity securities or as a gain or loss on investment in affiliated entity.
Level 2 assets at December 31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December 31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the
F-20

service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.
There were no Level 3 assets held as of December 31, 2022 and 2021.

6. Certain Balance Sheet Items
Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following:
 
20222021
Insurance recovery (a)$30,000,000 $— 
Prepaid manufacturing expenses1,401,028 27,474,159 
Other prepaid expenses18,729,453 11,362,832 
$50,130,481 $38,836,991 
Accounts payable and accrued expenses at December 31, 2022 and 2021 consisted of the following:
20222021
Trade accounts payable$19,862,487 $27,424,743 
Accrued compensation12,574,921 16,112,912 
Accrued litigation settlement (a)44,000,000 — 
Other accrued expenses3,249,477 4,106,875 
$79,686,885 $47,644,530 

(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under “Legal Proceedings.” The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0 million in cash and $14.0 million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.


7. Fixed Assets
Fixed assets at December 31, 2022 and 2021 consisted of the following:
 
CostAccumulated
Depreciation
and
Amortization		Net Book
Value
As of December 31, 2022
Leasehold improvements$15,803,108 $(10,036,080)$5,767,028 
Research and development equipment5,300,104 (4,295,217)1,004,887 
Office furniture and fixtures2,827,476 (2,803,800)23,676 
Computer equipment and other 5,360,712 (4,428,306)932,406 
$29,291,400 $(21,563,403)$7,727,997 
As of December 31, 2021
Leasehold improvements$15,803,108 $(8,258,608)$7,544,500 
Research and development equipment12,392,916 (4,279,816)8,113,100 
Office furniture and fixtures2,827,476 (2,599,643)227,833 
Computer equipment and other 5,374,084 (3,806,311)1,567,773 
$36,397,584 $(18,944,378)$17,453,206 

F-21

Depreciation expense for the years ended December 31, 2022, 2021 and 2020 was $3.7 million, $3.0 million and $3.0 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1 million and disposed of fixed assets with a net book value of $1.1 million. The Company has recorded a receivable from the sale of these assets of $6.1 million, which is included in prepaid expenses and other current assets on the consolidated balance sheet.

8. Goodwill and Intangible Assets
The following sets forth goodwill and intangible assets by major asset class:
 
 December 31, 2022December 31, 2021
 Weighted Average Useful
Life
(Yrs)		GrossAccumulated
Amortization		Net Book
Value		GrossAccumulated
Amortization		Net Book
Value
Indefinite lived:
Goodwill$10,513,371 $— $10,513,371 $10,513,371 $— $10,513,371 
Definite lived:
Licenses101,323,761 (1,323,761)— 1,323,761 (1,305,600)18,161 
Bioject (a)125,100,000 (2,988,889)2,111,111 5,100,000 (2,735,556)2,364,444 
Other (b)184,050,000 (4,031,250)18,750 4,050,000 (3,806,250)243,750 
Total intangible assets1110,473,761 (8,343,900)2,129,861 10,473,761 (7,847,406)2,626,355 
Total goodwill and intangible assets$20,987,132 $(8,343,900)$12,643,232 $20,987,132 $(7,847,406)$13,139,726 

(a)Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.
(b)Other intangible assets represent the estimated fair value of acquired intellectual property.
Aggregate amortization expense on intangible assets was $496,000, $520,000 and $547,000 for the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense related to intangible assets at December 31, 2022 is expected to be incurred as follows:
 
Year ending December 31,
2023$273,000 
2024253,000 
2025253,000 
2026253,000 
2027253,000 
Thereafter845,000 
$2,130,000 

There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022, 2021 and 2020.

9. Convertible Debt
Convertible Senior Notes
On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the “Notes”). The Notes were sold in a private offering to
F-22

qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.
The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased. Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.
The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3 million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2 million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.
On January 1, 2022, the Company adopted ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8 million, a decrease to additional paid-in capital of $3.3 million, and an increase to convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.
The balance of the Notes at December 31, 2022 was as follows:
Principal amount$78,500,000 
Principal amount converted into common shares(62,085,000)
Unamortized debt issuance cost(155,815)
Accrued interest355,655 
     Net carrying amount $16,614,840 

For the years ended December 31, 2022, 2021 and 2020, the Company recognized $1.3 million, $1.9 million and $6.9 million, respectively, of interest expense related to the Notes, of which $1.1 million, $1.1 million and $4.1 million, respectively, related to the contractual interest coupon.
As of December 31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were as follows:
20231,067,000 
202416,948,000 
Total$18,015,000 

F-23

December 2019 Convertible Bonds
On December 26, 2019, the Company closed a private placement of convertible promissory notes (the “December 2019 Bonds”) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.
The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December 31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December 31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. Upon conversion, the $4.4 million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.
During the year ended December 31, 2021, the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was 6.2%.

10. Stockholders’ Equity

Preferred Stock
   Shares Outstanding as of
December 31,
 Shares AuthorizedShares Issued20222021
Series C Preferred Stock, par $0.001
1,091 1,091 9 9 

The holder of a share or shares of Series C preferred stock has the right at any time, at such holder’s option, to convert all or any lesser portion of such holder’s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value was $27.20 per share, such that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.
Issuances of Common Stock
On November 9, 2021, the Company entered into an ATM Equity OfferingSM Sales Agreement (the “2021 Sales Agreement”) with outside sales agents (collectively, the “Sales Agents”) for the offer and sale of its common stock for an aggregate offering price of up to $300.0 million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December 31, 2022 and 2021, the Company sold 34,445,743 and 6,955,341 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $2.44 and $6.96 per share, respectively, resulting in aggregate net proceeds of $83.0 million and $47.7 million, respectively. As of December 31, 2022 there was $167.4 million of remaining capacity under the 2021 Sales Agreement.
On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1 million.
Stock Options and Restricted Stock Units
The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.
The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December 31, 2022, the maximum number of shares of the Company’s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, the maximum number of shares is increased by 2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At December 31, 2022, the Company had 3,831,240 shares of common stock available for future grant under the 2016 Incentive Plan, 2,446,257 shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase 10,132,969 shares of common stock and 111,941 shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive
F-24

Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March 9, 2026.
On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company’s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At December 31, 2022 the Company had 1,703,750 shares of common stock available for future grant under the 2022 Inducement Plan, 110,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 186,250 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.
The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March 31, 2007 and terminated by its terms on March 31, 2017. At December 31, 2022, the Company had options outstanding to purchase 1,902,329 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.
Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 was $22.2 million, $25.0 million and $14.5 million, respectively, of which $8.8 million, $13.4 million and $8.0 million was included in research and development expenses and $13.4 million, $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until five years after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $4.2 million charge related to these RSU and stock option modifications.
At December 31, 2022 and 2021, there was $10.5 million and $16.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years and 2.0 years, respectively.
At December 31, 2022 and 2021, there was $7.2 million and $13.4 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.7 years and 1.8 years, respectively.
The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December 31, 2022, 2021 and 2020 was $1.3 million, $1.4 million and $1.2 million, respectively. As of December 31, 2022, options to purchase 665,875 shares of common stock granted to non-employees remained outstanding.
The following table summarizes total stock options outstanding at December 31, 2022:
 
 Options OutstandingOptions Exercisable
Exercise PriceShares Underlying Options
Outstanding		Weighted-Average
Remaining
Contractual Life
(in Years)		Weighted
Average
Exercise Price		Shares Underlying Options
Exercisable		Weighted Average
Exercise Price
$1.56-$3.00
830,542 8.3$2.17 247,104 $2.29 
$3.01-$6.00
5,461,365 7.1$3.50 3,059,330 $3.67 
$6.01-$9.00
3,349,587 5.3$7.57 2,861,909 $7.49 
$9.01-$12.00
1,930,825 7.1$10.97 1,080,389 $10.89 
$12.01-$15.00
580,947 4.1$13.38 529,392 $13.34 
$15.01-$25.62
68,282 7.6$21.12 51,568 $21.11 
12,221,548 6.6$6.28 7,829,692 $6.79 

At December 31, 2022, the aggregate intrinsic value of options outstanding was $0, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.7 years.
At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $4.0 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $4.6 million.
F-25

At December 31, 2022, options to purchase 12,221,548 shares of common stock and 2,556,257 RSUs were expected to vest.
Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares		Weighted-Average
Exercise Price
Balance, December 31, 202110,488,993 $7.93 
Granted4,623,448 3.11 
Exercised(118,694)2.38 
Cancelled(2,772,199)7.46 
Balance, December 31, 202212,221,548 $6.28 

Restricted stock unit activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares
Balance, December 31, 20212,448,868 
Granted2,485,947 
Vested(1,618,235)
Cancelled(760,323)
Balance, December 31, 20222,556,257 

The weighted average exercise price per share was $8.47 for the 77,250 options which expired during the year ended December 31, 2022, $4.56 for the 7,000 options which expired during the year ended December 31, 2021 and $4.44 for the 78,750 options which expired during the year ended December 31, 2020.
The weighted average grant date fair value per share was $2.34, $7.61 and $6.87 for options granted during the years ended December 31, 2022, 2021 and 2020, respectively.
The weighted average grant date fair value was $3.12, $10.37 and $9.12 per share for RSUs granted during the years ended December 31, 2022, 2021 and 2020, respectively.
The Company received $283,000, $6.7 million and $12.3 million in proceeds from the exercise of stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $81,000, $7.0 million and $14.2 million during the years ended December 31, 2022, 2021 and 2020, respectively.
As of December 31, 2022, the Company had 111,941 performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December 31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.

11. Commitments and Contingencies
Leases
The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December 31, 2022 of 0.9 years to 7.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.
The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.
F-26

Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.
As of December 31, 2022, the maturities of the Company's operating lease liabilities were as follows:
Year ending December 31,
2023$4,089,000 
20243,050,000 
20253,063,000 
20263,139,000 
20272,526,000 
Thereafter4,223,000 
   Total remaining lease payments20,090,000 
Less: present value adjustment(4,630,000)
   Total operating lease liabilities15,460,000 
Less: current portion(2,804,000)
Long-term operating lease liabilities$12,656,000 
Weighted-average remaining lease term5.9 years
Weighted-average discount rate8.6 %

Lease costs included in operating expenses in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 were $3.4 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.
In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.
In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.
Legal Proceedings
Securities Class Action Litigation
On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. The plaintiffs’ complaint was later amended to include certain of the Company’s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $30.0 million in cash and $14.0 million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $30.0 million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.
Shareholder Derivative Litigation
On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class
F-27

action complaint described above. The lawsuit accuses the Company’s board of directors of failing to exercise reasonable and prudent supervision over the Company’s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company’s current directors as defendants. The Devarakonda complaint also names one of the Company’s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.
On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.
On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.
VGXI Litigation
On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company’s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.
On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI’s counterclaims, disputing the allegations and the claims raised in VGXI’s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.
The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI’s counterclaims.
GeneOne Litigation
On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys’ fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company’s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company’s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney’s fees, and costs. On October 18, 2021, GeneOne filed its answer to the Company’s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne’s new matter. A trial date for this litigation has not been set.
The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne’s complaint.
Other Matters
From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of
F-28

operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company’s consolidated results of operations or financial position.

12. Income Taxes
In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.
The components of pretax loss from operations are as follows:
Year Ended December 31,
202220212020
     U.S. Domestic$(277,440,803)$(302,614,003)$(162,664,355)
     Foreign(211,249)(610,320)(225,949)
Pretax loss from operations$(277,652,052)$(303,224,323)$(162,890,304)

There was no provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020.
The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows: 
Year Ended December 31,
202220212020
Benefit from income taxes at statutory rates$(58,307,000)$(63,677,000)$(34,207,000)
State income tax, net of federal benefit(3,601,000)(3,447,000)— 
Change in valuation allowance61,065,000 77,424,000 21,428,000 
Nondeductible loss on extinguishment of debt— — 14,450,000 
Research and development tax credits(7,534,000)(16,523,000)(2,650,000)
Stock-based compensation2,913,000 483,000 (1,953,000)
Uncertain tax positions2,291,000 6,509,000 1,068,000 
Deconsolidation of subsidiary— — 853,000 
Expired NOLs and credits1,459,000 616,000 468,000 
Limited NOLs and credits(1,337,000)(542,000)(368,000)
Change in tax rates(187,000)— — 
Foreign tax rate differential(8,000)(24,000)(9,000)
Other3,246,000 (819,000)920,000 
$— $— $— 

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are shown below:
F-29

As of December 31,
20222021
Deferred tax assets:
Capitalized research expense$41,252,000 $4,200,000 
NOL carryforwards212,768,000 197,144,000 
Research and development and other tax credits26,442,000 23,005,000 
Deferred revenue538,000 987,000 
Stock-based compensation3,945,000 3,599,000 
Acquired intangibles559,000 637,000 
Interest expense — 83,000 
Investment in affiliated entity1,569,000 750,000 
Lease liability3,247,000 3,793,000 
Fixed assets57,000 — 
Other11,062,000 5,973,000 
301,439,000 240,171,000 
Valuation allowance(299,124,000)(237,205,000)
Total deferred tax assets2,315,000 2,966,000 
Deferred tax liabilities:
Acquired intangibles(199,000)(194,000)
Right of use asset(2,148,000)(2,430,000)
Note discount— (321,000)
Fixed assets— (53,000)
Total deferred tax liabilities(2,347,000)(2,998,000)
Net deferred tax liabilities$(32,000)$(32,000)

As of December 31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $625.4 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized.
The Company also had Korean NOL carryforwards of $1.0 million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized.
In addition, as of December 31, 2022, the Company had federal and state research and development (R&D) tax credit carryforwards of $40.5 million and $4.7 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.
Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):
Expiration Date:Federal NOLsState NOLsForeign NOLsFederal R&DState R&D
2023$5.3 $1.2 $— $— $— 
202418.9 9.1 — — — 
20259.6 5.2 — — — 
202612.2 7.1 — — — 
2027 and thereafter249.2 277.3 1.0 40.5 — 
Indefinite625.4 — — — 4.7 
$920.6 $299.9 $1.0 $40.5 $4.7 

F-30

Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s NOL and R&D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of NOL and R&D credit carryforwards as of December 31, 2022. As a result of the analysis, the Company estimates that approximately $8.3 million of tax benefits related to NOL and R&D carryforwards will expire unused. Accordingly, the related NOL and R&D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&D carryforwards.
The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.
The following table summarizes the activity related to the Company's unrecognized tax benefits:
 Year ended December 31,
 202220212020
Balance at beginning of the year$18,819,000 $12,210,000 $11,204,000 
Increases related to current year tax positions2,902,000 6,602,000 1,043,000 
Increases (decreases) related to prior year tax positions(582,000)7,000 27,000 
Other— — (64,000)
Balance at end of the year$21,139,000 $18,819,000 $12,210,000 

The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $19.7 million, $17.4 million and $10.9 million as of December 31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (“IRS”), state, local or foreign tax examination.

13. 401(k) Plan
The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees’ contributions, up to 6% of their annual compensation. The Company’s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.8 million, $1.5 million and $1.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.

14. Related Party Transactions
Plumbline Life Sciences, Inc.
F-31

The Company owned 597,808 shares of common stock in PLS as of December 31, 2022 and 2021, representing a 18.7% and 18.9% ownership interest, respectively. One of the Company's directors, Dr. David B. Weiner, acts as a consultant to PLS.
Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from PLS of $34,000, $245,000 and $1.4 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $59,000 and $25,000, respectively, related to PLS.

The Wistar Institute
The Company's director Dr. David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.
In March 2016, the Company entered into collaborative research agreements with Wistar for preventive and therapeutic DNA-based immunotherapy applications and products developed by Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.
In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $1.9 million for all direct and indirect costs incurred in the conduct of the collaborative research.
In November 2016, the Company received a $6.1 million sub-grant through Wistar to develop a dMAb against the Zika infection, with funding through December 2021.
The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, with funding through February 2023.
In 2020, the Company received a $10.7 million sub-grant through Wistar, which was amended in 2021 to $13.6 million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0 million in funding through March 2024, of which $3.3 million has been exercised as of December 31, 2022.
Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December 31, 2022 and 2021, the Company recorded $8.7 million and $3.0 million, respectively, as contra-research and development expense from Wistar.
Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December 31, 2022, 2021 and 2020 were $1.4 million, $2.9 million and $2.3 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $9.9 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.2 million and $548,000, respectively, related to Wistar. As of December 31, 2022 and 2021, the Company had a prepaid expense balance of $375,000 and $261,000, respectively, and recorded $88,000 and $37,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.

15. Geneos Therapeutics, Inc.
In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a Series A preferred stock financing. The Company invested $1.2 million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held 61% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, Consolidation.
In January 2020, Geneos completed the second closing of the Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held 52% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.
In June 2020, Geneos closed an additional Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial
F-32

interest. Based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.
The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. Since the Company’s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company’s common stock investment and is therefore recorded as an equity security under ASC 321.
Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Any difference between the carrying amount of the Company’s investment and the amount of underlying equity in Geneos’s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.
Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, the Company’s investment will be marked to fair value.  There have been no observable price changes or impairments identified since the deconsolidation date.
In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4 million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.
The Company’s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5 million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss was allocated to the Company’s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance to $0 as of March 31, 2021.
In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.
In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0 million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.
F-33

The fair value of Geneos’s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.
The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:
Investment in Geneos Series A-2 preferred stock$1,999,998 
Remeasurement of Geneos Series A-1 preferred stock165,215 
Share in current and accumulated net loss of Geneos (2,165,213)
Investment in Geneos as of December 31, 2022$— 
The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.
The Company continues to exclusively license its SynCon immunotherapy and CELLECTRA technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology.
The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr. David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.

16. Subsequent Events
On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the “Reduction”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately 24 employees, which represented 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.
On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued 7,000,000 shares of common stock. Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. The number of shares will be calculated based on the average trading price of the common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.

F-34
 EX-21.1 2 ino-12312022x10kex211.htm EX-21.1 Document

Exhibit 21.1
INOVIO PHARMACEUTICALS, INC.
Subsidiaries

Subsidiary Name(1)
Jurisdiction of Organization
Inovio Asia, LLC
South Korea



 EX-23.1 3 ino-12312022x10kex231.htm EX-23.1 Document

Exhibit 23.1


Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the following Registration Statements:
1.Registration Statement (Form S-3 No. 333- 236202) of Inovio Pharmaceuticals, Inc.,
2.Registration Statement (Form S-3 No. 333-252256) of Inovio Pharmaceuticals, Inc.,
3.Registration Statement (Form S-8 Nos. 333-142938, 333-150769, 333-161559, 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to the 2007 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,
4.Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, 333-231872, 333-236201, 333-253736 and 333-263167) pertaining to the 2016 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,
5.Registration Statement (Form S-8 No. 333-265944) pertaining to the Inovio Pharmaceuticals, Inc. 2022 Inducement Plan,

of our reports dated March 1, 2023, with respect to the consolidated financial statements of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2022.


/s/ Ernst & Young LLP

San Diego, California
March 1, 2023






 EX-31.1 4 ino-12312022x10kex311.htm EX-31.1 Document

Exhibit 31.1
Certification of CEO Pursuant to
Securities Exchange Act Rules 13a-15(e) and 15d-15(e)
as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Jacqueline E. Shea, certify that:
1.I have reviewed this annual report on Form 10-K of Inovio Pharmaceuticals, Inc.
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:March 1, 2023
/s/ JACQUELINE E. SHEA        
 
Jacqueline E. Shea
President, Chief Executive Officer and Director



 EX-31.2 5 ino-12312022x10kex312.htm EX-31.2 Document

Exhibit 31.2
Certification of CFO Pursuant to
Securities Exchange Act Rules 13a-15(e) and 15d-15(e)
as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Peter Kies, certify that:
1.I have reviewed this annual report on Form 10-K of Inovio Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control
 
Date:March 1, 2023
/s/    PETER KIES        
 
Peter Kies
Chief Financial Officer



 EX-32.1 6 ino-12312022x10kex321.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:March 1, 2023
/s/ JACQUELINE E. SHEA
 
Jacqueline E. Shea
President, Chief Executive Officer and Director
(Principal Executive Officer)
Date:March 1, 2023
/s/    PETER KIES        
 
Peter Kies
Chief Financial Officer
(Principal Financial and Accounting Officer)



 EX-101.SCH 7 ino-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Short-term Investments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Certain Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Convertible Debt link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - 401(k) Plan link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Geneos Therapeutics, Inc. link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Convertible Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Collaborative Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Convertible Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - 401(k) Plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ino-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 ino-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 ino-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Number of common stock shares outstanding under the Incentive Plan (in shares) Common Stock, Other Shares, Outstanding 2023 Operating Loss Carryforwards, Expiring in Two Years Operating Loss Carryforwards, Expiring in Two Years Accounts Payable, Trade Accounts Payable, Trade Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total remaining lease payments Lessee, Operating Lease, Liability, to be Paid Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Net loss Net loss Net loss attributable to common stockholders Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Entity Address, Postal Zip Code Entity Address, Postal Zip Code Underwritten Public Offering Underwritten Public Offering [Member] Underwritten Public Offering $9.01-$12.00 Range of Exercise Prices Four [Member] Range of Exercise Prices Four [Member] Interest income Interest Income, Operating Number of shares of vested restricted stock outstanding under the plan (in shares) Number of Shares of Vested Restricted Stock Outstanding Under Plan Number of shares of vested restricted stock outstanding under the plan. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] 2024 Long-Term Debt, Maturity, Year Two Debt instrument, convertible, threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] $3.01-$6.00 Range of Exercise Prices Two [Member] Range of Exercise Prices Two [Member] Cost Property, Plant and Equipment, Gross RSU's expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number Operating expenses related to affiliated entity Related Party Transaction, Expenses from Transactions with Related Party Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Fair value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional paid-in capital Additional paid-in capital Additional Paid in Capital Commissions and other estimated offering expenses Proceeds from Issuance or Sale of Equity Number of potential shares authorized for issuance under a share-based compensation plan (in shares) Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan Number of potential shares authorized for issuance under a share-based compensation plan. 2007 Incentive Plan 2007 Incentive Plan [Member] 2007 Incentive Plan [Member] Financial Instruments [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Collaboration agreement, payment earned Collaboration Agreement, Payment Earned Collaboration Agreement, Payment Earned Expirations of Operating Loss Carryforwards, Components [Abstract] Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Proceeds from issuance of debt Proceeds from Issuance of Debt Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Debt interest based on the fixed rate Debt Instrument, Interest Rate, Stated Percentage Grant proceeds received Grant Proceeds Received Grant Proceeds Received Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Conversion of preferred stock/senior notes to common stock Stock Issued During Period, Value, Conversion of Convertible Securities Total goodwill and intangible assets, net book value Goodwill and Intangible Assets Net Goodwill and intangible assets net. Federal Domestic Tax Authority [Member] 2023 Tax Credit Carryforward, Expiring in Two Years Tax Credit Carryforward, Expiring in Two Years Net loss attributable to Inovio Pharmaceuticals, Inc. Net loss from operations Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of lease agreements entered into Lessee, Number Of Lease Agreements Entered Into Lessee, Number Of Lease Agreements Entered Into Total antidilutive securities (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Other Other Intangible Assets [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Schedule Of Maturities Of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Ownership [Axis] Ownership [Axis] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Total assets measured at fair value Assets, Fair Value Disclosure Proceeds from stock option exercises Proceeds from Stock Option and Warrant Exercises Proceeds from Stock Option and Warrant Exercises 2026 Tax Credit Carryforward, Expiring in Five Years Tax Credit Carryforward, Expiring in Five Years Department Of Defence Department Of Defence [Member] Department Of Defence Options outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Investment, Name [Domain] Investment, Name [Domain] Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Weighted average exercise price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Estimate of cash settlement Loss Contingency, Estimate of Possible Loss December 2019 Bonds December 2019 Convertible Bonds [Member] December 2019 Convertible Bonds [Member] Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Fair Market Value Short-term investments Debt Securities, Available-for-Sale Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Indefinite lived: Finite-Lived Intangible Assets, Net [Abstract] Net operating loss carryforwards that will expire due to IRC Section 382 limitations Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net Number of operating segments Number of Operating Segments Mutual funds Mutual funds Mutual Funds [Member] Mutual funds. Noncontrolling Interest [Abstract] Plan Name [Domain] Plan Name [Domain] IN O4800 I N O4800 [Member] I N O4800 Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Fair Value, Inputs, Level 1 Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Bioject Bioject [Member] Bioject [Member] Weighted average number of common shares outstanding Weighted Average Number of Shares Outstanding, Basic [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities U.S. agency mortgage-backed securities Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member] Operating lease liability Less: current portion Operating Lease, Liability, Current Options, expirations in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Collaboration Agreements Collaborative Arrangement, Accounting Policy [Policy Text Block] Upfront payment received Collaborative Agreements, Upfront Payment Received Collaborative Agreements, Upfront Payment Received Annual maintenance Cost, Maintenance Uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Expected charge Restructuring and Related Cost, Expected Cost Document Annual Report Document Annual Report Stock purchase agreement, commitment of additional investment Stock Purchase Agreement, Commitment Of Additional Investment Stock Purchase Agreement, Commitment Of Additional Investment Certificates of deposit Certificates of Deposit [Member] Loss on short-term investments Gain (Loss) on Sale of Other Investments Total liabilities Liabilities Remaining authorized amount Stock Sales Agreement, Remaining Authorized Amount Stock Sales Agreement, Remaining Authorized Amount Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Taxes paid related to net share settlement of equity awards Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Service-based restricted stock units Service Based Restricted Stock Units [Member] Service Based Restricted Stock Units Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of (discounts) premiums on investments Investment Income, Net, Amortization of Discount and Premium Grants Grant Revenue [Policy Text Block] Grant Revenue [Policy Text Block] Note discount Deferred Tax Liabilities, Financing Arrangement, Discount Deferred Tax Liabilities, Financing Arrangement, Discount Issuance of common stock for cash, net of financing costs Stock Issued During Period, Value, New Issues Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Aggregate intrinsic value of vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule Of Fixed Assets Property, Plant and Equipment [Table Text Block] Prepaid expense Prepaid Expense Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Number of positions reduced Restructuring and Related Cost, Number of Positions Eliminated Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Deconsolidation of subsidiary Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] $15.01-$25.62 Range of Exercise Prices Six [Member] Range of Exercise Prices Five [Member] Property, plant, and equipment, useful life Property, Plant and Equipment, Useful Life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Common stock aggregate offering price Stock Sales Agreement, Maximum Authorized Amount Stock Sales Agreement, Maximum Authorized Amount Convertible Debt Debt Disclosure [Text Block] Carrying value of december 2019 bonds Stock Issued During Period, Value, Conversion of Units Decrease in cash resulting from the deconsolidation of Geneos Cash Divested from Deconsolidation Korean State Income Tax Authority Korean State Income Tax Authority [Member] Korean State Income Tax Authority Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Increases (decreases) related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Exercise Price Range [Axis] Exercise Price Range [Axis] Accounts receivable from affiliated entities Accounts Receivable, Related Parties, Current Settlement of receivable with shares of common stock from affiliated entity (PLS) Settlement Of Receivable With Shares Of Common Stock From Equity Security Settlement Of Receivable With Shares Of Common Stock From Equity Security Financial Instrument [Axis] Eligible Item or Group for Fair Value Option [Axis] Financial Instrument [Axis] Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Former President and Chief Executive Officer Former President and Chief Executive Officer [Member] Former President and Chief Executive Officer Subsequent Event Subsequent Event [Member] Nonemployee Share-Based Payment Arrangement, Nonemployee [Member] Document Period End Date Document Period End Date Accrued Salaries, Current Accrued Salaries, Current Summary of assumptions used to estimate the fair value of stock options Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract] Assumptions used in estimation of fair value of stock options. Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Sales Agreement Sales Agreement [Member] Sales Agreement [Member] Certain Balance Sheet Items Other Current Assets [Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Convertible preferred stock Convertible Preferred Stock [Member] Total assets Assets All other, including affiliated entities All Other Customers [Member] All Other Customers [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders Earnings Per Share [Abstract] Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Total goodwill and intangible assets, gross Goodwill and Intangible Assets Gross Goodwill and intangible assets gross. Investments in affiliated entity Equity Securities, FV-NI, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule Of Accounts Payable And Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Issued 2026 Operating Loss Carryforwards, Expiring in Five Years Operating Loss Carryforwards, Expiring in Five Years 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Interest expense, debt Interest Expense, Debt Employees and Directors Employees and Directors [Member] Employees and Directors [Member] Net loss before share in net loss of Geneos Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Inovio Pharmaceuticals, Inc. stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Major Customers [Axis] Customer [Axis] Limited NOLs and credits Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share of net loss in Geneos Gain (Loss) on Disposition of Intangible Assets Goodwill, gross Goodwill, Gross Dissolution of majority-owned subsidiary VGX Animal Health, Inc. Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Award Type [Domain] Grantee Status [Axis] Grantee Status [Axis] Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gain (loss) on extinguishment of convertible bonds and senior notes Gain (loss) on extinguishment of convertible bonds and senior notes Gain (Loss) on Extinguishment of Debt Series C Preferred Stock Series C Preferred Stock Series C Preferred Stock [Member] Entity Registrant Name Entity Registrant Name Issuance of common stock for cash, net of financing costs (in shares) Stock Issued During Period, Shares, New Issues (Loss) gain on investment in affiliated entities Loss (gain) on equity investment in affiliated entities Change in Value of Investments in Affiliated Company The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis. McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member] McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim Subsequent Events Subsequent Events [Text Block] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exercise price, upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Stock sale agreement, aggregate number of shares issued (in shares) Stock Sale Agreement, Aggregate Number of Shares Issued Stock Sale Agreement, Aggregate Number of Shares Issued Entity Address, City or Town Entity Address, City or Town 401(k) Plan Retirement Benefits [Text Block] Deconsolidation of Geneos Noncontrolling Interest, Decrease from Deconsolidation Plumbline Life Sciences, Inc. (affiliated entity) Plumbline Life Sciences, Inc. [Member] Plumbline Life Sciences, Inc. [Member] Leases [Abstract] Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Sales Agents will be entitled to compensation Sale of Stock, Sales Proceeds of Any Common Stock, Percentage Sale of Stock, Sales Proceeds of Any Common Stock, Percentage Advaccine Advaccine [Member] Advaccine Awarded option amount Collaborative Agreement, Awarded Option Amount Collaborative Agreement, Awarded Option Amount NOL carryforwards Deferred Tax Assets, Operating Loss Carryforwards Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Deferred grant funding from affiliate Deferred Grant Funding, From Affiliate Deferred Grant Funding, From Affiliate 2024 Operating Loss Carryforwards, Expiring in Three Years Operating Loss Carryforwards, Expiring in Three Years Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Debt issuance costs, net Unamortized debt issuance cost Debt Issuance Costs, Net Auditor Name Auditor Name Investment, Name [Axis] Investment, Name [Axis] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Short-term Investments and Fair Value Measurements Fair Value Disclosures [Text Block] The Wistar Institute The Wistar Institute [Member] The Wistar Institute [Member] Net operating loss carryforwards Total Operating Loss Carryforwards Trading Symbol Trading Symbol Entity File Number Entity File Number Convertible Debt Securities Convertible Debt Securities [Member] Remeasurement of Geneos Series A-1 preferred stock Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Weighted-average remaining contractual life (in Years) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Schedule Of Prepaid Expenses And Other Current Assets Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block] Schedule Of Prepaid Expenses And Other Current Assets Research and development Research and Development Expense Purchases of investments Payments to Acquire Short-Term Investments Increases (decreases) related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Title of Individual [Axis] Title of Individual [Axis] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Performance-based restricted stock units Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] 6.50% Convertible Senior Notes Due 2024 Convertible Senior Notes 6.50% Convertible Senior Notes Due 2024 [Member] 6.50% Convertible Senior Notes Due 2024 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] $6.01-$9.00 Range of Exercise Prices Three [Member] Range of Exercise Prices Three [Member] % of Total Revenue Concentration Risk, Percentage Subsequent Events [Abstract] Subsequent Events [Abstract] Number of securities in a gross unrealized loss position for more than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Short-term Investments and Fair Value Measurements Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Accounts payable and accrued expenses, including from affiliated entities Increase (Decrease) in Accounts Payable and Accrued Liabilities Convertible Bonds Convertible Bonds [Member] Convertible Bonds [Member] Income Taxes Income Tax Disclosure [Text Block] Revenue from related parties Revenue from Related Parties Due to related parties Due to Related Parties Coalition for Epidemic Preparedness Innovations Coalition for Epidemic Preparedness Innovations [Member] Coalition for Epidemic Preparedness Innovations [Member] Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Earnings Per Share, Basic Grant funding liability from affiliated entities Deferred Grant Funding, From Affiliate, Current Deferred Grant Funding, From Affiliate, Current 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three COVID19 Vaccine S A R S Co V2 C O V I D19 Vaccine [Member] S A R S Co V2 C O V I D19 Vaccine New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total Inovio Pharmaceuticals, Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Director Director [Member] Tax credit carryforward amount Total Tax Credit Carryforward, Amount Ownership [Domain] Ownership [Domain] Other Deferred Tax Assets, Other Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Awarded amount Collaborative Agreement, Awarded Amount Collaborative Agreement, Awarded Amount Non Employee Non Employee [Member] Non employee. Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Nondeductible loss on extinguishment of debt Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt Contractual Maturity Debt Securities, Available-for-Sale Contractual Maturity Debt Securities, Available-for-sale contractual maturity. Accumulated deficit Retained Earnings [Member] CEPI MERS CEPI MERS [Member] CEPI MERS Proceeds from sale of or maturity of investments Proceeds from Sale of Short-Term Investments Lease, cost Lease, Cost Common stock Common Stock [Member] Lease liability Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Exercise of stock options for cash and vesting of RSUs, net of tax payments Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Number of shares available for grants under the Incentive Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Statement [Table] Statement [Table] Cash, cash equivalents, and short-term investments Cash, Cash Equivalents, and Short-Term Investments Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Office furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Operating lease liability, net of current portion Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Company's contribution to 401(k) plan Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Expired NOLs and credits Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits Leasehold improvements Leasehold Improvements [Member] Grantee Status [Domain] Grantee Status [Domain] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Convertible preferred stock, shares issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Acquisition of non-controlling interest Proceeds from Noncontrolling Interests Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Related Party Transactions Related Party Transactions Disclosure [Text Block] Non-cash interest expense Non-Cash Interest Expense Non-Cash Interest Expense Segment Reporting Segment Reporting, Policy [Policy Text Block] Options, expirations in period, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Expenses to reimburse Collaborative Agreement, Expenses To Reimburse Collaborative Agreement, Expenses To Reimburse Capitalized research expense Deferred Tax Assets, in Process Research and Development Number of shares of unvested restricted stock units and options outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Geneos Therapeutics, Inc. Geneos Therapeutics, Inc. [Member] Geneos Therapeutics, Inc. [Member] Intangible assets, gross Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset U.S. treasury securities US Treasury Bill Securities [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Series A-1 Preferred Stock Series A One Preferred Stock [Member] Series A One Preferred Stock [Member] Collaborative agreement, funding to be received Collaborative Agreement, Funding To Be Received Collaborative Agreement, Funding Received for Research and Development Document Transition Report Document Transition Report Foreign Tax Authority Foreign Tax Authority [Member] Local Phone Number Local Phone Number Schedule Of Stock Options, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Recent Accounting Pronouncements - Recently Adopted New Accounting Pronouncements, Policy [Policy Text Block] Debt conversion, converted instrument, shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Prepaid expenses and other current assets, including from affiliated entities Increase (Decrease) in Prepaid Expense and Other Assets State State and Local Jurisdiction [Member] Accounts receivable Accounts Receivable, Related Parties Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill, net book value Goodwill Accrued clinical trial expenses Accrued Clinical Trial Expense, Current Accrued Clinical Trial Expense, Current Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Acquisition of non-controlling interest in Geneos, net Noncontrolling Interest, Increase from Subsidiary Equity Issuance Name of Property [Domain] Name of Property [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Income tax expense (benefit) Income Tax Expense (Benefit) San Diego, California San Diego, California [Member] San Diego, California [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Deferred tax assets, valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Fixed Assets Property, Plant and Equipment, Policy [Policy Text Block] Deferred tax liabilities Deferred Income Tax Liabilities, Net Aggregate intrinsic value of unvested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional paid-in capital Additional Paid-in Capital [Member] Options exercisable, remaining contractual term Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm Licenses Licensing Agreements [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share) Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share Working capital Working Capital Net amount of current assets and current liabilities. Pennsylvania Pennsylvania State Income Tax Authority [Member] Pennsylvania State Income Tax Authority [Member] Options, exercises in period, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value 2022 Inducement Plan 2022 Inducement Plan [Member] 2022 Inducement Plan Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated Depreciation and Amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Grant funding liability, including from affiliated entity Increase (Decrease) in Deferred Grant Funding, Current Increase (Decrease) in Deferred Grant Funding, Current Expected life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Awarded exercised amount Collaborative Agreement, Awarded Exercised Amount Collaborative Agreement, Awarded Exercised Amount Accounts Payable and Accrued Expenses [Table] Accounts Payable and Accrued Expenses [Table] Accounts Payable and Accrued Expenses Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Investments in affiliated entity Equity Securities, FV-NI Collaborative Arrangement Collaborative Arrangement [Member] Research and development tax credits Income Tax Reconciliation, Statute Limitations Income Tax Reconciliation, Statute Limitations Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Summary Of Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] 2027 and thereafter Tax Credit Carryforward, Expiring in Six Years Tax Credit Carryforward, Expiring in Six Years Accounts Receivable Accounts Receivable [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Accounts payable and accrued expenses Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Expected annual savings Restructuring and Related Cost, Expected Annual Savings Restructuring and Related Cost, Expected Annual Savings Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021 Common stock, value, issued Common Stock, Value, Issued $12.01-$15.00 Range of Exercise Prices Five [Member] Range of Exercise Prices Five [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Preferred stock Preferred Stock [Member] Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Lessee, operating lease, area of land under lease Lessee, Operating Lease, Area of Land Under Lease Lessee, Operating Lease, Area of Land Under Lease Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Income tax expense (benefit) Comprehensive Income (Loss), Tax Expense (Benefit) Comprehensive Income (Loss), Tax Expense (Benefit) Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Convertible Debt Convertible Debt [Member] Aggregate intrinsic value for options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Number of shares owned (in shares) Investment Owned, Balance, Shares Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Procurement contract Collaborative Arrangement , Revenue from the Procurement Contract Collaborative Arrangement , Revenue from the Procurement Contract Current liabilities: Liabilities, Current [Abstract] Indefinite Operating Loss Carryforwards, Indefinitely Carryforward Operating Loss Carryforwards, Indefinitely Carryforward Proceeds from stock options exercised Proceeds from Stock Options Exercised Schedule Of Equity Method Investments Equity Method Investments [Table Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Investment in Geneos Beginning balance Ending balance Equity Method Investments Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Grants receivable Grants Receivable Right of use asset Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Deferred revenue Contract with Customer, Liability, Current Number of options expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number Amounts accrued for purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Maximum annual contribution per employee, percent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Unrealized transaction (gain) loss on foreign-currency denominated debt Foreign Currency Transaction Gain (Loss), before Tax Income Statement Location [Domain] Income Statement Location [Domain] August 2019 Bonds August 2019 Convertible Bonds [Member] August 2019 Convertible Bonds [Member] Number of securities in a gross unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Accrued clinical trial expenses Increase (Decrease) In Accrued Clinical Trial Expense Increase (Decrease) In Accrued Clinical Trial Expense Amendment Flag Amendment Flag Operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term Purchase price, procurement contract Collaborative Arrangement, Fixed-Price Contract, Amount Awarded Collaborative Arrangement, Fixed-Price Contract, Amount Awarded Intangible asset, useful life Useful life (in years) Finite-Lived Intangible Asset, Useful Life Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Change in fair value of derivative liability Increase (Decrease) in Derivative Liabilities Debt instrument, face amount Principal amount Debt Instrument, Face Amount Federal Internal Revenue Service (IRS) [Member] Investment Type [Axis] Investment Type [Axis] Short Term Investments Investment, Policy [Policy Text Block] Comprehensive loss attributable to Inovio Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] California California Income Tax Authority [Member] California Income Tax Authority [Member] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Agreement period from effective date for termination Collaborative Agreement, Period From Effective Date For Termination Collaborative Agreement, Period From Effective Date For Termination Entity Current Reporting Status Entity Current Reporting Status 2027 and thereafter Operating Loss Carryforwards, Expiring in Six Years Operating Loss Carryforwards, Expiring in Six Years Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other assets Other Assets, Noncurrent Valuation of Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Convertible senior notes Convertible Debt 2025 Tax Credit Carryforward, Expiring in Four Years Tax Credit Carryforward, Expiring in Four Years $1.56-$3.00 Range of Exercise Prices One [Member] Range of Exercise Prices One [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Stock sale agreement, aggregate proceeds from issuance of stock Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock Tax benefits expired Tax Benefits Expired Tax Benefits Expired Counterparty Name [Axis] Counterparty Name [Axis] CELLECTRA 3PSP Proprietary Smart Device C E L L E C T R A3 P S P Proprietary Smart Device [Member] C E L L E C T R A3 P S P Proprietary Smart Device Number of options outstanding to purchase common stock (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number PLS (affiliated entity) PLS (affiliated entity) [Member] PLS (affiliated entity) [Member] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Accrued litigation settlement Estimated Litigation Liability, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation and Liquidity Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Fixed assets, net Net Book Value Property, Plant and Equipment, Net Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Research and development equipment Office Equipment [Member] Options to purchase common stock Stock Options Share-Based Payment Arrangement, Option [Member] Indefinite Tax Credit Carryforward, Carryforward Indefinitely Tax Credit Carryforward, Carryforward Indefinitely Title of Individual with Relationship to Entity [Domain] Title of Individual [Domain] Title of Individual [Domain] Property, plant and equipment disposed of Property, Plant and Equipment, Disposals Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total Long-Term Debt Other (expense) income, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Change in fair value of derivative liability Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Increase in number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total operating expenses Operating Expenses Maximum Maximum [Member] Schedule of Revenue From External Customers Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue, including from affiliated entity Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current 2023 Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months Schedule of intangible assets by major asset class Intangible Assets, Net (Excluding Goodwill) [Abstract] Revenue recognized from deferred revenue Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Revenues [Abstract] Revenues [Abstract] Finite lived intangible assets, net Intangible assets, net book value Finite-Lived Intangible Assets, Net Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Investment in affiliated entity Deferred Tax Assets, Investments Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Operating lease right-of-use assets and liabilities, net Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net 2024 Tax Credit Carryforward, Expiring in Three Years Tax Credit Carryforward, Expiring in Three Years Other Unrecognized Tax Benefits, Increase (Decrease) In Other Unrecognized Tax Benefits, Increase (Decrease) In Other Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Fixed Assets Property, Plant and Equipment Disclosure [Text Block] Variable Interest Entities (VIE) Consolidation, Variable Interest Entity, Policy [Policy Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] D N A Encoded Monoclonal Antibody Technology D N A Encoded Monoclonal Antibody Technology [Member] D N A Encoded Monoclonal Antibody Technology Accounts receivable, including from affiliated entities Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Geneos Therapeutics, Inc. Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Ownership percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Related Party Transaction, Due from (to) Related Party [Abstract] Related Party Transaction, Due from (to) Related Party [Abstract] Short-term investments Short-Term Investments Prepaid manufacturing expenses Prepaid Manufacturing Expenses, Current Prepaid Manufacturing Expenses, Current Schedule Of Unrecognized Tax Benefits Rollforward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Subsequent Event [Line Items] Subsequent Event [Line Items] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Summary of common and preferred stock authorized, issued and outstanding Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Gain on remeasurement of investment in Geneos Gain (Loss) On Remeasurement Of Equity Method Investment Gain (Loss) On Remeasurement Of Equity Method Investment Other Accrued Liabilities Other Accrued Liabilities Class of Stock [Line Items] Class of Stock [Line Items] Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total operating lease liabilities Operating Lease, Liability Summary Of Intangible Assets By Major Asset Class Schedule of Intangible Assets and Goodwill [Table Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Net deferred tax liabilities Deferred Tax Liabilities, Net LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] U.S. treasury securities US Treasury Securities [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cost Debt Securities, Available-for-Sale, Amortized Cost Research and development and other tax credits Deferred Tax Assets, Other Tax Carryforwards Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Amount paid to other party Litigation Settlement, Amount Awarded to Other Party Expirations of Tax Credit Carryforwards [Abstract] Deferred Tax Assets, Tax Credit Carryforwards [Abstract] Deferred tax assets: Deferred Tax Assets, Net [Abstract] Income Tax Authority [Axis] Income Tax Authority [Axis] Other assets Increase (Decrease) in Other Operating Assets Debt instrument, unamortized discount Debt Instrument, Unamortized Discount Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Auditor Location Auditor Location The Company Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of issuance costs Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Prepaid expenses and other current assets from affiliated entities Prepaid Expenses and Other Current Assets from Affiliated Entity The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event. Percentage of ownership Equity Method Investment, Ownership Percentage Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Agreement amended amount Collaborative Agreement, Amended Amount Collaborative Agreement, Amended Amount Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Definite lived: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Revenue under collaborative research and development arrangements License [Member] Grant funding liability Deferred Grant Funding, Current Deferred Grant Funding, Current Funding received Collaborative Agreement, Funding Received Collaborative Agreement, Funding Received Accounts receivable Accounts Receivable, after Allowance for Credit Loss Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 Preferred Stock, Value, Issued Principal amount converted into common shares Debt Instrument, Convertible Debt, Converted Amount Debt Instrument, Convertible Debt, Converted Amount Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and Administrative Expense General and Administrative Expense [Member] Revenue from collaborative arrangements and other contracts, including affiliated entity Revenue from Contract with Customer, Excluding Assessed Tax Conversion of preferred stock/senior notes to common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Series A-2 One Preferred Stock Series A-2 One Preferred Stock [Member] Series A-2 One Preferred Stock Employer matching contribution, percent Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Entity Voluntary Filers Entity Voluntary Filers Options exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Net loss before share in net loss of Geneos Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Impairment loss Goodwill, Impairment Loss Term Collaborative Arrangement, Term Collaborative Arrangement, Term Revenue Recognition and Concentration of Credit Risk Revenue from Contract with Customer [Text Block] Deferred revenue Deferred Tax Assets, Deferred Income Investments [Domain] Investments [Domain] Non- controlling interest Noncontrolling Interest [Member] Forecast Forecast [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Schedule Of Deferred Tax Assets And Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Audit Information [Abstract] Audit Information Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Loss from equity method investment, recorded and allocated to investment Income (Loss) From Equity Method Investments, Realized And Allocated to Investment Income (Loss) From Equity Method Investments, Realized And Allocated to Investment Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred tax assets, gross Deferred Tax Assets, Gross Schedule Of Components Of Pretax Loss From Operations Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Significant Other Unobservable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Debt securities, available-for-sale, realized gain Debt Securities, Available-for-Sale, Realized Gain Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Contractual year term of incentive plan Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term Share based compensation arrangement by share based payment award maximum contractual term. Sale of Stock [Domain] Sale of Stock [Domain] Vesting period of incentive plan Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Noncontrolling interest, ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Summary Of Preferred Stock Authorized, Issued And Outstanding Schedule of Stock by Class [Table Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Collaborative agreement, period to receive funding for research and development Collaborative Agreement, Period to Receive Funding for Research and Development Collaborative Agreement, Period to Receive Funding for Research and Development Exercise Price Range [Domain] Exercise Price Range [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Customer Concentration Risk Customer Concentration Risk [Member] Plymouth Meeting, Pennsylvania Plymouth Meeting, Pennsylvania [Member] Plymouth Meeting, Pennsylvania [Member] Balance at beginning of the year Balance at end of the year Unrecognized Tax Benefits Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Acquired intangibles Deferred Tax Liabilities, Intangible Assets Schedule Of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounts Payable and Accrued Expenses [Line Items] Accounts Payable and Accrued Expenses [Line Items] Accounts Payable and Accrued Expenses U.S. Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Award exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Other income (expense): Nonoperating Income (Expense) [Abstract] Net unrealized (loss) gain on available-for-sale equity securities Net unrealized loss (gain) on available-for-sale equity securities Net unrealized loss on available-for-sale equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Schedule Of Maturities Of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Change in tax rates Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Exercise price, lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Annual maintenance period Annual Maintenance Period Annual Maintenance Period Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Unrealized loss on investments Unrealized Gain (Loss) on Investments Investment in Geneos Payments to acquire additional interest in subsidiaries Payments to Acquire Additional Interest in Subsidiaries Product and Service [Axis] Product and Service [Axis] Financial assets and liabilities that are measured at fair value on recurring basis Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Class of Stock [Domain] Class of Stock [Domain] 2025 Operating Loss Carryforwards, Expiring in Four Years Operating Loss Carryforwards, Expiring in Four Years Interest expense Interest expense Interest Expense Debt Securities, Available-for-sale, Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Equity Method Investments Equity Method Investments [Policy Text Block] Estimate of shares settlement Loss Contingency, Estimate of Possible Loss, Value of Shares Loss Contingency, Estimate of Possible Loss, Value of Shares Additional revenue to be achieved Collaboration Agreement, Additional Revenue To Be Achieved Collaboration Agreement, Additional Revenue To Be Achieved Property, plant and equipment sold Property, Plant and Equipment, Disposed Of By Sale Property, Plant and Equipment, Disposed Of By Sale Agreement, number of days written notice before termination Collaborative Agreement, Number of Days Written Notice Before Termination Collaborative Agreement, Number of Days Written Notice Before Termination Unrealized (loss) gain on short-term investments, net of tax Unrealized loss on short-term investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Change in prepaid expenses and other current assets related to fixed assets Change In Prepaid Expenses And Other Current Assets, Fixed Assets Change In Prepaid Expenses And Other Current Assets, Fixed Assets Estimated Insurance Recoveries Estimated Insurance Recoveries Certain Balance Sheet Items [Abstract] Certain Balance Sheet Items Subsequent Event [Table] Subsequent Event [Table] Acquired intangibles Deferred Tax Assets, Intangible Assets Deferred Tax Assets, Intangible Assets Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Reserved number of shares under the Incentive Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Proceeds from sale of investment of GeneOne Proceeds from Sale of Equity Securities, FV-NI Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Aggregate intrinsic value of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value 2016 Incentive Plan 2016 Incentive Plan [Member] 2016 Incentive Plan [Member] Total deferred tax liabilities Deferred Tax Liabilities, Gross Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Obligation period to pay royalties Collaboration Agreement, Royalty Period Collaboration Agreement, Royalty Period Proceeds from Geneos issuance of note payable Proceeds from Notes Payable Gain on deconsolidation of Geneos Gain on deconsolidation of Geneos Deconsolidation, Gain (Loss), Amount Plumbline Life Sciences Plumbline Life Sciences [Member] Plumbline Life Sciences [Member] Awards settled in cash, percentage Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash Schedule Of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount U.S. Department of Defense DoD [Member] DoD [Member] Sales made at a weighted average price (in dollars per share) Stock Sale Agreement, Weighted Average Price Per Share Stock Sale Agreement Weighted Average Price Per Share Fixed assets Deferred Tax Assets, Property, Plant and Equipment Commercial paper Commercial Paper [Member] ApolloBio ApolloBio [Member] ApolloBio [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Trading days Common Stock, Shares Issued, Share Price, Consecutive Trading Days Common Stock, Shares Issued, Share Price, Consecutive Trading Days Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Name of Property [Axis] Name of Property [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaborative Agreements Collaborative Arrangement Disclosure [Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Weighted average exercise price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price General and administrative General and Administrative Expense ASSETS Assets [Abstract] Schedule Of Operating Loss And Tax Credit Carryforward Expirations Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block] Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block] Impairment Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Benefit from income taxes at statutory rates Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Other prepaid expenses Other Prepaid Expense, Current Computer equipment and other Property, Plant and Equipment, Other Types [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Accounts payable and accrued expenses due to affiliated entities Due to Related Parties, Current Accrued interest Debt instrument, Accrued Interest Debt instrument, Accrued Interest Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Supplemental disclosure: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash stock-based compensation Share-Based Payment Arrangement, Noncash Expense Options, grants in period, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other liabilities Other Liabilities, Noncurrent Share in net loss of Geneos Share in net loss of Geneos Share in current and accumulated net loss of Geneos Income (Loss) from Equity Method Investments Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of capital assets Payments to Acquire Property, Plant, and Equipment Interest expense Deferred Tax Asset, Interest Expense Deferred Tax Asset, Interest Expense Research and Development Expense Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Weighted Average Useful Life (Yrs) Weighted Average [Member] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Lassa Fever And MERS Vaccine Lassa Fever And MERS Vaccine [Member] Lassa Fever And MERS Vaccine [Member] Debt securities, available-for-sale, realized gain Debt Securities, Available-for-Sale, Realized Loss Schedule Of Convertible Debt Convertible Debt [Table Text Block] Number of positions reduced (in percent) Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Name of Major Customer [Domain] Customer [Domain] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] EX-101.PRE 11 ino-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 ino-20221231_g1.jpg begin 644 ino-20221231_g1.jpg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end GRAPHIC 13 ino-20221231_g2.jpg begin 644 ino-20221231_g2.jpg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ino-20221231_g3.jpg begin 644 ino-20221231_g3.jpg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end GRAPHIC 15 ino-20221231_g4.jpg begin 644 ino-20221231_g4.jpg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end GRAPHIC 16 ino-20221231_g5.jpg begin 644 ino-20221231_g5.jpg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�H?AM-"-;E@(H7\P74EP7,J;6C\MO-_3S]K/_@I+\3+C_@K)X;_ ."8 M/PQ^(7B/P)H]G\*+GQ;XO\8>#? ?_"1:U.?$/\ X-K?VBOBM_P3V\*_\$Q?&7_!1O2A\-/A_P#$!]>\'75M\)B= M2%LYOG:"[D;4=LS(UZXB\L1*H>3?YH\I8O>_VR_^"._QB^-7[9'PP_X*/?LR M?M?V7PV^-O@3PXFA>(=5G\#_ &_1_$MF%E5A)9&[5HLB>92#+)E#& RM$LE M'COQQ_:P_P""W&O?\$2[?]MGPII&H_"KXY_#4W\!WEII._1KBUBBM[^6ZGM+6.1IY+V*Y9$WA%@DC8H&<)%Z!X]_9:_: M#^(?PDT+X2>)OVHM.U2VO-:BN_BK7_ (2JR\Q7FTNVBAOX8]-LY440 M-'MN"T.Y7:1Y)9'^6?V3O^"*?Q>_X)Y? +]H?X/?"W_@I(/#'@#XI0ZIJ?AY M=-\ R6$WPXO)4=5N[.[;59"R) (HWRJ.PMHV62)@20#](:_&WX:2_M1?$_\ MX.R_BW\,)_VO/$%C9^"/@K'<:&(]"L)X;?2+BXT&\ETB.&:-DBC=[@;KA1Y[ M&)27[#[U_P""0'PW_:=^$O["WA[P'^UA\7/$7CGQ#8ZUJZ:1XH\86DT&KZAH MOV^<:=->13O)-%+);".7RI7:6)9$C^#TOFN[>$V?S6ETUPBVK.MA;*2\,V,2$;Q)+?MX4MM5N+U[-[^>.U07> MZ"*-PDJNS1._*;=N&S]1>,?^"Z7Q^B_X)F?L<_$B,V6E?$[]I[QO9>%]8\4: M?X?:]31;:+419:AJ=K8*LGGW1S&T5OL==TK81]JQMZAI?_!!GXE:7XX_;!\; M1_MJ:*S_ +7&AW>FZK;GX3RX\-K.\PWQ'^V/])*PW$R8;9E]C\!3&V=\1?\ M@W5LOB'_ ,$NOA1^P3??M936GC;X&^(IM9^&GQ:T?P>UF]K-)OC;\$?VBO!7C74/!7A/6K&Z^$ M7Q5\8^ WT&X\2Z;=0EI[::'[+:QF6UF78'2",NC E>-S1?\ !4W]BCX(_P#! M0G6/A]^RM\?M&:XT/Q#8>)/(O+? N=+O$LHF@O;=C]V6)\,.S#B>%$T/3;>./=\Z6JRREYY&;,DK M.%.U%CCB 8,WXO? KXW^//VC/A]\9/!7QK\-Z)H7@I=1%]X;U'P)/?7&J?:X M5B;%XFHPK!M"[E_V4_B MC19O@1XT6%WM[F"36K65((V.2;2<)(T?),$ZRP-U C_9[_@H=^T%X>^!GP(A M\/7_ ,6M)\$:M\1M=@\(Z!XFUC5X;&/2I+I9&N;\33LJ+):V45W=(&.'D@CC MZR 5A_\ !0__ ()E_!/_ (*#I\//%7C)$TKQG\*_'6F>)?!?BJ&V#S6_V>\A MGN+*09!>"X2':RY^5Q'(,E-K=9J7[/'QNUG]MK2_VF]4^.GAZ;P?H7@Z\T/1 M/ +>!)OM-K)=SVTUS>_VA_:.UIG^RQ1C-MA(P5'+NS@'Y,?\&S7[0>@?L91;LMRC3,P4QRDGZ%_;[_X(H?$#]KK_ (*, M?#/_ (*2?!O]KW2OA=XO^&5M:P6$4?PSDU1M5C@GDE\N[E&J6XDC99IX6"HI M,4I0L<*1[-X<_91_:]^%7[3/Q._:'^%W[3_AN^TOXF:AI=[J'P[\3>#IS86= MU::-9:>)KS4/^$BUO1/@Z]EXAFL;[:+JSANI=8N+>%9%#QES;.P21@,' M#4 >2?\ !G5\:_&VI?\ !*CQI:?%;Q"Z>%/ 'Q*U�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htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Feb. 24, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-14888    
Entity Registrant Name INOVIO PHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 33-0969592    
Entity Address, Address Line One 660 W. Germantown Pike    
Entity Address, Address Line Two Suite 110    
Entity Address, City or Town Plymouth Meeting    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19462    
City Area Code 267    
Local Phone Number 440-4200    
Title of 12(b) Security COMMON STOCK, $0.001 PAR VALUE    
Trading Symbol INO    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 425.5
Entity Common Stock, Shares Outstanding   260,131,986  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be filed with the Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement’) are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2022.
    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001055726    

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Location San Diego, California
Auditor Name Ernst & Young LLP
Auditor Firm ID 42
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 46,329,359 $ 71,143,778
Short-term investments 206,669,397 330,170,940
Accounts receivable 1,701,726 5,466,850
Accounts receivable from affiliated entities 10,036,490 2,565,194
Prepaid expenses and other current assets 50,130,481 38,836,991
Prepaid expenses and other current assets from affiliated entities 375,227 261,192
Total current assets 315,242,680 448,444,945
Fixed assets, net 7,727,997 17,453,206
Investments in affiliated entity 2,007,142 3,906,796
Intangible assets, net 2,129,861 2,626,355
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 10,228,207 11,571,026
Other assets 684,044 1,425,794
Total assets 348,533,302 495,941,493
Current liabilities:    
Accounts payable and accrued expenses 79,686,885 47,644,530
Accounts payable and accrued expenses due to affiliated entities 1,220,439 548,032
Accrued clinical trial expenses 10,594,073 10,326,266
Deferred revenue 0 21,628
Operating lease liability 2,803,973 2,603,956
Grant funding liability 2,475,031 4,559,721
Grant funding liability from affiliated entities 87,673 37,500
Total current liabilities 96,868,074 65,741,633
Deferred revenue, net of current portion 0 64,361
Operating lease liability, net of current portion 12,655,586 15,459,559
Deferred tax liabilities 32,046 32,046
Other liabilities 0 14,826
Total liabilities 126,170,546 96,272,072
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021 253,090 217,382
Additional paid-in capital 1,710,656,191 1,609,589,797
Accumulated deficit (1,487,847,784) (1,209,855,522)
Accumulated other comprehensive loss (698,741) (282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 222,362,756 399,669,421
Total liabilities and stockholders’ equity 348,533,302 495,941,493
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible senior notes $ 16,614,840 $ 14,959,647
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 9 9
Preferred stock, shares outstanding (in shares) 9 9
Common stock, par value (in USD per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 600,000,000 600,000,000
Common stock, shares issued (in shares) 253,091,319 217,382,887
Common stock, shares outstanding (in shares) 253,091,319 217,382,887
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 10,262,268 $ 1,774,758 $ 7,411,220
Operating expenses:      
Research and development 187,650,503 249,240,324 94,245,436
General and administrative 90,185,285 53,752,353 37,247,828
Total operating expenses 277,835,788 302,992,677 131,493,264
Loss from operations (267,573,520) (301,217,919) (124,082,044)
Other income (expense):      
Interest income 4,782,030 3,363,080 3,311,846
Interest expense (1,253,952) (1,936,447) (8,702,450)
Change in fair value of derivative liability 0 0 (75,670,977)
(Loss) gain on investment in affiliated entities (1,899,654) (553,570) 36,556,658
Net unrealized (loss) gain on available-for-sale equity securities (7,846,172) (3,222,838) 1,695,497
Other (expense) income, net (3,861,584) 343,371 (704,896)
Gain on deconsolidation of Geneos 0 0 4,121,075
Net loss before share in net loss of Geneos (277,652,852) (303,224,323) (162,890,304)
Share in net loss of Geneos (2,165,213) (434,387) (4,584,610)
Net loss (279,818,065) (303,658,710) (167,474,914)
Net loss attributable to non-controlling interest 0 0 1,063,757
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (279,818,065) $ (303,658,710) $ (166,411,157)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders      
Basic (in dollars per share) $ (1.17) $ (1.45) $ (1.07)
Diluted (in dollars per share) $ (1.17) $ (1.45) $ (1.07)
Weighted average number of common shares outstanding      
Basic (in shares) 238,622,188 208,829,801 155,126,857
Diluted (in shares) 238,622,188 208,829,801 155,126,857
Convertible Bonds      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ 0 $ (8,177,043)
6.50% Convertible Senior Notes Due 2024      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ 0 $ 8,762,030
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Comprehensive Income [Abstract]      
Net loss $ (279,818,065) $ (303,658,710) $ (167,474,914)
Other comprehensive (loss) income:      
Foreign currency translation (25,556) (30,134) 27,205
Unrealized (loss) gain on short-term investments, net of tax (390,949) 4,048 (755,963)
Comprehensive loss (280,234,570) (303,684,796) (168,203,672)
Comprehensive loss attributable to non-controlling interest 0 0 1,063,757
Comprehensive loss attributable to Inovio Pharmaceuticals, Inc. $ (280,234,570) $ (303,684,796) $ (167,139,915)
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
Total
Adjustment
6.50% Convertible Senior Notes Due 2024
August 2019 Bonds
Preferred stock
Common stock
Common stock
6.50% Convertible Senior Notes Due 2024
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
Adjustment
Additional paid-in capital
6.50% Convertible Senior Notes Due 2024
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated deficit
Adjustment
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2019         23 101,361,034                    
Beginning balance at Dec. 31, 2019 $ 5,404,858       $ 0 $ 101,361     $ 742,646,785       $ (739,785,655)   $ 472,608 $ 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           66,064,886                    
Issuance of common stock for cash, net of financing costs 454,486,400         $ 66,065     454,420,335              
Conversion of preferred stock/senior notes to common stock (in shares)         (14) 5,147 11,535,660 4,962,364                
Conversion of preferred stock/senior notes to common stock 0   $ 43,694,386 $ 102,671,310   $ 5 $ 11,536 $ 4,961 (5)   $ 43,682,850 $ 102,666,349        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           2,922,402                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments 8,241,624         $ 2,923     8,238,701              
Stock-based compensation 15,647,523               15,655,585             (8,062)
Acquisition of non-controlling interest in Geneos, net 2,379,969                             2,379,969
Deconsolidation of Geneos (3,181,640)                             (3,181,640)
Net loss attributable to common stockholders (167,474,914)                       (166,411,157)     (1,063,757)
Dissolution of majority-owned subsidiary VGX Animal Health, Inc. 0               96,269             (96,269)
Unrealized loss on short-term investments, net of tax (755,963)                           (755,963)  
Foreign currency translation 27,205                           27,205  
Ending balance (in shares) at Dec. 31, 2020         9 186,851,493                    
Ending balance at Dec. 31, 2020 461,140,758       $ 0 $ 186,851     1,367,406,869       (906,196,812)   (256,150) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           27,310,341                    
Issuance of common stock for cash, net of financing costs 209,441,410         $ 27,310     209,414,100              
Conversion of preferred stock/senior notes to common stock (in shares)           1,009,450                    
Conversion of preferred stock/senior notes to common stock 4,377,892         $ 1,009     4,376,883              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           2,211,603                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments 2,057,393         $ 2,212     2,055,181              
Stock-based compensation 26,336,764               26,336,764              
Net loss attributable to common stockholders (303,658,710)                       (303,658,710)      
Unrealized loss on short-term investments, net of tax 4,048                           4,048  
Foreign currency translation (30,134)                           (30,134)  
Ending balance (in shares) at Dec. 31, 2021         9 217,382,887                    
Ending balance at Dec. 31, 2021 399,669,421 $ (1,468,216)     $ 0 $ 217,382     1,609,589,797 $ (3,294,019)     (1,209,855,522) $ 1,825,803 (282,236) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           34,445,743                    
Issuance of common stock for cash, net of financing costs 82,955,311         $ 34,447     82,920,864              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           1,262,689                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,114,609)         $ 1,261     (1,115,870)              
Stock-based compensation 22,555,419               22,555,419              
Net loss attributable to common stockholders (279,818,065)                       (279,818,065)      
Unrealized loss on short-term investments, net of tax (390,949)                           (390,949)  
Foreign currency translation (25,556)                           (25,556)  
Ending balance (in shares) at Dec. 31, 2022         9 253,091,319                    
Ending balance at Dec. 31, 2022 $ 222,362,756       $ 0 $ 253,090     $ 1,710,656,191       $ (1,487,847,784)   $ (698,741) $ 0
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (279,818,065) $ (303,658,710) $ (167,474,914)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 3,656,713 3,040,096 3,038,996
Amortization of intangible assets 496,494 520,415 547,081
Amortization of operating lease right-of-use assets 1,342,819 1,170,270 1,041,713
Change in fair value of derivative liability 0 0 75,670,977
Non-cash stock-based compensation 22,555,419 26,336,764 15,647,523
Non-cash interest expense 186,977 858,644 4,077,686
Amortization of (discounts) premiums on investments (1,320,546) 1,633,286 0
Loss on short-term investments 4,029,961 5,397 588,270
Settlement of receivable with shares of common stock from affiliated entity (PLS) 0 0 (1,713,770)
Gain on deconsolidation of Geneos 0 0 (4,121,075)
Gain on remeasurement of investment in Geneos (165,215) 0 0
Loss on disposal of fixed assets 1,074,830 0 26,913
Loss (gain) on equity investment in affiliated entities 1,899,654 553,570 (36,556,658)
Share of net loss in Geneos 2,165,213 434,387 4,584,610
Net unrealized loss (gain) on available-for-sale equity securities 7,846,172 3,222,838 (1,695,497)
Unrealized transaction (gain) loss on foreign-currency denominated debt 0 (176,927) 15,902
Changes in operating assets and liabilities:      
Accounts receivable, including from affiliated entities (3,706,172) 11,031,705 (17,015,471)
Prepaid expenses and other current assets, including from affiliated entities (5,336,525) (6,343,632) (38,475,465)
Other assets 741,750 24,531,654 (23,285,424)
Accounts payable and accrued expenses, including from affiliated entities 32,606,581 26,140,970 3,251,478
Accrued clinical trial expenses 267,807 375,921 5,962,381
Deferred revenue, including from affiliated entity (85,989) (39,853) (62,353)
Operating lease right-of-use assets and liabilities, net (2,603,956) (2,329,394) (2,091,855)
Grant funding liability, including from affiliated entity (2,034,517) (2,973,089) 624,173
Other liabilities (14,826) (42,837) 20,720
Net cash used in operating activities (216,215,421) (215,708,525) (177,979,046)
Cash flows from investing activities:      
Purchases of investments (248,528,843) (348,953,236) (156,216,677)
Proceeds from sale of or maturity of investments 361,083,850 174,839,758 62,991,023
Purchases of capital assets (969,153) (1,231,006) (1,520,665)
Proceeds from sale of investment of GeneOne 0 0 40,125,418
Decrease in cash resulting from the deconsolidation of Geneos 0 0 (2,774,851)
Investment in Geneos (1,999,998) 0 (1,399,999)
Net cash provided by (used in) investing activities 109,585,856 (175,344,484) (58,795,751)
Cash flows from financing activities:      
Proceeds from issuance of common stock, net of issuance costs 82,955,311 209,441,410 454,486,400
Proceeds from stock option exercises 283,022 6,668,741 12,269,801
Taxes paid related to net share settlement of equity awards (1,397,631) (4,611,348) (4,028,177)
Acquisition of non-controlling interest 0 0 2,379,969
Proceeds from Geneos issuance of note payable 0 0 171,620
Net cash provided by financing activities 81,840,702 211,498,803 465,279,613
Effect of exchange rate changes on cash and cash equivalents (25,556) (30,134) 27,205
(Decrease) increase in cash and cash equivalents (24,814,419) (179,584,340) 228,532,021
Cash and cash equivalents, beginning of period 71,143,778 250,728,118 22,196,097
Cash and cash equivalents, end of period 46,329,359 71,143,778 250,728,118
Supplemental disclosure:      
Amounts accrued for purchases of property and equipment 108,181 204,815 136,711
Interest paid 1,066,975 1,077,803 4,624,764
Change in prepaid expenses and other current assets related to fixed assets 6,071,000 7,709,337 0
August 2019 Bonds      
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain (loss) on extinguishment of convertible bonds and senior notes 0 0 8,177,043
6.50% Convertible Senior Notes Due 2024      
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ 0 $ (8,762,030)
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity (Parenthetical)
 12 Months Ended
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.22.4
The Company
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company The Company
Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company’s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.
In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA.
INOVIO's lead candidates are focused on diseases associated with HPV. In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases.
The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head & neck; other HPV-related disorders, such as RRP; and GBM.
INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation and Liquidity
The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December 31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December 31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company’s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.
In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0 million, $47.7 million and $454.5 million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1 million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Company also issued convertible notes and bonds in a series of private placement transactions. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.
The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.
The Company is and, from time to time, may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition.
Consolidation
The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.
The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.
Fair Value of Financial Instruments
The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company’s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.
Cash and Cash Equivalents
Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December 31, 2022 and 2021.
Short-term Investments
The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company’s affiliated entity, PLS, at December 31, 2022 and 2021.
Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.
Accounts Receivable
Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December 31, 2022 and 2021.
Fixed Assets
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.
Long-Lived Assets
All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December 31, 2022.
Valuation of Intangible Assets and Goodwill
Intangible assets are amortized over their estimated useful lives ranging from two to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.
License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2022 and 2021, the Company’s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1 million and $2.6 million, respectively.
The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2022.
Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.
Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company
cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. See Note 8 for further discussion of the Company’s goodwill and intangible assets.
Income Taxes
The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
Valuation allowances against the Company’s deferred tax assets were $299.1 million and $237.2 million at December 31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.
Revenue Recognition
The Company recognizes revenue, in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Collaborative Arrangements
The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.
The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.
As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
License Fees
If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Product Supply Services
Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer.
Milestone Payments
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.
Grants
The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.
Foreign Currency Transactions
The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.
Variable Interest Entities (VIE)
The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.
Equity Investments
Under ASC Topic 321, Investments - Equity Securities, the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, Fair Value Measurement, to estimate fair value using the net asset value per share (or its equivalent). The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. 
Research and Development Expenses
The Company’s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.
Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.
Net Loss Per Share
Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.
The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:
Year Ended December 31,
202220212020
Options to purchase common stock12,221,548 10,488,993 8,906,624 
Service-based restricted stock units2,556,257 2,448,868 2,558,052 
Performance-based restricted stock units111,941 663,353 663,353 
Convertible preferred stock3,309 3,309 3,309 
Convertible notes3,049,980 3,049,980 3,049,980 
December 2019 Bonds— — 1,009,450 
Total17,943,035 16,654,503 16,190,768 

Leases
For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.
Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.
Stock-Based Compensation
The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the
date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.
The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate2.05%0.91%0.63%
Expected volatility94%93%78%
Expected life in years5.766
Dividend yield———

The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate1.96%1.45%0.82%
Expected volatility87%87%76%
Expected life in years101010
Dividend yield———

Recent Accounting Pronouncements
The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
ASU No. 2020-06. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8 million, a decrease in additional paid-in capital of $3.3 million, and an increase in convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5 million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Concentration of Credit Risk Revenue Recognition and Concentration of Credit RiskDuring the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:
Customer2022 Revenue% of Total
Revenue		2021 Revenue% of Total
Revenue		2020 Revenue% of Total
Revenue
Advaccine$— — %$— — %$5,000,000 68 %
Plumbline Life Sciences, Inc. (affiliated entity)33,596 — 245,310 14 1,370,396 18 
U.S. Department of Defense9,591,778 94 754,853 43 — — 
All other, including affiliated entities636,894 6 774,595 43 1,040,824 14 
Total revenue$10,262,268 100 %1$1,774,758 100 %1$7,411,220 100 %

Of the total revenue recognized during the year ended December 31, 2022, $14,000 was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $46,000 that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date.
As of December 31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December 31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Agreements
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Agreements Collaborative Agreements
Advaccine Biopharmaceuticals Suzhou Co., Ltd.
On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), which was amended and restated on June 7, 2021 (as amended and restated, the “Advaccine Agreement”). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company’s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as “Greater China”) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company’s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.
The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company’s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company’s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.
Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0 million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0 million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine’s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.
Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5 million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.
Under the Advaccine Agreement, the Company will supply Advaccine’s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine’s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.
The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months’ written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months’ written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.
The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0 million upfront payment received in January 2021 plus a $2.0 million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.
Under Topic 606, the entire transaction price of $5.0 million was allocated to the license performance obligation. The Company recognized $0, $0 and $5.0 million of revenue for the years ended December 31, 2022, 2021, and 2020, respectively, under the Advaccine Agreement.
In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured. During the years ended December 31, 2022, 2021 and 2020 the Company received funding of $1.2 million, $4.5 million and $0, respectively, from Advaccine that was recorded as contra-research and development expense.
ApolloBio Corporation
On December 29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"), with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, its DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories.
The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the ApolloBio Agreement. In the event that VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio’s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory.
The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.
For the years ended December 31, 2022, 2021 and 2020, there has been no significant reimbursable program costs under the ApolloBio Agreement.
Coalition for Epidemic Preparedness Innovations
The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December 31, 2022, 2021 and 2020, the Company received funding of $6.7 million, $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December 31, 2022 and 2021, the Company had an accounts receivable balance of $1.7 million and $1.9 million, respectively, on the consolidated balance sheet related to these CEPI grants.
In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.
In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the years ended December 31, 2022, 2021 and 2020, the Company received funding of $1.1 million, $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December 31, 2022 and 2021, the Company had $2.3 million and $1.8 million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively
Bill & Melinda Gates Foundation
In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $233,000, $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December 31, 2022 and 2021, the Company had $153,000 and $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.
In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $0, $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant.
Department of Defense (DoD)
In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the “OTA Agreement”) with the DoD to fund the Company’s efforts in developing the CELLECTRA® 3PSP device and associated arrays to be used for delivery of INO-4800 against COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5 million. The Company determined that the OTA Agreement should be considered under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $6.1 million, $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement
Additionally, in June 2020, the Company was awarded a fixed-price contract (the “Procurement Contract”) from the DoD for the purchase of the Company’s intradermal CELLECTRA® 2000 device and accessories. The total purchase price under the Procurement Contract was $16.8 million. The Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA® 2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7 million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended December 31, 2022, 2021
and 2020, the Company recorded revenue of $9.6 million, $755,000 and $0, respectively, from the Procurement Contract.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Short-term Investments and Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Short-term Investments and Fair Value Measurements Short-term Investments and Fair Value Measurements
The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:
 
 As of December 31, 2022
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$117,036,232 $— $(9,373,514)$107,662,718 
U.S. treasury securities
Less than 1
95,001,209 7,567 (44,266)94,964,510 
Certificates of deposit
Less than 1
2,977,564 13,664 (320)2,990,908 
U.S. agency mortgage-backed securities*1,435,592 — (384,331)1,051,261 
$216,450,597 $21,231 $(9,802,431)$206,669,397 
 As of December 31, 2021
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$192,966,772 $87,069 $(1,614,411)$191,439,430 
U.S. treasury securities
Less than 1
94,193,441 — (9,921)94,183,520 
Commercial paper
Less than 1
39,967,853 — — 39,967,853 
Certificates of deposit
Less than 1
2,976,210 15,618 (338)2,991,490 
U.S. agency mortgage-backed securities*1,608,137 4,508 (23,998)1,588,647 
$331,712,413 $107,195 $(1,648,668)$330,170,940 

*No single maturity date.

During the years ended December 31, 2022 and 2021, the Company recorded gross realized gain on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8 million and $3.2 million, respectively. No material balances were reclassified out of accumulated other comprehensive loss for the years ended December 31, 2022, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December 31, 2022, the Company had 29 available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months.
The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were primarily due to changes in interest rates, and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December 31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.
The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:
 
Fair Value Measurements at
 December 31, 2022
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
    Mutual funds$107,662,718 $107,662,718 $— $— 
    U.S. treasury securities94,964,510 94,964,510 — — 
    Certificates of deposit2,990,908 — 2,990,908 — 
    U.S. agency mortgage-backed securities1,051,261 — 1,051,261 — 
Total short-term investments206,669,397 202,627,228 4,042,169 — 
Investment in affiliated entity2,007,142 2,007,142 — — 
Total assets measured at fair value$208,676,539 $204,634,370 $4,042,169 $— 

The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:
 
Fair Value Measurements at
 December 31, 2021
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
     Mutual funds$191,439,430 $191,439,430 $— $— 
     U.S. treasury securities94,183,520 94,183,520 — — 
     Commercial paper39,967,853 — 39,967,853 — 
     Certificates of deposit2,991,490 — 2,991,490 — 
     U.S. agency mortgage-backed securities1,588,647 — 1,588,647 — 
Total short-term investments330,170,940 285,622,950 44,547,990 — 
Investments in affiliated entity3,906,796 3,906,796 — — 
Total assets measured at fair value$334,077,736 $289,529,746 $44,547,990 $— 

Level 1 assets at December 31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company’s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain or loss on available-for-sale equity securities or as a gain or loss on investment in affiliated entity.
Level 2 assets at December 31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December 31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the
service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December 31, 2022 and 2021.
Short-term Investments and Fair Value Measurements Short-term Investments and Fair Value Measurements
The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:
 
 As of December 31, 2022
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$117,036,232 $— $(9,373,514)$107,662,718 
U.S. treasury securities
Less than 1
95,001,209 7,567 (44,266)94,964,510 
Certificates of deposit
Less than 1
2,977,564 13,664 (320)2,990,908 
U.S. agency mortgage-backed securities*1,435,592 — (384,331)1,051,261 
$216,450,597 $21,231 $(9,802,431)$206,669,397 
 As of December 31, 2021
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$192,966,772 $87,069 $(1,614,411)$191,439,430 
U.S. treasury securities
Less than 1
94,193,441 — (9,921)94,183,520 
Commercial paper
Less than 1
39,967,853 — — 39,967,853 
Certificates of deposit
Less than 1
2,976,210 15,618 (338)2,991,490 
U.S. agency mortgage-backed securities*1,608,137 4,508 (23,998)1,588,647 
$331,712,413 $107,195 $(1,648,668)$330,170,940 

*No single maturity date.

During the years ended December 31, 2022 and 2021, the Company recorded gross realized gain on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8 million and $3.2 million, respectively. No material balances were reclassified out of accumulated other comprehensive loss for the years ended December 31, 2022, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December 31, 2022, the Company had 29 available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months.
The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were primarily due to changes in interest rates, and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December 31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.
The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:
 
Fair Value Measurements at
 December 31, 2022
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
    Mutual funds$107,662,718 $107,662,718 $— $— 
    U.S. treasury securities94,964,510 94,964,510 — — 
    Certificates of deposit2,990,908 — 2,990,908 — 
    U.S. agency mortgage-backed securities1,051,261 — 1,051,261 — 
Total short-term investments206,669,397 202,627,228 4,042,169 — 
Investment in affiliated entity2,007,142 2,007,142 — — 
Total assets measured at fair value$208,676,539 $204,634,370 $4,042,169 $— 

The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:
 
Fair Value Measurements at
 December 31, 2021
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
     Mutual funds$191,439,430 $191,439,430 $— $— 
     U.S. treasury securities94,183,520 94,183,520 — — 
     Commercial paper39,967,853 — 39,967,853 — 
     Certificates of deposit2,991,490 — 2,991,490 — 
     U.S. agency mortgage-backed securities1,588,647 — 1,588,647 — 
Total short-term investments330,170,940 285,622,950 44,547,990 — 
Investments in affiliated entity3,906,796 3,906,796 — — 
Total assets measured at fair value$334,077,736 $289,529,746 $44,547,990 $— 

Level 1 assets at December 31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company’s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain or loss on available-for-sale equity securities or as a gain or loss on investment in affiliated entity.
Level 2 assets at December 31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December 31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the
service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December 31, 2022 and 2021.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Certain Balance Sheet Items
 12 Months Ended
Dec. 31, 2022
Certain Balance Sheet Items [Abstract]  
Certain Balance Sheet Items Certain Balance Sheet Items
Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following:
 
20222021
Insurance recovery (a)$30,000,000 $— 
Prepaid manufacturing expenses1,401,028 27,474,159 
Other prepaid expenses18,729,453 11,362,832 
$50,130,481 $38,836,991 
Accounts payable and accrued expenses at December 31, 2022 and 2021 consisted of the following:
20222021
Trade accounts payable$19,862,487 $27,424,743 
Accrued compensation12,574,921 16,112,912 
Accrued litigation settlement (a)44,000,000 — 
Other accrued expenses3,249,477 4,106,875 
$79,686,885 $47,644,530 
(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under “Legal Proceedings.” The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0 million in cash and $14.0 million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Fixed Assets
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Fixed Assets Fixed Assets
Fixed assets at December 31, 2022 and 2021 consisted of the following:
 
CostAccumulated
Depreciation
and
Amortization		Net Book
Value
As of December 31, 2022
Leasehold improvements$15,803,108 $(10,036,080)$5,767,028 
Research and development equipment5,300,104 (4,295,217)1,004,887 
Office furniture and fixtures2,827,476 (2,803,800)23,676 
Computer equipment and other 5,360,712 (4,428,306)932,406 
$29,291,400 $(21,563,403)$7,727,997 
As of December 31, 2021
Leasehold improvements$15,803,108 $(8,258,608)$7,544,500 
Research and development equipment12,392,916 (4,279,816)8,113,100 
Office furniture and fixtures2,827,476 (2,599,643)227,833 
Computer equipment and other 5,374,084 (3,806,311)1,567,773 
$36,397,584 $(18,944,378)$17,453,206 
Depreciation expense for the years ended December 31, 2022, 2021 and 2020 was $3.7 million, $3.0 million and $3.0 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1 million and disposed of fixed assets with a net book value of $1.1 million. The Company has recorded a receivable from the sale of these assets of $6.1 million, which is included in prepaid expenses and other current assets on the consolidated balance sheet.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
The following sets forth goodwill and intangible assets by major asset class:
 
 December 31, 2022December 31, 2021
 Weighted Average Useful
Life
(Yrs)		GrossAccumulated
Amortization		Net Book
Value		GrossAccumulated
Amortization		Net Book
Value
Indefinite lived:
Goodwill$10,513,371 $— $10,513,371 $10,513,371 $— $10,513,371 
Definite lived:
Licenses101,323,761 (1,323,761)— 1,323,761 (1,305,600)18,161 
Bioject (a)125,100,000 (2,988,889)2,111,111 5,100,000 (2,735,556)2,364,444 
Other (b)184,050,000 (4,031,250)18,750 4,050,000 (3,806,250)243,750 
Total intangible assets1110,473,761 (8,343,900)2,129,861 10,473,761 (7,847,406)2,626,355 
Total goodwill and intangible assets$20,987,132 $(8,343,900)$12,643,232 $20,987,132 $(7,847,406)$13,139,726 

(a)Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.
(b)Other intangible assets represent the estimated fair value of acquired intellectual property.
Aggregate amortization expense on intangible assets was $496,000, $520,000 and $547,000 for the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense related to intangible assets at December 31, 2022 is expected to be incurred as follows:
 
Year ending December 31,
2023$273,000 
2024253,000 
2025253,000 
2026253,000 
2027253,000 
Thereafter845,000 
$2,130,000 

There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022, 2021 and 2020.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Debt
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Convertible Debt Convertible Debt
Convertible Senior Notes
On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the “Notes”). The Notes were sold in a private offering to
qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.
The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased. Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.
The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3 million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2 million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.
On January 1, 2022, the Company adopted ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8 million, a decrease to additional paid-in capital of $3.3 million, and an increase to convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.
The balance of the Notes at December 31, 2022 was as follows:
Principal amount$78,500,000 
Principal amount converted into common shares(62,085,000)
Unamortized debt issuance cost(155,815)
Accrued interest355,655 
     Net carrying amount $16,614,840 

For the years ended December 31, 2022, 2021 and 2020, the Company recognized $1.3 million, $1.9 million and $6.9 million, respectively, of interest expense related to the Notes, of which $1.1 million, $1.1 million and $4.1 million, respectively, related to the contractual interest coupon.
As of December 31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were as follows:
20231,067,000 
202416,948,000 
Total$18,015,000 
December 2019 Convertible Bonds
On December 26, 2019, the Company closed a private placement of convertible promissory notes (the “December 2019 Bonds”) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.
The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December 31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December 31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. Upon conversion, the $4.4 million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.
During the year ended December 31, 2021, the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was 6.2%.
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Preferred Stock
   Shares Outstanding as of
December 31,
 Shares AuthorizedShares Issued20222021
Series C Preferred Stock, par $0.001
1,091 1,091 9 9 

The holder of a share or shares of Series C preferred stock has the right at any time, at such holder’s option, to convert all or any lesser portion of such holder’s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value was $27.20 per share, such that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.
Issuances of Common Stock
On November 9, 2021, the Company entered into an ATM Equity OfferingSM Sales Agreement (the “2021 Sales Agreement”) with outside sales agents (collectively, the “Sales Agents”) for the offer and sale of its common stock for an aggregate offering price of up to $300.0 million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December 31, 2022 and 2021, the Company sold 34,445,743 and 6,955,341 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $2.44 and $6.96 per share, respectively, resulting in aggregate net proceeds of $83.0 million and $47.7 million, respectively. As of December 31, 2022 there was $167.4 million of remaining capacity under the 2021 Sales Agreement.
On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1 million.
Stock Options and Restricted Stock Units
The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.
The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December 31, 2022, the maximum number of shares of the Company’s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, the maximum number of shares is increased by 2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At December 31, 2022, the Company had 3,831,240 shares of common stock available for future grant under the 2016 Incentive Plan, 2,446,257 shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase 10,132,969 shares of common stock and 111,941 shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive
Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March 9, 2026.
On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company’s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At December 31, 2022 the Company had 1,703,750 shares of common stock available for future grant under the 2022 Inducement Plan, 110,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 186,250 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.
The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March 31, 2007 and terminated by its terms on March 31, 2017. At December 31, 2022, the Company had options outstanding to purchase 1,902,329 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.
Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 was $22.2 million, $25.0 million and $14.5 million, respectively, of which $8.8 million, $13.4 million and $8.0 million was included in research and development expenses and $13.4 million, $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until five years after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $4.2 million charge related to these RSU and stock option modifications.
At December 31, 2022 and 2021, there was $10.5 million and $16.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years and 2.0 years, respectively.
At December 31, 2022 and 2021, there was $7.2 million and $13.4 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.7 years and 1.8 years, respectively.
The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December 31, 2022, 2021 and 2020 was $1.3 million, $1.4 million and $1.2 million, respectively. As of December 31, 2022, options to purchase 665,875 shares of common stock granted to non-employees remained outstanding.
The following table summarizes total stock options outstanding at December 31, 2022:
 
 Options OutstandingOptions Exercisable
Exercise PriceShares Underlying Options
Outstanding		Weighted-Average
Remaining
Contractual Life
(in Years)		Weighted
Average
Exercise Price		Shares Underlying Options
Exercisable		Weighted Average
Exercise Price
$1.56-$3.00
830,542 8.3$2.17 247,104 $2.29 
$3.01-$6.00
5,461,365 7.1$3.50 3,059,330 $3.67 
$6.01-$9.00
3,349,587 5.3$7.57 2,861,909 $7.49 
$9.01-$12.00
1,930,825 7.1$10.97 1,080,389 $10.89 
$12.01-$15.00
580,947 4.1$13.38 529,392 $13.34 
$15.01-$25.62
68,282 7.6$21.12 51,568 $21.11 
12,221,548 6.6$6.28 7,829,692 $6.79 

At December 31, 2022, the aggregate intrinsic value of options outstanding was $0, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.7 years.
At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $4.0 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $4.6 million.
At December 31, 2022, options to purchase 12,221,548 shares of common stock and 2,556,257 RSUs were expected to vest.
Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares		Weighted-Average
Exercise Price
Balance, December 31, 202110,488,993 $7.93 
Granted4,623,448 3.11 
Exercised(118,694)2.38 
Cancelled(2,772,199)7.46 
Balance, December 31, 202212,221,548 $6.28 

Restricted stock unit activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares
Balance, December 31, 20212,448,868 
Granted2,485,947 
Vested(1,618,235)
Cancelled(760,323)
Balance, December 31, 20222,556,257 

The weighted average exercise price per share was $8.47 for the 77,250 options which expired during the year ended December 31, 2022, $4.56 for the 7,000 options which expired during the year ended December 31, 2021 and $4.44 for the 78,750 options which expired during the year ended December 31, 2020.
The weighted average grant date fair value per share was $2.34, $7.61 and $6.87 for options granted during the years ended December 31, 2022, 2021 and 2020, respectively.
The weighted average grant date fair value was $3.12, $10.37 and $9.12 per share for RSUs granted during the years ended December 31, 2022, 2021 and 2020, respectively.
The Company received $283,000, $6.7 million and $12.3 million in proceeds from the exercise of stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $81,000, $7.0 million and $14.2 million during the years ended December 31, 2022, 2021 and 2020, respectively.
As of December 31, 2022, the Company had 111,941 performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December 31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Leases
The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December 31, 2022 of 0.9 years to 7.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.
The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.
Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.
As of December 31, 2022, the maturities of the Company's operating lease liabilities were as follows:
Year ending December 31,
2023$4,089,000 
20243,050,000 
20253,063,000 
20263,139,000 
20272,526,000 
Thereafter4,223,000 
   Total remaining lease payments20,090,000 
Less: present value adjustment(4,630,000)
   Total operating lease liabilities15,460,000 
Less: current portion(2,804,000)
Long-term operating lease liabilities$12,656,000 
Weighted-average remaining lease term5.9 years
Weighted-average discount rate8.6 %

Lease costs included in operating expenses in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 were $3.4 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.
In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.
In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.
Legal Proceedings
Securities Class Action Litigation
On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. The plaintiffs’ complaint was later amended to include certain of the Company’s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $30.0 million in cash and $14.0 million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $30.0 million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.
Shareholder Derivative Litigation
On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class
action complaint described above. The lawsuit accuses the Company’s board of directors of failing to exercise reasonable and prudent supervision over the Company’s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company’s current directors as defendants. The Devarakonda complaint also names one of the Company’s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.
On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.
On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.
VGXI Litigation
On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company’s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.
On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI’s counterclaims, disputing the allegations and the claims raised in VGXI’s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.
The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI’s counterclaims.
GeneOne Litigation
On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys’ fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company’s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company’s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney’s fees, and costs. On October 18, 2021, GeneOne filed its answer to the Company’s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne’s new matter. A trial date for this litigation has not been set.
The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne’s complaint.
Other Matters
From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of
operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company’s consolidated results of operations or financial position.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.
The components of pretax loss from operations are as follows:
Year Ended December 31,
202220212020
     U.S. Domestic$(277,440,803)$(302,614,003)$(162,664,355)
     Foreign(211,249)(610,320)(225,949)
Pretax loss from operations$(277,652,052)$(303,224,323)$(162,890,304)

There was no provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020.
The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows: 
Year Ended December 31,
202220212020
Benefit from income taxes at statutory rates$(58,307,000)$(63,677,000)$(34,207,000)
State income tax, net of federal benefit(3,601,000)(3,447,000)— 
Change in valuation allowance61,065,000 77,424,000 21,428,000 
Nondeductible loss on extinguishment of debt— — 14,450,000 
Research and development tax credits(7,534,000)(16,523,000)(2,650,000)
Stock-based compensation2,913,000 483,000 (1,953,000)
Uncertain tax positions2,291,000 6,509,000 1,068,000 
Deconsolidation of subsidiary— — 853,000 
Expired NOLs and credits1,459,000 616,000 468,000 
Limited NOLs and credits(1,337,000)(542,000)(368,000)
Change in tax rates(187,000)— — 
Foreign tax rate differential(8,000)(24,000)(9,000)
Other3,246,000 (819,000)920,000 
$— $— $— 

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are shown below:
As of December 31,
20222021
Deferred tax assets:
Capitalized research expense$41,252,000 $4,200,000 
NOL carryforwards212,768,000 197,144,000 
Research and development and other tax credits26,442,000 23,005,000 
Deferred revenue538,000 987,000 
Stock-based compensation3,945,000 3,599,000 
Acquired intangibles559,000 637,000 
Interest expense — 83,000 
Investment in affiliated entity1,569,000 750,000 
Lease liability3,247,000 3,793,000 
Fixed assets57,000 — 
Other11,062,000 5,973,000 
301,439,000 240,171,000 
Valuation allowance(299,124,000)(237,205,000)
Total deferred tax assets2,315,000 2,966,000 
Deferred tax liabilities:
Acquired intangibles(199,000)(194,000)
Right of use asset(2,148,000)(2,430,000)
Note discount— (321,000)
Fixed assets— (53,000)
Total deferred tax liabilities(2,347,000)(2,998,000)
Net deferred tax liabilities$(32,000)$(32,000)

As of December 31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $625.4 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized.
The Company also had Korean NOL carryforwards of $1.0 million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized.
In addition, as of December 31, 2022, the Company had federal and state research and development (R&D) tax credit carryforwards of $40.5 million and $4.7 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.
Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):
Expiration Date:Federal NOLsState NOLsForeign NOLsFederal R&DState R&D
2023$5.3 $1.2 $— $— $— 
202418.9 9.1 — — — 
20259.6 5.2 — — — 
202612.2 7.1 — — — 
2027 and thereafter249.2 277.3 1.0 40.5 — 
Indefinite625.4 — — — 4.7 
$920.6 $299.9 $1.0 $40.5 $4.7 
Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s NOL and R&D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of NOL and R&D credit carryforwards as of December 31, 2022. As a result of the analysis, the Company estimates that approximately $8.3 million of tax benefits related to NOL and R&D carryforwards will expire unused. Accordingly, the related NOL and R&D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&D carryforwards.
The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.
The following table summarizes the activity related to the Company's unrecognized tax benefits:
 Year ended December 31,
 202220212020
Balance at beginning of the year$18,819,000 $12,210,000 $11,204,000 
Increases related to current year tax positions2,902,000 6,602,000 1,043,000 
Increases (decreases) related to prior year tax positions(582,000)7,000 27,000 
Other— — (64,000)
Balance at end of the year$21,139,000 $18,819,000 $12,210,000 

The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $19.7 million, $17.4 million and $10.9 million as of December 31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (“IRS”), state, local or foreign tax examination.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.22.4
401(k) Plan
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
401(k) Plan 401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees’ contributions, up to 6% of their annual compensation. The Company’s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.8 million, $1.5 million and $1.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transaction, Due from (to) Related Party [Abstract]  
Related Party Transactions Related Party TransactionsPlumbline Life Sciences, Inc.
The Company owned 597,808 shares of common stock in PLS as of December 31, 2022 and 2021, representing a 18.7% and 18.9% ownership interest, respectively. One of the Company's directors, Dr. David B. Weiner, acts as a consultant to PLS.
Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from PLS of $34,000, $245,000 and $1.4 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $59,000 and $25,000, respectively, related to PLS.

The Wistar Institute
The Company's director Dr. David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.
In March 2016, the Company entered into collaborative research agreements with Wistar for preventive and therapeutic DNA-based immunotherapy applications and products developed by Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.
In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $1.9 million for all direct and indirect costs incurred in the conduct of the collaborative research.
In November 2016, the Company received a $6.1 million sub-grant through Wistar to develop a dMAb against the Zika infection, with funding through December 2021.
The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, with funding through February 2023.
In 2020, the Company received a $10.7 million sub-grant through Wistar, which was amended in 2021 to $13.6 million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0 million in funding through March 2024, of which $3.3 million has been exercised as of December 31, 2022.
Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December 31, 2022 and 2021, the Company recorded $8.7 million and $3.0 million, respectively, as contra-research and development expense from Wistar.
Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December 31, 2022, 2021 and 2020 were $1.4 million, $2.9 million and $2.3 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $9.9 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.2 million and $548,000, respectively, related to Wistar. As of December 31, 2022 and 2021, the Company had a prepaid expense balance of $375,000 and $261,000, respectively, and recorded $88,000 and $37,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Geneos Therapeutics, Inc.
 12 Months Ended
Dec. 31, 2022
Noncontrolling Interest [Abstract]  
Geneos Therapeutics, Inc. Geneos Therapeutics, Inc.
In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a Series A preferred stock financing. The Company invested $1.2 million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held 61% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, Consolidation.
In January 2020, Geneos completed the second closing of the Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held 52% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.
In June 2020, Geneos closed an additional Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial
interest. Based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.
The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. Since the Company’s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company’s common stock investment and is therefore recorded as an equity security under ASC 321.
Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Any difference between the carrying amount of the Company’s investment and the amount of underlying equity in Geneos’s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.
Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, the Company’s investment will be marked to fair value.  There have been no observable price changes or impairments identified since the deconsolidation date.
In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4 million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.
The Company’s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5 million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss was allocated to the Company’s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance to $0 as of March 31, 2021.
In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.
In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0 million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.
The fair value of Geneos’s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.
The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:
Investment in Geneos Series A-2 preferred stock$1,999,998 
Remeasurement of Geneos Series A-1 preferred stock165,215 
Share in current and accumulated net loss of Geneos (2,165,213)
Investment in Geneos as of December 31, 2022$— 
The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.
The Company continues to exclusively license its SynCon immunotherapy and CELLECTRA technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology.
The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr. David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the “Reduction”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately 24 employees, which represented 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.
On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued 7,000,000 shares of common stock. Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. The number of shares will be calculated based on the average trading price of the common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Liquidity
Basis of Presentation and Liquidity
The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December 31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December 31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company’s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.
In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0 million, $47.7 million and $454.5 million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1 million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Company also issued convertible notes and bonds in a series of private placement transactions. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.
The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.The Company is and, from time to time, may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition.
Consolidation ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.
Segment Reporting
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.
Fair value of Financial Instruments
Fair Value of Financial Instruments
The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company’s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December 31, 2022 and 2021.
Short Term Investments
Short-term Investments
The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company’s affiliated entity, PLS, at December 31, 2022 and 2021.
Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.
Accounts Receivable Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.
Fixed Assets
Fixed Assets
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.
Long-Lived Assets Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.
Valuation of Intangible Assets and Goodwill
Valuation of Intangible Assets and Goodwill
Intangible assets are amortized over their estimated useful lives ranging from two to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.
License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2022 and 2021, the Company’s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1 million and $2.6 million, respectively.
The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2022.
Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.
Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company
cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations.
Income Taxes
Income Taxes
The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
Valuation allowances against the Company’s deferred tax assets were $299.1 million and $237.2 million at December 31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.
Revenue Recognition
Revenue Recognition
The Company recognizes revenue, in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“Topic 606”), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
License Fees
If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Product Supply Services
Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer.
Milestone Payments
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.
Collaboration Agreements
Collaborative Arrangements
The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.
The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.
As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
Grants GrantsThe Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, Not-for-Profit Entities-Revenue Recognition, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.
Foreign Currency Transactions
Foreign Currency Transactions
The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.
Variable Interest Entities (VIE)
Variable Interest Entities (VIE)
The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.
Equity Method Investments Equity InvestmentsUnder ASC Topic 321, Investments - Equity Securities, the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, Fair Value Measurement, to estimate fair value using the net asset value per share (or its equivalent). The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.
Research and Development Expenses
Research and Development Expenses
The Company’s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.
Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.
Net Loss Per Share Net Loss Per ShareBasic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.
Leases
Leases
For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.
Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.
Stock-Based Compensation
Stock-Based Compensation
The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the
date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.
Recent Accounting Pronouncements - Recently Adopted
Recent Accounting Pronouncements
The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
ASU No. 2020-06. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8 million, a decrease in additional paid-in capital of $3.3 million, and an increase in convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5 million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect
The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:
Year Ended December 31,
202220212020
Options to purchase common stock12,221,548 10,488,993 8,906,624 
Service-based restricted stock units2,556,257 2,448,868 2,558,052 
Performance-based restricted stock units111,941 663,353 663,353 
Convertible preferred stock3,309 3,309 3,309 
Convertible notes3,049,980 3,049,980 3,049,980 
December 2019 Bonds— — 1,009,450 
Total17,943,035 16,654,503 16,190,768 
Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options
The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate2.05%0.91%0.63%
Expected volatility94%93%78%
Expected life in years5.766
Dividend yield———

The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:
 Year Ended December 31,
 202220212020
Risk-free interest rate1.96%1.45%0.82%
Expected volatility87%87%76%
Expected life in years101010
Dividend yield———
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition and Concentration of Credit Risk (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue From External Customers The following table indicates the percentage of total revenues in excess of 10% with any single customer:
Customer2022 Revenue% of Total
Revenue		2021 Revenue% of Total
Revenue		2020 Revenue% of Total
Revenue
Advaccine$— — %$— — %$5,000,000 68 %
Plumbline Life Sciences, Inc. (affiliated entity)33,596 — 245,310 14 1,370,396 18 
U.S. Department of Defense9,591,778 94 754,853 43 — — 
All other, including affiliated entities636,894 6 774,595 43 1,040,824 14 
Total revenue$10,262,268 100 %1$1,774,758 100 %1$7,411,220 100 %
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Short-term Investments and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Summary Of Investments
The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:
 
 As of December 31, 2022
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$117,036,232 $— $(9,373,514)$107,662,718 
U.S. treasury securities
Less than 1
95,001,209 7,567 (44,266)94,964,510 
Certificates of deposit
Less than 1
2,977,564 13,664 (320)2,990,908 
U.S. agency mortgage-backed securities*1,435,592 — (384,331)1,051,261 
$216,450,597 $21,231 $(9,802,431)$206,669,397 
 As of December 31, 2021
 Contractual
Maturity (in years)		CostGross Unrealized
Gains		Gross Unrealized
Losses		Fair Market Value
Mutual funds---$192,966,772 $87,069 $(1,614,411)$191,439,430 
U.S. treasury securities
Less than 1
94,193,441 — (9,921)94,183,520 
Commercial paper
Less than 1
39,967,853 — — 39,967,853 
Certificates of deposit
Less than 1
2,976,210 15,618 (338)2,991,490 
U.S. agency mortgage-backed securities*1,608,137 4,508 (23,998)1,588,647 
$331,712,413 $107,195 $(1,648,668)$330,170,940 

*No single maturity date.
Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis
The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:
 
Fair Value Measurements at
 December 31, 2022
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
    Mutual funds$107,662,718 $107,662,718 $— $— 
    U.S. treasury securities94,964,510 94,964,510 — — 
    Certificates of deposit2,990,908 — 2,990,908 — 
    U.S. agency mortgage-backed securities1,051,261 — 1,051,261 — 
Total short-term investments206,669,397 202,627,228 4,042,169 — 
Investment in affiliated entity2,007,142 2,007,142 — — 
Total assets measured at fair value$208,676,539 $204,634,370 $4,042,169 $— 

The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:
 
Fair Value Measurements at
 December 31, 2021
 TotalQuoted Prices
in Active Markets
(Level 1)		Significant
Other Unobservable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Short-term investments
     Mutual funds$191,439,430 $191,439,430 $— $— 
     U.S. treasury securities94,183,520 94,183,520 — — 
     Commercial paper39,967,853 — 39,967,853 — 
     Certificates of deposit2,991,490 — 2,991,490 — 
     U.S. agency mortgage-backed securities1,588,647 — 1,588,647 — 
Total short-term investments330,170,940 285,622,950 44,547,990 — 
Investments in affiliated entity3,906,796 3,906,796 — — 
Total assets measured at fair value$334,077,736 $289,529,746 $44,547,990 $— 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Certain Balance Sheet Items (Tables)
 12 Months Ended
Dec. 31, 2022
Certain Balance Sheet Items [Abstract]  
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following:
 
20222021
Insurance recovery (a)$30,000,000 $— 
Prepaid manufacturing expenses1,401,028 27,474,159 
Other prepaid expenses18,729,453 11,362,832 
$50,130,481 $38,836,991 
Schedule Of Accounts Payable And Accrued Expenses
Accounts payable and accrued expenses at December 31, 2022 and 2021 consisted of the following:
20222021
Trade accounts payable$19,862,487 $27,424,743 
Accrued compensation12,574,921 16,112,912 
Accrued litigation settlement (a)44,000,000 — 
Other accrued expenses3,249,477 4,106,875 
$79,686,885 $47,644,530 
(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under “Legal Proceedings.” The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0 million in cash and $14.0 million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Fixed Assets (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule Of Fixed Assets
Fixed assets at December 31, 2022 and 2021 consisted of the following:
 
CostAccumulated
Depreciation
and
Amortization		Net Book
Value
As of December 31, 2022
Leasehold improvements$15,803,108 $(10,036,080)$5,767,028 
Research and development equipment5,300,104 (4,295,217)1,004,887 
Office furniture and fixtures2,827,476 (2,803,800)23,676 
Computer equipment and other 5,360,712 (4,428,306)932,406 
$29,291,400 $(21,563,403)$7,727,997 
As of December 31, 2021
Leasehold improvements$15,803,108 $(8,258,608)$7,544,500 
Research and development equipment12,392,916 (4,279,816)8,113,100 
Office furniture and fixtures2,827,476 (2,599,643)227,833 
Computer equipment and other 5,374,084 (3,806,311)1,567,773 
$36,397,584 $(18,944,378)$17,453,206 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary Of Intangible Assets By Major Asset Class
The following sets forth goodwill and intangible assets by major asset class:
 
 December 31, 2022December 31, 2021
 Weighted Average Useful
Life
(Yrs)		GrossAccumulated
Amortization		Net Book
Value		GrossAccumulated
Amortization		Net Book
Value
Indefinite lived:
Goodwill$10,513,371 $— $10,513,371 $10,513,371 $— $10,513,371 
Definite lived:
Licenses101,323,761 (1,323,761)— 1,323,761 (1,305,600)18,161 
Bioject (a)125,100,000 (2,988,889)2,111,111 5,100,000 (2,735,556)2,364,444 
Other (b)184,050,000 (4,031,250)18,750 4,050,000 (3,806,250)243,750 
Total intangible assets1110,473,761 (8,343,900)2,129,861 10,473,761 (7,847,406)2,626,355 
Total goodwill and intangible assets$20,987,132 $(8,343,900)$12,643,232 $20,987,132 $(7,847,406)$13,139,726 

(a)Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.
(b)Other intangible assets represent the estimated fair value of acquired intellectual property.
Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense Amortization expense related to intangible assets at December 31, 2022 is expected to be incurred as follows:
 
Year ending December 31,
2023$273,000 
2024253,000 
2025253,000 
2026253,000 
2027253,000 
Thereafter845,000 
$2,130,000 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Debt (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule Of Convertible Debt
The balance of the Notes at December 31, 2022 was as follows:
Principal amount$78,500,000 
Principal amount converted into common shares(62,085,000)
Unamortized debt issuance cost(155,815)
Accrued interest355,655 
     Net carrying amount $16,614,840 
Schedule Of Maturities Of Long-Term Debt
As of December 31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were as follows:
20231,067,000 
202416,948,000 
Total$18,015,000 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Summary Of Preferred Stock Authorized, Issued And Outstanding
   Shares Outstanding as of
December 31,
 Shares AuthorizedShares Issued20222021
Series C Preferred Stock, par $0.001
1,091 1,091 9 9 
Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range
The following table summarizes total stock options outstanding at December 31, 2022:
 
 Options OutstandingOptions Exercisable
Exercise PriceShares Underlying Options
Outstanding		Weighted-Average
Remaining
Contractual Life
(in Years)		Weighted
Average
Exercise Price		Shares Underlying Options
Exercisable		Weighted Average
Exercise Price
$1.56-$3.00
830,542 8.3$2.17 247,104 $2.29 
$3.01-$6.00
5,461,365 7.1$3.50 3,059,330 $3.67 
$6.01-$9.00
3,349,587 5.3$7.57 2,861,909 $7.49 
$9.01-$12.00
1,930,825 7.1$10.97 1,080,389 $10.89 
$12.01-$15.00
580,947 4.1$13.38 529,392 $13.34 
$15.01-$25.62
68,282 7.6$21.12 51,568 $21.11 
12,221,548 6.6$6.28 7,829,692 $6.79 
Schedule Of Stock Options, Activity
Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares		Weighted-Average
Exercise Price
Balance, December 31, 202110,488,993 $7.93 
Granted4,623,448 3.11 
Exercised(118,694)2.38 
Cancelled(2,772,199)7.46 
Balance, December 31, 202212,221,548 $6.28 
Schedule Of Restricted Stock Unit Activity
Restricted stock unit activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:
Number of
Shares
Balance, December 31, 20212,448,868 
Granted2,485,947 
Vested(1,618,235)
Cancelled(760,323)
Balance, December 31, 20222,556,257 
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Schedule Of Maturities Of Operating Lease Liabilities
As of December 31, 2022, the maturities of the Company's operating lease liabilities were as follows:
Year ending December 31,
2023$4,089,000 
20243,050,000 
20253,063,000 
20263,139,000 
20272,526,000 
Thereafter4,223,000 
   Total remaining lease payments20,090,000 
Less: present value adjustment(4,630,000)
   Total operating lease liabilities15,460,000 
Less: current portion(2,804,000)
Long-term operating lease liabilities$12,656,000 
Weighted-average remaining lease term5.9 years
Weighted-average discount rate8.6 %
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule Of Components Of Pretax Loss From Operations
The components of pretax loss from operations are as follows:
Year Ended December 31,
202220212020
     U.S. Domestic$(277,440,803)$(302,614,003)$(162,664,355)
     Foreign(211,249)(610,320)(225,949)
Pretax loss from operations$(277,652,052)$(303,224,323)$(162,890,304)
Schedule Of Effective Income Tax Rate Reconciliation
The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows: 
Year Ended December 31,
202220212020
Benefit from income taxes at statutory rates$(58,307,000)$(63,677,000)$(34,207,000)
State income tax, net of federal benefit(3,601,000)(3,447,000)— 
Change in valuation allowance61,065,000 77,424,000 21,428,000 
Nondeductible loss on extinguishment of debt— — 14,450,000 
Research and development tax credits(7,534,000)(16,523,000)(2,650,000)
Stock-based compensation2,913,000 483,000 (1,953,000)
Uncertain tax positions2,291,000 6,509,000 1,068,000 
Deconsolidation of subsidiary— — 853,000 
Expired NOLs and credits1,459,000 616,000 468,000 
Limited NOLs and credits(1,337,000)(542,000)(368,000)
Change in tax rates(187,000)— — 
Foreign tax rate differential(8,000)(24,000)(9,000)
Other3,246,000 (819,000)920,000 
$— $— $— 
Schedule Of Deferred Tax Assets And Liabilities Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are shown below:
As of December 31,
20222021
Deferred tax assets:
Capitalized research expense$41,252,000 $4,200,000 
NOL carryforwards212,768,000 197,144,000 
Research and development and other tax credits26,442,000 23,005,000 
Deferred revenue538,000 987,000 
Stock-based compensation3,945,000 3,599,000 
Acquired intangibles559,000 637,000 
Interest expense — 83,000 
Investment in affiliated entity1,569,000 750,000 
Lease liability3,247,000 3,793,000 
Fixed assets57,000 — 
Other11,062,000 5,973,000 
301,439,000 240,171,000 
Valuation allowance(299,124,000)(237,205,000)
Total deferred tax assets2,315,000 2,966,000 
Deferred tax liabilities:
Acquired intangibles(199,000)(194,000)
Right of use asset(2,148,000)(2,430,000)
Note discount— (321,000)
Fixed assets— (53,000)
Total deferred tax liabilities(2,347,000)(2,998,000)
Net deferred tax liabilities$(32,000)$(32,000)
Schedule Of Operating Loss And Tax Credit Carryforward Expirations
Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):
Expiration Date:Federal NOLsState NOLsForeign NOLsFederal R&DState R&D
2023$5.3 $1.2 $— $— $— 
202418.9 9.1 — — — 
20259.6 5.2 — — — 
202612.2 7.1 — — — 
2027 and thereafter249.2 277.3 1.0 40.5 — 
Indefinite625.4 — — — 4.7 
$920.6 $299.9 $1.0 $40.5 $4.7 
Schedule Of Unrecognized Tax Benefits Rollforward
The following table summarizes the activity related to the Company's unrecognized tax benefits:
 Year ended December 31,
 202220212020
Balance at beginning of the year$18,819,000 $12,210,000 $11,204,000 
Increases related to current year tax positions2,902,000 6,602,000 1,043,000 
Increases (decreases) related to prior year tax positions(582,000)7,000 27,000 
Other— — (64,000)
Balance at end of the year$21,139,000 $18,819,000 $12,210,000 
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Geneos Therapeutics, Inc. (Tables)
 12 Months Ended
Dec. 31, 2022
Noncontrolling Interest [Abstract]  
Schedule Of Equity Method Investments
The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:
Investment in Geneos Series A-2 preferred stock$1,999,998 
Remeasurement of Geneos Series A-1 preferred stock165,215 
Share in current and accumulated net loss of Geneos (2,165,213)
Investment in Geneos as of December 31, 2022$— 
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Narrative (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Property, Plant and Equipment [Line Items]      
Net loss from operations $ 279,818,065 $ 303,658,710 $ 166,411,157
Working capital 218,400,000    
Accumulated deficit 1,487,847,784 1,209,855,522  
Cash, cash equivalents, and short-term investments 253,000,000    
Proceeds from issuance of common stock $ 82,955,311 209,441,410 454,486,400
Number of operating segments | segment 1    
Allowance for doubtful accounts $ 0 0  
Finite lived intangible assets, net 2,129,861 2,626,355  
Deferred tax assets, valuation allowance $ 299,124,000 237,205,000  
Minimum      
Property, Plant and Equipment [Line Items]      
Property, plant, and equipment, useful life 3 years    
Intangible asset, useful life 2 years    
Maximum      
Property, Plant and Equipment [Line Items]      
Property, plant, and equipment, useful life 5 years    
Intangible asset, useful life 18 years    
Common stock | Sales Agreement      
Property, Plant and Equipment [Line Items]      
Proceeds from issuance of common stock $ 83,000,000 47,700,000 $ 454,500,000
Common stock | Underwritten Public Offering      
Property, Plant and Equipment [Line Items]      
Proceeds from issuance of common stock   $ 162,100,000  
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 17,943,035 16,654,503 16,190,768
Options to purchase common stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 12,221,548 10,488,993 8,906,624
Service-based restricted stock units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 2,556,257 2,448,868 2,558,052
Performance-based restricted stock units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 111,941 663,353 663,353
Convertible preferred stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 3,309 3,309 3,309
Convertible Debt Securities | 6.50% Convertible Senior Notes Due 2024      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 3,049,980 3,049,980 3,049,980
Convertible Debt Securities | December 2019 Bonds      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities (shares) 0 0 1,009,450
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Employees and Directors      
Summary of assumptions used to estimate the fair value of stock options      
Risk-free interest rate 2.05% 0.91% 0.63%
Expected volatility 94.00% 93.00% 78.00%
Expected life in years 5 years 8 months 12 days 6 years 6 years
Dividend yield 0.00% 0.00% 0.00%
Non Employee      
Summary of assumptions used to estimate the fair value of stock options      
Risk-free interest rate 1.96% 1.45% 0.82%
Expected volatility 87.00% 87.00% 76.00%
Expected life in years 10 years 10 years 10 years
Dividend yield 0.00% 0.00% 0.00%
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)
Dec. 31, 2022
Jan. 01, 2022
Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Accumulated deficit $ (1,487,847,784)   $ (1,209,855,522)
Additional paid-in capital (1,710,656,191)   (1,609,589,797)
Deferred tax liabilities 32,046   $ 32,046
Accounting Standards Update 2020-06      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Accumulated deficit   $ 1,800,000  
Additional paid-in capital   3,300,000  
Convertible senior notes   $ 1,500,000  
Deferred tax liabilities $ 1,500,000    
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 10,262,268 $ 1,774,758 $ 7,411,220
Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
% of Total Revenue 100.00% 100.00% 100.00%
Advaccine      
Disaggregation of Revenue [Line Items]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 0 $ 0 $ 5,000,000
Advaccine | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
% of Total Revenue 0.00% 0.00% 68.00%
Plumbline Life Sciences, Inc. (affiliated entity)      
Disaggregation of Revenue [Line Items]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 33,596 $ 245,310 $ 1,370,396
Plumbline Life Sciences, Inc. (affiliated entity) | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
% of Total Revenue 0.00% 14.00% 18.00%
U.S. Department of Defense      
Disaggregation of Revenue [Line Items]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 9,591,778 $ 754,853 $ 0
U.S. Department of Defense | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
% of Total Revenue 94.00% 43.00% 0.00%
All other, including affiliated entities      
Disaggregation of Revenue [Line Items]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 636,894 $ 774,595 $ 1,040,824
All other, including affiliated entities | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
% of Total Revenue 6.00% 43.00% 14.00%
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenue recognized from deferred revenue $ 14 $ 46
U.S. Department of Defense | Customer Concentration Risk    
Disaggregation of Revenue [Line Items]    
Accounts receivable   $ 3,600
U.S. Department of Defense | Customer Concentration Risk | Accounts Receivable    
Disaggregation of Revenue [Line Items]    
% of Total Revenue   65.00%
CEPI MERS | Customer Concentration Risk    
Disaggregation of Revenue [Line Items]    
Accounts receivable   $ 1,900
CEPI MERS | Customer Concentration Risk | Accounts Receivable    
Disaggregation of Revenue [Line Items]    
% of Total Revenue   34.00%
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 11, 2018
Jan. 31, 2022
Jan. 31, 2021
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Oct. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative arrangements and other contracts, including affiliated entity                   $ 10,262,268 $ 1,774,758 $ 7,411,220
Advaccine                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative arrangements and other contracts, including affiliated entity                   0 0 5,000,000
Advaccine | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront payment received     $ 3,000,000             1,200,000 4,500,000 0
Additional revenue to be achieved                   $ 200,000,000    
Obligation period to pay royalties                   10 years    
Annual maintenance                   $ 1,500,000    
Annual maintenance period                   5 years    
Agreement, number of days written notice before termination                   18 months    
Collaboration agreement, payment earned                     2,000,000  
Revenue from collaborative arrangements and other contracts, including affiliated entity                     5,000,000  
Advaccine | Collaborative Arrangement | Revenue under collaborative research and development arrangements                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative arrangements and other contracts, including affiliated entity                   $ 0 0 5,000,000
ApolloBio | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Additional revenue to be achieved                   $ 20,000,000    
Obligation period to pay royalties                   10 years    
Agreement, number of days written notice before termination                   90 days    
Agreement period from effective date for termination                   1 year    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront payment received                   $ 6,700,000 10,000,000 6,400,000
Collaborative agreement, funding to be received $ 56,000,000       $ 6,900,000              
Collaborative agreement, period to receive funding for research and development 5 years                      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | Lassa Fever And MERS Vaccine                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Accounts receivable                   1,700,000 1,900,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received             $ 9,000,000     1,100,000 6,900,000 10,000,000
Grants receivable                   2,300,000 1,800,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received         5,000,000              
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received         $ 1,300,000              
Bill And Melinda Gates Foundation | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received           $ 5,000,000       0 893,000 4,100,000
Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received               $ 1,100,000 $ 2,200,000 233,000 182,000 463,000
Grants receivable                   153,000 384,000  
Department Of Defence | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Procurement contract                   9,600,000 755,000 0
Grant proceeds received                   $ 6,100,000 $ 27,100,000 $ 21,200,000
Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Funding received       $ 54,500,000                
Purchase price, procurement contract   $ 10,700,000   $ 16,800,000                
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost $ 216,450,597 $ 331,712,413
Gross Unrealized Gains 21,231 107,195
Gross Unrealized Losses (9,802,431) (1,648,668)
Fair Market Value 206,669,397 330,170,940
Mutual funds    
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost 117,036,232 192,966,772
Gross Unrealized Gains 0 87,069
Gross Unrealized Losses (9,373,514) (1,614,411)
Fair Market Value $ 107,662,718 191,439,430
U.S. treasury securities    
Debt Securities, Available-for-sale [Line Items]    
Contractual Maturity 1 year  
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost $ 95,001,209 94,193,441
Gross Unrealized Gains 7,567 0
Gross Unrealized Losses (44,266) (9,921)
Fair Market Value 94,964,510 94,183,520
Commercial paper    
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost   39,967,853
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Market Value   39,967,853
Certificates of deposit    
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost 2,977,564 2,976,210
Gross Unrealized Gains 13,664 15,618
Gross Unrealized Losses (320) (338)
Fair Market Value $ 2,990,908 $ 2,991,490
Certificates of deposit | Maximum    
Debt Securities, Available-for-sale [Line Items]    
Contractual Maturity 1 year 1 year
U.S. agency mortgage-backed securities    
Debt Securities, Available-for-sale, Sale [Abstract]    
Cost $ 1,435,592 $ 1,608,137
Gross Unrealized Gains 0 4,508
Gross Unrealized Losses (384,331) (23,998)
Fair Market Value $ 1,051,261 $ 1,588,647
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Short-term Investments and Fair Value Measurements - Narrative (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
position
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Debt Securities, Available-for-sale [Line Items]      
Debt securities, available-for-sale, realized gain $ 21,000 $ 394,000  
Debt securities, available-for-sale, realized gain 4,100,000 399,000  
Net unrealized loss on available-for-sale equity securities $ 7,846,172 $ 3,222,838 $ (1,695,497)
Number of securities in a gross unrealized loss position | position 29    
Number of securities in a gross unrealized loss position for more than twelve months | position 21    
Unrealized loss on investments $ 8,700,000    
Fair Value, Inputs, Level 1 | Common stock      
Debt Securities, Available-for-sale [Line Items]      
Number of shares owned (in shares) | shares 597,808    
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments $ 206,669,397 $ 330,170,940
Mutual funds    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 107,662,718 191,439,430
Commercial paper    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments   39,967,853
Certificates of deposit    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 2,990,908 2,991,490
U.S. agency mortgage-backed securities    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 1,051,261 1,588,647
Fair Value, Measurements, Recurring    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 206,669,397 330,170,940
Investments in affiliated entity 2,007,142 3,906,796
Total assets measured at fair value 208,676,539 334,077,736
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 202,627,228 285,622,950
Investments in affiliated entity 2,007,142 3,906,796
Total assets measured at fair value 204,634,370 289,529,746
Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 4,042,169 44,547,990
Investments in affiliated entity 0 0
Total assets measured at fair value 4,042,169 44,547,990
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Investments in affiliated entity 0 0
Total assets measured at fair value 0 0
Fair Value, Measurements, Recurring | Mutual funds    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 107,662,718 191,439,430
Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 107,662,718 191,439,430
Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | U.S. treasury securities    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 94,964,510 94,183,520
Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 94,964,510 94,183,520
Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | Commercial paper    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments   39,967,853
Fair Value, Measurements, Recurring | Commercial paper | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments   0
Fair Value, Measurements, Recurring | Commercial paper | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments   39,967,853
Fair Value, Measurements, Recurring | Commercial paper | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments   0
Fair Value, Measurements, Recurring | Certificates of deposit    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 2,990,908 2,991,490
Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 2,990,908 2,991,490
Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 1,051,261 1,588,647
Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level 1)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 0 0
Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level 2)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments 1,051,261 1,588,647
Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level 3)    
Financial assets and liabilities that are measured at fair value on recurring basis    
Short-term investments $ 0 $ 0
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Certain Balance Sheet Items [Abstract]    
Estimated Insurance Recoveries $ 30,000,000 $ 0
Prepaid manufacturing expenses 1,401,028 27,474,159
Other prepaid expenses 18,729,453 11,362,832
Prepaid expenses and other current assets $ 50,130,481 $ 38,836,991
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Jul. 31, 2022
Dec. 31, 2021
Mar. 09, 2021
Accounts Payable and Accrued Expenses [Line Items]        
Accounts Payable, Trade $ 19,862,487   $ 27,424,743  
Accrued Salaries, Current 12,574,921   16,112,912  
Accrued litigation settlement 44,000,000   0  
Other Accrued Liabilities 3,249,477   4,106,875  
Accounts payable and accrued liabilities 79,686,885   $ 47,644,530  
McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim        
Accounts Payable and Accrued Expenses [Line Items]        
Estimate of cash settlement   $ 30,000,000   $ 30,000,000
Estimate of shares settlement   $ 14,000,000   $ 14,000,000
Amount paid to other party $ 252,000      
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Fixed Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]      
Cost $ 29,291,400 $ 36,397,584  
Accumulated Depreciation and Amortization (21,563,403) (18,944,378)  
Net Book Value 7,727,997 17,453,206  
Depreciation 3,656,713 3,040,096 $ 3,038,996
Property, plant and equipment sold 6,100,000    
Property, plant and equipment disposed of 1,100,000    
Prepaid Expenses and Other Current Assets      
Property, Plant and Equipment [Line Items]      
Accounts receivable 6,100,000    
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Cost 15,803,108 15,803,108  
Accumulated Depreciation and Amortization (10,036,080) (8,258,608)  
Net Book Value 5,767,028 7,544,500  
Research and development equipment      
Property, Plant and Equipment [Line Items]      
Cost 5,300,104 12,392,916  
Accumulated Depreciation and Amortization (4,295,217) (4,279,816)  
Net Book Value 1,004,887 8,113,100  
Office furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Cost 2,827,476 2,827,476  
Accumulated Depreciation and Amortization (2,803,800) (2,599,643)  
Net Book Value 23,676 227,833  
Computer equipment and other      
Property, Plant and Equipment [Line Items]      
Cost 5,360,712 5,374,084  
Accumulated Depreciation and Amortization (4,428,306) (3,806,311)  
Net Book Value $ 932,406 $ 1,567,773  
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Indefinite lived:    
Goodwill, gross $ 10,513,371 $ 10,513,371
Goodwill, net book value 10,513,371 10,513,371
Definite lived:    
Intangible assets, gross 10,473,761 10,473,761
Intangible assets, accumulated amortization (8,343,900) (7,847,406)
Intangible assets, net book value 2,129,861 2,626,355
Total goodwill and intangible assets, gross 20,987,132 20,987,132
Total goodwill and intangible assets, net book value $ 12,643,232 13,139,726
Weighted Average Useful Life (Yrs)    
Definite lived:    
Useful life (in years) 11 years  
Licenses    
Definite lived:    
Intangible assets, gross $ 1,323,761 1,323,761
Intangible assets, accumulated amortization (1,323,761) (1,305,600)
Intangible assets, net book value $ 0 18,161
Licenses | Weighted Average Useful Life (Yrs)    
Definite lived:    
Useful life (in years) 10 years  
Bioject    
Definite lived:    
Intangible assets, gross $ 5,100,000 5,100,000
Intangible assets, accumulated amortization (2,988,889) (2,735,556)
Intangible assets, net book value $ 2,111,111 2,364,444
Bioject | Weighted Average Useful Life (Yrs)    
Definite lived:    
Useful life (in years) 12 years  
Other    
Definite lived:    
Intangible assets, gross $ 4,050,000 4,050,000
Intangible assets, accumulated amortization (4,031,250) (3,806,250)
Intangible assets, net book value $ 18,750 $ 243,750
Other | Weighted Average Useful Life (Yrs)    
Definite lived:    
Useful life (in years) 18 years  
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]      
Amortization of intangible assets $ 496,494 $ 520,415 $ 547,081
Impairment 0 0 0
Impairment loss $ 0 $ 0 $ 0
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
2023 $ 273,000  
2024 253,000  
2025 253,000  
2026 253,000  
2027 253,000  
Thereafter 845,000  
Intangible assets, net book value $ 2,129,861 $ 2,626,355
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Debt - Narrative (Details)
 12 Months Ended
Mar. 17, 2021
USD ($)
shares
Dec. 26, 2019
USD ($)
Mar. 01, 2019
USD ($)
day
$ / shares
Feb. 28, 2019
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jan. 01, 2022
USD ($)
Dec. 26, 2019
KRW (₩)
Debt Instrument [Line Items]                  
Accumulated deficit         $ (1,487,847,784) $ (1,209,855,522)      
Additional paid-in capital         (1,710,656,191) (1,609,589,797)      
Interest expense         1,253,952 1,936,447 $ 8,702,450    
6.50% Convertible Senior Notes Due 2024                  
Debt Instrument [Line Items]                  
Debt instrument, face amount         78,500,000        
Debt issuance costs, net         155,815        
Convertible senior notes         16,614,840 14,959,647      
Accounting Standards Update 2020-06                  
Debt Instrument [Line Items]                  
Accumulated deficit               $ 1,800,000  
Additional paid-in capital               3,300,000  
Convertible senior notes               $ 1,500,000  
Convertible Debt                  
Debt Instrument [Line Items]                  
Debt issuance costs, net         $ 2,200,000        
Convertible Debt | 6.50% Convertible Senior Notes Due 2024                  
Debt Instrument [Line Items]                  
Debt instrument, face amount     $ 78,500,000            
Debt interest based on the fixed rate     6.50%   6.50%        
Proceeds from issuance of debt       $ 75,700,000          
Debt instrument, convertible, conversion ratio       0.1858045          
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares     $ 5.38            
Debt instrument, convertible, threshold percentage of stock price trigger     130.00%            
Debt instrument, convertible, threshold trading days | day     20            
Debt instrument, convertible, threshold consecutive trading days | day     30            
Debt instrument, redemption price, percentage     100.00%            
Debt instrument, unamortized discount     $ 16,300,000            
Debt instrument, interest rate, effective percentage         13.10%        
Debt issuance costs, net         $ 592,000        
Interest expense         1,300,000 1,900,000 6,900,000    
Interest expense, debt         1,100,000 $ 1,100,000 $ 4,100,000    
Convertible Debt | December 2019 Bonds                  
Debt Instrument [Line Items]                  
Debt instrument, face amount   $ 4,100,000             ₩ 4,700,000,000
Debt interest based on the fixed rate   1.00%             1.00%
Proceeds from issuance of debt   $ 4,000,000              
Debt instrument, interest rate, effective percentage           6.20%      
Interest expense         50,000        
Interest expense, debt         $ 9,000        
Debt conversion, converted instrument, shares issued (in shares) | shares 1,009,450                
Carrying value of december 2019 bonds $ 4,400,000                
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Debt - Balance Of Convertible Debt (Details) - 6.50% Convertible Senior Notes Due 2024
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]  
Principal amount $ 78,500,000
Principal amount converted into common shares (62,085,000)
Unamortized debt issuance cost (155,815)
Accrued interest 355,655
Total $ 16,614,840
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Debt - Schedule of Maturities (Details) - Convertible Senior Notes - USD ($)
Dec. 31, 2022
Mar. 01, 2019
Debt Instrument [Line Items]    
Total $ 16,614,840  
Convertible Debt    
Debt Instrument [Line Items]    
Debt interest based on the fixed rate 6.50% 6.50%
2023 $ 1,067,000  
2024 16,948,000  
Total $ 18,015,000  
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - Summary of Preferred Stock (Details) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Summary of common and preferred stock authorized, issued and outstanding    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 9 9
Preferred stock, shares outstanding (in shares) 9 9
Series C Preferred Stock    
Summary of common and preferred stock authorized, issued and outstanding    
Preferred stock, par value (in dollars per share) $ 0.001  
Preferred stock, shares authorized (in shares) 1,091  
Preferred stock, shares issued (in shares) 1,091  
Preferred stock, shares outstanding (in shares) 9 9
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - Narrative (Details) - USD ($)
 12 Months Ended
Nov. 09, 2021
Jan. 25, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 24, 2022
Jan. 01, 2022
May 13, 2016
Class of Stock [Line Items]                
Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)       $ 27.20        
Allocated share-based compensation expense     $ 22,200,000 $ 25,000,000 $ 14,500,000      
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized     $ 10,500,000 $ 16,500,000        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition     1 year 7 months 6 days 2 years        
Number of options outstanding to purchase common stock (in shares)     12,221,548 10,488,993        
Aggregate intrinsic value of options outstanding     $ 0          
Aggregate intrinsic value for options exercisable     $ 0          
Options exercisable, remaining contractual term     5 years 8 months 12 days          
Number of options expected to vest (in shares)     12,221,548          
Options, expirations in period, weighted average exercise price (in dollars per share)     $ 8.47 $ 4.56 $ 4.44      
Options, expirations in period (in shares)     77,250 7,000 78,750      
Options, grants in period, weighted average grant date fair value (in dollars per share)     $ 2.34 $ 7.61 $ 6.87      
Proceeds from stock options exercised     $ 283,000 $ 6,700,000 $ 12,300,000      
Options, exercises in period, aggregate intrinsic value     81,000 7,000,000 14,200,000      
Nonemployee                
Class of Stock [Line Items]                
Allocated share-based compensation expense     $ 1,300,000 $ 1,400,000 $ 1,200,000      
Number of options outstanding to purchase common stock (in shares)     665,875          
Former President and Chief Executive Officer                
Class of Stock [Line Items]                
Allocated share-based compensation expense     $ 4,200,000          
Award exercisable     5 years          
Restricted Stock Units (RSUs)                
Class of Stock [Line Items]                
Number of shares of unvested restricted stock units and options outstanding (in shares)     2,556,257 2,448,868        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized     $ 7,200,000 $ 13,400,000        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition     1 year 8 months 12 days 1 year 9 months 18 days        
Aggregate intrinsic value of unvested     $ 4,000,000          
Aggregate intrinsic value of vested     $ 4,600,000          
RSU's expected to vest (in shares)     2,556,257          
Weighted average grant date fair value (in dollars per share)     $ 3.12 $ 10.37 $ 9.12      
Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares)     111,941          
Restricted Stock Units (RSUs) | Former President and Chief Executive Officer                
Class of Stock [Line Items]                
Awards settled in cash, percentage     50.00%          
Research and Development Expense                
Class of Stock [Line Items]                
Allocated share-based compensation expense     $ 8,800,000 $ 13,400,000 $ 8,000,000.0      
General and Administrative Expense                
Class of Stock [Line Items]                
Allocated share-based compensation expense     $ 13,400,000 $ 11,600,000 $ 6,500,000      
2016 Incentive Plan                
Class of Stock [Line Items]                
Reserved number of shares under the Incentive Plan (in shares)               22,000,000
Number of potential shares authorized for issuance under a share-based compensation plan (in shares)               2,000,000
Increase in number of shares authorized (in shares)             2,000,000  
Number of shares available for grants under the Incentive Plan (in shares)     3,831,240          
Number of shares of vested restricted stock outstanding under the plan (in shares)     2,446,257          
Number of common stock shares outstanding under the Incentive Plan (in shares)     10,132,969          
Vesting period of incentive plan     3 years          
Contractual year term of incentive plan     10 years          
Award vesting period (in years)     3 years          
2016 Incentive Plan | Restricted Stock Units (RSUs)                
Class of Stock [Line Items]                
Number of shares of unvested restricted stock units and options outstanding (in shares)     111,941          
2007 Incentive Plan                
Class of Stock [Line Items]                
Number of common stock shares outstanding under the Incentive Plan (in shares)     1,902,329          
Vesting period of incentive plan     3 years          
Contractual year term of incentive plan     10 years          
Award vesting period (in years)     3 years          
2022 Inducement Plan                
Class of Stock [Line Items]                
Reserved number of shares under the Incentive Plan (in shares)           2,000,000    
Number of shares available for grants under the Incentive Plan (in shares)     1,703,750          
Number of common stock shares outstanding under the Incentive Plan (in shares)     186,250          
Number of shares of unvested restricted stock units and options outstanding (in shares)     110,000          
Common stock | Underwritten Public Offering                
Class of Stock [Line Items]                
Number of shares issued in transaction (in shares)   20,355,000            
Sale of stock, price per share (in dollars per share)   $ 8.50            
Commissions and other estimated offering expenses   $ 162,100,000            
Series C Preferred Stock                
Class of Stock [Line Items]                
Convertible preferred stock, shares issued upon conversion (in shares)       3,309        
Common stock | Sales Agreement                
Class of Stock [Line Items]                
Common stock aggregate offering price $ 300,000,000              
Sales Agents will be entitled to compensation 3.00%              
Stock sale agreement, aggregate number of shares issued (in shares)     34,445,743 6,955,341        
Sales made at a weighted average price (in dollars per share)     $ 2.44 $ 6.96        
Stock sale agreement, aggregate proceeds from issuance of stock     $ 83,000,000 $ 47,700,000        
Remaining authorized amount     $ 167,400,000          
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - Summary of Stock Options Outstanding (Details)
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding (in shares) | shares 12,221,548
Weighted-average remaining contractual life (in Years) 6 years 7 months 6 days
Weighted average exercise price (in dollars per share) $ 6.28
Options exercisable (in shares) | shares 7,829,692
Weighted average exercise price (in dollars per share) $ 6.79
$1.56-$3.00  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 1.56
Exercise price, upper range limit (in dollars per share) $ 3.00
Options outstanding (in shares) | shares 830,542
Weighted-average remaining contractual life (in Years) 8 years 3 months 18 days
Weighted average exercise price (in dollars per share) $ 2.17
Options exercisable (in shares) | shares 247,104
Weighted average exercise price (in dollars per share) $ 2.29
$3.01-$6.00  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 3.01
Exercise price, upper range limit (in dollars per share) $ 6.00
Options outstanding (in shares) | shares 5,461,365
Weighted-average remaining contractual life (in Years) 7 years 1 month 6 days
Weighted average exercise price (in dollars per share) $ 3.50
Options exercisable (in shares) | shares 3,059,330
Weighted average exercise price (in dollars per share) $ 3.67
$6.01-$9.00  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 6.01
Exercise price, upper range limit (in dollars per share) $ 9.00
Options outstanding (in shares) | shares 3,349,587
Weighted-average remaining contractual life (in Years) 5 years 3 months 18 days
Weighted average exercise price (in dollars per share) $ 7.57
Options exercisable (in shares) | shares 2,861,909
Weighted average exercise price (in dollars per share) $ 7.49
$9.01-$12.00  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 9.01
Exercise price, upper range limit (in dollars per share) $ 12.00
Options outstanding (in shares) | shares 1,930,825
Weighted-average remaining contractual life (in Years) 7 years 1 month 6 days
Weighted average exercise price (in dollars per share) $ 10.97
Options exercisable (in shares) | shares 1,080,389
Weighted average exercise price (in dollars per share) $ 10.89
$12.01-$15.00  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 12.01
Exercise price, upper range limit (in dollars per share) $ 15.00
Options outstanding (in shares) | shares 580,947
Weighted-average remaining contractual life (in Years) 4 years 1 month 6 days
Weighted average exercise price (in dollars per share) $ 13.38
Options exercisable (in shares) | shares 529,392
Weighted average exercise price (in dollars per share) $ 13.34
$15.01-$25.62  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) 15.01
Exercise price, upper range limit (in dollars per share) $ 25.62
Options outstanding (in shares) | shares 68,282
Weighted-average remaining contractual life (in Years) 7 years 7 months 6 days
Weighted average exercise price (in dollars per share) $ 21.12
Options exercisable (in shares) | shares 51,568
Weighted average exercise price (in dollars per share) $ 21.11
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Number of Shares  
Beginning balance (in shares) | shares 10,488,993
Granted (in shares) | shares 4,623,448
Exercised (in shares) | shares (118,694)
Cancelled (in shares) | shares (2,772,199)
Ending balance (in shares) | shares 12,221,548
Weighted-Average Exercise Price  
Beginning balance (in dollars per share) | $ / shares $ 7.93
Granted (in dollars per share) | $ / shares 3.11
Exercised (in dollars per share) | $ / shares 2.38
Cancelled (in dollars per share) | $ / shares 7.46
Ending balance (in dollars per share) | $ / shares $ 6.28
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) - Performance-based restricted stock units
 12 Months Ended
Dec. 31, 2022
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Beginning balance (in shares) 2,448,868
Granted (in shares) 2,485,947
Vested (in shares) (1,618,235)
Cancelled (in shares) (760,323)
Ending balance (in shares) 2,556,257
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Narrative (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
ft²
agreement
Dec. 31, 2022
USD ($)
ft²
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jul. 31, 2022
USD ($)
Mar. 09, 2021
USD ($)
Operating Leased Assets [Line Items]            
Lessee, operating lease, area of land under lease | ft² 13,500          
Lease, cost | $   $ 3.4 $ 3.4 $ 3.4    
Number of lease agreements entered into | agreement 2          
McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim            
Operating Leased Assets [Line Items]            
Estimate of cash settlement | $         $ 30.0 $ 30.0
Estimate of shares settlement | $         $ 14.0 $ 14.0
Minimum            
Operating Leased Assets [Line Items]            
Operating lease, remaining lease term   10 months 24 days        
Maximum            
Operating Leased Assets [Line Items]            
Operating lease, remaining lease term   7 years        
San Diego, California            
Operating Leased Assets [Line Items]            
Lessee, operating lease, area of land under lease | ft²   82,200        
Plymouth Meeting, Pennsylvania            
Operating Leased Assets [Line Items]            
Lessee, operating lease, area of land under lease | ft²   57,360        
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]    
2023 $ 4,089,000  
2024 3,050,000  
2025 3,063,000  
2026 3,139,000  
2027 2,526,000  
Thereafter 4,223,000  
Total remaining lease payments 20,090,000  
Less: present value adjustment (4,630,000)  
Total operating lease liabilities 15,460,000  
Less: current portion (2,803,973) $ (2,603,956)
Long-term operating lease liabilities $ 12,655,586 $ 15,459,559
Weighted-average remaining lease term 5 years 10 months 24 days  
Weighted-average discount rate 8.60%  
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]      
U.S. Domestic $ (277,440,803) $ (302,614,003) $ (162,664,355)
Foreign (211,249) (610,320) (225,949)
Net loss before share in net loss of Geneos $ (277,652,052) $ (303,224,323) $ (162,890,304)
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]      
Benefit from income taxes at statutory rates $ (58,307) $ (63,677) $ (34,207)
State income tax, net of federal benefit (3,601) (3,447) 0
Change in valuation allowance 61,065 77,424 21,428
Nondeductible loss on extinguishment of debt 0 0 14,450
Research and development tax credits (7,534) (16,523) (2,650)
Stock-based compensation 2,913 483 (1,953)
Uncertain tax positions 2,291 6,509 1,068
Deconsolidation of subsidiary 0 0 853
Expired NOLs and credits 1,459 616 468
Limited NOLs and credits (1,337) (542) (368)
Change in tax rates (187) 0 0
Foreign tax rate differential (8) (24) (9)
Other 3,246 (819) 920
Income tax expense (benefit) $ 0 $ 0 $ 0
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Operating Loss Carryforwards [Line Items]        
Income tax expense (benefit) $ 0 $ 0 $ 0  
Tax benefits expired 8,300,000      
Unrecognized tax benefits that would impact effective tax rate 19,700,000 $ 17,400,000 $ 10,900,000  
Federal        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards that will expire due to IRC Section 382 limitations 920,600,000      
Net operating loss carryforwards       $ 625,400,000
Federal | Research Tax Credit Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward amount 40,500,000      
California        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards that will expire due to IRC Section 382 limitations 210,300,000      
Pennsylvania        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards that will expire due to IRC Section 382 limitations 89,600,000      
State        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards 299,900,000      
State | Research Tax Credit Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward amount 4,700,000      
Korean State Income Tax Authority        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards that will expire due to IRC Section 382 limitations $ 1,000,000      
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets:    
Capitalized research expense $ 41,252 $ 4,200
NOL carryforwards 212,768 197,144
Research and development and other tax credits 26,442 23,005
Deferred revenue 538 987
Stock-based compensation 3,945 3,599
Acquired intangibles 559 637
Interest expense 0 83
Investment in affiliated entity 1,569 750
Lease liability 3,247 3,793
Fixed assets 57 0
Other 11,062 5,973
Deferred tax assets, gross 301,439 240,171
Valuation allowance (299,124) (237,205)
Total deferred tax assets 2,315 2,966
Deferred tax liabilities:    
Acquired intangibles (199) (194)
Right of use asset (2,148) (2,430)
Note discount 0 (321)
Fixed assets 0 (53)
Total deferred tax liabilities (2,347) (2,998)
Net deferred tax liabilities $ (32) $ (32)
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)
$ in Millions
Dec. 31, 2022
USD ($)
Federal  
Expirations of Operating Loss Carryforwards, Components [Abstract]  
2023 $ 5.3
2024 18.9
2025 9.6
2026 12.2
2027 and thereafter 249.2
Indefinite 625.4
Total 920.6
State  
Expirations of Operating Loss Carryforwards, Components [Abstract]  
2023 1.2
2024 9.1
2025 5.2
2026 7.1
2027 and thereafter 277.3
Indefinite 0.0
Total 299.9
Foreign Tax Authority  
Expirations of Operating Loss Carryforwards, Components [Abstract]  
2023 0.0
2024 0.0
2025 0.0
2026 0.0
2027 and thereafter 1.0
Indefinite 0.0
Total 1.0
Research Tax Credit Carryforward | Federal  
Expirations of Tax Credit Carryforwards [Abstract]  
2023 0.0
2024 0.0
2025 0.0
2026 0.0
2027 and thereafter 40.5
Indefinite 0.0
Total 40.5
Research Tax Credit Carryforward | State  
Expirations of Tax Credit Carryforwards [Abstract]  
2023 0.0
2024 0.0
2025 0.0
2026 0.0
2027 and thereafter 0.0
Indefinite 4.7
Total $ 4.7
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of the year $ 18,819 $ 12,210 $ 11,204
Increases related to current year tax positions 2,902 6,602 1,043
Increases (decreases) related to prior year tax positions (582)    
Increases (decreases) related to prior year tax positions   7 27
Other 0 0 (64)
Balance at end of the year $ 21,139 $ 18,819 $ 12,210
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.22.4
401(k) Plan (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Retirement Benefits [Abstract]      
Employer matching contribution, percent 50.00%    
Maximum annual contribution per employee, percent 6.00%    
Company's contribution to 401(k) plan $ 1.8 $ 1.5 $ 1.1
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 30, 2016
Mar. 31, 2016
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]          
Agreement amended amount       $ 13,600  
Awarded exercised amount     $ 3,300    
Plumbline Life Sciences          
Related Party Transaction [Line Items]          
Number of shares owned (in shares)     597,808 597,808  
Ownership percentage     18.70% 18.90%  
PLS (affiliated entity)          
Related Party Transaction [Line Items]          
Revenue from related parties     $ 34 $ 245 $ 1,400
Accounts receivable     59 25  
The Wistar Institute          
Related Party Transaction [Line Items]          
Accounts receivable     9,900 2,600  
Expenses to reimburse   $ 3,100      
Term   5 years      
Awarded amount         10,700
Awarded option amount     6,000    
Operating expenses related to affiliated entity     1,400 2,900 $ 2,300
Due to related parties     1,200 548  
Prepaid expense     375 261  
Deferred grant funding from affiliate     88 37  
Director          
Related Party Transaction [Line Items]          
Expenses to reimburse       1,900  
Awarded amount $ 6,100        
Grant proceeds received     $ 8,700 $ 3,000  
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 01, 2020
Mar. 31, 2022
Nov. 30, 2020
Feb. 28, 2019
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Feb. 28, 2021
Jun. 30, 2020
Jan. 31, 2020
Noncontrolling Interest [Line Items]                      
Payments to acquire additional interest in subsidiaries           $ 1,999,998 $ 0 $ 1,399,999      
Gain on deconsolidation of Geneos           0 0 4,121,075      
Share in net loss of Geneos           2,165,213 434,387 $ 4,584,610      
Geneos Therapeutics, Inc.                      
Noncontrolling Interest [Line Items]                      
Percentage of ownership                   47.00%  
Series A-2 One Preferred Stock                      
Noncontrolling Interest [Line Items]                      
Remeasurement of Geneos Series A-1 preferred stock   $ 165,000       165,215          
Share in net loss of Geneos   2,200,000       2,165,213          
Investment in Geneos   $ 0       $ 0 $ 1,999,998        
Geneos Therapeutics, Inc.                      
Noncontrolling Interest [Line Items]                      
Noncontrolling interest, ownership percentage by parent   28.00% 36.00% 61.00%         35.00%   52.00%
Geneos Therapeutics, Inc.                      
Noncontrolling Interest [Line Items]                      
Payments to acquire additional interest in subsidiaries     $ 1,400,000 $ 1,200,000              
Stock purchase agreement, commitment of additional investment                   $ 800,000 $ 800,000
Gain on deconsolidation of Geneos $ 4,100,000                    
Remeasurement of Geneos Series A-1 preferred stock $ 2,400,000                    
Loss from equity method investment, recorded and allocated to investment         $ 1,500,000            
Share in net loss of Geneos         434,000            
Investment in Geneos         0            
Geneos Therapeutics, Inc. | Common stock                      
Noncontrolling Interest [Line Items]                      
Share in net loss of Geneos         819,000            
Investment in Geneos         0            
Geneos Therapeutics, Inc. | Series A-1 Preferred Stock                      
Noncontrolling Interest [Line Items]                      
Share in net loss of Geneos         4,200,000            
Investment in Geneos         $ 0            
Geneos Therapeutics, Inc. | Preferred stock                      
Noncontrolling Interest [Line Items]                      
Payments to acquire additional interest in subsidiaries   $ 2,000,000                  
XML 89 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Noncontrolling Interest [Line Items]        
Share in current and accumulated net loss of Geneos   $ (2,165,213) $ (434,387) $ (4,584,610)
Series A-2 One Preferred Stock        
Noncontrolling Interest [Line Items]        
Beginning balance   1,999,998    
Remeasurement of Geneos Series A-1 preferred stock $ 165,000 165,215    
Share in current and accumulated net loss of Geneos (2,200,000) (2,165,213)    
Ending balance $ 0 $ 0 $ 1,999,998  
XML 90 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details)
 1 Months Ended
Jan. 31, 2023
USD ($)
employee
Feb. 28, 2023
USD ($)
day
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Subsequent Event [Line Items]          
Common stock, shares issued (in shares) | shares       253,091,319 217,382,887
Common stock, value, issued       $ 253,090 $ 217,382
Forecast          
Subsequent Event [Line Items]          
Expected charge     $ 1,100,000    
Subsequent Event          
Subsequent Event [Line Items]          
Number of positions reduced | employee 24        
Number of positions reduced (in percent) 11.00%        
Expected annual savings $ 4,300,000        
Subsequent Event | McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim          
Subsequent Event [Line Items]          
Common stock, shares issued (in shares) | shares   7,000,000      
Common stock, value, issued   $ 2,100,000      
Trading days | day   10      
XML 91 ino-20221231_htm.xml IDEA: XBRL DOCUMENT 0001055726 2022-01-01 2022-12-31 0001055726 2022-06-30 0001055726 2023-02-24 0001055726 2022-12-31 0001055726 2021-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member 2022-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member 2021-12-31 0001055726 2021-01-01 2021-12-31 0001055726 2020-01-01 2020-12-31 0001055726 ino:ConvertibleBondsMember 2022-01-01 2022-12-31 0001055726 ino:ConvertibleBondsMember 2021-01-01 2021-12-31 0001055726 ino:ConvertibleBondsMember 2020-01-01 2020-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member 2022-01-01 2022-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member 2021-01-01 2021-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member 2020-01-01 2020-12-31 0001055726 us-gaap:PreferredStockMember 2019-12-31 0001055726 us-gaap:CommonStockMember 2019-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001055726 us-gaap:RetainedEarningsMember 2019-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001055726 us-gaap:NoncontrollingInterestMember 2019-12-31 0001055726 2019-12-31 0001055726 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001055726 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001055726 ino:August2019ConvertibleBondsMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001055726 ino:August2019ConvertibleBondsMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001055726 ino:August2019ConvertibleBondsMember 2020-01-01 2020-12-31 0001055726 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001055726 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001055726 us-gaap:PreferredStockMember 2020-12-31 0001055726 us-gaap:CommonStockMember 2020-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001055726 us-gaap:RetainedEarningsMember 2020-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001055726 us-gaap:NoncontrollingInterestMember 2020-12-31 0001055726 2020-12-31 0001055726 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001055726 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001055726 us-gaap:PreferredStockMember 2021-12-31 0001055726 us-gaap:CommonStockMember 2021-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001055726 us-gaap:RetainedEarningsMember 2021-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001055726 us-gaap:NoncontrollingInterestMember 2021-12-31 0001055726 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001055726 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001055726 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001055726 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001055726 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001055726 us-gaap:PreferredStockMember 2022-12-31 0001055726 us-gaap:CommonStockMember 2022-12-31 0001055726 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001055726 us-gaap:RetainedEarningsMember 2022-12-31 0001055726 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001055726 us-gaap:NoncontrollingInterestMember 2022-12-31 0001055726 ino:August2019ConvertibleBondsMember 2022-01-01 2022-12-31 0001055726 ino:August2019ConvertibleBondsMember 2021-01-01 2021-12-31 0001055726 us-gaap:CommonStockMember ino:SalesAgreementMember 2022-01-01 2022-12-31 0001055726 us-gaap:CommonStockMember ino:SalesAgreementMember 2021-01-01 2021-12-31 0001055726 us-gaap:CommonStockMember ino:SalesAgreementMember 2020-01-01 2020-12-31 0001055726 us-gaap:CommonStockMember ino:UnderwrittenPublicOfferingMember 2021-01-01 2021-12-31 0001055726 srt:MinimumMember 2022-01-01 2022-12-31 0001055726 srt:MaximumMember 2022-01-01 2022-12-31 0001055726 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001055726 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001055726 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001055726 ino:ServiceBasedRestrictedStockUnitsMember 2022-01-01 2022-12-31 0001055726 ino:ServiceBasedRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001055726 ino:ServiceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001055726 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001055726 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001055726 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:A6.50ConvertibleSeniorNotesDue2024Member 2022-01-01 2022-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:A6.50ConvertibleSeniorNotesDue2024Member 2021-01-01 2021-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:A6.50ConvertibleSeniorNotesDue2024Member 2020-01-01 2020-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:December2019ConvertibleBondsMember 2022-01-01 2022-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:December2019ConvertibleBondsMember 2021-01-01 2021-12-31 0001055726 us-gaap:ConvertibleDebtSecuritiesMember ino:December2019ConvertibleBondsMember 2020-01-01 2020-12-31 0001055726 ino:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001055726 ino:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001055726 ino:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001055726 ino:NonEmployeeMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001055726 ino:NonEmployeeMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001055726 ino:NonEmployeeMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001055726 us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0001055726 us-gaap:AccountingStandardsUpdate202006Member 2022-12-31 0001055726 ino:AdvaccineMember 2022-01-01 2022-12-31 0001055726 ino:AdvaccineMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001055726 ino:AdvaccineMember 2021-01-01 2021-12-31 0001055726 ino:AdvaccineMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:AdvaccineMember 2020-01-01 2020-12-31 0001055726 ino:AdvaccineMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001055726 ino:PlumblineLifeSciencesIncMember 2022-01-01 2022-12-31 0001055726 ino:PlumblineLifeSciencesIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001055726 ino:PlumblineLifeSciencesIncMember 2021-01-01 2021-12-31 0001055726 ino:PlumblineLifeSciencesIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:PlumblineLifeSciencesIncMember 2020-01-01 2020-12-31 0001055726 ino:PlumblineLifeSciencesIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001055726 ino:DoDMember 2022-01-01 2022-12-31 0001055726 ino:DoDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001055726 ino:DoDMember 2021-01-01 2021-12-31 0001055726 ino:DoDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:DoDMember 2020-01-01 2020-12-31 0001055726 ino:DoDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001055726 ino:AllOtherCustomersMember 2022-01-01 2022-12-31 0001055726 ino:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001055726 ino:AllOtherCustomersMember 2021-01-01 2021-12-31 0001055726 ino:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:AllOtherCustomersMember 2020-01-01 2020-12-31 0001055726 ino:AllOtherCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001055726 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001055726 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001055726 ino:DoDMember us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001055726 ino:DoDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:CEPIMERSMember us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001055726 ino:CEPIMERSMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001055726 ino:AdvaccineMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-01-31 0001055726 ino:AdvaccineMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:AdvaccineMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:AdvaccineMember us-gaap:LicenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:AdvaccineMember us-gaap:LicenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:AdvaccineMember us-gaap:LicenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:AdvaccineMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:ApolloBioMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember us-gaap:CollaborativeArrangementMember 2018-04-11 2018-04-11 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:LassaFeverAndMERSVaccineMember us-gaap:CollaborativeArrangementMember 2022-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:LassaFeverAndMERSVaccineMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-01-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-04-30 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-04-30 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:INO4800Member us-gaap:CollaborativeArrangementMember 2020-04-01 2020-04-30 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2022-12-31 0001055726 ino:CoalitionforEpidemicPreparednessInnovationsMember ino:SARSCoV2COVID19VaccineMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2018-10-01 2018-10-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2019-08-01 2019-08-30 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2022-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:DNAEncodedMonoclonalAntibodyTechnologyMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2020-03-01 2020-03-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:BillAndMelindaGatesFoundationMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:DepartmentOfDefenceMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2020-06-01 2020-06-30 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0001055726 ino:DepartmentOfDefenceMember ino:CELLECTRA3PSPProprietarySmartDeviceMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-01-31 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2022-12-31 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001055726 ino:DepartmentOfDefenceMember us-gaap:CollaborativeArrangementMember 2020-12-31 0001055726 ino:MutualFundsMember 2022-12-31 0001055726 us-gaap:USTreasuryBillSecuritiesMember 2022-01-01 2022-12-31 0001055726 us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001055726 srt:MaximumMember us-gaap:CertificatesOfDepositMember 2022-01-01 2022-12-31 0001055726 us-gaap:CertificatesOfDepositMember 2022-12-31 0001055726 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2022-12-31 0001055726 ino:MutualFundsMember 2021-12-31 0001055726 srt:MaximumMember us-gaap:CertificatesOfDepositMember 2021-01-01 2021-12-31 0001055726 us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0001055726 us-gaap:CommercialPaperMember 2021-12-31 0001055726 us-gaap:CertificatesOfDepositMember 2021-12-31 0001055726 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2022-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2022-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ino:MutualFundsMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2021-12-31 0001055726 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001055726 us-gaap:FairValueInputsLevel1Member us-gaap:CommonStockMember 2022-12-31 0001055726 ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember 2022-07-31 0001055726 ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember 2022-01-01 2022-12-31 0001055726 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001055726 us-gaap:OfficeEquipmentMember 2022-12-31 0001055726 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001055726 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2022-12-31 0001055726 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001055726 us-gaap:OfficeEquipmentMember 2021-12-31 0001055726 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001055726 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2021-12-31 0001055726 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-12-31 0001055726 srt:WeightedAverageMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0001055726 us-gaap:LicensingAgreementsMember 2022-12-31 0001055726 us-gaap:LicensingAgreementsMember 2021-12-31 0001055726 srt:WeightedAverageMember ino:BiojectMember 2022-01-01 2022-12-31 0001055726 ino:BiojectMember 2022-12-31 0001055726 ino:BiojectMember 2021-12-31 0001055726 srt:WeightedAverageMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0001055726 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001055726 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001055726 srt:WeightedAverageMember 2022-01-01 2022-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2019-03-01 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2019-02-19 2019-02-28 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2019-02-19 2019-03-01 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2022-12-31 0001055726 us-gaap:ConvertibleDebtMember 2022-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001055726 ino:A6.50ConvertibleSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2020-01-01 2020-12-31 0001055726 ino:December2019ConvertibleBondsMember us-gaap:ConvertibleDebtMember 2019-12-26 0001055726 ino:December2019ConvertibleBondsMember us-gaap:ConvertibleDebtMember 2019-12-26 2019-12-26 0001055726 ino:December2019ConvertibleBondsMember us-gaap:ConvertibleDebtMember 2021-03-17 2021-03-17 0001055726 ino:December2019ConvertibleBondsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001055726 ino:December2019ConvertibleBondsMember us-gaap:ConvertibleDebtMember 2021-12-31 0001055726 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001055726 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001055726 us-gaap:CommonStockMember ino:SalesAgreementMember 2021-11-09 2021-11-09 0001055726 us-gaap:CommonStockMember ino:SalesAgreementMember 2022-12-31 0001055726 us-gaap:CommonStockMember ino:UnderwrittenPublicOfferingMember 2021-01-25 2021-01-25 0001055726 us-gaap:CommonStockMember ino:UnderwrittenPublicOfferingMember 2021-01-25 0001055726 ino:A2016IncentivePlanMember 2016-05-13 0001055726 ino:A2016IncentivePlanMember 2022-01-01 0001055726 ino:A2016IncentivePlanMember 2022-12-31 0001055726 ino:A2016IncentivePlanMember 2022-01-01 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember ino:A2016IncentivePlanMember 2022-12-31 0001055726 ino:A2022InducementPlanMember 2022-06-24 0001055726 ino:A2022InducementPlanMember 2022-12-31 0001055726 ino:A2007IncentivePlanMember 2022-12-31 0001055726 ino:A2007IncentivePlanMember 2022-01-01 2022-12-31 0001055726 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001055726 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001055726 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001055726 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001055726 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001055726 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001055726 ino:FormerPresidentAndChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001055726 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-12-31 0001055726 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-12-31 0001055726 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-12-31 0001055726 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-12-31 0001055726 ino:RangeOfExercisePricesOneMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesOneMember 2022-12-31 0001055726 ino:RangeOfExercisePricesTwoMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesTwoMember 2022-12-31 0001055726 ino:RangeOfExercisePricesThreeMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesThreeMember 2022-12-31 0001055726 ino:RangeOfExercisePricesFourMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesFourMember 2022-12-31 0001055726 ino:RangeOfExercisePricesFiveMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesFiveMember 2022-12-31 0001055726 ino:RangeOfExercisePricesSixMember 2022-01-01 2022-12-31 0001055726 ino:RangeOfExercisePricesSixMember 2022-12-31 0001055726 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001055726 ino:FormerPresidentAndChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001055726 ino:SanDiegoCaliforniaMember 2022-01-01 2022-12-31 0001055726 ino:PlymouthMeetingPennsylvaniaMember 2022-01-01 2022-12-31 0001055726 srt:MinimumMember 2022-12-31 0001055726 srt:MaximumMember 2022-12-31 0001055726 2019-10-01 2019-12-31 0001055726 ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember 2021-03-09 0001055726 us-gaap:InternalRevenueServiceIRSMember 2022-12-31 0001055726 ino:CaliforniaIncomeTaxAuthorityMember 2022-12-31 0001055726 ino:PennsylvaniaStateIncomeTaxAuthorityMember 2022-12-31 0001055726 us-gaap:InternalRevenueServiceIRSMember 2018-12-31 0001055726 ino:KoreanStateIncomeTaxAuthorityMember 2022-12-31 0001055726 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2022-12-31 0001055726 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2022-12-31 0001055726 us-gaap:DomesticCountryMember 2022-12-31 0001055726 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001055726 us-gaap:ForeignCountryMember 2022-12-31 0001055726 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2022-12-31 0001055726 ino:PlumblineLifeSciencesMember 2021-12-31 0001055726 ino:PlumblineLifeSciencesMember 2022-12-31 0001055726 ino:PLSaffiliatedentityMember 2022-01-01 2022-12-31 0001055726 ino:PLSaffiliatedentityMember 2021-01-01 2021-12-31 0001055726 ino:PLSaffiliatedentityMember 2020-01-01 2020-12-31 0001055726 ino:PLSaffiliatedentityMember 2022-12-31 0001055726 ino:PLSaffiliatedentityMember 2021-12-31 0001055726 ino:TheWistarInstituteMember 2016-03-01 2016-03-31 0001055726 srt:DirectorMember 2021-01-01 2021-12-31 0001055726 srt:DirectorMember 2016-11-01 2016-11-30 0001055726 ino:TheWistarInstituteMember 2020-01-01 2020-12-31 0001055726 ino:TheWistarInstituteMember 2022-01-01 2022-12-31 0001055726 srt:DirectorMember 2022-01-01 2022-12-31 0001055726 ino:TheWistarInstituteMember 2021-01-01 2021-12-31 0001055726 ino:TheWistarInstituteMember 2022-12-31 0001055726 ino:TheWistarInstituteMember 2021-12-31 0001055726 ino:GeneosTherapeuticsInc.Member 2019-02-01 2019-02-28 0001055726 ino:GeneosTherapeuticsInc.Member 2019-02-28 0001055726 ino:GeneosTherapeuticsInc.Member 2020-01-31 0001055726 ino:GeneosTherapeuticsInc.Member 2020-01-31 0001055726 ino:GeneosTherapeuticsInc.Member 2020-06-30 0001055726 ino:GeneosTherapeuticsInc.Member 2020-06-30 0001055726 ino:GeneosTherapeuticsInc.Member 2020-06-01 2020-06-01 0001055726 ino:GeneosTherapeuticsInc.Member 2020-11-01 2020-11-30 0001055726 ino:GeneosTherapeuticsInc.Member 2020-11-30 0001055726 ino:GeneosTherapeuticsInc.Member 2021-01-01 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member us-gaap:CommonStockMember 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member ino:SeriesAOnePreferredStockMember 2021-01-01 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member ino:SeriesAOnePreferredStockMember 2021-03-31 0001055726 ino:GeneosTherapeuticsInc.Member 2021-02-28 0001055726 ino:GeneosTherapeuticsInc.Member us-gaap:PreferredStockMember 2022-03-01 2022-03-31 0001055726 ino:GeneosTherapeuticsInc.Member 2022-03-31 0001055726 ino:SeriesA2OnePreferredStockMember 2022-03-01 2022-03-31 0001055726 ino:SeriesA2OnePreferredStockMember 2022-03-31 0001055726 ino:SeriesA2OnePreferredStockMember 2021-12-31 0001055726 ino:SeriesA2OnePreferredStockMember 2022-01-01 2022-12-31 0001055726 ino:SeriesA2OnePreferredStockMember 2022-12-31 0001055726 us-gaap:SubsequentEventMember 2023-01-31 2023-01-31 0001055726 srt:ScenarioForecastMember 2023-03-31 0001055726 ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember us-gaap:SubsequentEventMember 2023-02-28 0001055726 ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember us-gaap:SubsequentEventMember 2023-02-01 2023-02-28 iso4217:USD shares iso4217:USD shares ino:segment pure ino:position ino:day iso4217:KRW utr:sqft ino:agreement ino:employee false 2022 FY 0001055726 http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member P3Y P2Y 0.1858045 0.50 10-K true 2022-12-31 --12-31 false 001-14888 INOVIO PHARMACEUTICALS, INC. DE 33-0969592 660 W. Germantown Pike Suite 110 Plymouth Meeting PA 19462 267 440-4200 COMMON STOCK, $0.001 PAR VALUE INO NASDAQ No No Yes Yes Non-accelerated Filer true false false false 425500000 260131986 <div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive proxy statement to be filed with the Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement’) are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2022.</span></div> 42 Ernst & Young LLP San Diego, California 46329359 71143778 206669397 330170940 1701726 5466850 10036490 2565194 50130481 38836991 375227 261192 315242680 448444945 7727997 17453206 2007142 3906796 2129861 2626355 10513371 10513371 10228207 11571026 684044 1425794 348533302 495941493 79686885 47644530 1220439 548032 10594073 10326266 0 21628 2803973 2603956 2475031 4559721 87673 37500 96868074 65741633 0 64361 16614840 14959647 12655586 15459559 32046 32046 0 14826 126170546 96272072 0.001 0.001 10000000 10000000 9 9 9 9 0 0 0.001 0.001 600000000 600000000 253091319 253091319 217382887 217382887 253090 217382 1710656191 1609589797 -1487847784 -1209855522 -698741 -282236 222362756 399669421 348533302 495941493 10262268 1774758 7411220 187650503 249240324 94245436 90185285 53752353 37247828 277835788 302992677 131493264 -267573520 -301217919 -124082044 4782030 3363080 3311846 1253952 1936447 8702450 0 0 -75670977 -1899654 -553570 36556658 -7846172 -3222838 1695497 -3861584 343371 -704896 0 0 4121075 0 0 -8177043 0 0 8762030 -277652852 -303224323 -162890304 -2165213 -434387 -4584610 -279818065 -303658710 -167474914 0 0 -1063757 -279818065 -303658710 -166411157 -1.17 -1.17 -1.45 -1.45 -1.07 -1.07 238622188 238622188 208829801 208829801 155126857 155126857 -279818065 -303658710 -167474914 -25556 -30134 27205 -390949 4048 -755963 -280234570 -303684796 -168203672 0 0 -1063757 -280234570 -303684796 -167139915 23 0 101361034 101361 742646785 -739785655 472608 1969759 5404858 66064886 66065 454420335 454486400 -14 5147 5 -5 0 11535660 11536 43682850 43694386 4962364 4961 102666349 102671310 2922402 2923 8238701 8241624 15655585 -8062 15647523 2379969 2379969 3181640 3181640 -166411157 -1063757 -167474914 -96269 96269 0 -755963 -755963 27205 27205 9 0 186851493 186851 1367406869 -906196812 -256150 0 461140758 27310341 27310 209414100 209441410 1009450 1009 4376883 4377892 2211603 2212 2055181 2057393 26336764 26336764 -303658710 -303658710 4048 4048 -30134 -30134 9 0 217382887 217382 1609589797 -1209855522 -282236 0 399669421 -3294019 1825803 -1468216 34445743 34447 82920864 82955311 1262689 1261 -1115870 -1114609 22555419 22555419 -279818065 -279818065 -390949 -390949 -25556 -25556 9 0 253091319 253090 1710656191 -1487847784 -698741 0 222362756 -279818065 -303658710 -167474914 3656713 3040096 3038996 496494 520415 547081 1342819 1170270 1041713 0 0 75670977 22555419 26336764 15647523 186977 858644 4077686 1320546 -1633286 0 -4029961 -5397 -588270 0 0 1713770 0 0 4121075 165215 0 0 -1074830 0 -26913 -1899654 -553570 36556658 -2165213 -434387 -4584610 0 0 -8177043 0 0 8762030 -7846172 -3222838 1695497 0 176927 -15902 3706172 -11031705 17015471 5336525 6343632 38475465 -741750 -24531654 23285424 32606581 26140970 3251478 267807 375921 5962381 -85989 -39853 -62353 -2603956 -2329394 -2091855 -2034517 -2973089 624173 -14826 -42837 20720 -216215421 -215708525 -177979046 248528843 348953236 156216677 361083850 174839758 62991023 969153 1231006 1520665 0 0 40125418 0 0 2774851 1999998 0 1399999 109585856 -175344484 -58795751 82955311 209441410 454486400 283022 6668741 12269801 -1397631 -4611348 -4028177 0 0 2379969 0 0 171620 81840702 211498803 465279613 -25556 -30134 27205 -24814419 -179584340 228532021 71143778 250728118 22196097 46329359 71143778 250728118 108181 204815 136711 1066975 1077803 4624764 6071000 7709337 0 The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company’s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidates are focused on diseases associated with HPV. In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and GBM.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div> Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December 31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December 31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company’s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0 million, $47.7 million and $454.5 million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1 million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y also issued convertible notes and bonds in a series of private placement transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time, may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December 31, 2022 and 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company’s affiliated entity, PLS, at December 31, 2022 and 2021. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December 31, 2022 and 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December 31, 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2022 and 2021, the Company’s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1 million and $2.6 million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. See Note 8 for further discussion of the Company’s goodwill and intangible assets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company’s deferred tax assets were $299.1 million and $237.2 million at December 31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue, in accordance with Accounting Standards Update (“ASU”) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“Topic 606”), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent). The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943,035 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-06”), which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8 million, a decrease in additional paid-in capital of $3.3 million, and an increase in convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5 million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December 31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December 31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company’s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (“Sales Agreements”). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0 million, $47.7 million and $454.5 million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1 million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y also issued convertible notes and bonds in a series of private placement transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of </span></div>liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.The Company is and, from time to time, may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails. Any of the foregoing consequences could result in serious harm to the Company’s business, results of operations and financial condition. -279800000 218400000 -1500000000 253000000 83000000 47700000 454500000 162100000 ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. <div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div> 1 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div> Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December 31, 2022 and 2021.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company’s affiliated entity, PLS, at December 31, 2022 and 2021. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. 0 0 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div> P5Y Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2022 and 2021, the Company’s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1 million and $2.6 million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company </span></div>cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. P18Y 2100000 2600000 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company’s deferred tax assets were $299.1 million and $237.2 million at December 31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div> 299100000 237200000 <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue, in accordance with Accounting Standards Update (“ASU”) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“Topic 606”), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (“Topic 808”) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div> Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div> <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div> Equity Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent). The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div>Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. Net Loss Per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span>For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. <div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943,035 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12221548 10488993 8906624 2556257 2448868 2558052 111941 663353 663353 3309 3309 3309 3049980 3049980 3049980 0 0 1009450 17943035 16654503 16190768 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div> <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the </span></div>date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0.0205 0.0091 0.0063 0.94 0.93 0.78 P5Y8M12D P6Y P6Y 0 0 0 0.0196 0.0145 0.0082 0.87 0.87 0.76 P10Y P10Y P10Y 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-06”), which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8 million, a decrease in additional paid-in capital of $3.3 million, and an increase in convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5 million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).</span></div> 1800000 -3300000 1500000 1500000 Revenue Recognition and Concentration of Credit RiskDuring the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the total revenue recognized during the year ended December 31, 2022, $14,000 was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $46,000 that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December 31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</span></div> The following table indicates the percentage of total revenues in excess of 10% with any single customer:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table> 0 0 0 0 5000000 0.68 33596 0 245310 0.14 1370396 0.18 9591778 0.94 754853 0.43 0 0 636894 0.06 774595 0.43 1040824 0.14 10262268 1 1774758 1 7411220 1 14000 46000 3600000 0.65 1900000 0.34 Collaborative Agreements <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), which was amended and restated on June 7, 2021 (as amended and restated, the “Advaccine Agreement”). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company’s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as “Greater China”) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company’s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company’s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company’s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0 million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0 million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine’s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5 million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine’s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine’s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months’ written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18 months’ written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0 million upfront payment received in January 2021 plus a $2.0 million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0 million was allocated to the license performance obligation. The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0, $0 and $5.0 million of revenue for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020, respectively, under the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, 2021 and 2020 the Company received funding of $1.2 million, $4.5 million and $0, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, its DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the ApolloBio Agreement. In the event that VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio’s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there has been no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December 31, 2022, 2021 and 2020, the Company received funding of $6.7 million, $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December 31, 2022 and 2021, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $1.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $1.9 million, respectively, on the consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $6.9 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0 million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the years ended December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $1.1 million, $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December 31, 2022 and 2021, the Company had $2.3 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $233,000, $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December 31, 2022 and 2021, the Company had $153,000 and $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $0, $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the “OTA Agreement”) with the DoD to fund the Company’s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device and associated arrays to be used for delivery of INO-4800 against COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5 million. The Company determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December 31, 2022, 2021 and 2020, the Company recorded $6.1 million, $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the “Procurement Contract”) from the DoD for the purchase of the Company’s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 device and accessories. The total purchase price under the Procurement Contract was $16.8 million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7 million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022, 2021 </span></div>and 2020, the Company recorded revenue of $9.6 million, $755,000 and $0, respectively, from the Procurement Contract. 3000000 200000000 P10Y 1500000 P5Y P18M 3000000 2000000 5000000 0 0 5000000 1200000 4500000 0 20000000 P10Y P1Y P90D 56000000 P5Y 6700000 10000000 6400000 1700000 1900000 9000000 6900000 5000000 1300000 1100000 6900000 10000000 2300000 1800000 2200000 1100000 233000 182000 463000 153000 384000 5000000 0 893000 4100000 54500000 6100000 27100000 21200000 16800000 10700000 9600000 755000 0 Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8 million and $3.2 million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material balances were reclassified out of accumulated other comprehensive loss for the years ended December 31, 2022, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December 31, 2022, the Company had 29 available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December 31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December 31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company’s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December 31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December 31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the </span></div>service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December 31, 2022 and 2021. Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8 million and $3.2 million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material balances were reclassified out of accumulated other comprehensive loss for the years ended December 31, 2022, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December 31, 2022, the Company had 29 available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December 31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December 31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company’s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December 31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December 31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the </span></div>service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December 31, 2022 and 2021. <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December 31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div> 117036232 0 9373514 107662718 P1Y 95001209 7567 44266 94964510 P1Y 2977564 13664 320 2990908 1435592 0 384331 1051261 216450597 21231 9802431 206669397 192966772 87069 1614411 191439430 P1Y 94193441 0 9921 94183520 P1Y 39967853 0 0 39967853 P1Y 2976210 15618 338 2991490 1608137 4508 23998 1588647 331712413 107195 1648668 330170940 21000 394000 4100000 399000 -7800000 -3200000 29 21 -8700000 <div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December 31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 107662718 107662718 0 0 94964510 94964510 0 0 2990908 0 2990908 0 1051261 0 1051261 0 206669397 202627228 4042169 0 2007142 2007142 0 0 208676539 204634370 4042169 0 191439430 191439430 0 0 94183520 94183520 0 0 39967853 0 39967853 0 2991490 0 2991490 0 1588647 0 1588647 0 330170940 285622950 44547990 0 3906796 3906796 0 0 334077736 289529746 44547990 0 597808 Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December 31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,424,743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under “Legal Proceedings.” The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0 million in cash and $14.0 million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30000000 0 1401028 27474159 18729453 11362832 50130481 38836991 <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December 31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,424,743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under “Legal Proceedings.” The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0 million in cash and $14.0 million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. 19862487 27424743 12574921 16112912 44000000 0 3249477 4106875 79686885 47644530 30000000 14000000 252000 Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December 31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for the years ended December 31, 2022, 2021 and 2020 was $3.7 million, $3.0 million and $3.0 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1 million and disposed of fixed assets with a net book value of $1.1 million. The Company has recorded a receivable from the sale of these assets of $6.1 million, which is included in prepaid expenses and other current assets on the consolidated balance sheet. <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December 31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15803108 10036080 5767028 5300104 4295217 1004887 2827476 2803800 23676 5360712 4428306 932406 29291400 21563403 7727997 15803108 8258608 7544500 12392916 4279816 8113100 2827476 2599643 227833 5374084 3806311 1567773 36397584 18944378 17453206 3700000 3000000 3000000 6100000 1100000 6100000 Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $496,000, $520,000 and $547,000 for the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense related to intangible assets at December 31, 2022 is expected to be incurred as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022, 2021 and 2020.</span></div> <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div> 10513371 10513371 10513371 10513371 P10Y 1323761 1323761 0 1323761 1305600 18161 P12Y 5100000 2988889 2111111 5100000 2735556 2364444 P18Y 4050000 4031250 18750 4050000 3806250 243750 P11Y 10473761 8343900 2129861 10473761 7847406 2626355 20987132 8343900 12643232 20987132 7847406 13139726 496000 520000 547000 Amortization expense related to intangible assets at December 31, 2022 is expected to be incurred as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 273000 253000 253000 253000 253000 845000 2130000 0 0 0 0 0 0 Convertible Debt<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the “Notes”). The Notes were sold in a private offering to </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased. Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3 million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2 million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8 million, a decrease to additional paid-in capital of $3.3 million, and an increase to convertible senior notes of $1.5 million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December 31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,614,840 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, the Company recognized $1.3 million, $1.9 million and $6.9 million, respectively, of interest expense related to the Notes, of which $1.1 million, $1.1 million and $4.1 million, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company closed a private placement of convertible promissory notes (the “December 2019 Bonds”) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December 31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December 31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the $4.4 million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</span></div>During the year ended December 31, 2021, the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was 6.2%. 78500000 0.0650 75700000 0.0650 5.38 1.30 20 30 1 16300000 0.131 592000 2200000 1800000 -3300000 1500000 <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December 31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,614,840 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 78500000 62085000 155815 355655 16614840 1300000 1900000 6900000 1100000 1100000 4100000 <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.065 1067000 16948000 18015000 4700000000 4100000 4000000 0.0100 1009450 4400000 50000 9000 0.062 Stockholders’ Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder’s option, to convert all or any lesser portion of such holder’s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $27.20 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the “2021 Sales Agreement”) with outside sales agents (collectively, the “Sales Agents”) for the offer and sale of its common stock for an aggregate offering price of up to $300.0 million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December 31, 2022 and 2021, the Company sold 34,445,743 and 6,955,341 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $2.44 and $6.96 per share, respectively, resulting in aggregate net proceeds of $83.0 million and $47.7 million, respectively. As of December 31, 2022 there was $167.4 million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1 million. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December 31, 2022, the maximum number of shares of the Company’s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, the maximum number of shares is increased by 2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At December 31, 2022, the Company had 3,831,240 shares of common stock available for future grant under the 2016 Incentive Plan, 2,446,257 shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase 10,132,969 shares of common stock and 111,941 shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March 9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company’s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At December 31, 2022 the Company had 1,703,750 shares of common stock available for future grant under the 2022 Inducement Plan, 110,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 186,250 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March 31, 2007 and terminated by its terms on March 31, 2017. At December 31, 2022, the Company had options outstanding to purchase 1,902,329 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 was $22.2 million, $25.0 million and $14.5 million, respectively, of which $8.8 million, $13.4 million and $8.0 million was included in research and development expenses and $13.4 million, $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until five years after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $4.2 million charge related to these RSU and stock option modifications.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, there was $10.5 million and $16.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years and 2.0 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, there was $7.2 million and $13.4 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.7 years and 1.8 years, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December 31, 2022, 2021 and 2020 was $1.3 million, $1.4 million and $1.2 million, respectively. As of December 31, 2022, options to purchase 665,875 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.56-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,829,692 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the aggregate intrinsic value of options outstanding was $0, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.7 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $4.0 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $4.6 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, options to purchase 12,221,548 shares of common stock and 2,556,257 RSUs were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $8.47 for the 77,250 options which expired during the year ended December 31, 2022, $4.56 for the 7,000 options which expired during the year ended December 31, 2021 and $4.44 for the 78,750 options which expired during the year ended December 31, 2020.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $2.34, $7.61 and $6.87 for options granted during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $3.12, $10.37 and $9.12 per share for RSUs granted during the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $283,000, $6.7 million and $12.3 million in proceeds from the exercise of stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $81,000, $7.0 million and $14.2 million during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">had</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,941</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December 31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.001 1091 1091 9 9 27.20 3309 300000000 0.030 34445743 6955341 2.44 6.96 83000000 47700000 167400000 20355000 8.50 162100000 22000000 2000000 2000000 3831240 2446257 10132969 111941 P3Y P10Y 2000000 1703750 110000 186250 1902329 P3Y P10Y 22200000 25000000 14500000 8800000 13400000 8000000.0 13400000 11600000 6500000 P5Y 4200000 10500000 16500000 P1Y7M6D P2Y 7200000 13400000 P1Y8M12D P1Y9M18D 1300000 1400000 1200000 665875 <div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.56-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,829,692 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1.56 3.00 830542 P8Y3M18D 2.17 247104 2.29 3.01 6.00 5461365 P7Y1M6D 3.50 3059330 3.67 6.01 9.00 3349587 P5Y3M18D 7.57 2861909 7.49 9.01 12.00 1930825 P7Y1M6D 10.97 1080389 10.89 12.01 15.00 580947 P4Y1M6D 13.38 529392 13.34 15.01 25.62 68282 P7Y7M6D 21.12 51568 21.11 12221548 P6Y7M6D 6.28 7829692 6.79 0 0 P5Y8M12D 4000000 4600000 12221548 2556257 <div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10488993 7.93 4623448 3.11 118694 2.38 2772199 7.46 12221548 6.28 <div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company’s equity incentive plans during the year ended December 31, 2022 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2448868 2485947 1618235 760323 2556257 8.47 77250 4.56 7000 4.44 78750 2.34 7.61 6.87 3.12 10.37 9.12 283000 6700000 12300000 81000 7000000 14200000 111941 Commitments and Contingencies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December 31, 2022 of 0.9 years to 7.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December 31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,090,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,630,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,804,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020 were $3.4 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. The plaintiffs’ complaint was later amended to include certain of the Company’s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $30.0 million in cash and $14.0 million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $30.0 million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action complaint described above. The lawsuit accuses the Company’s board of directors of failing to exercise reasonable and prudent supervision over the Company’s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company’s current directors as defendants. The Devarakonda complaint also names one of the Company’s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company’s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI’s counterclaims, disputing the allegations and the claims raised in VGXI’s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI’s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys’ fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company’s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company’s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney’s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company’s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne’s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne’s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of </span></div>operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company’s consolidated results of operations or financial position. 82200 57360 P0Y10M24D P7Y <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December 31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,090,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,630,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,804,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 4089000 3050000 3063000 3139000 2526000 4223000 20090000 4630000 15460000 2804000 12656000 P5Y10M24D 0.086 3400000 3400000 3400000 2 13500 30000000 14000000 30000000 Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,998,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $625.4 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforwards of $1.0 million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2022, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $40.5 million and $4.7 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December 31, 2022. As a result of the analysis, the Company estimates that approximately $8.3 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $19.7 million, $17.4 million and $10.9 million as of December 31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (“IRS”), state, local or foreign tax examination.</span></div> <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -277440803 -302614003 -162664355 -211249 -610320 -225949 -277652052 -303224323 -162890304 0 0 0 <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -58307000 -63677000 -34207000 -3601000 -3447000 0 61065000 77424000 21428000 0 0 14450000 -7534000 -16523000 -2650000 2913000 483000 -1953000 2291000 6509000 1068000 0 0 853000 1459000 616000 468000 -1337000 -542000 -368000 -187000 0 0 -8000 -24000 -9000 3246000 -819000 920000 0 0 0 Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are shown below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,998,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 41252000 4200000 212768000 197144000 26442000 23005000 538000 987000 3945000 3599000 559000 637000 0 83000 1569000 750000 3247000 3793000 57000 0 11062000 5973000 301439000 240171000 299124000 237205000 2315000 2966000 199000 194000 2148000 2430000 0 321000 0 53000 2347000 2998000 32000 32000 920600000 210300000 89600000 625400000 1000000 40500000 4700000 <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5300000 1200000 0 0 0 18900000 9100000 0 0 0 9600000 5200000 0 0 0 12200000 7100000 0 0 0 249200000 277300000 1000000.0 40500000 0 625400000 0 0 0 4700000 920600000 299900000 1000000.0 40500000 4700000 8300000 <div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 18819000 12210000 11204000 2902000 6602000 1043000 582000 7000 27000 0 0 -64000 21139000 18819000 12210000 19700000 17400000 10900000 401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees’ contributions, up to 6% of their annual compensation. The Company’s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.8 million, $1.5 million and $1.1 million for the years ended December 31, 2022, 2021 and 2020, respectively. 0.50 0.06 1800000 1500000 1100000 Related Party TransactionsPlumbline Life Sciences, Inc.<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned 597,808 shares of common stock in PLS as of December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a 18.7% and 18.9% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr. David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December 31, 2022, 2021 and 2020, the Company recognized revenue from PLS of $34,000, $245,000 and $1.4 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $59,000 and $25,000, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr. David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar for preventive and therapeutic DNA-based immunotherapy applications and products developed by Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $1.9 million for all direct and indirect costs incurred in the conduct of the collaborative research.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a $6.1 million sub-grant through Wistar to develop a d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infectio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, with funding through December 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, with funding through February 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7 million sub-grant through Wistar, which was amended in 2021 to $13.6 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0 million in funding through March 2024, of which $3.3 million has been exercised as of December 31, 2022. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December 31, 2022 and 2021, the Company recorded $8.7 million and $3.0 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December 31, 2022, 2021 and 2020 were $1.4 million, $2.9 million and $2.3 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $9.9 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.2 million and $548,000, respectively, related to Wistar. As of December 31, 2022 and 2021, the Company had a prepaid expense balance of $375,000 and $261,000, respectively, and recorded $88,000 and $37,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div> 597808 597808 0.187 0.189 34000 245000 1400000 59000 25000 3100000 P5Y 1900000 6100000 10700000 13600000 6000000 3300000 8700000 3000000 1400000 2900000 2300000 9900000 2600000 1200000 548000 375000 261000 88000 37000 Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a Series A preferred stock financing. The Company invested $1.2 million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held 61% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held 52% of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest. Based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value. </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. Since the Company’s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company’s common stock investment and is therefore recorded as an equity security under ASC 321. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Any difference between the carrying amount of the Company’s investment and the amount of underlying equity in Geneos’s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, the Company’s investment will be marked to fair value.  There have been no observable price changes or impairments identified since the deconsolidation date. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4 million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s share of net losses of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2021 was $1.5 million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the total amount, $819,000 was allocated to the equity method investment, thereby reducing the balance to $0 as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss was allocated to the Company’s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0 million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company’s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos’s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos’s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr. David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div> 1200000 0.61 800000 0.52 800000 0.47 4100000 2400000 1400000 0.36 1500000 -434000 0 -819000 0 -4200000 0 0.35 2000000 0.28 165000 <div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2 million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -2200000 0 1999998 165215 -2165213 0 0 Subsequent Events<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the “Reduction”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately 24 employees, which represented 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued 7,000,000 shares of common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. The number of shares will be calculated based on the average trading price of the common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.</span></div> 24 0.11 4300000 1100000 7000000 2100000 10 EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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ŋ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Ȅ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М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�S_3GE;73TTD[ M]KN3SM4WT)J!I%F<6@8N\/X'Z[=&:Z?@]+?&^S5DG@*D)C!!%K M10Z[2K^/VW2N^(\;U87L$,3\,*)$E^^S*DZ2L1P[@88\6VAL:X,]1#7\ M$BF39V$BS8_%5UB\,U# D-Z]%N("7"OZGJ,D<@>4.<^.-M"&#AH(MD8\XO2[SSLD!]L_1ZM%>UZ6A6ZM(;;O%.PG'AVCPM6)2 M* J4*U6' ^Q*/WD/)QZ"+'(.VYW9<-7Z*_Q-ZL# M/O1KE:KRKFLJIFMDI]D M>C$-9/QDP8J47,W=5!Z(]@(=7+:AJ$0]R'0Y$B$^O0^J;6@V&:0Z' MX,UT7C0Q3>'&1=2%&%\UW1E0?Z$/M(FVH(Y@3A(W$C1/4N(H#3_)=[\ E:^ MAHX6?2"VJIXZ0]($-C,\2L+MX#TO7[4<:Z_ ^JHH6)I&O79I@XSH;=Q4&7J M^&H0/.]'1:K7P;0:,@F(&4:_)L..PL >B5[=,]D7;3%?8ID=/ A_\+'>H\[5 M$'E&H9!1H10G\0,G4E2>H;=#E<6#E(;2)@[N?IYJV6T0RHAD6GV6)U.?HFKU M8&4B\>KA;@.MMW&2^>B;BVGD)$0EP4VH"\J%-2IR'7(?LZULR)PHB_<7,&OZ M]0-W[[%DTCP6PX\.6>@IF17IIOM.O+6JL;R)]M[>NN8*BG (#Q5'/$@@BM]J,C NN[M,6OKN8*/5/?6>6DR]=4;\Y?A8 MPG'-@!?"10DM )@ T[R606/=R['!0/>[:39AHXX,77K$7>CZEKM4]C;/.RRD MP%>[^-:S],3>Q=;X..C3=<@5'+!KF6A^=>#M,_DVIUHJH_4:I^)%=D"03R9KM8O"AR M]TZ'X)E8Q%E%XE_CN_^,UC3,<_AHYW_\N*VIFZ.?DLNNGI@3BS=EAE&78( N MAJLI5!5Y,,6&HOU-0$JE/T#RBCW2)E;@DS.K]LM#.QYG/ T8]U5X\67W_(1Y M2_AS^_CMFZ&>O#*1<@C(X+MT[#.,6%:JA'"2+R0XC:S^,;"_(O?GGQI=RVY. M&8\Z*Y&]^CY_,)Z8JCH>P@ISG\01Y,H!^PYZ]6.1-I9-4@'*#E?S6/%(6Q$4 M(R>R+9@>LK@QX?_=!7M1(^+0X6Y-,A?(OGA*&G?^E-4,FBMU"[T8+U0F_D5O M(+=G\7""0N!".,==Q[ZNF1F\UQ5WJS2P]&:@7T![CT5S1=8/@VT)9VN*[WX1 M;_1 OA*FHS1@P,.EKT.PB'&9[G,J&9(A[2U60)+6 W<%]972-W7U"0*.OFWH M?..-A]>K=OK&0W[@ &-2%W7L2"=+C739[ X,TL @I;X=87P\.3LC75"@3W$; M&!:WRY!/#5(C57SV9S=?LC79\=%DS]^F"Y\KWH.&T,* 0TQ9A\C 15?J #KG MG1QZ>)E^V5UI7HR3_^H5)@C2^,-$P]QK\N22IS1KSUS/]^(F&A@)$S MERZ\]DT'4@=DA'.@VQ9(LC\/Q?*^,^C;?W;WU\&@UJ/]174YBLE%P?<5SB!T MCF--SVA\(O)2/EB$P!JV%W7H$)C1^9RPY=_1AT9DA$BMW?4O7@XY=* MP4OF!_]3C6B?2=?K2R\_'68?.:*I*_,7B8?#M2+BIVV ,&' )+Z;;9,4'3.$ M"J=JAVH\&*0]*?.E=:I&F.<&NJQ$[4OJZ6(V/W4L?Q9>KNV MZ<(\;A-P1%#*)V;PQMUR?0>_>2]B84M/*'D&Q@_FHA^6+.>MD %=5#MK$_&3 M!GKQ["N1S=IKAR VU@V]]K+Y4O3!O>QU2*JY[$+>WGSO^B;%@(G)_8U!^]IP M6(<4C 1A>.7!K@5R*RZ.M15U&77O-JR5&D^4J]\H(&VV#\6N5NX>>I:PJ7-J M:K*VQZ#)OCGSKZ6EOQBU2H[('2!@*]E<&W;?FL.X-^@_28%[YKKV MB!0.'24RV>)W_%T<4M)GI"*(JI^!'K,VR=&!UEWS]C=R#H0P?[I]3S/!#CON M+ I-^J!N9G0=>>^?+=?XUUZK! PC0_O&&^^:7G. M0^YQINLEGQ-]=Z/NA>IOA=-K6OV/3E_-KO>7<[]N=:3VUUO?&&R>=WIN)RO M$WZT^YX[H@J=C<=,?AA<[W)Y8N(4F+IC\SP&L+-IXRV0>,?3^M):MH?I\?LV MCBW/J0^W[%S("U&K'Z]=R!$D8W.)V'G[E"UR@X5/M0L+@7XC.D*D%22TZ.$T M7B2?(8WU,,J\,I57++I\_E0;M;ZVB''Z9T\X#&$G3YN>L(K0%/D#V7S-#I9\ M]!:$6 >/YNQ*N=A2_2FRSP%U1M3)80 M?P2M)ZP+)B&*!;*C9N7!G]N'E^1E&* +G3V?Q M&VG9P:&DNGT3#7LZKT495KVV^L>=%1=XBHXF^*#G6@YQVT;-.(BZIQB::A)/ M;A9#%J&#^9MGG>\['./_.#F\%#%]T+K/:S!FJGM3F,#[M;_%P"O/]Q#)OQ&R MV3YS8+AQ0SP!FO6CZY#1*,$2GYK88H;_[L2W21"%STPA#Z(<^0T=, 7KC!=M M0>KZ]J?US"BQW$G1G*U5$.6I(J]675F:WG'**=P0#V%!Z J7Z\:(: M:#T24318USNUX\.KI"2Q27^S!R\_@%EGEER4Y)GGH^P>?B'TNR#>G!SQ8NOV M1WO2(QS0/3!)PBYV[!WQ=B+ IH83=6J;W_730RA0]^+ 0']SJ(T[2(#M*MZGNZ1&5Z'!.$ /3+77:@H\,L,KY8IUH9<3'#8,]SKU28J>M%WQX((1=4*TT# M^RH0$S)B68^9BD [R0&/3MO=)PM>2VS-^>+6>(L5S=J!IJV-Q4/[@?5_O1+&@W_Y8"-^A1B]>LNLIO M15Z#>&L0+VH&E!!SX!?[2QUC_8GT6P;@$Q#;OUW[VN6%GZZ=.O&MH#)'JS1\BC1#+U 5'S.[HN#B;!'Y/B+!D7CJ$?*J^@CSG!Y('9KX M7FR_EKH/-ZK,R7Q$ M6^W=%Q(<*;)82VC1P<,XJ"2D)>$X4#G;ETHTX05G=)8EU%%3_#Z^F_BZIS?A MP/2T??@=?/J*DR0VVM3UZFFS^<68;1(KRQFHSU=0,J2Q+-#Y77"_=@;\6A8E MY78#@YY"JB\MX8>E /G01=]7QSBV2Z19SH1KZK0F=C>K@)"<,[U@VX0]G3G? M0ADFS3RE;(FF3Z3VB65W1O%AW:Y\ P_03(D,!#%[PA7DC&FX _-VN#'W-^GM MYYPONE@M8:?/GU=' _$@2OX,2#+&;VIBTM]=WWB\]N_#P5HR,^X))4F@+KO[PS_ [ARA?0*Z\2%A8%'G#&4HWY?=OC15TJQXE$T0[ /Q\C1'"SG\ M48++( 8&B,R;?H_"JOV_MB@#)#[&V_U2CX:48ELQ/*VWAD^&Z[>O0B0<83=( M;5A4$%15=&DMV;S%A/CQ-^&4R'^MX&<:+ADF6[48,>CR*^^6C0DY$WSS%PPPPG$?!PG5 MQ=TM6H#GKKLWWLD$#E8A')QGM?<>\Q2$8T.\&N\T5>!3>?V. VFA9-%*/7D@ M[N *W1(UDQ'O+Y8#U;B4GN0F:(:#UA;0$8CUH[O_#+=_YNSVALG]&9ZVM:P! MSVFA^8S[7P[6=4DX<\.\>$[&.R ^VT!7-"(\ '+(M$5&_&$=0MN52;\"O8=2 M11H>FH6F-(1'\S?]\.3+OYNTFWPYL ]KKC2A_NEYCGN!5VEK)UKV.!A>DGC' M*!+X76(=%6$LOA%P.XGU1"+KBF_?]7V>:_$YOB0'?MVJ? 726Y1D6E)+"YKI MZ4LA(C?X*OV6$#U 5.V[519VG3C@-W(_^L"^FE/?QN6[7F\*.*)CZS(G/Z?X MJ;('RJ&.P<9 ,U/)HPI\^+\8U TOFFA).$(;05HL]%7@YP5"=&V36EX*(HV6 M&>[D8HC9T^HS%-0&>2[[/&H=$L("8W7N0^%!8A_RP%K6C1Z$ KZ(36?X]_3T MJ>#=NM[6+"@$! 9*"8]^U\NXG#%9:.WMJ#)H)T7*BT-> /5P[BHF<:,SF"-= MX9S(GDE[0; IF<0?GFV[[N-4.CW^:<'Z:JM@[NH+0=AQ$UCKW(W]KX5NA,-# M"/H,AYJT#MG/"%Z# 9]O(*/6 M-2Q8 NEGGHC-CKD@: B*!C?H!['3;X3[^9K0 .CC_.J&*HALU')J0PNVCR!- M)C]>>.XL]>&D;FW2^3/IW#V?.]X:/MHR;?697$X?RJ5)W$50 MX$"AEQ?N);4=%84)/2?$ RR%YM-\#*Q$^,]#(7K-);=97.FW M^I=9SL(G9\=:KIF/>NOEH@[^7-Q(3.5J@Y \DM6)NC2<)= &*OFE>RK*5X)X MO63^R7YU\\Y;B)+*\8SN7UD)@35/B8=H]$'5O@ M_MNRC,5'K$Z84AUII]L=3OYHT;;7NH-&7A=\^N=\AN&'8'E+\92[@H'>8SGC:HT*(7.A'.3%Q.SF MDFFNG_L,[%CTMV/72+5?VBS,!#< UR+13MZOC&8W:MAMJ4*_,#31?$AJD>O] M9^K#=B87_8=Q@'16U._7D"#:_U -Q7^P7FPTW0N8U&S*D.UU]:T9>/=2==>( MX>6J_XWRQG]=UCZ%!4;W0X?Z!RN*MMV7*3=H+/-T5#%?U8:>S%_4(&:$23[I MSI5_6Q'$U#W[]M^0GNN@$'AX^)=E\>M6!E^A7$&CWH'PI\LP^LR2N]9WO=V]-T<=%6FO%?ZVH@*_+^>0_7_ZS^9 MS[4^]B]02P,$% @ ;81A5J46O-6]: $ ,<. !0 !I;F\M,C R,C$R M,S%?;&%B+GAM;-2]>Y/;.)8O^/_]%-B:B3M5$8DJ/D""Z#LS-]*ONHYU.;VV MJWMF*S84>#HYI91R2,IV]J=?@*0D*J6D IDLJ.C74XG"9SS _GCP<%Y_.O_ M_GZW!%]E4>;KU;_]$/X<_ #DBJ]%OOKR;S_\_OD-S'[XW__^/_['O_Y?$/[' MBX_OP*LUW]S)505>%I)64H!O>74+_B9D^2=0Q?H._&U=_)E_I1#^>WW3R_7] M0Y%_N:U %$3QX]\6?Q%)C%.6!A"12/\1$0Q)R#)(99C0 (?OK%C^O"Z^_!(%0?S+]NH?VLN_'UW_+:ZO#@DAO]2_W5U:YJ8G^#V,FC^ M"881C,.?OY?BAW__'P TG)+^8*WY9R2]F93_((E^+ M3Q4MJG>4R:66OAZM>KB7__9#F=_=+^7VWVX+J4X/NRR*@U&-E,1(&:9&RG]Z M:K)?+A#?D[S5L:P>A*O5?>]+QCY,WWL3][/F!SF^P)UI+A:Y>:!>K\14S^YN MJHM%'U]B7X_%NJ++"1Z+_30=D9?F'][IO[73F(%ZR+2>IZ7NCJCR>R570C9L M>3 TR,6__:#_MMB4\ NE]XN7Z[N[]>I3M>9_WE2WLOAT2PM9WFPJ0^[F>[E0 M- P126/(4*(@DD$*,Q13F$:$"DHRGM!DH;^U;-T^Y@NY@K]_VDI43^LXYP\. MVG=G/D1!C[G>%'S_!;Q;GOJLZ2^:^09FOZSHG2SO:7N#%MP8"XTN__Y^<\=D M =8*\%IX4!KI05E+#M9[T<%& U\ K19XJS^.JRK_*L$'/1;X,5^UU__TK[_L MH?&Q1,OI85^.BW\4O M?*V?POL*'JR7,6D'JE^M!SY4S4)HL7X ZT*_(MHL/Z'B[N'/5^O%S;TLM#FY M^O)N798O:5$\J'7QC1:B?/W]/B_T+_+5YV_K_Y2T*!<9CU04Q1A&B388D<(< M,A9KPF(DCK$@+(G1HMI]BY]\6UPG=GEIJBDM M6R%I*5_)YK]O&\OV=KW48Y2O_WN35P\?U\OEFX8-%S@-D@2'!-),,&UT2@89 MUNR4AD*(5$K!P]2%DQSGGQLU;<4'/VX5^,E\P;LZ_ MHM !_&#U J\C_Y\9> MKLMD1V(C@C\REXV NS/=#43/$^NYSCXI^0V$YC$'#AUF&!6^DV4IY=X0-#.^ MRRG+EWH:3<-FCU"^VLB%P$D6$1+#($48(JJ)D*DX@MI B\) ,951M:AVWLZS MKZ'MQ$[D]X1/U^=+6#MT02'O:+XR6Y=E_4;>MP*[$9PU^';,-@:D(U-:(_(5 MZ.P3C=178"?W%:C6@$EMO^7"'XVY0N6)OZRGG92X7,%XS%C.]P^C*DUX,O^R M:NQ!_J"-PU5)N?%?E-HXK']L+Y/?JA=;SSP5GVG +.8 MDM,(4J;MMX3$<9@)%"'!7>RWP9+,S9)K%0%;34!7%38CLUTO MW("N!.CJ 1I%P!_M?XU&H%;)HSUW,:R>F'&X')-2Y<5P/>;.RP<<1J8?BK7* M*^/W6Z0L%5*J1!-CJB *: ()$Q$,PY E7&91FE$7RVX_]-QLM_>R DLMEQNS M=:#"+.*8(_TA88$V@AGF,#/>@#05*:(Q3>,0NWQ(!D(UP9?A8J@R$E$L,862 M8@%1R@2DF>00DY3Q3$0RP55J^ MI;GL[4H_^+*L_'W\CJ'R]#7K##SIY^E8H5MNROA=#+ MH;]+I6;N_S>_?[D6V M;"0%K:A7H!$6:&F!$=?NC3^#;/_;[P^OD9E@*%36+[<=$B=>]%+RG[^LO_ZB M!VC>>YNP0 MD\70V"K3C9NQOL>=6S_JI90WZO5W6?"\E!^*G,ORC7XXVDB%6#H1JB4Z/7QZ;H3)Z-12E2Z; MVMXR--:G\1HTWH?=(=4"ASP+HEC 4$04(HHB2"AB$'..4*RR, NDFW_JB9GF MYZS:"@KR6E+7H)S3>-HYISQ@-#*'[L!I1.P<3?L,HNE%P5NPS.E9)@Z*Z57U M./BE_W)W@ZI)Z;I1;<:*^JL>78J/^D_-,_IO34[+/I&EMNU,)M#&R/-3I\[,GLU(O5[UJPEP\V^!!??R&K!S.4"9 WP:'W MYD&^9GIJRJN%2G"2!B* 5'^_(!(9AU2@!$:2"RHC+ 0GC@?6_3/.S6FP%?BJ MYK:J#K+9"0W^V(KM&)E^'GCKLUI_<([\9;D8R2''LW;H^#NU/3/?U(>Y=NJ? M...UO'$H[4@EBZ+EM>,Z!8)(%H9) FD:91 1D4*FD@@*@@/!1,*2U,I':3G? M_"BG%;?YE%^=*A\QN$K$.>QM><<;HJ.SSA;,MDA$:]:.4AW"$A9O=-,_V\1D M8Z7Z,=78W3:,:#Y*(WV^S&O#_$;]OBKTOWQ9Y7^7XC/]_D*NI,JK\O7W-I+H M^J[)'M3DUV1G?%Z__D[O\E5]^4=9;8I5VHO/6 ()2C%, M>2BPDD&$T\"%J<86>&Y4=ZBOV<]T-09:![#5V63[;P.^6K7!7F\3[K75O+ZM MU?VB_,'1'Q\[LIW30S'V =1O)*M^HWKPO,IE^5%NDPUOU(B$4YR*,*0R, MPQK)1$ 6101F09 I3D(>I\+EDS9$B+E]IO3K@QPS,X= ;_B ^- M_, H< 5:%1ZNZNH]IHR/QRS-"Z#RE;$Y1(1ILSERM0;;4Q_[Q5!U2- M/D!HA=RH%R3$JN%\/UF&$O'] 'S5Y_S\M%J#*!>*@@1U$*41PFD+&40I)PEC(1F=KV MP_G33#%+8MR+"/XP0CHZ%4X .83'7.&9EJ#.(7,A[725'X5/Z@F>D2BZ"O8S MP,&5GL+%M5'6!NAF 29)JD*8"FD*7Y 8,I(&D""19 K'<8S51='BNZGF]JK_ M7QXKOT>Q_S_UB-+:C[JGH9E.&U5.@^!ZX"^/$!P'XW&'B5D!>'B5^ MA(UKD/A^@.>-$3]2Y&R(^/$=GJ-H?BU,UGV2:)I$6,(H1I'>9L8FXX8RB)$* M.0]32KB3F=0_W=QX].6Z)^%^")RV!]2^0!K]?+HG*N8*U.).$!%S ,O8X3#- M9/.(A3E0W#H0YO N=[.K/N@V?:OT;NWN7J[*^BMS712&I\P$[&%_25L![=J< M"-3-$S[?TM7-?5W4Y_7W>VDB!*NUB1GLG)PW(84+$6:Q"A,%:9PAB(AF():% M(8PCKL(H591SJP/J*86>&X5]_/3[OY1 MD*;DT43=#LL_'RRA3]O:\YQ.4LV!+M'PT!PT'OF"C0PS/ 9 ML3>KY_BL3&2@S_*9<;+[IUZ\GAW$9*),MA>9&MSNKF;RN8=&X2WK3H%46U*= M^H1FTE4IRS<:SV[9PK_EU6WWED64BB@P_>001<;/3"3,>*!W48*&^A="Q!RY M9=I>*)$+2TV34;9G MV,']2]9W\C/]_BHO^7)=;@K9R?C2A)K2#,9(,H@"D<(L80JRB,>!I %.D5/_ MI)ZYYK;1:PM,FG#1O;"#<[SZ0+:C1$_0C4QW@U$;TCOD'![^^H0\.=/4/4'. MJ7RB_\?96X;& #2Y&GKL;7G^7)9/.LD6),B8X(& <4@E1!&FD$2$01GR*$12 MVW"8+8[:7ULY[C,X81!TWB(7W&:?.*QA$#3',0_#AAG8*(3FQ5_I+L#Y:N!A->>T MS3I<8#AJS.%T\\"FN$+D9G](EZ:[U=O52WJ?5W2Y""E"*!%Z#Y?@$*(,I=KP MB@5,4$R"6,9AG DWC]D3,\W/$[87%-QK26&^ KR1U;'S[1/0QH&(%),8&HJ' M*-76+5&,0!7)),XB$L:1VMJTXT-[:+;^@T.KE @"J1#$A$40F28 &6?Z@YIE M%"="\93@ =L%?_A.L2T8&V2[+Z>'UWWD;V4')R.BZ6/Z\@Q.[JV9^U'PU8GY MB5FF;;S7E^6NX]NZ/ER6997?U4<' MZVW=^^U)D'/TW;DUL*,0O\B.S"9;89MSF:VX^N$%1N Z/+<6V6LDGB4\_J+Q MSDTX=42>)0 GHO)L[QQ>[O7#NC)GI739U*2YWE2WZ\+D];]9%]M)ZS)\]>]? M/#Z$KZM4(A2E"J4*)A%%VE8TJ?24AC )"<,<)3&*N7L!6 ^2S<]LWY>VO-^J MMRU[17<* J5?R'S[[IM:LC6%X$7QP%7PXK+^EA#]W*S$Z_EY 5H_;ZEGDO2>@3? MHDBMC]DF+UOK$:)3A6Q]#N_^#;_6J."W>HJ528(V@[5Y9 IC082*()(!@4B) M%-(H3F 8HR",HX23P#H:_JE)YK9?,&*"G9R.)/HDDN>_:C[P&?D3=0*: ;F+ M3V)D_]7P@=5$GX!!F#FQ^#DP>BCYR5LGX]=SPG?)\NRUP[PH==R8TLQRO1*? M9/$UY_GJR^E#B,]ZAO+TKUZM[VB^6L2(FH:+''*>QA#%*8$9D2;V%D4L#'$6 M4.3B;_$IW-R8]N2!'?BC$=8Q>,SK(@J"(Q11I3][,85(Q )FIO]XHC]^C&4< MZ]?([3CHN99QFLWH;!?2SO/V7(LS]NGXL%5Q]LR- 9\G'YY7T2;U]HT!ZF._ MX"ASN.\^7JZ7^J_KHDG&^5+(.A6G3;]Y38N5% L5X "I.(4L85AO1*)8;XT# MTSP.2UM M@GB]!W&;??AZ!!#M]S2>P9QH>W,IJ$X['0>(>C8]-J-,MO]Q4*F[%7*Y[>+8 M]>LZYGJ7,O=N798O:5$\J*;HN5^1;L\C6$#%-*TP1F,C$!55A;T!'" M$!.A1,R3),FL&M)[D69N;/[Z^WW>K%S=D6R?BVAT 0?*7(&].H,3:RY;2CL; M>K(%&ODC<1 ;WVARY76%+@F6'XZL_]#Y ;(\5R#]<-AZPNHO&-2-D,NB:LIQ MM5[22(6!DFD&@R@U^88RA!D*"8R2#!,9J@Q3JRK,C\:=&TE^,I9+6>5<[U]_ MD]1D936%,IV\"H_!ZR>S"R 9F98&HV%--T_HWD<<^I8.:>B?]H3Q>+1)7OTG M5-B^Q$_]>JA]=%](WC2R6*2$A8KR% 9(Q!#)5$ 6H!!*(E@J99IBFKHY#+O# MS\_AUY7.U1;IP":23)-6@"!.LPRB.):0")S"4+(LHRJB*;?:U5\*VC2ED+U M9FN-#0-B=./* H,!!M*QLM[LG<[0$YLOQTH=6R,GKAG&9G4W.1-H(,6KC8F& M_2"+?"V::(2FF^ZV\DU3$50L>$8$,B4/ A&F$+$PAC0) JA?9;WW"Y(T2*,! MV0?NDE@]X-,G)NSD&]Y[4R^4*36_$!G.DB2.H&)*&X,B8)#P M,((<<6T4QD0FRLFJ>7JJN=DXAUD!NY#&M0)"2^LAKZ(!V([C_, V,I<]E4>A MZF9?(V=/'( Q9M9$,]'S9TL<*&R5)7%XQS"JV/N(],9=_DWF7VZU"7*M=VKT MBS0U9TR/PX_:+-&<96*;%G%,,):A@B)D1&^+< 9(1@2F2&2$L4Y<>VD?T*;*4'K?A@*S\P"ER! M5@5_Y#04/$^4Y3S]I$0V%)S']#9X'!_MK]ZN-$_(LA[?N#*E:&?1XE;NEM$9TL)=]K$9<-GB-TJ"K=^)G;-QE TA_ M0R^K$=RCTGXMZ*K:VH0?)9?Y5RD6 4X9E@F#(5)UH1C-6DG&81(%3+(D2:F= M:?;D#'.CI%I(<+_=IA2MF/9!4J=Q[.<:+^B,3"D-,+O]VT=/P-C'BUT,T$01 M8JY .46$]8+0$P-V^K[)HKYZQ>[&>?5?.,PTZ_I,VQK)INE46V'+U$>KRZ,M ME(A#$44,*JDWGR@,",R02"'G,0HRP0@EF8M=9CGOW!BP]AZ><#>[V6&VH-L9 M82- .3)='CCJMU7;:YFGJ=#GB)@G&\QVUDD-,$F'P]=V=OK+^I9?32\LEO.@@T__" MC'VF:?0 C2*@T:0]CKQJ"IQN.]AOEZVC$-AK-/K9I1NPXQYC6LHRAQ---]@L M#S<=!QVP!5ZOQ;=\N;Q>";W)UH^K&;F)>WTOJP56!">4$ACQ6-N'*,.099S" M*),IYD0AF<2+:EW1I<5>N'V_K9S &^M#+75>7RG=1MB?HKL)(5 M8.OUGTVY9X>-83_L%EMG;V".O8?N(K@7M8V[!UI8;Z@Y[*N]H3?5!KOW.32/ MH:=R07;(].VZ^P>8;OMMIL[4XZ2OS1',,5#&ZJ.TSA5%$MH M2DI 1,WY9Z80I#R(0XXCII#;L9FF[Z1&C;7TKVG\;,\SK@4E;%/+EKY MFGRDIBQ4]>"Q@HP5$+Z.)$[.,>WI0Y^:1P<-O1>[&U1Z#5_JG59>=3.%ZFQ M;=3EJ\_?UO\I:5$N2(@9B@,)@S14$ F!(.%9#+'^1RP3C@,4VYXR6,XY-R+0 MSTYL__&W!?:\[30"7",SA"&&1N2#Q,2Z=V(MM0EMU7*#6G#_F-I;5B-@.Y&) MY0EC)VO+$:T>L\MVI,GL+T?5NH:8ZZW#+#)MTS5=X4Q:YR*A* T3%D,:A10B M1A!D<11#:0)]0T88B9G-1O?DZ'/;VVKAP-)D.=.J*G*VJ:C92U1KO3];?\W7 MX,,M+>[TK9LZ&;$TH13\Z?V%!;JQB'D4<@%CCDS1YU3"#,D,JD3BB&,59TJZ M-0AQQW?2MB [A.N8WW43E[5>.=:=/P31SM@=_."-_ DSB+1=,7\THOT$KA\] M?!]HX37D\"02GJS%S.OH\EU!JO)U'9QI?*;K!:()3P*5040%@2B(4TA2EL XR%B$U^' M3I-J"^O;<6"U]WZ, >]$[@]?,#OY/USQZG& 6 \UF0?$5;FN"\3YWFFX8^#ZD?X6<))['3W9?G',-*O0*/9;.SS0Z#G89RW,OTC6>:','HVRQ\- M/C#MW/2Y?!RLT)Z-DTC$A/$8IFD60$1P!FDH$=06. MI1J.(2#=6[IEM?EQ; M"^N8-]Z#IAU!>D)H9-JKI3P1B^4_X, "#U\)WCTS39O+?5[EH[1MBUO,'2 MJ9:I"T 7%#FUFF:RZJO7ELRSN M3$KW9W/8M\^$PS*@@8E_9&G,(%))!K,X3B"+*4-**)9D3F6T7 68&QUMY3?N ME[T&M3-&ZP"-$OU%H_PLBYVQ,R;8(U/5#N?U <[KQSB#/VH5QDE7'(J?KXP; MU^FG3;(9",Y17LW0<08RX(:5\K\WID''5_V'::E4?^P#(J7B/((\(I&VLS(" MB0GT9H1E<2*#*%%.O3*>F&=V?+83$]1R B.HDSEU#EA+JKHUG-L4J+]+\?M*C]TI[6SZ09AC79@KQZH M]0--+8-&P[K?>7D%7CSL2JV#6DU0ZSETKSK:$^*ZNYW#NH]M?9XJH[^OM+\M MIG]UM]6C"?Q,&_&Q%^#IK?OH,P_[FKW^[XW^5.Z:P+7]R*,X MPQD6&(I,:>L]XA12'$N(21KI_U$2(J6ZO M7S\]G+_!/?*BKE!M[.9/7*YHD:]K3[5*@RQ)N8",$:;M A-J09B *<,I5Q'. M5$)L0RU.SC [2FAEI2\(>C@][F11#KUJ M=<,:^B_TT=CBHQ3RKME1F"U$IYN"# (9"60:@(42HDQ_Z#.L8AAF4NLK,QH* M-KRKQ9/SSNU%;UM:[#LO%#O)P;T1_0KLSMK(X"T5_'XOSMP_,X^%ZEZ/?NC?Y*J_D.U- _G$\ MZ;M=3C:A@B,21%!EIM0)%9%F+19#A01C(@@E8DY%YUPFGQMU;64'C?"PEOY4 M:/2[P:GT+DMC1V-C 3XREWG%VCVE9@!HOC)G7*:>-D%F "A'>3!#QG#?5-U\ M6VD^N,WOZ\V "$7"&$]AI$P_,2D22"E.89;%H1(X31,A;#=3!R//C:!VPCGO MH@X!.[][&@S#R+1AC8#3MNFDMA=LEP['FVR;=%*-[O;H] 7#K(RFHM!G^OVC M-*+ERZ8M_>U.\O+[B>KE8+):V7)DI#&D:SX%#[:[ ?JFV&C85?!LS9J;!T/ M DUJ ?D#\+%=Y''D@9O">M@W-"_J+A*F_^MR76X*N>",\RB@S+BB%41Q%$&B MN*D]G" A,\)"E;H4NWQR)B=RG:RI0ULT_TY2(Z, M )*R^[2P^$\QI9;.1_( MC;UO:WM=&"F;1C5@+Z?'#=HY*'SMQIZ<9]JMUSEUC_999V]PK^NU[3IHQ.M$ MSM"5^!LUX5_5-GBF7+ 0J4Q2!9,8)5 3!=.<(4,HH@"3- TB2I!=.0&WB5U> MA&DJ"^S:7-;50>JF6:!-;I5;J>VK4#DL03^EC ?KR/QRB.=!9*GI=M)*O@L] M' =;^QI?XV \494O;U@[E?ERAZRGT)?#8).5^G)7L%OL:\#=WOM2F.#^IM9_ MJ'57IOUUJLSQ0" S3?2I@ %),I(B3C-I=3S@,NG<-N'ZH4N]=5'80WN>P,< M;&3ZMNJ;8 3WW)QB#ZNW[A2#X)U3>PH+F'WVISC":WB#BOU0<^E0<:2<0XN* MXWO="?N5O*=%99ZL&V6\%-7E)K:CV9/(TFN=)V0M&([/P27C.5_1RP,F>9;W@-1&MNCU6 M3N1Y%H8>MGSZWLGH\:SX73X\?_' 2/OAF3_'>3_;=&TJU88+V7%/RH[9)!E6VG M6GL[3^T,5W3D3\I%2:%7V]3ACHH>LQJF70Q?.1(323UMQL6T2W&4OS'Q].Z! M2TT"VF]2RR+>KK[*LI+RO7[MVI2F. XYQPF"<18CB,(T@5210'^(\IG"GOOK#NLP;$P:E08(0B:%*(Z9)A,:0R8S!%"'*XX@'(K!J)NQ7K/D1 M3BL^*.32-($TQ8UX(SUX,%6-*OH=W&_%=[-6/:VDG3$Z_?J,3&]=A>H@JJU* M=>_16BFP4ZIMR] N7%MCV-STX>S2.5N:?I'V9$AZ$FI2.]$OD(_-0,^C7^"L M8)YLT6,;]&\R_W*K6>OZJRSH%WEPRPOY)5^9_A(OZ-*$CH6+))%!0"2&48JU M72E0"!FF" H<)U*Q#$N"G3T:,U%N;A^6K?" -M+OXD#^YS^%:?"_ZAS(V@\B MULLE+4J3#MGX1(:X1&:R""Y^DYF(/*,/WH7.E0X05V#W^+4@/+K'L]ME9FOI MTS%U6^9W>B]PH;864)F6N M[O7.TLA\LAF,8IQ O;7#)D4F@HQD$54T3+AR*P%L,^OG NA4:F,L\UO-U M MU^L"PU%]7J>;A\27\/J$-@I"HN?1U%>945^L5V+;]$QQ) (8&[NV$H): MQ(&%(D\ :6?$70;/R$3JB(RS",?++:XV#\VM[2F%/+^S!T).^JJ>4>OR2GKQF8$K\5YHO3;."-^OB M$UUV^G:;.FW[GQ8L#D6:T0BR#)GFV3R&E.L_DHP(I!*B/]-.E1UM)Y[;:VW2 MC9M#C-]H\:>LFK__=4"BO"WR-):4TEA!@B.]YPSB"-(TP#!)2:)"FL8RL,PS M'A/[:3*-/]VNBPI6IAMEOHO_<8Q+L ;>CG;' '/TC2FKP%ZR*[#3 :IU 8T6 M'JL8..+CJZB![;33UCAP!..HY('K_<.^"B>3N3IAA(BFB0I"#J,,AQ#1B$%& MF>DPQ408,!G$L5-TU9GYYO8->#+S<$#0IBWD=F3D$A"#)UIR!(93^QS M;K9)2<=2]<=<8WO;,(KI*8[Y7E;7K*P*RJN%U#O%)(XS*&NS4YG.(10E,(HP MSD*4,)01-^/';N+YF3YO5T*J6G:P-,+_Q8U?+/&VHQG_&([,-OT%=C7IR$IO M3UNY/;*.&U">R,=RTDDYR V(QU3D>+?[T=^^Z:'&OFJB8\T M_14V1IJ[O#GM,#(L8DJC+.,$8D$RO3_.4LA";1# MR;Q>ZUU+W:4Y@.==M4!U2ROP+5\N@30:2B VTL2BO_WXTFQ4ZG(\<19IYMNI M:7]J=OGB]K/BY$LV,EEVFA_7H1)=;=KJ&DT9SWS5QII?@58GT%&J9M4I5\G^ MZ'/2U9KH9'2257,Z/?6&$+N/-&^T5@ MC,R++0JU< ,B!8_AL+>.+X)E(FNW^Y#\[,=V:AT]? M--#U*$ZDL7;V'_8/,Z!T\%!1L)1W%4V@'BB\SI7^R:6T5 M*\6/#!:[NRZ+66N/WAA)5!8JI+8C\.PH83@D(U. QJ#X]=&.8%\-/BSQ+#UGR\^<97[1N/M^QN4!4%K MYYBFPW' "8QYG$*$D7Y;22P@952H*&.AI-:.^(.1Y_:BOGT/:NGLC<)#H,[; MQX/5'_FE? M:U0<8QH<8V!O%@[&8R"#>8>+'&#ZI;H\A?'C]9$;P23&[!O#I M"P96,]DV5K]1+VEY^V:Y_E;N3%\:,1RC$,& HIY#C+! 3&9("J<^ M?GV3S8V)=K(:-YZ1%M3BVMC)[D#;&12^X!N9R2Y SKU6A04DOFI']$TU;2T' M"Z6/:BO8W.-&(4+FB]>K*J\>KH70#U!9SW%3?"C67W/35I)G F)$DEH5?3RW$1SHXY&5M *VYQ(2@TIV ILQQQG\>UG#9^H MCS T]"#;;J;6G!^OJ!@9#; M_G5O5_>;JGPGO\IEV)JG,8]XD(D0DBSB$"&<02HQA20-41CRA*=9XF)4],PU M-V+8]U8T!0^-M%>@EA>$CH&//?@RBA2*T@!&@B&(N"ER'ZD,2JJA59))&L6. MT:5^$)[FI.7_V:SKM%I3U::H/1%,^L@VVVA39?R>:_N_U+F*59&@01I&',((H2 BE-&*1IJ&28 M97'HQNF7BS0WZJ\U KRK$OC1!(W^I#G*J.88^NYAT>P8:]JE&)G8FE4XT&;; M__U'H]!/3=2\WK>:5)XQ-JS^X/3$B1X$FI0Z_0'XF&$]CCPP;]W$.'[6]S9U M)3A-HDCOF4-%)$3:/(:41"&481R&#!-,4^&4G-X=?6[T6 L'C'2#*DL<(F=' M;(/Q&)FC[*%P3UL^I;*OW.2#L:=-0#ZEUE&6\-B-/AW$FM>P[G#J^?['#NI)C=P[G3%PPS"!Y5 M+-X&-#<5D3L%CE_0,N<[NS[3?(004C"@*(*(9112\T>@[894XYA$L5-5X4%2 MS(V_CHKWKW8Q^MK&NUMONQ=VFQJZV2##%LO.5AE]"48FT:/:]?L,B>,&@E>@ M5F.4[==%0'JRE(;),*E%=1%,CRVORP8;&-,KOUUSOM[4A94_%.N5_BNOSS_+ MF^+EK2D0_W;5O2)?\?Q^*=_E*_FVDG?E F$64"PX3$E"36>5!+(H0! SQG#" M990IY)3J=:E$Y07RS-MF+DO^(XBT;T-/)2^*Q.E4I]&"RE>//Q> MFBH9NTR^^DRO*6@G8Y:@.$UAK.($HA1Q2+)4P"S, H51),,@653KBBYM>=IV M:B="W@DPYBM>-0TT-J;=D'Z1]ZFZ=">T*]-:KX,MI8Z![NC<635Q;%NQ 7L M/_[>H/Q3)\?W^CS, RC2%3%O7&@]\<2DYPK(,;LYCS",QGY;%]47;?*^H/Q/ M*?:5#-^6Y::>]].O:VT4KPRQ?KI?K\IU(<5KD_=S7^2EW&8Y9@&7*0XD##-I MBJ4& 60AD9#&6.K_Q4I%3DW^_(@U-WOT]Y\__0QHW44%W+4:0E:K",J=CF[\ MYVD![;AQ^F49F3>W"L%&HX/JK(U2ADA__P3V>H&=8J"CV0A!)W[!]D2YGH2: ME([] OF8JCV//C! 9E>/QASVOLLIRY=Y]= VF%VP-" T) P*'&D+-&-,T[/( MH&;F+(RC6.%$N07<]4\XOYB[O06TK'LX+[<2.\:TG,$9AXE 4L D1BE$B"I( MD-(<'Z6$$!:$.,6+E?QB>CU\=H@UNAQLTH!]-/=XB+^39?F775?S>_V6Y.N5 M5[3MOEG^GM21OT6=2F)&TBNPD_5JVV/<8Y"/%2J^ GCZ)YLV.,=*\:/ &[N[ M+FC7_>)Q4]%.$]X7#_M+VAZ]=:Q VS5T7W*L?-O6'%M$<1CA(%4PB+!FHB3- M((E(!BFF69HP)0AVZALQ@HQSL\Y;2:^:6IB-K,9'<5]+6[?-;@[@AO3*]KR\ M=M3WS(LV,E]V.U=W]>NVKS;6^\D.UTW1\]V2OSY<\D97S_VJQUD(GVVG/4LX M???H<2 ^V01ZI*F&?4%>KI?ZQ[49]*OL"-+Q?Z^7.7]8I$HPG*D$QK$,( J2 M!%(: \R1.?A Y"[Q M7AV=E Q=P7C,<,[WNP>I'DZQ M>P%_O]?:K*J6-3]*+DWU^85B!-$XS" *XQ BP0-(]5I C#GB,LMP3*TBS9UG MGAMQM5*"^]:0*5HY[6,^W8#O9ZY1X9R6NG:"7X$MQEMC\>/(&-O'W8Z&]41Q MN1XQ=XK<'81;3V2OVWB31?X.4K,;&3QL@*$V:UG]1O-5)5?4E(J02":*IDS; MHHDV35.<0)8F%%*>)#1$:9Q0JU(<3XP_-R*_7JU,)=6[O82NMN(%Y5&'U3T.[A?E[E#(QU7S.UH8 0D1Z:'UTK)IDI&FPQMLI\_FAH\ARI< MU;_8:_&@-Z)W9L_BCTXK_!;*39+>:.N]: B M7V[,<[0_J'_]G2\W0HHW6CWCT-LT5O"->DV+E1:B_""+VI_WV72 79 ,2N?/!'K:EK<4._3X'E W89R\NRZH>+^MZT+*ZG[J,@KZO M Q>_PDU[UC(*L$?'+./,,NPC\E&65;'AE9Y[]>5Z)3[*I0FD,8;UZ^_WVC1I M_AXN*.8LHSB $9.Q"0%BD)CVN6F@?Q%E0K#(J?^6[<1S(_ZM<(#K)?CBN+FU M1MN.AL? <&2"/1 9T)4 K="@V2COX#4_^J-,5Z0\D:'UM)/2G"L8CPG,^7[W MXK:O6K]MXTWZ*$V8W8)%B >12&"64&VARA1#BK( 8DP$X:' :685C/_4!'.C MFJV,H/6I-5+:5[ ]"6(_L_B 9F0&<43%J4QMG^J#RM.>''"RLK1]ZG3+T?9> MYWX$^JE:\S\_Z/6^-06ZMMYV;@P$>9& +46X+Y5 ]"M'E=UX8Q&$[/I MH#M=0+Y3QOY4;^!ZG3]"'7\5QMX.U@NPU6!_L'<%]DJ8S?Q>#?!VN@6P/U\= M?R$F.F@=9T&/"AZ;XG&98%E[1LMH !$C448C@CF23F>T3\\UMV],5U3S+1&-L(Z' MMCW86A[@^D%L[,/<1V"U]=8":M^XZEJCCD?!9Z.T8Q0N2T]"*$;6M@FU -/+6'>SK MDMEO+7!TIA=;<#QQS-GI)B4:6^4?LXWU?<,H9YM]9\(=4KW?36BGJCNR-/^O*>4.GQ>WKJDH%>+/.BE[L=RD=IPAJ-TWM3Z0]=_GRGPL%NPQA1S?3"$A/ZESR@KB[1\D1MG-^ M)-OAIO4>.2IYY#-RO=]'T9E'-71WD]:_U'NKNW A0AJ',5)0"F(*(68,9HD( M8:!BA$QSIHCA2\K0G!?!Y6V:IC#-5F:XK?I=[%ZCIE*-V21>4C;%8EWL[,$Q ML1[Y&W%46N6HVO>>O.HKP.<^U"^LMF(/W2CU5RRF?\:*+/;@]-=H<1C'W>;] M4*RYE*(TH6=M5E3Y9EW4W+M+\I<%STLIZ$IL_WZC_D9-,FVU:];TM[RZO5TO M36WQYI3 +$@"F+ $TPR'- FMDUQ'D7!N5K063YL@]S07 MFC6;Z*AJ#5:R:@JU@%)6U7+7YUO^]\:T\*6F$H/EYGF\M3YOCC_["H[,R5O] MFJCO'[.9U=]IQC+HF/5N3<>:=; \S*FS=SW=KO=#3!1#L?&242Q, MR[8(LB!.(1SK/W%CFM_7=#;P\,"VVVXIEVV ML=UTEU9K&ZF_AS^0G[L2V[OGZ?#A#T!O==:.1QYPK"&+KSEOQJX#^7,3KU]_ M67Y?Y=6V;KI4/%0LBR *Z\K*)(0T#%)(. J#+"51G*36!QI64\Z.BANI6Y(M M=G*#LK;E-D9R!X^['>P6IQG>P1R;(!N!04-]>Y%;F[@6>D"+3TM '0XOO ,[ MU;&%!<">#BJ<(.H[HK ;:+K#"2?%#HXEW.[TVI.I"3TYZ)JR:VY)L4JR(,&0 M8*X@0EP;W5@Q&"<)"7B6Q))';D<2[D+,[U"B;B6DENMO99.\G6^%[[1I^HN7 M/DU]:V-G)8^+]\BD?Z9OTTZ)3M^F49J.#@=QW%9.?0+,H:63!4"6K9UL1AI: MKFD;>=?46]$"7)ON0_G?VWSY5WE9E_6\7HD/A;S+-W<+FHHT4BJ#),U2B&@< M0Y)0#E4J:!2G(HR3:$#4[@!1K%[6Z0-YNV*;PX4?12MY^1.X;R2O WT'1_<. M634[PAQK$:9AS+WT;26HV@5<5WDZ6)"M$K7KN%7#9PVHP1AZJP?E+L'$M:$& M0W1<)VKX4.X[_U^-9_BC_"I7&]F4.38%J^MZU8LT261"$Z[7@]5%*C5#2DJA MP$G,$I*D!%EO]WOFF=L>OQ;581??!^'YK;LG8$8FHEI*T(KI5-O<"2[[C;DG MV";:C0^'SVDK;@%*S_Z[[^[)-MT6*G1WVC:7NY/B*ZED46C;BG[OA(V_R4T] M46.T[IVR6RY>9 %*6"P4E$$0Z:TU9I $ 8(R00$/DHRI%#G8D,.DF*GY^'Y= M2; U&>V)8L JG*?;D4"=J,I)*WP= - 1_PKL%#AL2_%J"M#M27M<\"?BW:8OZJJZ)U?0^^BM=;K1)_ZW^ M3;G((A5SDH102%,U.B019%E$("4<$49B$L=.K:2M9IV;P6VD,I6ZS4[6U+ Q M*U]D+ M;U>FI&A]G%!75?A\2U=MH.OUER]%O8%]NZHT)Y8YK_GPK[+4>]I%$ @ITT! M%H?$'.@02%@J(2)8A0ASBKE5T=+C! G3 :"O85!J.?4OB_:.U@V1KE_ZU_\$:%@/[?,OJ M,W#V&;28/MKV^9;J9(CN,XKC7C'[]:K2$[^L]]1-KGS=T_UF4Y4579D$D$62 M$(%0G)H,=1/8*T)(N1"0I%% ,D+#,$MLZV>?GVYNG[1&8M"(W,1&7C5TIGEJ M+[9]>6T+Q/N_/OYQ'/DC<2F$3K6X[9$95)G;8OC)ZG3;J]JMVNUPUS";_@W- MBYJ/_R?5VHN"W#Z_6)@5]P8.8)XS%,)5,:(KA$2224)CR M,$P%)RISZW/I-/ORJ!X^Z(?)Q%098^W>3-@) M2U&Q3()00AP2K&TD%6@6TS923 .&$$]HAIQ.:C/3SDWVFDE!K(1V95MSB)LRS8^<1N=;1K(7I^!; "9V*+@C4S.3C@Q MF=@"<$PFUG>Z!RN^R)=+/=9O4O]>T%]-U?LWZXW^J_$LM0FO*@T((IQ!A @S MV=LAS%@<01E'E'%"I:#(-I+;8KZYT8@1&6B902LTJ*4&>['MX^-LT.YGE1$P M')E2SL(W(%/;!D?[P$+/>$X423C\L72*&'0 IR=$T&:4R6("'53J!@&ZW#:T MB@V]:=K 5 M?IQ4E,N0\]9EUVGRB7OM#@'FN./NH%&\MP1_OS'$>:,^F#Y+=16Z97Z7K\RO M%Q2)(.42P302(428*_()'W&+8 GFAO? M[21M\CJNFHK5)_B> MO:L^BUZA\$5C:!>'7QG MP/#GV'MJHJD=>F<4/N'(.W>'>Y#6MM'Z9WWK0F8L4G$60ZHR A%F$20\CF 2 M,YQQFA(<6OG\'P\\-TK8R@:,%0!T, M-%FPTRGQNV%-)W_O[BM_K90T%:=D4UKE,_W^47_SC;]AQ?-E7ON!7IF?2KUY M$FV]E4\;5N8BI\7#(J984J&_WDK%^NUD"8.,B0!B0AFC@E.$K/WH%\HRNQ?Z M4%1C59<[8>W]PI>NT'G?^X2XCTPC.TW:XE!U1KI1!AQJX?^ MA(LTD;-_[,5R.A+P!&_/<<&E,TQVE. )BNXQ@Z\A)V[)T.8B=$*%'[65VG:4 M^%#D7'Y<+Y=J79@;%\C4E8V8A&F,S]SJ/_/7VD%RW2Y_K '&BW=_ALS-*2=WG M6\GG;D0Q7(%_C,85%R^0MT87ETOBOF'\:(2Z40!/*-V4R=1=)I7V0'3L^V MY\P D^UJ[!3I;EHL[_"<8_-[*=5F^2Y7(HQ"IQ2!2WFG!NI[C-%[HW05_69M=S*?04VM>1@J47WE'C3P=_VQ,PKJJ,? MG?6DWER!1F;PK@]/?TDWQPB-G773F7$>:3?'$%CGW9RX=6+_R-DJ#N_7JZ8* MCK$]W[0[X80Q$6&O+@5IG5% MFAT:W3BA]N3]#X,0:"&:JJ'FL,=O9$?,Z _5_)TPTSU/TWEE+EK6Y_;(#!/^ M'\,;<]'">//$7";%L,_V2X.LB7(V$WS,RS]?R!6_O:/%GVUQ"Q%+@07.H$(T M@BB5&+)(Y[S4TUW2N;51C^69O_R_3YO)"W?KIK* MS8N QHE*,[T;$(Q#E%$%,Q0RR 5%D60BB$2\[14RS8'I69FM7M'#SB)CTYVI M&+]<7A(^//Y*3W,,ZF?U_F$,[IU)W=&[\>SL-0?ZF6ATGX$U[;I,SVU 6\O[ MCV$SN\+O^\#2?N*!%?GR55[)=_E7TUFUTD+E;"F;\DR_T?]:%R^7M"S?ZW>R M-=I20ADE20"#))00F8Y^1# %:8HHUO^3BCKEY#G./S>[N1$?UO*#O0)M@:LK M4.L :B6 T6)HI3['5;+[=(R(_<@? O^PNU?P&P:>KQI^CK-/6\5O'=?P& M#N,>J-$DY-"EYM@OA:QI^3?Z/;_;W%UOJMMUD?]=BNN[NE^90EF8B"S22R(1 M1#$AD)%80)R0%,6RVVB)[LJOKY62=;KLO7V

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

@ZE@-$ZCF!Y(F*[&2.RD9.,!P3DMO-_3BI#G,UI1--VKB)&?Y[ MOOGV>EML5H]JO0LL-G'&^O_E5_9C+F,6$T4%3!4*(*9,01*$$^@P-;YJHH7+*K*'P<+MF.!V(>#:TF*F%]9-!/]Q)6#'3E=]!M..\P8> MHH$9\&!T&OVK$K&-!:8T63,*C1% 6^&/$6^ T!,_]M%@5+:\ :)C[KSE43V3 M[6IYS 2"6I:32/!7%LN'A!TM0HM5(6&&WA/XVZH-&W^HHM^[]? M1[B;"+WB-C#']8>L1YO&*W##EB-@*4[Y1G7H9TF#Y"Z^T4.&/GR?FQ$CNOC M.(!PXLFXW.L>Q?)%^T6JN$/W2W48'M.DX6,<1(+$D"+3:XM) ?7;A:!B:28B MCI50UHEG5V1-CH)*=<$=1$!K#(YBMNQC):Y!W$TVGH$;FF,Z,;N^]>\,GGUL MB4<01PHGZ?D".D6.6*+2$2QR[0FCQ8=8FM(.";&]I9^S5]8K4F6%W'7.M^9E M,<>];Q^?%JMGM?Z5;<0WDT/<_GW5G^4^*W\Y1YR1U!3(#F/M_V%D:ET*02&3 M+!!A$*% .AU^W*S1U#BZT1P\UJI71QVU[C-3L5!8UPOP-VYV_N.HHS$P\=>V M@+:R923*#.S&J#'HX*)9TU;*N*7E%?Z<3V\ >_),;]=G5+?5&WS'/JV_![MO MT+U>?5=KR^)N)]=/Z(,K]?):>^VBM;UV?PZ?--INSUD#VKL[YR_H.\&W(TJK MK0.5*A4H(B#-B()8(@F90GK*ID$4"8(S266 MG$H:7I8U-8JHE'2L4M@!I1T%> )H8"JHM)Q5.['ZDZ\T!4954.KJLZ;A=41\ M53CLD#1NO\4.NR>@>HE <_ ME>K7:<6.T35=L-M1B2]:"F+[7+#UL_O\H6>Q>RT!)6:KM$DQSA>WQ:X&9V!F< 5F!XQ(Q>,OR%6Y/B) M(\>(7##H-#;DTH4^&V=5H6K[@AR_F=+@Y=E$U-O+:&6.ZS M^C=F JT;7\RY"CEA@82$,0YQA*0A!PJ3+*::+C")B5/+S9'TGAKEU&H!M=?T MAK#?D<;>SLF9X(@.O0USK8=\I?+LJ+$1*"UL8HU!R\2A6QX--AB#MCSRK_4$ M6AX--A1V+8^&$]^WY9%8/2I3W[+)@\F7VWSY4(].%33%;TYOE7I6W4O_FN+RFW1>>92J5,DP"&482UGYLB M2$.D8!QC$::SG86#,> ']4&++3*@)<65M,8T//9 MLOG%*@,F.73EN'TWYOM@-[U-=)0'GN(J?<%/1N.?]UF)E>E@;WOS E06@UJL3!/:B#RV01J]/'RUC=J/,U';C4U^I"<=J<: M7X6>)3CJ_ECO'Y]8OBZ+>VAY\XP13E H8!Q&>ATF PQI2@+(&(U0(' <"^%4 M<^.LF*DMF_;:E;.*8T6-\TC:T?[M^ S,T(V"FF#W(/DM%-Z-@:^2&.>%C%L# MH]/0DZ(7W5??VLUEOY TI_OS@%#%*(E@&*(,8AHK_>$C!M,D%5%(D$Q"V:^) MRZ&@J7WZ1J>^34:.(.S^XGT",_ W?]1"I+WEX!&NOJU8^L/V,AU8K.&[H>_* M>4RLVZTP%3PUXFQ*R7Q68O6PS,N8:E/4Y[49]N6F6&9 ME^0\)':NUA! #TS$%N5ZP!^#Q.*X@C5.89X7BM)Q!<.Q!(^O^)VF!Z!>5E;Y ME\T/JO7D/%(IXC2,8*(B"K$PI1XD#R%'B&L*"WF8.-53O")O:H2UZSRYKH;# M.>^F$UP[#O((V<#4LT-+JUHG8,_ [H>5NEZ386QP\9?JTBEM[$06&]//I*E8 MW=;WO*399_JJ'_":;=2#.<@IY_0Z-$U((3*FV40E(H8XP-H/"H30:/,P"T4@ M@M!II^BZR*D12FLS#OSQ9O7(\J5C H$%S+:G!S[!&WS3WP&W'AOSME!XVT^_ M*G#D;7!; $YWKZWO[$*-8;^9?A%JR=;YZMUHKP79O<\2QI@G$($F4@#A3"60D"B&) M91@2R0475M'$ET5,C2,:[>PHH0.Z;B+P \C GW^CF,?O_;K=75^YOKOUA>M_ M[;_NC@>/\DU?-ZSYDBVN]!E%W-K ??6\OZ0.=;S[DZWE+C]!KW&VCU4HF-E( M?+=6JF&8S]I/F;.$"L%9!).(:3H@L5Z-F#*65&9IQ$SR(G,K2S>TQE-C%Z,C MS+22.]<#K+6:/B*&?8ZSG1,SJ=$;F K;4<)M:]L'3X _@[/1Q,;F&=AG9H&6 MW;-RRQX8T_?^U>>N=\)3&/$ XS1H +%/?2<0.CP _'9!PT,(=D]>>U,?$A=F M(VW]9 X;E7SU_-ELKRD-Z_[8*48J3-,P@Y'")BV M.4F=VKRQ4QRT-3>$L]/=/N'-'OON>6 P1(?>=+\.IN?SOEY(][954 \-MJH>\OJL#0>88"%@>9A&&BU[]8801I M1 ,HJ2F+&B:,9-0EW^":0"<&&B%)X*N1 19[KK )/3A",FWW:BYE_FPA,)7K8]KXL8M^&%I_$G5#]O[;BW]?G*N MJ,6UA)=EB/;3,%(B32CE4'&10DR)@CQ)30W0D!,>2D50TJ\:O),>4W.*=@6T M[C-PYB =:%M RYB^1>+=QLIRZ3S\" R](&Y5+SL'/CL$ORYC-DQ)HQO1]%YT MWDV+%ZI#WPNJRZ7I^SVN'X^:<]/[K+60O?N1%W,6410)O3*,$X8@#G$":1HS MR&*59B@+$Q1F+BQY5LK4./!B%'35?K7U[_NR#>3F&UN"PYO^,'8YAE2<'P$[ M[KL9UX&9;7A(G0FN$S)/]'5>QJCDU&GF,?5T7^R>MW.WE?GF_3);K1^K?3*[ M L%=MT[HI2Y5!"T=;>H&VV-DGV7B ZN1,DQ.,/.34W(-@8Y\DHNWCI9+/'_57W^A'UGF_#ZW?U-.2!(GB'&L8$*9V;1))"0T MXC 21":2RIB(P"V+Q%;TU/R$6C]0*MAKRG> W^2"ND'C+ M"+$6/').B"L@IUDASD_HN8.\6CZ8JN>FH+3Q3_: M8_;^Q<;,?AD[^MB-M.8=<0R=%LU>\>Y88?N1,]IRW"LL[;6[WP?W\ZCOUP]L M62=&O=8N^VJ1RVHC82D_Z9>^^1KNLW?YDBU%SA9?]$_*SL@7->?7@%VM-RQ8].HZYOO,)XO"#R^W!/Y31^69NZ M?D0HF:I0P)283),DE'J!E E(PP3CF&0DXI%+N-UY,5,+LML%4FS8#\#JJU?<=>GM?7WM&6@,*AVYVJ21XNAN MA[/%T_;5XHKNXFZ"['U]WV M6'^M"E%31R1,0I69A@L !V8"R\W+$0C-2Q$@Y09Z9+TX@T+47>1$9M;W',^7V^UZ[C< MO,L+P1;_4&S]=BG?F'3S2!*5Q#* L52FETL@(!<9@@$AW#1R24..;5,\+PF9 MFE=6ZPDJ18'1%&A5P1OK<@"=D'8SA"^@!J:&7A@Y)65> Z%7#N;%AXZ6L1(11<^Q8J(6G$G&H]VXN>&BD8S4&Q4WT&6*,\U'X?++3ZYK"[/G1[ MT!:X[@M9#XKM7M$04 ^^?Z11_M)"^>X Y2\ERKNCS5^Z4.ZQK^0*F+>])FO! M(^\_N0)RNB?E_(2>$7YE3_AZCV3Y4#:';U*O=H M_C4/)"<981ARC#G$""60)#*$62"9D@)GD@7SI7HH#T\=(@'[*&/U$=+J(SQ1 M:< 0'ZW@OX.GZL0!?"]+Y##YGUN7()#;!LF.[8;#?*2PPU+_&=A9 $H39KM$ MS><9:)L!*CM 98C'R,1;IV][1!4G3VS>J%2O; M14N3,[@N@!Z3JN>FXP[1)7CMR,P#9 /35:,AT"I6A=5FH-;2'Q==@<$3VUR2 M,BJ?7#'UF#&N7=ZWYOU&CW&N';3J /&CVFC&66RE%M7T8IM+$84!$Q%$DB<0 M8Q5#2K" ."18J@!A*J@;0=B(G1Y;[+7>10,LE:-#9 6X'67X!G%@_FBAUT0) MF%;'/^UT!HW2EXFW1V%\>XR\E<:W$#ER<7Q[$$[+XSOH[44!,]F M/[=,%%ME("_[F9GB"4_Z!OO ?]_CVNZIWI\63F^C_7XBM;X MFB_X;WZR/ 8:@HY\#]\21\O\& BJ=@[(4")Z1@DR$P93UN3[J-_Q^ZR5S5VU M-YK')!!34#I",QF8V+77NV2[+ M FB[Y8)?^(:>^]R0,N' M3VJ=KV0X5TIE09 &D-,P@)@&"!+$8IBJ4 D:HH0'TFWOPJ=ZTUL1U/J975"M M8-^EP"!#F:1QJ&>1!"8X2"&.)(,TB!!$$6;83#5AY%2]XZ4&P,;GK3V5UASBB@60< M0Z+*Y4'"],RL& Q,,]U0X)BBM(G$L"-T.\$]HBZ&#K@P&3^:!&1>/*T*O8;7 MLVZ6_S %5,H]5S>VMH3?CH<]0CH.PQJ%FWH9&M(W):1YDV_=J ]*_<'. '\$ MZ@:8)VJT%#HJZ;D!<4QGCG?W(ZI?\^5JG6^>FR9*]W\NM6OV+7_2/&A\7O:@ M7CU_8B8>=RX4C3BF$FHG-#-!$@CR0$D82$R8Q!PSY>1\.LB>FF]YU(:V:9TW M ZO&!N-PUD88;^:I-,.-Q5S&QH[*!D)\8#Z[T/-W!G;J@T\'8'_J!MN9T'K MYHG57"2/2FT](#GFMSZ/N#6=N]RR>?7\>J&]BE8W$Q:A-(X(%"'7J^J0QI#@ M-(22A!$F,>4\=(S^NB)Q>GL>7[:/CVS]7.=@U]4,JIW'N^WFFVD'K_3*ZWU1 M;.OB6O?;3;%A2W,(WCZ^K1\)W>W"QXNOJSLI2X><+3ZQ7+Y?OF9/^88MRN4I/U[! M?C9E)K4#K[ZH]?=OYZ=WR[<;_V8 M3&ZQ-B'F(%NMP>N5Z6F\M\D?[8X%O"?>'ES=48E_+/"/9X[1Y+I'%QZT ;I[ M6*ORV>5%YDU :>-8YZ:NT'[--NP&JCP+O6@'UN#]B;EQLP M^R#"T0=NI-#!L0;0*5S0*]@=08)^Y(P6&N@5EG9 H-\'^XS5*7]:[/=.?EOJ M)Y9+C/LG\WNSBU^\_:'6(B_4I[6>^C\;7[6)&PQ8S(,@@4$0AZ;^3&IFWA3B M5' 4TU 0)&^/\[A)QZG-P(V>H%04E)KVC3<<8$1OB?D8;9P&GG/[#9&G XO M( X:QW&;AA,(Y_ "L5U4AQ]1_0C_]:H,!ZSJDG[.BW^^>MXU@\HDPB)0#"89 MHGIYE I(@]3DB;(D$TPF*78*^.Z0-34"/E 5&%W[-]KJ@MB.23T!-_@JI!=F MSI1H@88G:NN2-"I%69A\3#4VM_0LU+/O.UY7-YM+FF1IPA5$840T4Y@TS2RA M,,%1A"(6!1RG+O7D3T4X$<0(M>2_&AE U"7T%GM]'>OIG&)I1PFW(30P$[24 MFX%:/8_U;2Z:[JMXS:F <2O37#3PI.S,Y2L'*,)5'T44;[;*5#+\^N=JCA,> M\S@*81H2_>$CFD%&99D=%J$T88*PU*D#IYO\J;D-^E7"'@MJG0'G3*9EU&1JG8ED=C^FYPMD6 MF]6C6I\X1'6U;\6C,#*!ZD0AO;9)DQ R%B%(HX0R(7G )7):Y73+FQIE->J" M4_?=<9ES!6?+I8X_](9>[EP&;H#*ZI:X^%KX7)$V[N+'SO23!9#E;>['T)\6 MSX^K[>;;KTI563;+9?&\^,Z6.:O?=4YDI"BA9K]$.T.1=HLH#P4,PB@)LI2E M*K(^8KXJ;6J,TB@,:HW-*=9>9_O#Q>LP7S_I]0K>P(32C=MU3ND!H/W)JU<@ M1SI5O150I]-2:X Z3D*O/V.T4TYK<]HGF/8W]7/E?ENNJV"B?Y4]TEZII5%/Y8Y MW+O^BNE_"@781J^-'O*EJ2UI@K0WWU29(^[FRUT"&DD44"$$5*$,(69*0$*# M"!(-N2 DCF..:J#?+BVS/+W!W$@*;VLAJ(=/<^)>GK61O["%K\+3[_F]%:>"/_VS_6%,95M.E"0"N"V0L M%JL_#9D.V%2VA@Z9,RT-. (OP&$'IYDG5:\'X:_; /1/=CWU>2EFO V^#AJ]\<$W9WR? M#1_[K(K-.A>:D,J8L=^6VMNK2@&)3?X]WSP?M8,.>8P1CR2,)=>+N-"<== D MA&$@$:4*!TSV;.CM1;^I;6>V&WSO3:FSGXTQH+&C=^JXEV&U8^D7'*R!.?MJ MTN39P9OM1F^L!':?L/M/>/>BW4LER/N$MB.AWJL8KSNA7[^QS=]7VX5\_ZB_ MDLW;+%-&NFEF_MGTK44DE%BH %+3#Q@'&$,B&(--J#/XS^H#3 X;C:83"N'_P/ _' ]#<1=.VC H9! M>:3P "NT_00'N./4$27@\+#1P@7<#6S'#?2XNV][1+%Z5*80Z3NMONF@DB^W M^?*ACD5=+8M7*ENM576=GE]4\4;_I=CD8HZC2$J:Q3 2.(8X5 BR(),PI1(I ME*1$2.+B.]^@R]1FA=_^]N5OH%'.M7]B_Q&Q_L@;"D6<5( Z MK4_/C^O3:TK/*]VJRA9SQ;BD/. P2Y(48D4BR,V>1,J42C(:Q#$+G,M#^-!L M:BQ;=8I051ZXF2=[%(+P,F*6.\TO,0XC[C'W[/>QMVZ89A\^$?=9(<*+7N/7 MA? )Y]EJ$%X%N'%YL=[,7V\?MXNRXE"UK5(]\#Z[DZNR]L2^&F =,AY+SF@: M2@'>S[= P#DRH>]7K M_=Q=R;-5!AK]9V!O@<>H_5N@ZV)&_=P6*^I_[1FQE\A12.\6,!I>N^D9_=S0 MCZOEJLDCK9S<>LO@CA=E=]1YI#*2D2B$0B41Q(E4D&*90H2#,.,1)BI2;O7P MK\IT^;[&J8A_O_FFUJ;S7[F&5)6Z/_^[FP-Y'6L[Q] K?@/S4UO79DW]4ZWN MS^"/1F./D0+6Z'ARSJ[+&]7ILC;_V)FRO[$?TY@F19OG+TILUV7\U[OO'W-S M7L46YK2JZ6\TSY@(>!JG,,$F0R:C)CE<^0,I'HGP=".O45LA,[-5E^J%_9_G"+&!AMEK#PK0&5J69H-C9Z49-EH,C188%9MI9 MS3"&F)$4DB ,((M0A)B41"9IC]ACCV,T?H#QT5"9D0(_F9'Z^46'*B$)C]), M?T*4)OH["B-(::A@@%-DFL8J&6.W;H*#C=(+#-!+CHS=).^?MP:>Z2N%P5[C M&7CW._SX?@;V:H-6-T)_,[X;5)ZF?4NAH\[];D <.P".=_?S CZK[VJY5LTA.(:4TP#*4!')$,4@@#QC"11#!'%!&*<9I":UELRC64:H!@Q M(;Q5\SNOP]18K)W]46NLYQ;SKZ,*=>TT,8\E "^,E!VW#8S_P$QG4PJP,6+0 MY(T;8!RC*N %#:93&; ;(J?J@%<>Y4:54N7SM\N-?MR=E/K-+>K_?,B7"LTE M39%2/(,A98%VXI" W#0C9#)#&59IC&(K,NR4,C6ZJQ0%M8JSYB_ *-M99M,! MV&[N\@;7T.O%ODA9TX\5$F<(1J____:P^OYO^OZ*6_1?]I32_=112,/*L(86 M["Z^)1S4I!$HH[)FF/)0_?4WF^28H# Z7MY[''WX[7I[*H Y,XUH?I96TY_%4CL=*TB781NS 4VPG=JSJ7[>OV 70!VTP=DFFOU5V M.*>95!S+ $8,$8A#0B$3DL!4ZOE#I8Q%-+YUE1U.COB[UH[W2\O _FY@^Z^R MG>!ZR55V%U)>5MEA![?U7V6?^UI&7F6'Q_QA=_&-J^R:@#;/=1M1121+><)A MQI($8AR$D"B1P21F6/\H)4G@U!CVDJ"I??ZM1=Y.TY[=72]BZ[A@O@&Q@1F@ M'UC]%[L7D/"]KCT6\S)+V O&7ERM7KJ^1^6-Y7++%K_JAVS4TM2!K7/+>"!% M*"*SG@R9"==.(>&A@BR-<$+2B/$(6Y?9."]C:G10J0D>]WJ"I^[,,<NUG M$T8#$T -3TO%:XESUO X%+JX'::QJEHXP^56R:(;B*ZR%1?N'*]&1;?J!P4I MKEPZ3"%/JV7:J^?3A5IY&CHG7"^::"1@F 4!Q&D80\)8 &,19C)D* XRMZVX M0=6=&@M7FS>\W^9-'7[@Z+P-_#Y8[LU-9I2GO#MW=8"]5P3U@_M(!4)O5'92 M]4+] .]:/M23U/[51 _#I.^7[Y??596H6:WTUR,?*^T>S70+N#M*-P'CN/5]SQ-I3 0OK> ML%<93PM@/-;K[)(V>F%."]//5>"TN:T?SS2]?;^NZK86=U+FAMW8XKWVM/6; MMGF__++E12YSMLY5,==^:XA3*J%*@AABA#+(8TE@' N6T(2J* IZ,(^S(A/E MHOW0F)"07]12K1P9R'U(!#<-WT4"%='S #:M7'B(!50HD@33.(FQU0[-L&,Q M9K_3V@#3EYQ5)@"VL\$T;BF-,"-4M,P8>ISLYHY!T1]X-FD#7VL/]NJ#]RW@ MO]@ [SR_] ;/TXSC+G_4.:@W/,>S4O\'N1=$^K1>R:W8W*^_J/5W[63?_9PB+J.4053VB.=I!'F:2+K3(+P+5)W%Z;+"_.BMS1.[IYE.VVP]9RY89V/^X MZ=S9]#PN+0([DP:I?>0+7T_NUFR]9YHYHR 48GCLH''5-!QI7L$T#[#=U44K]EZ_9RM MUJ:Z;5&6M]6_R)?O]&OR#\76Q5RH((T9PC *S:Y3A@5D69#!3,4R3!*)8[LX M86?)4Z,"_?K$]I$O;B!WT\&@T W,$JT: N;,YD#SNB:W^66^!$9[4*H_%,KV M44>#H3U2+))7U)W"E'HAUQ&\Y/:\T4*:>IG9#G3J]X"^<>#55EU=EW.N5] ( M)UQ!%B,&,4DI9&G,H=(,QQ,68"YIC[.=(S&3/;FI-Z?K8KRN8=^'4(I8IIBQ M$$:"+4H?>ZR*E]W&\4WQR4X;P[J70Z \84FRVHOL-@ MQPE^P1V8)J[@:HNH,XG8@^2)5RP$CDHU]@ <"3*(N3 "8BE=JK0)J5@D#!0 J4B8#'BE+W6N87I$V-ANIZP)6V5N%I M/1"VHQEON W,,!H%JR5?,/E\D^=I-[IMYY?*Q M;#_XH);B^6VQR1_U4NH^^Z1_D6L&,Q?\;L[ZZ@#H8BZ(4$+$1*_\A((XX@FD MC"4PHFE(0IX)AQT]=_&3HYM:9;.3759Y*4"A-IN%LN\NU7,4&U0S\7IU&9U4#/X<=P!ZXVV\##HO_2'N!@XR#TYY@?Q@[ M-@9[/'2TW<'^!K>W"&]XBOL\\MH4N^*KJKGAW<-:E?RW#_>K*V=_7;U2=^); MKO\EYS$1-$HC[9R&'$&LE)Y(>(B@E%2&'$UXC-S7ZOZ[ *P7N1L'=?CH9&/^1 MYI,!QL%I-KD!Q8[II,]31YM/;C"Y/:'<\ACW&>73VK2%VSR;!,K-W5*:%="3 M$?@F+YY6A9+WV:MGL[DR3[ (LS@-H8HYASC-$DB8C" /S']HE"6IU=:KD]2I MS1Z-XC/P9%0O(SE5HSPH5@L'&K.'_OJD,0B@ T\5>RP_[;#:FF<2K MYW)+>PAL[2>&03 >:3KPB+73-.",60?YVS]K-,IW-J]-].XWW[1@^*YVD\G' MK>F@L\K>L.?B[^M\LU'+CZM-+M0KE:W6ZJM:/^;+ZH.@/&,HC1A4@=2K!YF% MD"*]F ABA0(5<4Z"L,?JH9G5A+ &; MO2F]G-U^(^BTXAA\7,9;?GQ7;;?WXVZ C#V@-@A4%H'*)/#U10:HU])D\($: M?YTRT(#U7;;B6W9Z-X5EUNJ;6A9:AZIX MX[ZPP__1/GR^?-C7=VB=*J_S0O_JS=8$_E4ESSZJS7WVE?V8IV&8X 03F FB M5T>*<0U^.G#GI%UU:W"QW-&D?Y3O[GMAKW&6"9 M?A5,?6-_$1%##XFG8(K!U!PU#F-HL(]#. :7UV,17K)=6OC"U 5,8TV?9KM3!I"^:8+S.6U3]W6.'U'#^+ ME??PHS+T@KL:D/=+4-O0A-D70%L!2C- ;<?CC&6E8/ M-BQNR^G; .U:1?=\\GB+Y]M,/U@SW_BHGL'/=22+?+\LMFM3P, TX]/+ E,] M#26Q9'K^@7$6"8B15) @1& 0Z?]#::H$L8I.M!$VM3EHIRO8*0OVVCK&/W>! M;+? \ 7=P!-%3]3[IX>RJ]49[UNV:)^\W MZM$V=\CF$1-ZJVM5C\H E=HZYU]9H>?@S'A$<2ROY3*:GOP12TRZ'(]KCQC/ MP[ TYL"5L+VG9PN/+2_4?VWUF_+VN_ZC:K00,X9I*B5,LL0L8Z,,4I8F4 48 MI3*.<.*6?7U.R-1\A+V.H%2R9P>,06W@C0P;SKCX]Y H@, 7VT?SHD8 MMUE#AY$G+1:ZKG6?Y]^H3.EUAVG"72TWWNOI8?E@(M[K=3?B*&4Q0I S&NKO MG@A(]+( )I)D@8PI":E5_T(K:5,C@+H2KS3UK6M%';8ZKH-[W8OR"MG =-#H M6O4QK+C_**XTB.U(UX.OE4UOAT.%77GS&:5V5M3MNMLK^I MIU]UMBE.JSW3J^?])74Y\#M3IZA*:&V5IBQWC+Y^8\NJ;T[QNRK*)6#=\B]E M)(DS*F'(%84XC@)(2!!KAXVK*)922)GV*#HTEOY6G^+XU8PJ)<%/IL5!F0+V MLZ,?.-;P6_J64QK-\;NCM8UNMT@#_!F<[:)F3)^!.OV_97V]#;_1]M?=U4QN M9_6NZ%?%5U_*EQHV7U[V6&J/Z[F//!@GJX&QY;M-?/N&ZWI*?2^UG#S+1:EC M%2LX)TG& AY',.,RT*L+CB%120@192+*L)1$6:TNKDJ:VLJB4K;T[ [5K4-F M[::6ZP!WSP5>81OZZ*$O8M84:XW&&4XLE/C;P^K[O^EG5'2H_[)GP>M/'H6V MK UL>,;^AI$]XDIZDXN_[R@Y9S3-! H4I+%"$'/.(0O3%,J8(!S$,998N85Q M>M?1Y9L:)W[SLRK4^KOV5_8),'5YEJWIT*E]&Q.$(,SP?U=E[MD+>,$7AWQ@ M=]?',$[?K]TG:E1V@KVA$_!=KXW!2SNI%_7[:WBCU^#UYG9>%=2SY>9Z)922 MQ3L-B0E1OL\J_W8?$OKN^\=\'L09%4&D9X1 ,8B%0)#*#,$@IH)0R6D86F5! MNHF=FN?9: W,"P1,I5'SU>^#],V_3)/-^Z5CR6'+4;"C:__8#LS!A[!^J6&M MMPO:$?7O?HC'9"QVW$Z 3$2?=%M[O'=G=7];K\=-V^W10; MMC2A\/6*#T4X(Y(G4(;"5(H2L?:%DU2OJ^-(,(94G%G%FX^I]-0XLG*4>.DH MB;9#Q0X=JJ)UW5/M4+'*H5JNEG!5FE^6%M$DD+=[D*WV$+R$+^WP/@WM7@_S MEOP%/&[]@E26G]E4GH&6]3-O.QPO,5HO[IL[J/P7<=?=!\&?!]]#MGM82F_U MZMWKEBYW#P_K\HSP_7*SUA2IF6@,ZRES&+>AGL0XBF]5*,%(,TG9?#*9QIO+'JB(<:08G1 JK& [0= MD36B5'4;W/HU6O[[64VP;)578ZO[,>'G/%\46Z5SB5& M#*>!=@@XCR&F2$#*HA3B+&2Q)"PB1.T"4%<;MK#;BNR2V2=H="=YN!>YE %D M$\F]83_ 8J^TVW9?)^1VVW0W(_@"F00M%6?@E_6J\)AG;(.'IPVL3E&C;CS9 M&'V\861U3S\FJ4NAFY,7TX+#)##^/=]\>[TM-EK4>I5.S=-JZOV7YXR-XN!/K3EH5._=--)V*.S(9@" M!^8=3]@ZTY C4IX8R5;JJ.3D",4Q3[G>[JM[S^?5,UMLGNL,C"C@B$F10!5G M$<2(A)!HEPCRB 6()D20"-W6K>= WM0HZIXO\H=JF^BI5-!4[7IBSV!=:FWM M^-C"?7V9Z!G$@6GH8MN76N%K226]0+RUMTYO,%^ZEXXEJ!X:YYR%R+E1SN%3 M7K@QSEF3KC?".7_;[=%_'U<;57QBSV6-!9'@1 8!@@@Q K%0VE?,TE"O0B5/ M1(1D)'K'^[4%38U^#T/13"S?J@!Y46S+:^J&VU)$DR0R"#BB$-,](J>)51I#UD:I+4#'9)FAW \ MO _W!___0MQV@]#;6SOX'N&!IK/#&N25NCXW"JUP\;97V"UMY.U"*]-/=PSM M;NO1[7"Q?=0KS*7ZD&?JB\B5-J-HSEX#GD8)E3#C%$$L^N1URIL;>.U6!T14TRCJTVNO ]/KRVA-20[MVYT'J<1C;A99#*T(_J(W5 M?+ O>FZM!J]CTM54C1M!6<;W'Y2#T0MT<(+,']45M M-@MS#O2:%=_F84Q)A&,.119KNL5!6A89@ESJ_X@4A4I859 >3^6I,7=I00&* M2D=3,49H+6=FX[16?X1P2;=!OSX?3&\H!YY:/(1)UDD@536AKP?5A/;V@QH MTQ/ 0#"Y=V.$<-K!WI&_3DBMWW=EG,C:7L,V1'2MFR+3C[#M!:R7*-M^DGOF MSHIO2F[+Q-PL4V*S:PGUE?WXS#9EV?NER!=YJ7Q9%_>K^K%YI>']YYPS'N$P M83",3$%$F::0\S2!,DD2$H:"!$'BE!-[@S)3J.J_^M^+K/M#E&V1C F587-&)6-!DL$$90SBC!!($RF@TLM)FB81 M%8+,-_9!P^.J[\3N(\0?_]3H_+->6E9_:]:89:^]\B]J;[ ;LX_\:MC-!=,= M\(%GC]?EQH'Y$[0LFH&]L:"ZQ S\T0\/[ZA0 T,8/\6F0+D-1:@ :.:E2HX M_$T]+S.,GB:KD94?=7I[F8$YGA!?2(M^4^A^JCZ8IK]LM "MYP?],2QVUZAB M'J%((*HDC(,XA3@4*:0\YI ))$.$!.',*=3=4?[DEBB;*E&X=(,W[,>NC7BF M]!BP!>!JJ;+\,OEX&12[V6= J >>/FP7'#-0C8>914IS6M>7+<,]'[WW1-03 MD[M*'Y6*>T)SS*5]'].CW]#J37U,BI,TBU3$8))D1+OYB8*<$ '#((Z%XCAQ M")'?/75JQ/7;W[[\#;Q13VR]*ZUH$JF6A<.ASAZRZ^ M:H<>/WVL'ZN7CPT*;AU[CJWMZLRSNW:\#CS'ZAUTVCGY98\3[LU*_-.4:MP% ME?]=Y0_?M+-W]UT[!0_JDW;]E/;TRKWK>4(2RK41$$6FUW&*(DB3)(9$1E22 M1 2)7?%7=]%3(R6C> $>F=13^ 8P\&>M.V"5\N#):%]6)90F>']=F,/HJD*A M98'"'N-C<:@\&.I#[^H:Q:N2L*VTDT9Y4&L/2O7-TKLZ^1L,:8:?; \<[M^QEZ,'Y8[\GW%:W8M?D[=-ZI>EM\VPJ8VRT MMVNV"9Z,$G.2B91&F$ >I1)B%8>0XYA"J3W7 %/,:(+=,@)L14]MRGB7_S#S M@T/_QAYPVZVOAP%Q:!_X7"?'1O%96=YF4ZZG=\K[+W%A#YCG@A<6@E^D_(4] M()>*83@\H>?1V^KQ4:U%SA:?F!;0K(C",.9$A#!!7$&,C"N;I02&49(0@408 M9U9!EYU2ID9!>R7!D]'2\:#J+)"6YTFWPC/TL<\>F5)!C^M,*PA\'9FVK?]DX]AW)X1VA=7S[>@,' '_!.LSYE 8]P<*@&V!^/D59O#KBX ME?X[;WE7Q;^C.\8K]'=>U8/Z?A=QO,N7^49]R+^;L,W#[M=WCZOU)O]7 M.>AO?Y@X4?4/Q=;O]+7S),),TU4 DQ9C1$ MS$F"68/%0D"2B@B2A.O569R(.+%:@UV4,#4?K5(2U%J"4DV@]71M5'P,9#=M M>8%G8$9R1J9'0^(+UM_0B/CXB2,W(+Y@T&GCX4L7]BG<]_AH@AK,9G/9;>M] M46R5+/]>[C"_7FG&$%L3 O-US4P@V!OV7,RQY-JS03$,LBB#.$@%Y$AIWX8& MB*N4Q(I8GQSVU&%J9%"K!J36S:4*7;\!N+ZV&P'6$39Q5DM0FC!K>O!65M3_ MK(ZI9J!E"FC&XFOM,3FJ1Y40V\CWH:B\P+8 M%AI/2]VKXD9=U-H:?[Q\M;ZOY_8=R]=E7Z-7S[\J5FS793C%N[7ZKZU:BN>[ M'WDQ5XA&IC(+C )!(48)AC14$0P9"42( DTYF0O;6,B<&N&T] 0[1<$?1E5' MFK$!W')GSB^, Y--+P3=]]CL,?&UH68A<=S=,WL(3K;*'&[MV[JC4/HFDVOU M1GU7BU49]%#OO7U:+7+Q/,^R)*5"4IAEB$"4(JN*? XR MIT8WC=XQG)@SKD&XPQ4*H,_ZO\.4A+! 3-O?3JN M2QRY1XQO=>.D8KW13V>+MT6=MG0GQ/9QNS"5?-^HI[4255;3&U6( M=5Z6JKG/FL"MEF\M&17M@AG,%VIJ\O('416E:2(O.]+_V5':[_%$(SAM, M#>WY>Z#W< [M%++_7*U?+UA1E)]9F&9!%&0,/=>AO!6O5ZH)J$G."\7*/0EH&_*U*[?W'?5$OHF+\1B939! M][5%LTR%@9(8\@!E$(=4:(^79C#C@@>2DXQ%3@WB'&1/C=8/5-\G2[O6 W0 MWXYZ!X)T8'(]0K-5UWNOMZ;,(;8G>P#F+8'+7O+(:5W.D)PF>[D_HB]_+449 M\FA(\W->_//U6LE\8_XVIQ%5/"8$*D$5Q&FLF2N1#*)$I"3#H4P2IZ.4#EG3 MXZ>6JL9GJ50%1E=7CKH,L"TG>8%M< YJ(V:4F[5!&^>PQ (J;^QS6=+(;'/5 MY%-VN7Y+/S;YJF^[S^[DJMQ:;$JOL40F* X@B0F#. @#R'%"(0M2'F!!.$F= M:.2BW)VDJ M/?J/'>L"PQ,AG!4Q*A-T&7E, 9W7NB[^VL M=TH^.F=JKYRC@P>-EFIT3OUVAM'9W_?CUOI$Q@[7[OO+VG* MN!OV$QBTDSW^*>C4;W[^12U-IP 3@2,?\V5>;*J]O#KR M$]JX'>K:!";[HW)+5#RQ[35IHQ*BI>G'G&5[6\_4SJKP"#=/-;W+5,"X3",8 M96EF2H,$D*I$P"1C,26Q"AGG;BQR*&!ZI''WY\FHOOCAJ1II&+$R4=@L090SBQ)0YXTD M0T3U\EM_X%)8-RWQI=34%LSM?K([RX Q#6@2+BL@U\=0;?- RSZ'RO>^!K:; M@UYJN(9>S+9"P(Y&BMF-E$OOV>$&SZ&AP0L,XEBM#D8=3+=6")Y1[VJ2X$O4 M>.T3/(-ST%C!][-[=C]\?&+YVGP#]]EQ0/C;'W7/Q5]6*_EGOM DC&,I*)%0 M_R4TY0DBR#+M2 ="BABE H72*@NOE_2I3:9[Y1U[&SI!;N>!#P;DP-/<7F_# MC:-]I?W[]V[%_9!S5?O0B?9XW8N[ /+2=_"7@_I1V(?5LL'_<4_ MOE%\8P[KZRI"+$H21L(,!E(%$"MJ5OPHA(J'2D241 (G+FQU7LS4:,EH"8V: MP.@Y V5T3;^(F@NXVE'2[6@-S#TE4%]=@7(FF6XF?=J_N*+CKRF,M>2Q6\6X0G*F M@8SS(WH&)YGB Y6;5)[+?ELM],V%Z5*U>=Y]*3@+0QJF*10!DA G&8+<=+^C M/$:8QT$<8[<46!NI4Z.IG=)E7F1+[?\%*L5[DY;=(-C1E7=HA]YI](&J>]R+ M"TJ^ E2L9(X;2>("PTG(A]/-/>EIRXM<):F,)8BM6C^LI^?%9&]7Q1E4C:_;B.W*@]WKO- M.R5-A(=AJJT>T>?]_9JZYBKFW!S-0J%D"K$T[7P#16$L2,H"%D5!ZK1!XU6[ MJ=%.K34P;P?(2TW!AOU0A>D47S0F@+56W3$SW.^@6FY8O]10#4Q[;[-,B3*^ MK-*P/-PS.H)#0\V@U3:!G5'']\Q,IZRMSX;#@\#N:T?O)COH@ M0OK- _>;;VK]::V>6"YKN:^WZ[5I%1Z11(69BB&-$J']PA"9W#8,PRPF4H18 MDE2ZD/IE45-CZ%)3\%2I"E2O^L$=P-H1JQ^X!F;)"JE:RWV)X%I1?W1W'0Q/ MW-4A:%0BNF[P,:M8W-&/(B[V72\EFBW_HL[13E&4QIGB, TX@3@S.; JB: 2 M24!HK(@DQ(4QK"5/C4#,KN-6"P*JT;B,#UH9M=UHQ!Y\.U89!-*!2:;1>09* MK4LH=WK/0,5!I>H#=&5W!LP3$=G+'967G.$XIBGW!_1CK8]J\YH5W[2X[[E4 M\M7S;X6IE/DN7S+MS&23XP!H!LL?JSJ%:L6:,\8#OM_]V-U'J,C1V[#8OWP#2G ME0KDH!C'*>:_0A*$XBI""%+,@ZC(!5)AJ*$1([L=UG8 M]%BNKLQ3@"?V7 9HEPF:0JRW:K\"!'*KP&8%6):5BW;S*],_-W==''8,@QW1 M^8%V8$)[4Z%5JPEJ/0=8'5Y'PQ,S=0@:E8&N&WS,-!9WN*=\F9"O?*F)JI6D0)BR&@5*:4$+.((V8@"DBBF,N$X2L*B)=E32UU5^M MGIZU*_WLLW6Z >VF!J\P#>X;,/FO)&W0CI2+UA] IK<@* MEHY[[1TL LC*CG=5C=T,_)^PM6R^U084VAD>*2!8HR@9V2D>KW'*SEHBY,GUNB9M5/_+TO1C)\SVMO[),U_K0/Q?V:;N>OQ9/54E MM K3\RK7R\HGMGB__*B%?OU3+;ZK7U?+S;=B+A"7*$82$DDBB$4:0Z*"!"(L M8QJ&L8A3JZQ[+]I,C9+TVQBY9]ST'PP[BAH-XH$)[#A_I[;E>0;^H=@:W"\] MUO;Q@IG'7)_^NHR>$G0S;.[=8_?E1VZ__^G[Y7?MU9L=M M*<_LOIU)>:%$H#2E(61IHB#&2D'.,84Q)U$@949CYM8FX$:%ID:97[9/3XLR MJ)DM@-RIZWA20+O)#7*UW-O*.9\TL%JGJ PPR%%, RB%&*N/5**-,/&,F88 M$T5HX,2KY\5,C2WU&,#R6RU,?'?=Q$^T%.Y1Z_@46SLRO!VQ@2GN:GW@AOB\ M5X;LAL9G^=U3(>,7QKUHZ-F2M9>O]LD/K7&^U."N+G3[B[YP4[Q?ZL5VOI)' M96_+7[YA&_6.Y>O?V6*KYBP6B"@<0Q5FW#2FE]JABS/(@X0+%=)$VC6F?R'] MI\9HM14S\%#: ?*EJ=RN+9F!/X^KO9>7@+(+2J;M =^-0?Z*OH_X$MW"L)-X M-4:D[DM-4#M[H#;%W_6+]O-BKVB,/Y#RF=I.%'Z0&YO4*I):6E1,^2!I( M)Q8^TT#."QH_#:33X+-I(-UWW)(Q; YFWVDUJ]H$OZK-MY6L=@[*+=MYF$11 M2$("&4)Z^9X2[4 C[46'IMHDXQ+SV"D%Q$KJU"BCI'3CF"S5!BS,4?8J Z9& M_JI70N\US+,$DYA)#A.1Q1 G408)BB-(<4Q"A2@*8S1?J@<3^S4VZK1"O2W] M_QO<:4HS(H($ACQ%$,=<:\_*:Z47#V]4]=_WR](!V)>BWGL"<\4#F:E40$(B/4_$VI'G M$4^ABF421!@IP9PZ&#K(GMH,?:-3[X*Z-2L-@>7PW%1J"WYJ]/[93 ,5NJT" M^18X]V$H5\3\\92UY+'9RA62,YSE_(B>:>5UE,?7U9W0U+A6%S-#YP&B::8B MDS\@*<2!"""-4PH3'/* \P2IQ-'!M1<^/2_WDW[0-V;2D;0W)=A3;B(L6%F/ MVS&WW'X$[$C,,ZHC99?72IM4I5IM<)1Q/CM,.?>87.X,F*_LUF;]IF>K^^RS%K/K\5*MLNP(<\4^"G?ZP+RRC/RY!V,X<7H :F MBA.,_#DE5\WOH@-]YUDI MXJ!1XMWC:KW)_U4R2NVWG"3]\CA"04H11%@AB#%'D.O5(Y0B$X% E J6N843 MW*;0].(,W-.P;QP2.P=D/)@'YIS*$%A:N7WZ]O/7WYG0F@WK)[D RI$&/( MIM24FXX9@TS$$4Q%&F9*9#PCW':7O5O4U!RH4EM0J@NTOL H#&J-[;>-K\![ M?;_='V@#$UL77M<=*U?@[+?;_0$XTF[[;4 Z;;?;8=.QVW[E :-MMML9TMYK MM[RCYU:7XILO2M35-NZ^LWQA"IZ^6ZU-AZG/BBWR?REIHM;F6*(XED)"RC6W MXD00R%26:M\T2&4F4<294V==>]%3(]RRVEZQ4WT&6*,\S%9K6&CU9V!=&P > M6.Z8L.TP*):;8H- /?BIJ$;Y2POENP.4OY0H-[J7->(\;I4Y ^9KT\Q>\+C; M9\Z G&RDN3^A;[?PI>;*C7%+RR[D1DJ[G*+)7=.K:@I7A9:G-(0*1BG68#3 MF">:>1QC%&[5:6J,5.EMSKZ>&LVUYR2W0D_I/U55(HS:CH4>? R>'8>-/"0# M,]V!-65 1%.NWQ@T _O1VAD%]E;-ZM(+H#;,:\"$+Y3]!53^(#P3 MD.'MT3?V+SYLEJGGATV^W&JMZHP%K<"%=IN[$H%1B!,:1!AFL?X#XU1!@GD, M0X69%(GD441[-2^^6;6I47>KJVT3*O53;=W/,[ W$.PMG!VTPCWLG&M1:7#H ML;>C_)<9T8&9OWLP;=L?-YV-!RD;Z1]WWQV.;U?L9=H;>P/T8F]C?Q+=J_7I;;+24]9O5(\N7A5#%O+XKH%(<_+%7';Q= M;A]KOG9TTFP'Q,X#&P#F@;G$*\+.GI,C7I[<(ENIH_H\CE <.S2NMU^BK_;8 M?M!_^]__K?F)_L/4>_[?_^W_ 5!+ P04 " !MA&%6@4\?=@K5 !EA0D M% &EN;RTR,#(R,3(S,5]P&ULW+UIDYLYDB;X?7Y%;NW7]4K<1UOW MC$7JJ)%-IB235%,S^X6&PR%QBT%J2(92ZE^_#C).QL4@\<8+55N7,B(4(OQX MX'!W.-S__;]]/YW]\@V7J^EB_A]_X7]E?_D%YVF1I_//__&7OW]Z#>XO_^V_ M_I?_\N__%\#_^NW#[[^\7*2S4YRO?WFQQ+#&_,N?T_677_Z1__KYF\O?W4UO>L7Z6/YK__KC]\_IB]X&F Z7ZW#/-4%5M-_6VU^ M^/LBA?5&YH_2]FO]:]_?;$@,+P/GRNQFW^\_O$5_^,OJ^GIU]GE MS[XLL?S'7^B?TII"<+%=\?^^^K>_7BW^=8DKPLN&V=_I!^YG;<+8FBXJ;WVRA\9/Y_"S,/N#7Q7(]\5YK;BR9R* E M*,4UN&(99"]YM#ZZ@JJ)YJ^ONA<"1/\(.%B2G2#A/2ZGB_QJGE_2X3LI61>O M?0 4!ND$M1D\*W0T9F=8"@H=\TV@<&/9O; @^\?"X;(<&0POSI954J^GJQ1F M_QO#\H*'7&PTKCCRC2)Y2>@%Q"@)U>@4)O*PO'+'G67WK+P7)%2_D&@BT4Y, MQ*=EF*^F5?;G9DZCBD)K TI79%O&P)'+#=8Q';Q2R'ANXRKLK+P7*G2_J&@B MT9%1\6J^GJY_O)[.\.W9:<3E)$;/G$<#/"$AFE$X%01*<%PHF:SDH:2CT+"[ MXEXH,/VBX"@)=J']#_AY6H4P7[\-IW32):71%PG!"G)[)/WA"SE VA$'VG$2 M1FR @)NK[H4"VSL*CI!D%TAX,T^+)9FPC> _DOSQQ>)LOE[^>+'(.#$N!$/! M/$1KZF%7/)US]=@KQ;N 18=P7"B\!Q%[X<3UCI-V9Q#4@1&^0P%OG0,RCD5*-#HD; "0.Y;>+V7%>D?'L4+M M%!EBXF-13M.!R90EL3 >('HER(E"QSF=JBS*09 A]D-&Q]G,-D+M"1DOZ,MW MRT^+/^<3SEC43&1(GA.X(Q,DE,@@%\<,%ZZ8V"(\N;7P?JCH.,/90J ]86+C M-;U;OE\NODWG"2>R!)>$R1!#S!1X2P%19T\G(X8BA.;TGW; V%E]/W1TG/-L M)MJ>(/)^L5J'V?\[_;KQJ@/62V+IZ%A4!90(Y%]G)Z H$R46AI;I=@"YL?9^ M\.@X_]E(K&/GQ2L/2PP;NGUF0DDK(1M&H.8LU&L>XD!FH8Q!SOAQKN?UU?8# M0,>ISH-%-[+*:QG%[/V7Q?PB.2>-"3FX6(T7J\FY#,YI!Q*]U@HC8CK.K]Q= M<3_5=YS?/$J$(ZO_(Z:S)4&7B_AINI[AA#X_QZP405=Q$D+2Y %+ ]GG[,D7 M#MD?=P.VN^)^ZN\XL7F4"$=6_Z=EJ(5J'W^6VT_Q'6)YO^U??T) MD#YR-6'%"6T,F3B5)2B;,WC4"$P4'J3$:%6+3-/.LONAHOOLXS'" M[ (-YQ4_VX*.>@R2$LY6$\Y%*<9;0!L$*.,D!!D4<%NBTIB9RRU,QMVK[X>- M[G.0#43;!43>S.G32!S3;_@RK,,Y6Q,C!8\Y"Q YDG!J<5C()H!*Q2GNO,F& M-X#(W:OO!Y'N$Y$-1-L%1#;6[T58X^?%\L=$5C)E"2"5%%4F&KS3'J+QV489 MNGN/Q,1][?EHL_UU]>+$Z_AOF/ M21&$91\\$,T$9\L5.,,B!.T5-Y*I)%I<7=VY^'ZXZ#@]V4JP(^/C32K+D[,\ MI=\X6:]QM=7!ZUGX/$D\,(>&N(BA1E*E@)>:D:#HYTIP+?-Q*>O[U]X/'1UG M+QN)M0OC\?$+A=H7T':"&6T\ D_UP:MV#KR0"8I)3&"*1?CCGO;<7G,_,'2< MT3Q2C%V X/U9G$W3Z]DBK"?16XO&>F#.&E#9,PC>*I V21)-\;&TJ,>]MN1^ M$.@XH7F<$+M $'WM!8-+](_/WXAL:W>G:WK^_&:K)_(Z(63.I,K+#(HIG4M MV@@@L(1BG2F*'?>6YW$:]GO^UWU>LYF8.WGVM;JJ._ MT2__ACI.@PPA]9"2= M$$>Y#PD=9SA;"+0K M3&S?R6^98(X1Z\P!S[S>#9-DG'8,I(DR>R<=.[*^YMZE]\-%QXG.-D+MPT4E M-I9A]F:>\?O_P!\363/SL=A:(TH,&.'!&TD^$_,EJR*X+2V"U9UE]T-$]RG/ M8X39# W__NLM(?Y./SBLA]0F(?-F7A;+T\TGW:1VKU92MSZB04>IA\DZLK$4 M+3;97> 2(%ZGPF.6((42Y 022KQ' 9STH4V(*:![1" /??Y13M\V>?;[>3NR MB6)1,.,T 2]L4JH6HB\.A+5%\T)GESJN;'IGP7%:2S73U@T7\ A1CNWZ;TG? ME'\Y%8+FF0'F0+0SLFO>HH/$E-$REN#PN!*(:XN-TU9J2.T_681]:/[U='GZ M)D^$\9&'PL&J9$!YIB%89< I FY200A]7,;QQG+C-)(:4OL'B+'/(_S%8KY: MS*9YD]<(L]J]\N,7Q/7J@+/\_L]JTB9R+T*//-W/5O YA*^3SN^#4VS9ELRL% T-K MA^)R0\$XGL-@2+BP)@W$/>*13X>*%>TC N78W7\(&0.%/B(P-DX;N:OFM&9 M_PV7ZRGMH8\XGY+3O5CCZN49DE[5'[AYQ&B$RQY5K#=XCGB2!7PV])4/"J/( M(;J]0NX]U^L)*(=J=C&PF#NP.9<&F%Q,?$-?KB99>^?IH*8(C6=0T=!7*030 MF0D*WCTKZ:&,]E%^S"45X\3! QQ+1PJX XB>E1Z"#QN4M")QW*@/A?-A'LP-,B&Q453<)P_5[AD(\A4 MGSAQB$X',GW.@V>AU-R]]$'0OA&M0Z$["1D7*L?H]DZ8'"/F+M#R(JR^G,QS M_<^K_W,V_19FM63D9/TB+)<_IO//_S/,SFH3T9(=)V9L9(8$E35$33O+\\"T M\9XI^5#.[1#T[$58#V@Z"@*+H;71!<@^?EDLUY]P>?J&O+75>E.5-"E*TX;3 M#GS(M:.32N <%I!<)HT^HS0/W>(X;DU["!TMZRX0Y US@R,X0#66A.CVK&:ZKK)T.J"HPN9;1A[ M38(]*64ZF]:MM"W;FL20O,?=KC=3T\/@5V33%,SH7=A72KUZQ_G3=W(VWO][>WT M8G_-\]O%/)UOC6ARS$%82-5X*J<\!"<8V!JR&JPOE%I'>?O2UD/$UP1:@RBC M U_\#:EC_KG>"FZ%13OEU?9>T5[9Q(H(13X()' M2%&[XC&R^.#,N4, M@]=/81[3<#57 E=V*]+RCG1JK(L(+S&;>ETJ,-OD.RQ M-#P4YQ^J03X$/D^"R, !6Q.('"3,+F#PCH[D4#O'_8YAA1_J]/AWY>^K+=0G MV::LDW.0I*?H$FT&QXV$9.E+8M0ETSK.?Y"@'@*Q)H!I)_8.3JEK:8EK1ZW/ M405,#$QF548R0TC,0RJ8F8W>N=*ZV.-.0GH(O-I@YF@Q=V%QMAQ,#%%&H!;@ M%*<#LT@!7FL-3*HB?+;D]+?V6K8KCS/U<+";^R<)LH/0^_=IB-/9QDLGUWS3 M$^3+8D9"7VV=^$O1,):X,=IO?'-0WA1P.1LH468II67V3DK(?F]2 M)S2(0KJP--HH@M87=S[O0\_ZJ4?"8U^LCPC2FXQ.=&& @(LQ)>JG=N-HP!1TA8- M(69;2F"^M,XE/H&\;H!W%";NN99MK9XNL/?R##\M[KYFCBD;"AHDH!%U?I1R M$*TJ$.OUC'>6>&E]7MY/S;@GY$#(:B3\T:]AS_?#"_J[:0JS3\MIF)W?!U[P M(W+2P1@D#R+4F@7CP47!(''T@2-&4W;.Q[N?=#RZTK@IZ,9 &4"X75B=%XOY M1BC_F*Z_O#A;K1>GN+P0W8_++>#16>DM<(>!;&DF]!,K0&+D02*C,*1U'G$? MNL9-0P]DB9HKI N8W4R*W>+'11=5=+196-TV*5CPD;X*+&B9$)UK7KS],$7C MIJ\'@E9#)8Q^T+T\7_1ORS!?OS[;]!N]+ !U61OF(QC!Z<3V2I+KYVQM%B>5 M+?2UWJ>DZ($EQDU6#W"TM1+GR.]:[V+C1L73U8B4@EY[#0XK)S$E\)@\^)*2 M"(&+6X4@>T/DKO7&350_$UZ.%G0']QUW!)+.YI#K$"YI:_U3RA%"?0N: MZ^1S>6CL1)M\TKB9[8'.HR.%W4'&^T%G[=I-CN4EL^P52*EJ!Y/*EB4[*GQT MC"MAL'G=V9ZD=1/-#Y>@'$))73C5USH+U-8%DTQ^OS>T \GHUN&S:,%Q,KA) M:Y]H7UDI6Y>C[9#03<@_*)H.%GH'!]P],<"U;1!\00R"@XW6U[FUFB* 2#Y? MKB/+31$VM'[T^"A1W43ZP^&JK6*ZL$\73F+M[G^*G\+W:X*LA<&6,>292=#2 M"U#.>(C**L#DDLD%D]"M'_P_0E(W8?]P.&NIE"Y0MJF=N<[$U8X1WKL2/2/B M/>T8PSBXQ#24$LF3C$6&T+J%X/W4=),S&-"&M5%%!\?D-28F.B2C(\M@F"#2 M-<4Y@>D R3%A-3)F3>O>-=>6[R9U\"P5!$\2=AD! & M9"'4!WA6DH0$0XA:*/ H)%?9,-G<'!U9+M=\T-VSHJJ1*KKPE=Y?K+QA:MNJ M)YA<#V $=(QV1I()8N$*BLY1.($DN-9W;W>0,79_MC8ZOOW*_RAQ=V"(KLWW MV](O TNY< $!=6U0Z2@ 19; IZBE*465V/K=R"X-8]?H#H*5HP3=A7$YR7G3 MMSO,WHG9YN2O)=8IFFZGGAF"?;%0M9U+ M'()2=2*Q8L%G@8(_-"'K$"@]3M6XR;CY6V M/%XOS7#V//.KWF_4\ 77M1#^)@_'#;.Z^<%#3K9Z@(7G''.%1M062 5,?>FM MLE7@F$I@6::_2I&C:9TE?HXQ5S=3'R3K=\O-LGD3W+['Y<M,$3%#.O=SJ Y%T"""=4$JYEAS?_YABL9.9#TKR(Y21Z?@ M>K-:G1$G6 PW/M:G$H:#4H$.>E4"&.LT!<)9^MTI28, :TO-V$FN$4!U@!HZ M!=2[L_5J'3;E]).2F Z2V$F:4UPK? 8?M 531''9I\*:-S)XA*2Q,UTC0.M0 MA72 KVLW"O<>\,5Y6U@RD.L=E-(I4?QC!&0=LPC9&25:M\[=@ZRQTUH#XZRU M8OK"VJUSGK9%+B@D%.83L5(3Y SMA)KN?#UE&*Z!%3 MY\>\QB)MG2VD+",VO% 0T3L@GU$[9Z/WS6/&>T@9MS;O^;%T@ )ZQ-'U,YV) MJ+&&M!AY !5E@9!$ 6ZB2]E*%TSKUWT/T3-NE=[S(^I0532#U6#ITDM9KA;E M_&T'_>V1J=)[/K1QFG0?TANE2+?7>9<+7HU\=SH;4Y^Y1%^KI&J;5!T\9)XI MI&.1L-+:QM]#2K-9N=NIL#+S$#CSP#0=Q$H)"T$GA&13RCPF)7GK-WHW*1@W ML=E"W_<.RWVZA#LXG>Z83H[,6>7KN&GF'*B@Z&AE D&;F)(W3O/2NF#J-A6= M), /T.F#\]J?+.#N(')]+KG5B#:2#Q9K!8Z.%N+F&3ZWV7C-\-J(Z4& \CMFLSKK5Q$$F_\I'&8!;QITK ML;!L'W%([O_TGD!PJ-86344X,@A.S%\UN\;&1YQ/%\NWBS6N7IXA:56=\R2- M*"XF#Y@+R0F3K'TW&&A-_KPM622^3S^CT4D5"G6*(UK>]0;U/1R;WI\;[)D0+N "(?\!O.S_"J[7TV MT1@D3%NOD,Y=2Q OB;Y5+EHO>="L=8"S2T,GKNN!.KU5B'V$@+LH=SWGH+8' MNZL5S^7 I3KT@/X_UYI>RZU2)L@Z^8"\MXR&)!8]"+19"(W<\M9WGP>0.2[0 MCD/&W3 ;3$D=F*K+#BN7 U(OJT U4R5@(A?.U,Y/IG8=XPJX0A>BC):BA\9H MNY>83LZV-L:KC<@[L6(K)!*^G,SS2]HKL\5FON4Y7Q/,DM%I3_+QR=1H4T&( M-?@L&6,LSO/4_F'2 P2-:YD:J?V6B6JE@2X ]3>*] MX$1K@(RI=NV5$9PM"-S[F(2)Y!6T3B??(F+)6DN#)&SB&%%**665O6NB;G'E+&=:,;J_SV M[.NCI=\5C"YC2_F]_^N]H755KF M Q<6?'W'2RF_GE2(U<&V&$^8^)M3R*@ HH^B3&/&V^H'($'EA(!;U1 M9:<%U]UW^$]9=%Q?:AAH#2OY+L[&;2>"CYC.EIM&!:^_O9W^?;[$,*LO BYV MT,0E*U5 "[IL9E7S0F>^Y<"L]XG98K5KW=1M/\K&?0DTL$5KKYL>;EEJRYY[ M!3<1'K4M4D()JH"RO+YK4@IT$"IDH9V)S?,+#U(T[GN@81'64!==6+.7F"[+ MU$E!=8N\6]9-V?R&9;'$R]D< MN/J#G%1R#WYQ!^X_K+(U[S7B7?92!8='!Q<-^3 EM(K,N \5@ 51P'(+Q"+3]8_1> MAO:-?=JA=/BWYD.@M(4J.K#([Y>+,EV?7\F9('0ND!5GH)SF)"7FP0D77!04 M3N/9NE9Y?UK464:U,'(QFVV< MG:W=G2C-&;?107&N^C=&$H.N@&2);"L96B5:3^-X,I&=/"IO= \ZJ(J.O:%H MC\*)99;K;!$DUNJVC+7--I?UN8$S3EB99>MYC#<(&'?$RY#H>9)H.[!.%[W8 M+YH$7059AF?/N=M,4Z-#-U$$5-T[&ZR7C 7%5.ONT??1,G+CW\9P:2+Q+E)G MNYS\%E;3-&$Q&\.9@^ HB%92(_BB!93(G9"E",Y:/R"^DY!QZRS::/D1Z#Q= MX!VXQ[M,O)S.SM:U U"62O*L( :&H(2N=Q+, K(HA/1%2-8ZT7H/*>.66CP+ M<@X1>AU9?0/[KMSJ_+/9&E?]A63"7.H#IN)(=,E+ M".@CF,29]^BR9JWCL(,(W<]F_2S/#(?750?F[$E,3L@F6ZU* 2SUL;8G25+0 M*B&J:$N2VG+;.K1[$H'C'IK/ )AC(/HD[?5L+<^M_^UV:5IXC!X14#I.#&IB M4.D .8F4**JIV97G@>=])(Y[-G<#T"8:_+D:WMT8V;1)(MQ@XZB^=[<_>\#V M=X\PTGY0R#8[L1E??&OJU25(931>.8*F5I:!BLINAQEK)8U)3I%'V'IDZQ-) M;)B7ET8%RVNE712.MJ6GKT)B('VT05J-AK5O@_ZDO/QSC %ICHL'DO9/D7@' M7MT^0^(HEIK6BZJTQ+#"E[C][Z7@4F!)&.E!A]K9O4CRH6VNXP.DDSH4GD7K M^L?CJ>ZD4\ S8/.9-=PYIE\OEN1HS%^<$5WS]./3,LQ7Q&+5^SQOOIMM49#_ MO[/MM>SEJ$0NG,^&:7 D;8H0Z8^ Q4 QNFBFV9D, ++L$G$P,J[1VVOFULS$(G[06>P7,:4_<=W)@_P/Y> M[$;'3)#*UZV=0*FDZ\6=@*(0!;,D^=CZGNM(DCOI>3 NM)OKMHNRH <8GAB? MLRRZ=KNN0SE\$1 XMZ"C4HXGSLH0,Y;N(Z>3ZNQQ0?@DG?0__OEZ5O2.>=_M M\KOW#1,?)L'[&"OM,[P/3"/GBF*P*"7YE*I6A[ (D7$&1O&4=?%,V=9IJ+T( M:SP#Q07$(G6!9*PEIUXI<&@])(6JU )Q45I7-/8T Z4]%AZ9B/(4>7<0KUQ2 MOY5(-;&+>=VMF[D.(91$ F#UEDR!,H)#",0,=Y@D:J5R\VO/!PGJ!$L':/H^ MT!PM]@XPM,/#>7]_GX/C=":#8H;V5! ,H@X&/'(KZ*1WR8O&V+F3D$XP<[RB M[^QH<(S4.X#.^QM3@,\'-RCI',6Y 5(0"(KG"#XS!)Z-CN32$&>MY^3>125+51'-K^_(@0>-F2-O#IYWT.X#2!UR3/#!?%(J?<^%G9K"9 [KL9NV#,"^-B M]?[F[AQ4XL#&*9!M-(!W.[.NE\87):C2#J M"_59N*IQJLL(C!OI4W0<9>OQO@_1,VZ?AO:@:B;[#G!TQVA/I6TRWD@P6#V_ M0%)Q=>*11G32H&8L#3OV=.^\SW/-H#LF[W.D@+N#R+5YCKH$9Z20@**V3@R, M_+HZ7SI[)57@)5K9.A#[:>;C/DG'^\['?8K ?Y;1J,PG3J:8XDR4'%3VD@RQ ME<"LX$I1[&G+3CG8\*-1GW^&[I,T>\AHU*>(>6SHG'T^6ZT%X_Z^"<&ZE%@; MYUM%08&2(0/)R@%R)T+)09K=!-#=D'EDG4ZGZ!X,E99B'1$BJ^5Z\F+KU-=! M4J5@6F\K"-^5D[SXNE%0-<%<*A)%CA"SC*"B$.!L8@1Y;85!GJW;ZQZ4%KQV M--%W5\?2OK1T4A%WN#_)HJMD$T3# QC-;"3K M*YC>*RMTK+7:H:M?P!V"B:=8LV,4U$'4=D<#"RZL0F$TY-K%0D5+NY,\"0C1 M9B<B*)G51^'(B(VQUA!U-/!^C;-FQXLUJ= MU>9+S"O+G08=E*'PU"4(/BC07&?%52X4B;0V3=?6'QSX[2MIKJX72^FZO-'+ ,]%*X,R M:=>ZXGM^JF [@.H=E^<;S9G(\SRUB]*8X,;)1T8K"D M((C,:MED4(EQ9IL_ISB*X''+?#I \0!Z[1?$VRU[T7M[.\,5YZN-OB<1E4!' MD21SNM3,;( H#$DXH67,Q)!+ZUK9 \@<=RI,!X!MIL-^8;K9D_=PR%0.)MD" M.29+1TJQX)/(H&M%1#329N&>T< > =+!ILMT -)6&NP HU=W2JM/BWO>3&PX MC;N;3]E(:4+>?41>"S=D?=5<; )7O 5K M79 FQ11Y:[L[-$_CSL=Y3OQWA8X.=LO=Z;P+C=0I>1_/XFJ:IV'YXSP]2,8C MS!.2&J)QBE.\&R79!47!@K-2D\>EI10FE-A^;-C!U(X\T^>$&\,-5HPK$10F8XQ"@MT;4MA=1]?Z=O7)1(X\E&-\J+92X+$= MKSX-,:*3)69,*1X2&DW>5$Y ;A6#+(*1SH7"FX^&>6HK\'^)>ZT#1=[%&(W= MRLV:,43!I5?.J@%&;$_-_B4NP M+N#0A7D>J'>Y2LI$FPV4* U%CK6NFV, 6207ON3B9>M,V9B-[?\EKMHZ@$(7 M6^)&Q9OQ+)F@)5#H2 (UV8%3L8 4F6>'(;#2O 7DD^L,_S7NR X5^Y$E6*_F M;5R,1L5G1CEA.?=09+3D7VV"PLU7)A5K8@BF>6'K\Y49\G^=V['G5753D#_/ MS+FP^O)ZMOBSZ:RYR\\<%-IWG@ENDO YMR^SZK+/\'&: M?Z2]\%/$W$'B^XY>&,[;V@(N$LF&;#/W=;Z%Y,"09<95\$6VOHTYL*',1:ZT-$G,>8TP@.=.@'*/S.VKZ(Q,+7F;I=6N+\M,TE'F2 MCO=M*/,4@??>%:0.R.%:%HB&MI,J=6Q4;>O%<[8Q:J/MKJ<]7%>0YV\@\R1- M/J4KR%/$.C9$]FV&8[F@_RL,C"FZ-O]W$+U#"D>U0G+6==9\'ZBT[#GT_(UD M#H;,$&+NX%BZX_FNC)$'SS)XG6L@%SP$1B(RA:<4M9,FM:\0/.C%_'.UPCO& MS$.3X0%[N5&\,JJ8ND]K42 BYS MTI:LK(B%=B0+&8)A 4*VPOM@+*K6=4.]#' ?6M/WUVT\1>@=V*T;I:6U+G2> MIK,Z2NWJ2NC3XJFB#,F7%+,$B9L^NAA)!IS^T%$JKS4ZVQIX0_ Q[O'ZS! > M'0A=6,^72&NGZ;9L+V4,PGH$JXAP%4BFCD=.?(C LDV1Z]:S(:ZO/ZX%'1\/ MMU(5!ZJF"V"=G-;[HO_<4%_'8Z[#_',-D4Y6*URO)E9*FSD=&+S47F7&!/ N MTOFA-*,0*1EN6^>W'J9H7-O7'?@:JJ\+.%[*Z?=ZA?IA^OG+^ETA$6[XN<[L MJ^_U+0E.DC>&HZ$-%T.JT\D2Q&CJHZJ(0@M.>ZYUL/)4&L=M+-(=9 =5<0>> MZ^TZ@)>XG'[;-&[\?1KB=+9]5!V"=:6P6CY=[_^=,>!],5"*\<))09)MC=P] M21NW%TEW@!U"H1W@])X'JJB48I$;L*8V#2U)@]/6@1!750?79CW&*/"XHEN:24)Q0:(& J9]\Q##L;&W89@ M=UYMW/WIXW;XZ 9$C<3?@=5Z,_^&6Y%N9?CVIL_PKKR?W2SR= MGIU.-(N!RZA 9U\G2= >"8&",HM"A% DIZW3_*1],IGC]O;H!JK/I>A^WC-> M>^(19OBN;,K@K]A?3514TM8G3B9: TH6"='G#-+2SC5<9&U;%^4]1M.X/3ZZ M VM3%8Z/S'IG9>+4@B1G)XXPS_,5U_V=;)UUY1EQ-XZ_.\;1WR^2NE M'Q,,J*)W#K#ZP$I*K.>* 2E-9-P$EI/:XU@_DHQQ>W%T@]/G5NCX$+[*SMYX M\EXWZKME%3P=)G1X3&P6NF2;0,5$[H]5&9R2'))&VIJ(QF??V+8^0M+(S36Z MP>P0&ASU*7#=A%<'Q0?:BF%UMCS?D=O-]@>NORSRU<$Q\0*=R$% 2'1:J#JC MQK&406@1Z1!)5L1]9LT]<=F1FV9T \&A-=:/F=QU8$BR),OUC_>S,%]73K]N MF',560>T- @J3@BACK90S/F*QR>\>ZLT]T;LI&[D71S>('5"?H]O.%U_" M_#.^V;8&JY==E^[UF_E)*=/9M"Y3LV-A_F.2"EK!O2;6:BFGJ^.2$T=P6DE6 M8L9;\SGNM)Q/6G3D1AW=H'!8;771S^-J@[VVN5,AK%LYHU%R)UK4:>Y(V-;L ZI$:[@>JJ+;38A? O)%@ M(#F]_O9V>M4 YV(_3I(4,:CH08GZCHRI0+ZUUH"8G>2)\]A\".!^E(W<&Z,[ MB Z@SWXBI/L;T%PP]AL6^IW:<2;PP(TET15;)S_XF,!A2)"S-@)3",6V3BH] M@;R1^V1T!]NA--L/=F]7L%S*\KQ+\U4; &49J]X-LX%V:! !HDD!,)2[ID+WP=26A=EGK=Y.TF;R]S5U+22.@7? MA?U_'WY4XT^[BWZR/*/UKI5 <^&"$#Y5#SS3B1 MD(M,\@PA!:V#B/E:,7]-O3%&:?EM,PNRAV]9[<<2<]:,4Y[4-' MAP!C!3@FF0UGRJB=1.>=ET)/6K2W49E-H3:L"KJH-]YE[D5MI$GRJI53+\Y6 MZ\4I+B^VSX^)T5FX(NOH;E8?@3 $+S79?)FB\SXRSH:/GQ\DL;>AE\]D^MJI MK4.;]^";NLW/+EE]B^M)BJ).2G3@-X%;C(4L? CD$(LBDF!%[O:4WM,,/HV. MWJ99/H-E'%!1([_NV>5U.K^(Q_ZV#//UZ[-Y[4Z\3;*N)\8$Q:W1X)D6H*R3 MX#E])1F+%G5*11]R$#^X:&]S*0>'6SL5='D0WXRT;K[$=-P7LN%"U9)023&7 M*][77NZ1HS=*EM;W+T\@K[?YD*,$QH>JJP,D[G\/,!%9H.%& $]U6%8.M<>[ M9(#>\L*<0=L\.;,_=>/&P,]\FS*0T@Z'XX)VVI!PW!;)+B'FU&"-MQ@>9#.,F-% M\V*;_:GKLMCFV0QB&Z5U:A7O*M2<:%:8-P8A^UI"5^B/H)B#$HJ)BFEFV != M>?>@K,LXY?FLXM'*ZB!DKA)\.:T2PWS7('(9D@U(KC7F5"^%% <7+ .&$;GE MVHCF,^<>(6G<6[MG!EU+]?13]7K+II_DO'G4$V8739#>S#^>Q=4T3\-R<_.M MIA)*>9:HW1_:D;]T;OF<$YD-+Z32F^GL[#/-V3FW7% M,Q\,Y(U7' HY)#%Y8"Q)\D>XP=#Z!'\ZE>.&-,^34FREI#YBZ6O>IQ&:X>"!@.5Y%H]?6 M7+!3Y;HA_]W7C;\QS_\(RWJ+_NH[+M-T149=^X!9J%(/"T&;MW8;C!B@7JR3 MGYR$S?LT+MU_Q2[3@ZUQ-: 2N@%7W2L7KNWKQ?(:BZL+SC(Q>_'UNW+.]HIT M\*Y\"M]K$5L=_TUB)Q%P6Z)+2(YNH>@LYMH[0YO-G$WZ*T6<[E/--0AQ7281 MAX3L>*KM(,US70A_D%1JW\!-<\'S4?43%,5I# ZDE1H4?0?.&/*^T2J/)1G% M6L]5?HRF+K.+SW%8'ZV@S@"W&>=Y_K!ADC.72BH%PCI7?0X!SM$!P9''P+GV M7K8>@WD?+5UF$I\#8 >-R\"&X"-<8_O MQBF=L=7<@>$]BMGWN)S69JR[I<=I=E;]Z>MBW8IZHIV1SG(!PGFR S$HB$$[ M" (C-\ZB$ZTKQ9^7PW&]C\;[HV-P='!('& 5N8C2TD4B*(*NW /T11R M$[43TDL;F&U=.3<\6@>[&.T*K4]1W9%H?35O4T%767@]6_SY=C%/FQ%:%S>\ M\WQ'<%$'$\T6M5'\950C?)!<&0%^,V2+4_0;'!TL1GB&(J&)J?4[H&-I'O>U MY "(?38%=N%%;U[R;7HNY.F:.%F1HU,??N;?SM9O%^O_C>OW89HG045+P6Z& M;&*I X(31.TCE)1#MAI3S*T;MNQ+V[BWJ,^+F%MP'4!]'<#RHF:KTEZ?MZ,, MG$4AP4E11PJ1@QU(+B"S$-$)R^/NS56#=[HW2!CW2G54D!VCC)%[#5S,%CAO M_';>6F9UT?'M_(7[MO?6Z^EWS.=MN"AJLTR3CYQ#L;6.%2$FY<#GH'4)DGA^ MRDR()RX_[EWH*%A[+F4UP^.__WI+.>2!_'/S5YN_J?_J Y9?ZG___N'-C<\G M;K]-%W]-B]/MA[^X+*+&?.G0K!9EY_OU'A%US7=DDWF5I-3[_. M\!%4'KK2KU>,[;)\ON M# [")'Y?TTF'^2]'CK2^6/_='G8B[!C3]?SYFZTCVFY>0[+O/K[UZJ75U6ZJSK" MXO?I:CV1KN@82@+-?!V8IBW$(CE(Y@3I@&'0K?OI[TG:N"Y?>_3L'KE#:*A/ MT_?I"U[,1'JZ-;OVCQL8J/M(:61SWBT_A_GY4.(7UU_-;.<27Y+\KIP?LV%V M92:O^M?[[!QIFX);3LZ7EA3<9JO *JELUL8HT_I5?!/"C[YG#S6Z>5?.^W 0 M&1-AE3>"_% F:@.VXAQYI*J 4;3-LM':B]9MOV]3,:XE>GY,W;I*/TXO?1JE MCV>GIV'Y@WR3Z>?YM) ;0G[GI4E^3U).M63BZ09KSP]N8,P.8:&1H;N]S%5H M4%R.)GO@LKX/-"S0>>43%*R#V#&%$EN7]=U/S;$FZ4')?B)A_C:K5>V*6^:4 M9^7"@W*YP J%@%!.D\0Y>B"2E[9UJ_8]B3M6*OVR#)76R@+$ZWB#$K( M6!_0.@BH2"(H=$0=:^^?YQ5!)Y9M" SMFKE!M-2GH7NQF!%,%]4 ?,.3STO< M>J\');_N_J0FR:T]B.PJD-0F.H/,012Z3B>M/;N\8N"5B\B99L*W?A[>12!Y M4U/U2RKS<,#=Z)6R6C.:8?6.<->,P:V&("FY]GZ9L\SA^ER,SG[#PR5Y4-MXY,^OD5\>C [C:SH MM77K4-SSSEW7^R==@M3%&#P+";3R%^!QTD VJ%A)649L70"_/W7'7[5?F[=^ MOM8?8?E/7-?G.+=6)8<DB"P*VM"VCG"-6&C+J02B M)/1,22^;-WH8BI>Q)_D-@M3;U_P= *&+9A*71NB*FVNI V/(<8ZB0(FJ7F^+ M"(Y%^D,+Z4*(4>K6CM.#!(T]R^]9P-E.)7V>[N=[Z;XEIY+'?VVGWZN(@>"NQ>XT]72(COA,J 3&91G!B)+"GQ"8QA+"57K2.4I M](WK1[?%SQT-#8;14Y^6YV^+1?YS.B-F\QOZL/GG6I-TL"5ZZ-,:6*:]B6UD MJ2[6.[F]WIWULDAG&*%.9DW'4-$*G%(%0@[H4DA2RM9^P),(/-:"[;78U=Y( M99/VXZ#1U&%2J0[OJ6]X>$#T@B)&UMJ&/8W"<:W8<-C:M6@#ZJUAF-^Z$)M6 M6%=&:S1[6('UC4]H4SA]/U&-+%;]X#O@PS!F+F7MPU@]9"5KVKP4L"X7&;FS MUK>NU[F;DF-MT,U/O58'@CEZ1R$ -R6 D@[!::GIQ"])9"UCB:T?%MU#RKA6 MI8'^=\U'"Y'WZ?O<+OH^Y,+E]H>TN%9YA+1F[R=VEZD]O"YA@YMNK:18D84% MA1&A#@8 0:$[!L>4Y*T]FH4_T_EGG!]8DOS0IS5Q M7O8DMI%EVHS&OI8Z3%GGB HP;UI*5_\W:#I[E/"%YQ"8:6V);E)P?+G*I?Q. M=N1W)[Y9UBP@ QV3 %7O1+PT HQWDK84*I];\_LT"L>U04>@XW;UR6"*Z=/K M>3.G+_%3^'Z0F;G^KQN8E7N):58=]^]+4\)>>,T=$(*?!Z7%IBU0H.L7 6,6>)O'5"_2%Z MQJ[#:(.).R:@M]% GW;C1#'^SYH5/\!J7/W;!C;C'D(:68SZ=!3GJXL2R ^X MGBYWRA&O*B&44,HS.@(*RZ"LI*]<[:5AE=8F"&=CZX?53R#OZ!NK^D)YL\KF M\O7]@C[VG<&,3NNZ41F('6N/<5= .>#H]-9*UM;.J7#T[Q#(40 *0RO<7T$5Z>$6W2NT/\4*MEX4Q]"Y_'/ MINY6Q%V[0WHE)*(!C3S5GN("(AH)3H><6&2986NOZ@GDC?UX:F",W7Y)-8SB M>LT>_8W,]F+UB,.N;*_\W-:7-8_3F C>U8[7-7']EVA(]^D;'/KINBM>1AY!%\[!-XJ?!Q3V7WZ='7^+_Z? M,_J@5]\.?2:U^Q%-6G4\1%:K&[N=1:Y>X,DL)#,((2"YZK(0QA2S4)23"IWB M);9ND'T?+4??TNU\[A5VF0N\&*: ,Y>V&RFB5Y"+3CJF(()M?BMW'S$CW\*U MP,&M^[@5!W?Z!D#98.26B0.('*C 5QM_';5 FXB>"Y)H %T MK'8N14FLR #9*"E;.Q$V[AR[@=#57B4=X.Q\LMGN M6,F=D]KYG(KG$2Q+]:2NEU8H-)@8L_31132M^R?N1=BX$^B&LF+-5=(!SJYZ MK]QB)!C.19'$" 4:*CDRS"$JD#[+8)-!;H;KO70(G@:;#S<0GMJ(O@,,U>Y- M>%'@.!THG-&H3&Z=B#^$SOV0^+/EY0?76 >H?*"IPBYGTA<1 MLBB@0R!1UF&V41&3FPRUVLD;2I M16)"!5#<&/"JMGE(D0<;ZYBZ]D7.3Z%P/[3];+G^ ;74 0;O:_F^>Y4_$3XY M"H<4%%5GP)?(@8)O#=X5Q[1R7*;6C6OVI6T_W/U\UP0#:&;DZ=%_(R[6YQMJ M=^,$A<6P4J#H'$'1)H+@ZBP7-%X:8U+P.]G;._O//K#$?CCY61+^+>79@2%Z MO5CB]/-\VU@VW7@X0K[CYMO9=ASBK2BZ>&4Q>" +FVHC "2Y.05TWLNDN786 M6UNF@XG=#X(_VUW \^BN Y#>*$CZGV$YK>G#BT<&KTBPZ_/RD4F(+**W"E1B M'I2J52,A9[ 4W$CKDA"A_7&Y)W'[@?!GNT 81C<=@&[;?^D/7']9Y&O# 7\!?7(;HF)-2PH"(DC9*-!PB[0Y F16Y#RP6UOHAVAYD M[5?E^K/=%[361P<0>Q66N@ 5K_C:H6X[3EV*_$B2BXATC%NE*BG>H(@ MLX22&4.DJ#C+UA[7 ^3L!Z>?+9O?2OX=0.EZQY?SC@4O%JO;MQ)6RI3(O(+= MS%B2*8-3I?:W-%%+CL;EUH4:>Y*V'\1^MN3^$'KI &YO\<]K ELNYO1EPFM. MY"Y_.13I2I3@&*^5P 7)I^016$S6<<-9X:VK-IY*XWX _-GR_8-JZF=^D?NI M!M3#O<<]__AG>XU[%SO#O\5-129NE(&2+"$SL ).^P+,.ZL4-UJGUMMZN+>X M'],7S&!CU#4,\+Z%Z:P*_/5B^3', MKOG]]=2AV:4RVSQ!(Q+]/0R0^*]/G!B:_HR.&!+&DX&+3W&J'?1%4 M2#D(<%[1T>9)$-XH!XESI;V/WI36U^--&1@W<'MVD#^WROOT&U[@^< 6P\Z>0/*19W^MI[UON:N>GB9IY-8!UXR32ZLM M!?-6 /<,F5-26ET>$=H^ZQQ38WV%^O=+_!JF^;R09'7Q 'I;IKG>;H4=D"M3 M%"N1\"V\(/X, Q^2!1E2DJ6.VV)J#_Z.H6&<\[>Y]J^7:3^;2CJXZ+SF69P_ MM'\??E2.B%?ZR?(,K]O>'5ZMDDXFXC!AS$"<)XA&<)!%ZD2<\R":=Q4^@MYQ M3M'!H/KL*NSSF'P]_7[Q-/K@D_'V9S0X#!\AK%'L>V_W@JOA((EGI4,!P64! M5=VQF!4'QK5.FR'6LG63RD>)&JR;QK5&D$RXA 1EXC$2VX:0C46!48:\/R># MQ]:Q[.-4C1NMML7*WGTT#M-)G];FXH%\N/U _F#K\_AGMI@J\S3"&UFG!_H) MW#&J30.F^U+1)*1 ?*)0?14F14G*^S%[6R M:J@8H07]XV;>GA_8SZ[S/H_Y%XLY[:AU9;VF/ ]/N=WY.2TR;8\3V.@(KQ]_ M!]B*XB$$3*"S#*!J]XQ@48 J**S/9-5,:_?Z;DH:/!*^)\ VXD_JZR:7^$]?G=R+:!VR=< MGM[!7Q&93*(6(&SU""*/X)F+$*1Q626II-"#>7?[T3CN"3@ X@954I_'V:8& M\LMB1KI:;>_N#B\TN>^C6I23[$5FJX& MQ9[NUA?0YBPQB%',,;[VH4%P9E M@$,FI#0Z1MN\V/=!BAH60]=U?OOQ8A96UPJME+! )?#@H'AM M54I9<]9\ELW#)(T\*+ =/AXH63Y:%5U%C-=KL*^_#-S\='5RMOZR6$[_$_/? M:?\NKQ5FUY3AZKR1R[9G"25I/OUVK5Y@G,/^\))Z[DN4#L\@0M2^'G-9J\1]<;O5.8/C^8DLC#LM;41P#ZGJ M/D,HXOYT>EGA7A]23.DXFA_UTOKQSVR2*7P2X8VBJVW3D6M8=#P:&R#QVNHY ML$0>K7^JFQ2T:67S[BO6!V;SSYL/OZBJ^7&>1]@%/7(>@B>\ M5]I &4:@1V$@E<(*M]'+V#JB.H#,<:.L(W!R=[>;X534IUVZ[*Y^A!VZ_1D- M[,XCA#5[^G.^RAU)0D$'778H@1M5&T>: E'0 9@\G8416>"J_5N?>\EI63Q0 M%_D-RV*)5PO2?U;K:3J9Y_/^KKM0ISC)<&4 K:)XR<UF1[^D4ZMI7C-OA MBC4/(GGLISUMD/50"<'0>NPJ:'A5"E;O\(K7#V&-#SY;P;YG>X50F[TRP M&61 !;3U/#@L!H(M(27E:R@VF/U\*K7CCKD?WH0.JKT^H^B_$8^+U:;-L[:0_3-% $QRN\*YU(6WK##:*BG?!(9C:*8>[%*TN MR;C6M2&/T31NK-P0(7N.F?H]OK_0_SZIDQR=8* M:ZTC!Y/7(2C!093D-'#&+87H3A<^7&7-P[1UVYGU*4BYW]%JJ)@>W'_2S*;5 MUZ::[;RV[>3[=#7AR4O.7+U6J1.<4 MPG+[UQBE;2(0F-"\MO(^8D8L*!]'] M+L":**(#1%VG_^7B-$SGDY1C1,$#T#:+H"PCXEU B)H"8V5]T#+XO3TO.SJ#SR-N)PX+6S1M7!6\UI?Y13X6A#CO57!1R=Q M@"&X.T2,BY5CM7I[VL<1(NX (Q_/XFJ:I^2*UN9YU_=.H! BV2S !BY!A2+! MY>PAD:AD8754>?,,U'W$C%P6_"QG5!-%]("H*_+?AE/Z\MHXU?,=ET/B4DN_ MW1[*X69U\7N+FL+^P MMTG49]ZTTPHB*#KP(5"L >AXYES&X,1.L';WYH'DL- M[;/.R,?2< !I*N 1P;):KB>;5S(;2ZJ23**V)#ADS$O=Z:[X.',4^4(Y2UJ^X#)#>RPO^8SJ>G9Z?GA$>))A?)P?-:?87* M06#U9I@%B\[GS*1KH/(;BXZL]$-4MF@AO[$5'[Y?(UQG&7W19-5DHI,P9(K( M8_)04)%Y"XJ9LE=._S'%7U]T'/>@F>(/EE\'0>B]1][OTSEN.LU.9)&.6,_ MR.35^K8"-44#/!!?(18M\-FZ@%Y2-?+[N>=(=#1630=@>XOK;0U2+6J;,"]I MK]19026Y^@R[]KOF-9V8E>11DHA:]VR\04"G'54/U.ZMX;:'BOKI./%;G,SQ M2(75E_J_ M*JIO858KP^H4N3J6[-/-L603F7W6/@4(AK-M,;7S7$.QEC97,U<&&;U:KLSK=X5VY=DLZ84'8E V%C+%F#LF!!.^R M YN]B"%PQ7CK!G^/$C5N_?K 8&NKD@XP]O:L1J3OKMZ2?,3/V\V"+@NF;9T7 MDC>A+KD%SDFPB6O-G=:LM"YON)>8O3!E?E),M5%!!U@ZF,TQ3[D>EI) M[!K+6Q^D^]"U%];\3XJUYHKI&FRKM[B>T+Z1T3($J>JL-69]%1<'Z[0C_R$$ MYIX/9I6B_7*G[%\.84_61@?8NM77H [(W>KJPE.8"&-]5,: =+Q.>28K[0,S M@-RBTS$H7MK/9'B4K/U0]K.FZ%OKY6=^HGA"W^7I[*P^X;L:#KVY0QOZT>(> M2S_;,\:GBF'XAXV)R1 B#Z#E=@25@%@< U,X4[*DI%GK)]K/\;#Q;D&_^IYF M9R3.F@&J/4O/MGI^5RX2W^]QN>EJNKWD>TU DN]*7+SS)C7@OX!D$ MZATUV0$RWY*_N_B)>&LWP%7!8109C==UC( F1B2#4!C](WF!C'B*KG7H]B0Q M/6)Q5YW?GR;31 &3UMAL.IIP^6.6+L;R/S:*_ZIM)7/%74U,(:/[Q&GBCJ< MR*((QF!*O+P0?0W_VK3%6*.@9B11=V"('N/DT^<_KLZ",=R;^NR*&(#X*A = M,6-D]C9Y&5-IW;#Z+$'3EF6-:I#:*:(#5-W:Y?GQBH3;PP(4C\P6$4#P5'M[ MU:;[T@.74BL1T=KF]3;$W KMDB,O@8O 68@YT M6+!XV/QK$5A,]"A8;/V0\P))TQ9:'0I=>RNC"W15+M[/R1B?U]S )G)QG"NM M@@2C3&TGIA-"L4H":8Q-FFLTLO4U^)"*7F:!3/[ L:>".K@>[W)PZR *4[3/ MWH#+0EZ.[;4F@F%DHJ,F@=T?ZM 8:+V\0^RKXVS//U-4VJ+[&VPZ>Z:;B.T0VAEA%: M9W/.2GD<,D[FY2]-OT6^*5P:B[:#RVG/^_VFF(*3=7:H&20O,BA??< 0.91B M.3JA69'-JX8;T=[+!)/)?:U)P'#\A^#564V%GSA/U@.+@NP3 Z63IY,O-?#D MI..^\)1:O^4W(;S'=_^Q,=<6^#L H&'P.T'%U\W?JB]+#]8$OUJMSL\N5F"/ M70"V/24'JP?;4TCCEX(V3"Z.(ZP/.SQU=6O MELLZ+F;3O_7ZY\W?^1A^;H+.Z_TV)]H'5(ELB!&,Q,(9.8?&&/"*',7 Z9 W M[Z]K1GRW16';8&W;K>3CJ';BP4Y?9NN+9:%Y]F.6S\/IYEDD2LS(,@F/J;I0 MW06ZY!B"EG6SHM8Q1SD$FR\,>'KTX[W47!T4!(N6&ND-4O\Q6W_[A*<72^B^ MS;Y_6;RET[O^>1DE2RM33IH.*:O=A9R<:SU6 %<"@Z)C0JZ= M5TD- ,>#'SS=E,)#06(_6?;P"K.YHNDO;\RJ#)8YF1UX6?=5.$/AO*'8FF&P M20IEA6J='+M#0"\)V"F\G?TUT@&<=A?<#=OS7-L';R4.9"'CR6L'?*I#9(1* MX",9V%P$-R[%DDWSG0XC\#%QF+@[K.Y'AE/KN .$'Z%DKK 'TO2O8IP=X\W&O!0O;2 D^H017& MZ7(R!NA3$US. Z+SE;6>Q2@'+,K\YA WO[U'6M[SS\7]:'G M=+;^N1$)XRI&8SU85;MB;:RS^NA747M5JP>23:VGVQV K6G>2OX^IZ^++0HG;"*7.BN8GSJ,RRC%P.AD*BSC]*ED)S/""W!IDMO4HF_&XF29XF/Z\ M3 ^-?HY):]OQ2\TNX#Q?W+Q.1"Q%0JXO:0J9 F\#&1+.73()4V%'<X/?SVW]C-D\S0MO% MJYRA0QA3%&"UMW6N-QF-;"QXI5-QG$>96GL[>Q'<;=GA-IAZN(7K4"KL(/A] ME?_S_'(;R[O%\AG6-SD[C)E%$P0(%/52RP5,! M@7,_83^:%CN :,W"?2BO\N+N_*:NZNLI(A%#0 $R9OF#3-F+ED*BC'(R\<@LV./&/K M(#J48(D;9YU*B;4>*S*(L&F1MK_^[UNLYLKH &&[7@ WN:X2B;60ZP:TS00H M5J?TA +2I>"#DNW<-JNP-X#]@HF7A1P1L'19FZL[:0 MWTV2!"NX]]P1P\VW+C9:\]F=5[@C3+;? KJ-SKIX1WV5\ZQJ+YQ^#+/\?GZU M-[<(43@W J+T&51Q'ARGFXDS%*@TIA!:U[T]07;" M+6;O) >QV<>=8P"'JI"[HYB4JKX--M\H>Y>$:8O/IH75/MKHX.Z\VAMSL=_] M2_CKUUF(->5;9_3A^D3D'%QMWI&L>%#>2@C>.7 UCQ69(N^Z]1B5%TB:=E;F MM&!KJ:U>TR>?\ ?.S^FOI\77^87%GFK-4EGN4<2I3T-#5(I(PNF44+E\KL7,TKFFU?OVF!V]>WKE_!- M-:^E&SH\/6%?OB'7YYXZ&(SC2Z: MB7=B<-0NH _E#@^734'>&&)9:/((ZGAM*0P$0R$.XT*%*!QC<5 2^P6,/$G M=*WO^VITT5J\4_>+Y!\A)7)#KR>(.AT%RQ 2KWYHH0C8>@4R4CQ,7J@2);S@ M)CWR8Z?3=R,E+=I(;&)E?SP]/XOT!UCW%W].,R0O<451PR4G&%BJQ;P@DHG$ MB?3@-<]02L1@A' 8_ #=/_^5Z48OAL>'[E[]P&E>@<;1]VY2FMK"GYY^6'_#FTOODH6DLN$I M)=BTM2MFR)$NEKPCE:/F HO@,Y+%;R#!#A[U[CP*U,> US]? MD\7Z=A:6_[5QA$36'NO\%;K$**!205%H%0QPYF+QV6=4>HA7N-V3\;,T33R9 MNW5,,8HJNH36%3>71X_IS 73!62IVW:-2.!+K//,=;%*2Z%=ZP*HEVB:-EQM MBX 7X;6'.CJ UPLO0I?FV(:02^(>--;.:Q85!*8U<"M]$$')'%H/BAU$6&] MVP<+#_+UK173 =H>.9K78X!0&2U#X. S.7_*> Z1,0/D"B 69]$T+^1\AIQI M,ZR'O!UW4D"/6*J,7+FCMFY(U X,*\0*L^1(JE0@B:!-8-8JWGJ"\S/D]&:E M=E3Y2U#:4?X]0.G2J#Y@Z=+*QN HK-$6LO1U(J-CX V+8$K2+)04DV_=C?," M29U!:E?5WX=40SUT *LGK/BOUY4)#)-2(C/0-I(E9UZ!(Z^ W 6&)OCJ.[0N M)'J)IFF+/4:[]YJJH@-HO> =7BPNF512L" M!"$3B."-+=HH)EN7E.] 9I>ISAUQLIU+O[?2.L#E \O]$9?U-\)7K',:8N2L M[L/Q]5'/>@=1"@Y,%"XHZK:VC+ &^DEZNGP :X.T9FIH!JD)*]9NZI#?S\MB M>3&WX5"E:L]^_. U:L-%<>#BM)!L5BY&"*Z.4DV,0\!@")."D<\7F39_Q^(T MS50R%YV8=1-W9G7NIM802RH>4\@J--\T??3%:=M@9:OBM&VTT5]QFJ00/CKE MH61%P9$DB<3H!(7V4H:2O>=AT)O'WZDX;2N-/E^+NI2G%")0JC*8XVY DJ:02X M*!@@ES'S0 MY/^>80F ! MDJ7 42FL53F"D%N\D3R:@*SYN_6>*;5I"DYV\1-:*Z!'+-UZUV=H(^:2(!=; M0#F!$+&^O@JK1:V:<+IU3_51IM2V4OD6*;5MY-\#E%Y(Y3BMLPZR@%&:K*SG M"GPBQC2R8@W+2:;6 ?_1IM2V4OV6*;5M]- #K%ZJ[7*H9!+6@Y:,T^U=I\UK M(6OG6BK"<6;<"+WY^Q=:3E-*TOC>VUT574+K7C57"L)[E)+L>:1CB#F!-]8 M:L4]+THRW[J3],@++;="P+:%EMNHHP-X78XHV$S>G?VHI^_* MN8@\H"3'+U M&8*,;Y N Q(SEIC1JOGVJZ=HZ0U.^VC\\3%S^XF_ QB]F#;4=*A*HK!7J4)" M\HE#3 XA\%A,X;ZDT+J,\HAK2O:Y )NJH@-H/99TN1IW\O-NGO%_,)]PXD)Z M$R#S.D4TD4.ZB7M\T$K0@8E=D3'P\MQ+%5U ,2'MKJ.VE$Y M*2^$)P$))TEB_@/<\?;['QH;R;S<,\S<+I M9_J=RUGEU].(. N\OG])@^2B9VLAN,*@SH"@F#)$KEI;_B:$[[TFZGK)[UW5 MW=KM2^3\3@?MB3_^0K]:$2%$Z.K"WQ6NSGY'"L%]H8.GC (7D8,E=X [20+U MK1MCVG,QK6-W>$P_V HU+2XFKFYY4UT47)*RUC]K,GCSTA1=01]$!)Z8!;5Y M)%!%@1ZV+^>%PI;'OCWQ6N6)L;!HJ)B)@?4)OY\OT[>PNKD<[[-T M^1 5G$DHA($8T-4)QAE\00LY,.8P>QV'37-X 6V#"9JNY&9_G2_&5L#4,V+N MS;3"X+TTLH 0BF)Q$00X:2-$YF@FTCP:F5_YVL M[N+U;'%)>O%1L]IZH5(M49)D56/V1#_'8I,HSO-!RK_[8Z0X-1U M>(MPNNFV*(OEV^^SC&>S1 YBE6J>XVKU?DX!VD9-5U./=#3>296!U]96Y4,! MEXA#'R77.I",N!X CZT_/-T@L?$!-*X6)H;8Z]GI*;EWOR']80[_H"AC]8[$ M=Q&/7+(CO! LD2<7T=>"),_ ^Q! Z. C3YQ%]M+;Q,!/33>8;'P8M9;TU.7? M]0!L%L9]*'7&_3Q=S]Q,,9MH$RCC;&TXU>!M1M DDXFZGJ@[P]E!XX7%Y78V],@JY49P $S(H71(=)Q&@B.2YRJRN^VB="]R. MQ"ZV-.X#BONIP1$UU $ GSK*5^-(,]%=M\<(1BS1Q6[ .\ZF,TJD8-&A;AY)ZF6OMA:%01)K &4J'0_I!NWF ;J2D9QZ< MMY'8Q ;AXW*1S]/ZP_(S+G_,TD4^1LOH/"\21.:"Y! *U$IJ\%*Q6#(%H+G% M2IK'OCUMZ6]']\S>BND#6%5>EQRLK@8^HDE.*0_.1%4']!/]9>.!&10FV-H: MWPY=#PF8SO+LK].' -E3P!V$4K\2Z?/5E>TL@GOE@R62-S%G]<^-SQ"8P.J> MYX%3:;:(G.X0,#DZ]E7HHI5T)W9#?@VK57B'/W!9G]'??OK\SSMW+%>6HD3. M(4=6[]C:AN.$!IZS""AM"9H-\$J>_\ITB=*V8&@LSXF1\?G5I\]O%O\4;S[\ M\_TOW-_E0Z-7:#4Y6_7A2FFKP*-',%&4Z#4AWJ0!N'CN&]-E/]NCHIDLI\Z= MO_WUU[=OOGQZ)3]^_DAB^KZ6 MO'SPEL[2,(^6)H?/^]P_*,795+.0Y"I4+%"DW MB^(DN.("%!88.L-SX$.RWW=^Z'0IS/80V%U:4V>P?W_UEN*VC/FWQ7R13NM0 MTU?S]2PN\L\OF+[-%Z>+KS^O7HF]+R9C .EJ9IZ[BEP5R1 &%.BU3X-6;V[S MS4$@,<:R8$QM>OU>)O8']])8_/UQ_"S_NM%ARCFDV""]"5MRIWJIG@3 MP'GZ5Q$4X\(X9N6059=;?73J,153X6)Q""7U@SY2YQ5C-W/+KZ8W+%[C*U(4 M5O8$A379F@C2DJ^BI&1 5PV'@FA+CC7%,R@$V/[3TU8B]8;$4136)1X_+7Z& MT_7/C[B<+?))CD&G+"W$4L(\+7%KZ+>MM&N)=#OC4M&G[CO&VNT*Z M<$%7Z]_(/U]C[1?%$QU4T#&1:$)==,1K(6I6DKC16F65XH,]X0V\R#LD3)NV MFQQG+10S==9_/C\/I[>(OSP:@8RK<]E"YJ5.-Y8&G"STKQ@SA8+.,Y$'V*HG M?ORT <3DN&DE^'[NO%O.Y>_G-;Q?E%_"S]5_+&=K8N_WQ7J6\#66Q1*_X/)L M-M_H^L0$C,*1Z96H(]WOSD-@EH%4D8QQ0E_"D$?[?>F8Y@FF*S0>5)7]P/:6 M9W 9"[T-RSEYGLEF*45TD"6K)4$E0XPA0 G9,E0.LS$[NVIW/C4(?/9?!7Q- M%-*!J[;+"C\90Z&#HJ!.-@)5%$*(P8%FBFM9HM7AP+NM=MZ[Z/ZV>#V4@ONQ MD;?N@PL7I?+\MA1,]<]^"6M\MUC>O@JTL%9XXI#+DHC-XL%KGB$E0?&4]S&: M+@6\3S7$TC^ MB?59FOO6=0M4/O+!88_/[%\0A/MJITO(79RL]>*2HTL>R4O^1(H/M9UXGG^A M.^-T\;W^]1,NI2N)'.2ZC9S.6*HBI0NAGK!@0RE%[6LD!Q,S#*K_BHF2,;7: M@9?Z^!Q7EX-.C$=P1M7R+Z; >5T@*_I-'U+RHO5JC-T'Z/*_;]:DG98Z@-H_ M2"RW63CQ7&"6(4'2'LGB(]E^91U@/2.&U>?WUM'.?1J& >SOFR9IHILN;^-+ M0WWM7C!%8*BKD$+R==(??;]M['AJ'J[YL4&4>J/Z\@T_+A?I?'DYSFA^.5TX%)N0O 9; M!_53J$7R#"J"03J:$:64@V9^[4S ,(#^*Z5>QM+>Q!#=N!B5!\2\NKX LE,R M,6+ <*6!/ P-KLZ#]<(5E57F.@U9*?WH#Q\&K;]W8F5_J?>Y5.'SM\5R35\X M>S__@:O-(+451>+OPFSYSW!ZCK]A6%T>EM7G\[.SL/RY**]^A-EI=6\I?%^% M4_R,=*!FZQGNL8QA)$(:+'$XA(@:+7^X1>$O&-=T0-[^]_EL_?/FZ]?3\)U0 MUN*]OHQ]_ZJ5>Z>+=8?B9= M7!2J%W(](A8#-H5-9T:IA>H:D,DDZ?26'&5C 0P@:]I"ZY'P\V"-6V/U=/ H M<[UXXOVR&)C50@6G*%,RH5K4K*A]9C\YX@9>+=;*U5 MOF@O_PY@M'%:2AVB=-5)1E'^K;4F-]RMZL#!U>-_=+7$VA2,A=R16)BJ,Y@$ M>$1R?43P2"&98Z7UNL"6]$\+V": NC\X="KM3ARR_':^/@^G]PBQD%PR!B:-KO=&8ZOV/$73=B1-CKD1U-8! M"-\LSLYP6:7T,7S'Y243(62KI2#CKV,&)84!)YB$&)U!E[*RT37&WJ.$3-N4 MU WD]E=2#TC#Y7I69JGN-Z@S[+\O5K.K4;LFI6R5"!"?O=?,BT?AVL[]A.5M=VW8EK$G,*^ 4J8$JVI!/G ((JQ.+Z)'G MUA/GVE ^;?-4-XB> 93+QZL68)-/"><3;E874,Y1\XQ17:.Z0PF.6-$22D, M"Y)?6BQX]<&)=YF/] RSNTQ[ ,*5BZJ(PU0D6+L9W&"P#MLJ8%!S88(T+ XR M8T.@,/6HS!V5=5_=.TAN\I4 ?\W.SL^N]D=9IT0R#(+1M;V8&0@RG- L=^T1]/5U./T7M<<.6"N:N2E$U'^[K^I9\G M&(J- @T(5\]JE.18Z2QKK8%D=PGM/7D\LB-ORP[WLV6X.@,6AM-&!S7M: M>->Y7(/"RZPT.%./*?,(KG)D8NTAXB5@:EU _C)5O:R<&PM\(^FG0\3=.V)G M%&W._@=S'?7R.JS(!25O0;O,+&17IR3[I,#1?T!)SF-*3CO=^IEK6QHGWO[5 M&",O0+"IPG8'Y&(=3@\!R)3.S\Y/PQKS/Y:+U>J/^1+#:67X'V$VOYS/$?XZ M,2&@$XH#%]& X(JMT9SS]P&1>' M,;%/LOTK_=L-VYB]*L(QJ$-9Z=K*#D(0%HQ(0: KUM@#V]UAA$\;^'2*Z-U5 MNSVB_06BY_BU$C*RFWI7 "X/\]NHS+V(4]+UD6C+5. 6)NV MDZR#]4T&;I2)$JW'^ULF#E^^O4,9\97,7_^\_N7_-\-E'9#P\]1G!=E()3,:E=QCK;$F%&,A;R'Y'2"L_8@ M> IN>VJD W#=N#>UG&9S$&,TB@>G0,B4Z#9@=;RT#Y"9(5\5B]&R-:8>4M%_ M2<@^E^:>4N\.-V\HY/VZ6,[^9Z.AJY-0Z,-%(N@:^"@3$$)6&6Q*625KM&B> M*GZ9JEYZ"7?3^[,PVEL)'<"J5B\OYI_7B_1?5QM$<<9K<@NQ) M4I4#-"KZUB_,#XCH"33[:_F1@O'=1=X!9K9,2SKMHLBJ/OV56A/*Z-XO',B( MEU18,LS_WP*6T2Z^\735 1"?%]ZG6UF6$Q0V)L,S(.,OGHA)> M*=NZ3V$X=4=5[S(Z$K?65P=(O#\KX]V/WV=W,\X;KEADI3C+P-B,H(JP$%BR M=-*QX=#X AZZB*%^OS)NILI_EB;UDBS%WMI/I2K?U^= M:,6XS,:"YM*!RIQ<'B$U^=?(8DDQR! .:B0'$CYM\K47^SF&ECLPK<\S7:MT M9_/SQ?GJ!>LY.3FFK@I+ EQ 3YG&82P MB+SU.^#(+/6R6'K:XW!89'1P4![>8Q_FM]+Z)YA+]E%ED$Q30&N,!J]L!*.+ MEY;EXK!U^NX%DJ9=&7:RNX:QWY/T?/M/OA#H>T9CHY_NJLNC-L\Z>_SD*< MG5X.I-G\>0[KZ__)8AX^524L9_.OFPKWPQ1S[4O=@6N_F@KS\!-/Z_N!$E8! M%RG0D4DY-$?1,[5@;!77@;-[BZ9:=>+?$ M_S['>?JYR?DFF6+64H#5M5LRA0Q.HB0.C% <8$KY1$RH@.E;8+J/@/C5GCI"N>L=6PSA*Y.P-8* M#$-J7_?13 ]H>V+0L$.A$J&#F5TM3+%@5!:%,F1J^:S__:9'#Y:9G+\ MR[*! KIH"FTZ3TY'K..!2MV#4W.O>C/?7P*R9(1U7KO<^D7\[S\\?"M(C3D\ M?!OM3HKMQR=:NY28U@;!Y&Q)CD* 5\+5F8-U(3RF@NF%=YJ_^_CPK33\[/CP M;83=A1V\F43]8 JU) QP5S=Q%D/WA"2W(++ZTLZD%$8IFUCK:/1I:OY&@\-W M05MC=77@RCT^CSHI[HS@EB2B5/5'B0GA [! '(3"@L;64>G??6CX/G#;7TD] M(.V9&=0I1>&8-6!<[@@ MZXP<%(N)CG3F0#PJ$5SF#GEC<#<0"8LF=(-PEB<'1R M.+MYC!EQQ4P(EOGD0"/6Q4X> M(2#=#E8:JV(J(F/KS6_/D--)5F02>.VBD6[A):\V(ICZ7U00BR*3+Z,%5U@! MY,%$E#*C3 > E^SAM69:>.VBD;[@]9AW>QV'?28];B3Z)GS?-!G\>EWVFX6* M&F4 $;2L_>8($8V 4)S'*%E$-]J,HQUIGO:!YX 1Q0%4VH-_]\AKP?7O750 M/R:)FR+)K!"3+QIT*A84*DM.L]3D@7B/0G/%9.ME OO2W(FG>!"$O5S\,)ZZ MN[#1@^?8VJ %E]R :MIZC 9-:KX:XS$Z)@YVI@3-+!F%$/25"T]U1IQRAD;J0SR1+ZY$H3Q(S M<<@SJ55KHJ!FJU::]NO5U&?=MG%+>!N_Y>,2OX=9#O/\8?T-EV_.EU5-%Y+8 MO?]NGZ\UZ*=KQNR>_7&UE.LI6JX1*RBLSMX+B,:1XZAC <=-!IUS#A1C&_K% M@#*ZE[ZS]\6X6L_.:MLRG;K'F>)%@ D<*;9S&H*FNU[$ M5)2MA\>T?K5YCIYI/+/FVGYP";92P<2[%R^/X6]A?E[J6K_:-O#VK^\X7^'J M\DR>H!":/$0/4GJ2DU*1[O;$(;DLG6*6B?MO,(^>B@&?FL:K&@TL8PBX ^=I M8[ O^;IDY8H3*;37D5G0+),;R(F3B*EZ !*C]EGDYF\=3U,SC?LTNNEI)/X. M@'27B5>7KL"%#W#%4G%)">\*I)#KW(<8( :=P+"@F4@.0_,4Z@"RIGGC'1U: MK15R7/[WJY06YQ3D? P_ZWL*N:;T.\MSO)+'"$[XX$^.Z(GOQO8AW'&K5(E1 M"!!)!U",_*C:, 0)BQ8,4U+23>B.UY]]3WBO'@COG \P8>ETT M$W)7$*G%RY?E!9PN\6!3 A2FKHU 2ZAA,22=)K^H=6@-_"M@'+S_6G@TD*? M3T)C1^%.'+S_EG[!Y=DL__/]YJK_^"TLST+"\_4LA=/5^WFB\_2__M=BA=^_ M_?^SL\L:$A\88Z'F_EFAL\2-A:"\!LNM%L9(4\J0:'Z7;_<"G%VUO3B@Z">& MUHN&^=?K;+MBHF3N#*#F$917'(+#"$R:G#US)I/%L3E[XMYNHPNG0ATXC2#5#8YH\P@LBP@EZ Y#RSDYA.+AM+6 ML9>T(R[NY]S&4%(?X*O"^DQ127V>OWK($,E[Y>K>+9,T>0Z&3BD:#XPB$@I' M7$'=O)SE44HZMF?-@+6O CJ T8T/\8DTM/QQ_>KJK6)%"@0IR-(KGPP$ST3= M)LFDMDE(;/U$^10MTSUY'PA*3930 9@N'E8O)'1K>NRCYE8D#+QV0FMC2%Y: MUT>3@D#1C>4\"2&;ESQM0=YT3^$'@MQ8JNH A4]*\"&?)UYIZ[/C4$(=U21< M/6")6&..IZ*+<:+UI)@MR)NF!WTZYZR9JIJE:/:X6!>KU<5>BJ]U+.)5:<5F MZ<1J1LQNM@\EHTJLPQ$9BP&4M E-=\#WZQK']EZ=9 MT7 =!U $1U^ .D%HMIMS7[R4Q'A3_M55.SWB[E0$VD4F64@;G2@9EO &G,4/V,:=D M7-*N];O& +(ZM6Z[0F$HU';42P=0^Q7#"K\M3O/[L^_+Q8^+ 2&7>7\;C4=. MLDFHZP*&)"AH";:N4,Y:*\8T;^[7/TU.I]#:5?7W7?A&>N@ 4A]*F26\%M#U M<-20 ]<,6%(UOJEMW,(5T$Z(DK#431^MLP&/$3)M!_38,-I?]AT Z-WY#I24EM'D4VTW6O&.,\"@J H*2Z&,$6"<%;!M$6+C2:Y$KKE.5@XJ:= MSS0VVL;140?@N]U4\&O]VU5AU1&5 5G1S #W=?2$E0F"R!9L\?5W(A.R]13$ MIVB9]DX\2)381 V=PNGR^%EEHU!8Q^/4_2XQ(QU$3[YBB#X79UQI/HC]:6JF M]=;;:'L A'80?0<@NMLON7KUV#"+JR5\V4AOZ:0IFV)MS:TIK*0A%\QHT^>M'?4_%%[;*Z,#:+U*Z?SL_+2.T?D%B8@TN[#]^/T4-PJ;YU=G MB^5Z]C^;WW^2^9/ 5"S6>T@JL[I&4H*C\!EDT-EGEU C:PS"5K1W^HS6!JZ3 M*'A[8/L+8,_Q:Z7TR_BF\W>LK?#.1EDT6*G)YW")SJHH"G3"7+RWEL6#&4ZB MI],WN)'-YK:*Z*!:]O9!.K':I&@P@4!+WJM6",&Z DQQQX--Z'GK4/7V]SM] M2FL#FIT%/?E(MR?$\LML]7VQPORAO/Y9)P6?I, *&BE!WG[J(>VRM=G"#/\W:ZC9OF]RA4M*YK!$,DF15).2?Q M%N3U4ND].F@>+CX:18-]@_.&L=_#V57]C51HI31UC\EF.HD/X!+%;"8(32(V MV31O^=F2Q,GW'8T#E>&0W%MO'<#RUUG"^6HV__KJZQ+O%"H7G:*L<[PYK]R$ MS"#8.ME0ADP"95S)UEL/GR2F6ZCM#X$'W9\M]#'IZJSZ&/5ZMOA/3%,O1#0/?NCDRZ]&A\1^T"2SR7(=B)0JBE0<13%0.32J)MP+)U(.&=U36?77O(+F)%?X? M./OZ;8WY%1F9<,V )3<_"EOS6Y+^$53%/)E+$5.0W(7B[WL?.ZG^T8]/#()= M5+AH*<\.O)"7S>2MP2TV*UT\B085=W0%&@65'^ 8E<8LN,/6B^NVH:^7XM5# MOPN-IL,.\'F?D=]Q_?:O='J>*0B\?BB^>@M6GIM"P@*=E*TK;A4X)@KX1%Z? MU#R%U+K69AOZIHW3QT/)XD JZV+E]3/B(T9O9LN@UT2[ E9\K2*I.W!K*!)\ M(*=#R2)*Z\SX,,JF!>%XV!C^,+FKFKJ WY60+JK)C=YLQT#(HE"LR\EU"9%\ M#\%ER,SF8&SK"_D. =V^/.ZLXT4K<7=P=UX1?Y*MM)XYLN$8R,.-H78K6P9! M>\XIS"F>M4[G77V[VX?(U@C92L@=%"F_GVA\#(8"=L1W5U#L+5A9O@2Q"^+BNSJB:B M9(S@'<7R47,559')I=;%<"_1-+4E[ I\.ZBI=^#=:N.[W:YWXC/7CC,!MG;, M*T^^J^.)+AB7=>0RYWC(,/0)*J=]M^L-G"U4N6^#Y0%>2D[(L4E6D.0T)V=' MU9Q]M#$#N>+:R^@ULL.^D$S;*M<;#+=5T80A32T%>:9H^,+:*\Y8S,F#MH&L M/4\20A$6R.EVRNF2D[OW-OQHE,L0ESU!TX'=F18RVXJYF9WIL)?IY%YF^(#=3/3I;OJ9 M[HOANJ/IWYLKY_>P7!*7/W"4;K('/WU<$3_/S"1]89$SR[/,$+@GYT0[#:Z8 M#$(6=)(I"L%:U^D?M"_LMH?^H=S_WDET*'Q6#CBC2U!E0PY4\J+.L2BH/(:2 MFN]*?I:B8^KLV@8[#THBVNFE@T3.^[/O8;;^]:#Y;8B<-JWJ,-A<#RM=0#)*[IOF-SL&&0YIZ22O9B& MK *YBHYB14@4-[*,R&/SOJS'*9DV#CL_3/$Q.8S; M8&^;!_G&>NT^E_20W_^-8?GES\6)C\(;I0K(6!"4,@A>60?,T.\7A8&G:>%[ M2>@QN9B'0^TN6CQ6L!+Z\$0%5DK$ $9$\H*4Y;6S/0,OHNCLH^2Q=?B](ZG' MY*X>&+!;:_)((?MN<;X\49O^5"W!V%J3$(R H#SQ&5%1%, 4LZWWT.U&Z;1) MBYX!N[4>CQ6O]'=/++-%IZ*@KA,!9>F$>JD9E)BCI7_EJKCI\4I_=]K!IEWC M=5L]'B%>7Y4U+J^91-%X=."]@ZYTPY*[16Y MNVNT@\?3%\INT#&7O=(0L+808VTAQF"A$$_"UM5SIG573X/*J-'&JW8!P6WU MTF>9PIO%G(SPNK+U"\9U@^SW2S^QP:/H5D0W>O2L'WH$7$+7EW-3(((U^>!KSJ"N"Z]O M6"K)H)-P3K>^%A\A8]H'QP9Z?[BD8#]1=W!?_;J8?Z6?=E99N=XN3^&,J/\% MJZ2K$]>P3BQ(8)R1BI6Z(+7U67B,CNGQLI=R[P^XVU?2':+EYQ2J9%S/X:?@$R.XB[ ]#;Y:;Z: OELL M?\<_+SG'&"D;O/0=NZQUN5:KBJO/[/#.11T.10^M: MO&T(G#9GU?HB&T\W'0"O'L(/Y55>?*_JN3P\6+0G.ZW J%SJ(:3HD&D#6'+. M48<8FK<=/T;'Q$.&QE/[HK$..L#1C7 ^K\,\AV5>_?$]AS62IADS5X-'9;$N M(P?!/0/%7&U190EX\<)KQ5.0K:=W#")L6J3MK__'U^PT5$8'"+MKUC>'SND8 M9:I"T2+60\? )SJ#&JTJS"=&D>VH8?[@RVZT?'?KRVY/*7>'DUO3E%$ZQ7W1 MM9U4U[F$%GQ]7D^"92TU.8IBT'C0G='2RT:%?77\+&1V%/C$S9.OS+]I=BN2 M^(SS&5WZBS6N?CFO9E-=&DV%+IMJ-%%',IK.;:,< M^KV>@+*K9A(&7::JAQW9G=Y-T=;-Z%A*_.JH=_0HHF<55O\!!4 M!HM,1)>5IEAA5-S*?+MF*C[K0PX#,J%@CK%UG?=T]3T M%+VWP50CR7> H;O2N>4 7OQR14KZ5%7%3XHJ.7GM@/-0P]30S6&U6JEE^, W,?E+"$_0;+&6<902^=JPC(A1!\"2!N=SB4Z MUGP:QF#BIJT/GPAP.^BE9\#55J'5M\7I+0_@0_F\7J3_VC#Z93G[^K4^DY U M5W7!#W!DY;-R:Y&E+P \*SA%T>!20_;(,=1S(+^'G MZB10G&2LB1!M** 4LQ"UY""RB]HG9QB.^^;^ H'3EH-/ \==]7,4X*/?6V$Z MKT75M_CD)\J';')24&1Q=="L F>\!\M80)>")B$<'(A/$#L(E.[O!

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end XML 93 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 95 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 365 477 1 false 104 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.inovio.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.inovio.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.inovio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://www.inovio.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.inovio.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 9 false false R10.htm 0000010 - Disclosure - The Company Sheet http://www.inovio.com/role/TheCompany The Company Notes 10 false false R11.htm 0000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk Sheet http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk Revenue Recognition and Concentration of Credit Risk Notes 12 false false R13.htm 0000013 - Disclosure - Collaborative Agreements Sheet http://www.inovio.com/role/CollaborativeAgreements Collaborative Agreements Notes 13 false false R14.htm 0000014 - Disclosure - Short-term Investments and Fair Value Measurements Sheet http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements Short-term Investments and Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Certain Balance Sheet Items Sheet http://www.inovio.com/role/CertainBalanceSheetItems Certain Balance Sheet Items Notes 15 false false R16.htm 0000016 - Disclosure - Fixed Assets Sheet http://www.inovio.com/role/FixedAssets Fixed Assets Notes 16 false false R17.htm 0000017 - Disclosure - Goodwill and Intangible Assets Sheet http://www.inovio.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 17 false false R18.htm 0000018 - Disclosure - Convertible Debt Sheet http://www.inovio.com/role/ConvertibleDebt Convertible Debt Notes 18 false false R19.htm 0000019 - Disclosure - Stockholders' Equity Sheet http://www.inovio.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.inovio.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Income Taxes Sheet http://www.inovio.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 0000022 - Disclosure - 401(k) Plan Sheet http://www.inovio.com/role/A401kPlan 401(k) Plan Notes 22 false false R23.htm 0000023 - Disclosure - Related Party Transactions Sheet http://www.inovio.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 0000024 - Disclosure - Geneos Therapeutics, Inc. Sheet http://www.inovio.com/role/GeneosTherapeuticsInc Geneos Therapeutics, Inc. Notes 24 false false R25.htm 0000025 - Disclosure - Subsequent Events Sheet http://www.inovio.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.inovio.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 0000027 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.inovio.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables) Sheet http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables Revenue Recognition and Concentration of Credit Risk (Tables) Tables http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk 28 false false R29.htm 0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables) Sheet http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables Short-term Investments and Fair Value Measurements (Tables) Tables http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements 29 false false R30.htm 0000030 - Disclosure - Certain Balance Sheet Items (Tables) Sheet http://www.inovio.com/role/CertainBalanceSheetItemsTables Certain Balance Sheet Items (Tables) Tables http://www.inovio.com/role/CertainBalanceSheetItems 30 false false R31.htm 0000031 - Disclosure - Fixed Assets (Tables) Sheet http://www.inovio.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://www.inovio.com/role/FixedAssets 31 false false R32.htm 0000032 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.inovio.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.inovio.com/role/GoodwillandIntangibleAssets 32 false false R33.htm 0000033 - Disclosure - Convertible Debt (Tables) Sheet http://www.inovio.com/role/ConvertibleDebtTables Convertible Debt (Tables) Tables http://www.inovio.com/role/ConvertibleDebt 33 false false R34.htm 0000034 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.inovio.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.inovio.com/role/StockholdersEquity 34 false false R35.htm 0000035 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.inovio.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.inovio.com/role/CommitmentsandContingencies 35 false false R36.htm 0000036 - Disclosure - Income Taxes (Tables) Sheet http://www.inovio.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.inovio.com/role/IncomeTaxes 36 false false R37.htm 0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables) Sheet http://www.inovio.com/role/GeneosTherapeuticsIncTables Geneos Therapeutics, Inc. (Tables) Tables http://www.inovio.com/role/GeneosTherapeuticsInc 37 false false R38.htm 0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 38 false false R39.htm 0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) Details 39 false false R40.htm 0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) Details 40 false false R41.htm 0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Sheet http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Details 41 false false R42.htm 0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) Sheet http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) Details 42 false false R43.htm 0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) Sheet http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) Details 43 false false R44.htm 0000044 - Disclosure - Collaborative Agreements (Details) Sheet http://www.inovio.com/role/CollaborativeAgreementsDetails Collaborative Agreements (Details) Details http://www.inovio.com/role/CollaborativeAgreements 44 false false R45.htm 0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) Sheet http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) Details 45 false false R46.htm 0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details) Sheet http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails Short-term Investments and Fair Value Measurements - Narrative (Details) Details http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables 46 false false R47.htm 0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 47 false false R48.htm 0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) Sheet http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) Details 48 false false R49.htm 0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) Sheet http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) Details 49 false false R50.htm 0000050 - Disclosure - Fixed Assets (Details) Sheet http://www.inovio.com/role/FixedAssetsDetails Fixed Assets (Details) Details http://www.inovio.com/role/FixedAssetsTables 50 false false R51.htm 0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Sheet http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Details 51 false false R52.htm 0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 52 false false R53.htm 0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) Sheet http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) Details 53 false false R54.htm 0000054 - Disclosure - Convertible Debt - Narrative (Details) Sheet http://www.inovio.com/role/ConvertibleDebtNarrativeDetails Convertible Debt - Narrative (Details) Details 54 false false R55.htm 0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details) Sheet http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails Convertible Debt - Balance Of Convertible Debt (Details) Details 55 false false R56.htm 0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details) Sheet http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails Convertible Debt - Schedule of Maturities (Details) Details 56 false false R57.htm 0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details) Sheet http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails Stockholders' Equity - Summary of Preferred Stock (Details) Details 57 false false R58.htm 0000058 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.inovio.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 58 false false R59.htm 0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details) Sheet http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails Stockholders' Equity - Summary of Stock Options Outstanding (Details) Details 59 false false R60.htm 0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details) Sheet http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details) Details 60 false false R61.htm 0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) Sheet http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) Details 61 false false R62.htm 0000062 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 62 false false R63.htm 0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) Sheet http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) Details 63 false false R64.htm 0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details) Sheet http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails Income Taxes - Components of Pretax Loss from Operations (Details) Details 64 false false R65.htm 0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details) Sheet http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails Income Taxes - Reconciliation of Income Taxes (Details) Details 65 false false R66.htm 0000066 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.inovio.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 66 false false R67.htm 0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Details 67 false false R68.htm 0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details) Sheet http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details) Details 68 false false R69.htm 0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details) Sheet http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails Income Taxes - Unrecognized Tax Benefits Activity (Details) Details 69 false false R70.htm 0000070 - Disclosure - 401(k) Plan (Details) Sheet http://www.inovio.com/role/A401kPlanDetails 401(k) Plan (Details) Details http://www.inovio.com/role/A401kPlan 70 false false R71.htm 0000071 - Disclosure - Related Party Transactions (Details) Sheet http://www.inovio.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.inovio.com/role/RelatedPartyTransactions 71 false false R72.htm 0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details) Sheet http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails Geneos Therapeutics, Inc. - Narrative (Details) Details 72 false false R73.htm 0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) Sheet http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) Details 73 false false R74.htm 0000074 - Disclosure - Subsequent Events (Details) Sheet http://www.inovio.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.inovio.com/role/SubsequentEvents 74 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash, us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:PropertyPlantAndEquipmentUsefulLife - ino-20221231.htm 4 ino-20221231.htm ino-12312022x10kex211.htm ino-12312022x10kex231.htm ino-12312022x10kex311.htm ino-12312022x10kex312.htm ino-12312022x10kex321.htm ino-20221231.xsd ino-20221231_cal.xml ino-20221231_def.xml ino-20221231_lab.xml ino-20221231_pre.xml ino-20221231_g1.jpg ino-20221231_g2.jpg ino-20221231_g3.jpg ino-20221231_g4.jpg ino-20221231_g5.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 98 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ino-20221231.htm": { "axisCustom": 0, "axisStandard": 37, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 1115, "http://xbrl.sec.gov/dei/2022": 38 }, "contextCount": 365, "dts": { "calculationLink": { "local": [ "ino-20221231_cal.xml" ] }, "definitionLink": { "local": [ "ino-20221231_def.xml" ] }, "inline": { "local": [ "ino-20221231.htm" ] }, "labelLink": { "local": [ "ino-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ino-20221231_pre.xml" ] }, "schema": { "local": [ "ino-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 741, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 4, "http://www.inovio.com/20221231": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 9 }, "keyCustom": 94, "keyStandard": 383, "memberCustom": 47, "memberStandard": 49, "nsprefix": "ino", "nsuri": "http://www.inovio.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.inovio.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - The Company", "menuCat": "Notes", "order": "10", "role": "http://www.inovio.com/role/TheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "11", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk", "menuCat": "Notes", "order": "12", "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk", "shortName": "Revenue Recognition and Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Collaborative Agreements", "menuCat": "Notes", "order": "13", "role": "http://www.inovio.com/role/CollaborativeAgreements", "shortName": "Collaborative Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Short-term Investments and Fair Value Measurements", "menuCat": "Notes", "order": "14", "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements", "shortName": "Short-term Investments and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Certain Balance Sheet Items", "menuCat": "Notes", "order": "15", "role": "http://www.inovio.com/role/CertainBalanceSheetItems", "shortName": "Certain Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Fixed Assets", "menuCat": "Notes", "order": "16", "role": "http://www.inovio.com/role/FixedAssets", "shortName": "Fixed Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Goodwill and Intangible Assets", "menuCat": "Notes", "order": "17", "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Convertible Debt", "menuCat": "Notes", "order": "18", "role": "http://www.inovio.com/role/ConvertibleDebt", "shortName": "Convertible Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "19", "role": "http://www.inovio.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorLocation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.inovio.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorLocation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "20", "role": "http://www.inovio.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "21", "role": "http://www.inovio.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - 401(k) Plan", "menuCat": "Notes", "order": "22", "role": "http://www.inovio.com/role/A401kPlan", "shortName": "401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "23", "role": "http://www.inovio.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Geneos Therapeutics, Inc.", "menuCat": "Notes", "order": "24", "role": "http://www.inovio.com/role/GeneosTherapeuticsInc", "shortName": "Geneos Therapeutics, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "25", "role": "http://www.inovio.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "26", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables", "shortName": "Revenue Recognition and Concentration of Credit Risk (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables", "shortName": "Short-term Investments and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "3", "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Certain Balance Sheet Items (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables", "shortName": "Certain Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Fixed Assets (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.inovio.com/role/FixedAssetsTables", "shortName": "Fixed Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Goodwill and Intangible Assets (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Convertible Debt (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.inovio.com/role/ConvertibleDebtTables", "shortName": "Convertible Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.inovio.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.inovio.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables", "shortName": "Geneos Therapeutics, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "38", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-5", "lang": "en-US", "name": "ino:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)", "menuCat": "Details", "order": "39", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails", "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i666a23e01c6442398866e53b58f368d5_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)", "menuCat": "Details", "order": "40", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i666a23e01c6442398866e53b58f368d5_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "menuCat": "Details", "order": "41", "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ib54af4db6f934822936c9df96da62d29_I20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)", "menuCat": "Details", "order": "42", "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails", "shortName": "Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i24234386041445bca5cb6066f1a957bc_D20220101-20221231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)", "menuCat": "Details", "order": "43", "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "shortName": "Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Collaborative Agreements (Details)", "menuCat": "Details", "order": "44", "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails", "shortName": "Collaborative Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "if01705c616d24d9da3e0014282dd5837_D20210101-20210131", "decimals": "-5", "lang": "en-US", "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)", "menuCat": "Details", "order": "45", "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails", "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)", "menuCat": "Details", "order": "46", "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails", "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "menuCat": "Details", "order": "47", "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i72d5d82697444dd38fb5e557609c0c36_I20221231", "decimals": "0", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)", "menuCat": "Details", "order": "48", "role": "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails", "shortName": "Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)", "menuCat": "Details", "order": "49", "role": "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "shortName": "Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "5", "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Fixed Assets (Details)", "menuCat": "Details", "order": "50", "role": "http://www.inovio.com/role/FixedAssetsDetails", "shortName": "Fixed Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "menuCat": "Details", "order": "51", "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "menuCat": "Details", "order": "52", "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)", "menuCat": "Details", "order": "53", "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Convertible Debt - Narrative (Details)", "menuCat": "Details", "order": "54", "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "shortName": "Convertible Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i1242ebcd358e4468bb5a2b7b601e0e98_I20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)", "menuCat": "Details", "order": "55", "role": "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "shortName": "Convertible Debt - Balance Of Convertible Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231", "decimals": "0", "lang": "en-US", "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details)", "menuCat": "Details", "order": "56", "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails", "shortName": "Convertible Debt - Schedule of Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ibda181353d814282bfd46ddc089e9aed_I20221231", "decimals": "0", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)", "menuCat": "Details", "order": "57", "role": "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails", "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i29af49ccbb494cac8290ea49a3d605f0_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Stockholders' Equity - Narrative (Details)", "menuCat": "Details", "order": "58", "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)", "menuCat": "Details", "order": "59", "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails", "shortName": "Stockholders' Equity - Summary of Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "6", "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i6327975f86354d84adb2cb38dcd5ea52_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)", "menuCat": "Details", "order": "60", "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails", "shortName": "Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i2ce9a943aa164c8c8f02796513f3578c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)", "menuCat": "Details", "order": "61", "role": "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "shortName": "Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ifdb2a873738e472696885e376b3e567b_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Commitments and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "62", "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)", "menuCat": "Details", "order": "63", "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails", "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)", "menuCat": "Details", "order": "64", "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails", "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)", "menuCat": "Details", "order": "65", "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails", "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "66", "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "67", "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i3d82d3ec063a42378ab880fcb038f565_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)", "menuCat": "Details", "order": "68", "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "shortName": "Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i3d82d3ec063a42378ab880fcb038f565_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i6327975f86354d84adb2cb38dcd5ea52_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)", "menuCat": "Details", "order": "69", "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i1bb91b86850c4019853cfafe96543ff8_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i91313ea012fb4e29a82373b1216240c7_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i91313ea012fb4e29a82373b1216240c7_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - 401(k) Plan (Details)", "menuCat": "Details", "order": "70", "role": "http://www.inovio.com/role/A401kPlanDetails", "shortName": "401(k) Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ino:CollaborativeAgreementAmendedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "71", "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ino:CollaborativeAgreementAmendedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)", "menuCat": "Details", "order": "72", "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i876fc07681a44ee487cf4e512393be2a_I20200630", "decimals": "2", "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)", "menuCat": "Details", "order": "73", "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails", "shortName": "Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "74", "role": "http://www.inovio.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "if1a9994a0e9c42d682a6382e17a889cd_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ino-20221231.htm", "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "9", "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null } }, "segmentCount": 104, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r827" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inovio.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ino_A2007IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2007 Incentive Plan [Member]", "label": "2007 Incentive Plan [Member]", "terseLabel": "2007 Incentive Plan" } } }, "localname": "A2007IncentivePlanMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_A2016IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Incentive Plan [Member]", "label": "2016 Incentive Plan [Member]", "terseLabel": "2016 Incentive Plan" } } }, "localname": "A2016IncentivePlanMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_A2022InducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Inducement Plan", "label": "2022 Inducement Plan [Member]", "terseLabel": "2022 Inducement Plan" } } }, "localname": "A2022InducementPlanMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_A6.50ConvertibleSeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]", "label": "6.50% Convertible Senior Notes Due 2024 [Member]", "terseLabel": "6.50% Convertible Senior Notes Due 2024", "verboseLabel": "Convertible Senior Notes" } } }, "localname": "A6.50ConvertibleSeniorNotesDue2024Member", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "ino_AccountsPayableAndAccruedExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable and Accrued Expenses", "label": "Accounts Payable and Accrued Expenses [Line Items]", "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]" } } }, "localname": "AccountsPayableAndAccruedExpensesLineItems", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "ino_AccountsPayableAndAccruedExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable and Accrued Expenses", "label": "Accounts Payable and Accrued Expenses [Table]", "terseLabel": "Accounts Payable and Accrued Expenses [Table]" } } }, "localname": "AccountsPayableAndAccruedExpensesTable", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "ino_AccruedClinicalTrialExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Trial Expense, Current", "label": "Accrued Clinical Trial Expense, Current", "verboseLabel": "Accrued clinical trial expenses" } } }, "localname": "AccruedClinicalTrialExpenseCurrent", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ino_AdvaccineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advaccine", "label": "Advaccine [Member]", "terseLabel": "Advaccine" } } }, "localname": "AdvaccineMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "ino_AllOtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Customers [Member]", "label": "All Other Customers [Member]", "terseLabel": "All other, including affiliated entities" } } }, "localname": "AllOtherCustomersMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "ino_AnnualMaintenancePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Maintenance Period", "label": "Annual Maintenance Period", "terseLabel": "Annual maintenance period" } } }, "localname": "AnnualMaintenancePeriod", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "durationItemType" }, "ino_ApolloBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ApolloBio [Member]", "label": "ApolloBio [Member]", "terseLabel": "ApolloBio" } } }, "localname": "ApolloBioMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumptions used in estimation of fair value of stock options.", "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]", "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options" } } }, "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "ino_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.inovio.com/20221231", "xbrltype": "stringItemType" }, "ino_August2019ConvertibleBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2019 Convertible Bonds [Member]", "label": "August 2019 Convertible Bonds [Member]", "terseLabel": "August 2019 Bonds" } } }, "localname": "August2019ConvertibleBondsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "ino_BillAndMelindaGatesFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bill And Melinda Gates Foundation", "label": "Bill And Melinda Gates Foundation [Member]", "terseLabel": "Bill And Melinda Gates Foundation" } } }, "localname": "BillAndMelindaGatesFoundationMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_BiojectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bioject [Member]", "label": "Bioject [Member]", "terseLabel": "Bioject" } } }, "localname": "BiojectMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ino_CELLECTRA3PSPProprietarySmartDeviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "C E L L E C T R A3 P S P Proprietary Smart Device", "label": "C E L L E C T R A3 P S P Proprietary Smart Device [Member]", "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device" } } }, "localname": "CELLECTRA3PSPProprietarySmartDeviceMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_CEPIMERSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEPI MERS", "label": "CEPI MERS [Member]", "terseLabel": "CEPI MERS" } } }, "localname": "CEPIMERSMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ino_CaliforniaIncomeTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "California Income Tax Authority [Member]", "label": "California Income Tax Authority [Member]", "terseLabel": "California" } } }, "localname": "CaliforniaIncomeTaxAuthorityMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_CertainBalanceSheetItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain Balance Sheet Items", "label": "Certain Balance Sheet Items [Abstract]" } } }, "localname": "CertainBalanceSheetItemsAbstract", "nsuri": "http://www.inovio.com/20221231", "xbrltype": "stringItemType" }, "ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets", "label": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets", "terseLabel": "Change in prepaid expenses and other current assets related to fixed assets" } } }, "localname": "ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.", "label": "Change in Value of Investments in Affiliated Company", "negatedLabel": "Loss (gain) on equity investment in affiliated entities", "verboseLabel": "(Loss) gain on investment in affiliated entities" } } }, "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ino_CoalitionforEpidemicPreparednessInnovationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Coalition for Epidemic Preparedness Innovations [Member]", "label": "Coalition for Epidemic Preparedness Innovations [Member]", "terseLabel": "Coalition for Epidemic Preparedness Innovations" } } }, "localname": "CoalitionforEpidemicPreparednessInnovationsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved", "label": "Collaboration Agreement, Additional Revenue To Be Achieved", "terseLabel": "Additional revenue to be achieved" } } }, "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborationAgreementPaymentEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement, Payment Earned", "label": "Collaboration Agreement, Payment Earned", "terseLabel": "Collaboration agreement, payment earned" } } }, "localname": "CollaborationAgreementPaymentEarned", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborationAgreementRoyaltyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Agreement, Royalty Period", "label": "Collaboration Agreement, Royalty Period", "terseLabel": "Obligation period to pay royalties" } } }, "localname": "CollaborationAgreementRoyaltyPeriod", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "durationItemType" }, "ino_CollaborativeAgreementAmendedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Amended Amount", "label": "Collaborative Agreement, Amended Amount", "terseLabel": "Agreement amended amount" } } }, "localname": "CollaborativeAgreementAmendedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementAwardedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Awarded Amount", "label": "Collaborative Agreement, Awarded Amount", "terseLabel": "Awarded amount" } } }, "localname": "CollaborativeAgreementAwardedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementAwardedExercisedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Awarded Exercised Amount", "label": "Collaborative Agreement, Awarded Exercised Amount", "terseLabel": "Awarded exercised amount" } } }, "localname": "CollaborativeAgreementAwardedExercisedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementAwardedOptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Awarded Option Amount", "label": "Collaborative Agreement, Awarded Option Amount", "terseLabel": "Awarded option amount" } } }, "localname": "CollaborativeAgreementAwardedOptionAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementExpensesToReimburse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Expenses To Reimburse", "label": "Collaborative Agreement, Expenses To Reimburse", "terseLabel": "Expenses to reimburse" } } }, "localname": "CollaborativeAgreementExpensesToReimburse", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementFundingReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Funding Received", "label": "Collaborative Agreement, Funding Received", "terseLabel": "Funding received" } } }, "localname": "CollaborativeAgreementFundingReceived", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementFundingToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Funding Received for Research and Development", "label": "Collaborative Agreement, Funding To Be Received", "terseLabel": "Collaborative agreement, funding to be received" } } }, "localname": "CollaborativeAgreementFundingToBeReceived", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination", "label": "Collaborative Agreement, Number of Days Written Notice Before Termination", "terseLabel": "Agreement, number of days written notice before termination" } } }, "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "durationItemType" }, "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Period From Effective Date For Termination", "label": "Collaborative Agreement, Period From Effective Date For Termination", "terseLabel": "Agreement period from effective date for termination" } } }, "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "durationItemType" }, "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development", "label": "Collaborative Agreement, Period to Receive Funding for Research and Development", "terseLabel": "Collaborative agreement, period to receive funding for research and development" } } }, "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "durationItemType" }, "ino_CollaborativeAgreementsUpfrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Agreements, Upfront Payment Received", "label": "Collaborative Agreements, Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "CollaborativeAgreementsUpfrontPaymentReceived", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded", "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded", "terseLabel": "Purchase price, procurement contract" } } }, "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeArrangementRevenueFromTheProcurementContract": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract", "label": "Collaborative Arrangement , Revenue from the Procurement Contract", "terseLabel": "Procurement contract" } } }, "localname": "CollaborativeArrangementRevenueFromTheProcurementContract", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ino_CollaborativeArrangementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Term", "label": "Collaborative Arrangement, Term", "terseLabel": "Term" } } }, "localname": "CollaborativeArrangementTerm", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares Issued, Share Price, Consecutive Trading Days", "label": "Common Stock, Shares Issued, Share Price, Consecutive Trading Days", "terseLabel": "Trading days" } } }, "localname": "CommonStockSharesIssuedSharePriceConsecutiveTradingDays", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "ino_ComprehensiveIncomeLossTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Comprehensive Income (Loss), Tax Expense (Benefit)", "label": "Comprehensive Income (Loss), Tax Expense (Benefit)", "totalLabel": "Income tax expense (benefit)" } } }, "localname": "ComprehensiveIncomeLossTaxExpenseBenefit", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_ConvertibleBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Bonds [Member]", "label": "Convertible Bonds [Member]", "terseLabel": "Convertible Bonds" } } }, "localname": "ConvertibleBondsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share", "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share", "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "D N A Encoded Monoclonal Antibody Technology", "label": "D N A Encoded Monoclonal Antibody Technology [Member]", "terseLabel": "D N A Encoded Monoclonal Antibody Technology" } } }, "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_DebtInstrumentConvertibleDebtConvertedAmount": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible Debt, Converted Amount", "label": "Debt Instrument, Convertible Debt, Converted Amount", "negatedTerseLabel": "Principal amount converted into common shares" } } }, "localname": "DebtInstrumentConvertibleDebtConvertedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" ], "xbrltype": "monetaryItemType" }, "ino_DebtSecuritiesAvailableforSaleContractualMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale contractual maturity.", "label": "Debt Securities, Available-for-Sale Contractual Maturity", "terseLabel": "Contractual Maturity" } } }, "localname": "DebtSecuritiesAvailableforSaleContractualMaturity", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "durationItemType" }, "ino_DebtinstrumentAccruedInterest": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument, Accrued Interest", "label": "Debt instrument, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DebtinstrumentAccruedInterest", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" ], "xbrltype": "monetaryItemType" }, "ino_December2019ConvertibleBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2019 Convertible Bonds [Member]", "label": "December 2019 Convertible Bonds [Member]", "terseLabel": "December 2019 Bonds" } } }, "localname": "December2019ConvertibleBondsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "ino_DeferredGrantFundingCurrent": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Grant Funding, Current", "label": "Deferred Grant Funding, Current", "terseLabel": "Grant funding liability" } } }, "localname": "DeferredGrantFundingCurrent", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ino_DeferredGrantFundingFromAffiliate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Grant Funding, From Affiliate", "label": "Deferred Grant Funding, From Affiliate", "terseLabel": "Deferred grant funding from affiliate" } } }, "localname": "DeferredGrantFundingFromAffiliate", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_DeferredGrantFundingFromAffiliateCurrent": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Grant Funding, From Affiliate, Current", "label": "Deferred Grant Funding, From Affiliate, Current", "terseLabel": "Grant funding liability from affiliated entities" } } }, "localname": "DeferredGrantFundingFromAffiliateCurrent", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ino_DeferredTaxAssetInterestExpense": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Asset, Interest Expense", "label": "Deferred Tax Asset, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "DeferredTaxAssetInterestExpense", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ino_DeferredTaxAssetsIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Intangible Assets", "label": "Deferred Tax Assets, Intangible Assets", "terseLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxAssetsIntangibleAssets", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ino_DeferredTaxAssetsOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liability", "label": "Deferred Tax Assets, Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiability", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ino_DeferredTaxLiabilitiesFinancingArrangementDiscount": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Financing Arrangement, Discount", "label": "Deferred Tax Liabilities, Financing Arrangement, Discount", "negatedTerseLabel": "Note discount" } } }, "localname": "DeferredTaxLiabilitiesFinancingArrangementDiscount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset", "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ino_DepartmentOfDefenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Department Of Defence", "label": "Department Of Defence [Member]", "terseLabel": "Department Of Defence" } } }, "localname": "DepartmentOfDefenceMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_DoDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DoD [Member]", "label": "DoD [Member]", "terseLabel": "U.S. Department of Defense" } } }, "localname": "DoDMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 12.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary", "label": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary", "terseLabel": "Deconsolidation of subsidiary" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 10.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt", "label": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt", "terseLabel": "Nondeductible loss on extinguishment of debt" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 3.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits", "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits", "terseLabel": "Expired NOLs and credits" } } }, "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 13.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits", "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits", "terseLabel": "Limited NOLs and credits" } } }, "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and Directors [Member]", "label": "Employees and Directors [Member]", "terseLabel": "Employees and Directors" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ino_FormerPresidentAndChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former President and Chief Executive Officer", "label": "Former President and Chief Executive Officer [Member]", "terseLabel": "Former President and Chief Executive Officer" } } }, "localname": "FormerPresidentAndChiefExecutiveOfficerMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_GainLossOnRemeasurementOfEquityMethodInvestment": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Remeasurement Of Equity Method Investment", "label": "Gain (Loss) On Remeasurement Of Equity Method Investment", "negatedTerseLabel": "Gain on remeasurement of investment in Geneos" } } }, "localname": "GainLossOnRemeasurementOfEquityMethodInvestment", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_GeneosTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Geneos Therapeutics, Inc. [Member]", "label": "Geneos Therapeutics, Inc. [Member]", "terseLabel": "Geneos Therapeutics, Inc." } } }, "localname": "GeneosTherapeuticsInc.Member", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_GoodwillAndIntangibleAssetsGross": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": { "order": 1.0, "parentTag": "ino_GoodwillAndIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets gross.", "label": "Goodwill and Intangible Assets Gross", "terseLabel": "Total goodwill and intangible assets, gross" } } }, "localname": "GoodwillAndIntangibleAssetsGross", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ino_GoodwillAndIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets net.", "label": "Goodwill and Intangible Assets Net", "totalLabel": "Total goodwill and intangible assets, net book value" } } }, "localname": "GoodwillAndIntangibleAssetsNet", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ino_GrantProceedsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grant Proceeds Received", "label": "Grant Proceeds Received", "terseLabel": "Grant proceeds received" } } }, "localname": "GrantProceedsReceived", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ino_GrantRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant Revenue [Policy Text Block]", "label": "Grant Revenue [Policy Text Block]", "terseLabel": "Grants" } } }, "localname": "GrantRevenuePolicyTextBlock", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ino_INO4800Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "I N O4800", "label": "I N O4800 [Member]", "terseLabel": "IN O4800" } } }, "localname": "INO4800Member", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment", "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment", "terseLabel": "Loss from equity method investment, recorded and allocated to investment" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_IncomeTaxReconciliationStatuteLimitations": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 6.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation, Statute Limitations", "label": "Income Tax Reconciliation, Statute Limitations", "terseLabel": "Research and development tax credits" } } }, "localname": "IncomeTaxReconciliationStatuteLimitations", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense", "label": "Increase (Decrease) In Accrued Clinical Trial Expense", "terseLabel": "Accrued clinical trial expenses" } } }, "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net", "terseLabel": "Operating lease right-of-use assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Deferred Grant Funding, Current", "label": "Increase (Decrease) in Deferred Grant Funding, Current", "terseLabel": "Grant funding liability, including from affiliated entity" } } }, "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_KoreanStateIncomeTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Korean State Income Tax Authority", "label": "Korean State Income Tax Authority [Member]", "terseLabel": "Korean State Income Tax Authority" } } }, "localname": "KoreanStateIncomeTaxAuthorityMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_LassaFeverAndMERSVaccineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lassa Fever And MERS Vaccine [Member]", "label": "Lassa Fever And MERS Vaccine [Member]", "terseLabel": "Lassa Fever And MERS Vaccine" } } }, "localname": "LassaFeverAndMERSVaccineMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_LesseeNumberOfLeaseAgreementsEnteredInto": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Number Of Lease Agreements Entered Into", "label": "Lessee, Number Of Lease Agreements Entered Into", "terseLabel": "Number of lease agreements entered into" } } }, "localname": "LesseeNumberOfLeaseAgreementsEnteredInto", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ino_LesseeOperatingLeaseAreaofLandUnderLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Area of Land Under Lease", "label": "Lessee, Operating Lease, Area of Land Under Lease", "terseLabel": "Lessee, operating lease, area of land under lease" } } }, "localname": "LesseeOperatingLeaseAreaofLandUnderLease", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "areaItemType" }, "ino_LossContingencyEstimateOfPossibleLossValueOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares", "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares", "terseLabel": "Estimate of shares settlement" } } }, "localname": "LossContingencyEstimateOfPossibleLossValueOfShares", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim", "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]", "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim" } } }, "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ino_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mutual funds.", "label": "Mutual Funds [Member]", "terseLabel": "Mutual funds", "verboseLabel": "Mutual funds" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "ino_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Interest Expense", "label": "Non-Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_NonEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non employee.", "label": "Non Employee [Member]", "terseLabel": "Non Employee" } } }, "localname": "NonEmployeeMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.", "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan", "verboseLabel": "Number of potential shares authorized for issuance under a share-based compensation plan (in shares)" } } }, "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of vested restricted stock outstanding under the plan.", "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan", "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)" } } }, "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net", "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net", "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations" } } }, "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsExpiringInSixYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiring in Six Years", "label": "Operating Loss Carryforwards, Expiring in Six Years", "terseLabel": "2027 and thereafter" } } }, "localname": "OperatingLossCarryforwardsExpiringInSixYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsExpiringinFiveYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiring in Five Years", "label": "Operating Loss Carryforwards, Expiring in Five Years", "terseLabel": "2026" } } }, "localname": "OperatingLossCarryforwardsExpiringinFiveYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsExpiringinFourYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiring in Four Years", "label": "Operating Loss Carryforwards, Expiring in Four Years", "terseLabel": "2025" } } }, "localname": "OperatingLossCarryforwardsExpiringinFourYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsExpiringinThreeYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiring in Three Years", "label": "Operating Loss Carryforwards, Expiring in Three Years", "terseLabel": "2024" } } }, "localname": "OperatingLossCarryforwardsExpiringinThreeYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsExpiringinTwoYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Expiring in Two Years", "label": "Operating Loss Carryforwards, Expiring in Two Years", "terseLabel": "2023" } } }, "localname": "OperatingLossCarryforwardsExpiringinTwoYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward", "label": "Operating Loss Carryforwards, Indefinitely Carryforward", "terseLabel": "Indefinite" } } }, "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_PLSaffiliatedentityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PLS (affiliated entity) [Member]", "label": "PLS (affiliated entity) [Member]", "terseLabel": "PLS (affiliated entity)" } } }, "localname": "PLSaffiliatedentityMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ino_PennsylvaniaStateIncomeTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pennsylvania State Income Tax Authority [Member]", "label": "Pennsylvania State Income Tax Authority [Member]", "terseLabel": "Pennsylvania" } } }, "localname": "PennsylvaniaStateIncomeTaxAuthorityMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_PlumblineLifeSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plumbline Life Sciences, Inc. [Member]", "label": "Plumbline Life Sciences, Inc. [Member]", "terseLabel": "Plumbline Life Sciences, Inc. (affiliated entity)" } } }, "localname": "PlumblineLifeSciencesIncMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "ino_PlumblineLifeSciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plumbline Life Sciences [Member]", "label": "Plumbline Life Sciences [Member]", "terseLabel": "Plumbline Life Sciences" } } }, "localname": "PlumblineLifeSciencesMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ino_PlymouthMeetingPennsylvaniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plymouth Meeting, Pennsylvania [Member]", "label": "Plymouth Meeting, Pennsylvania [Member]", "terseLabel": "Plymouth Meeting, Pennsylvania" } } }, "localname": "PlymouthMeetingPennsylvaniaMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.", "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity", "verboseLabel": "Prepaid expenses and other current assets from affiliated entities" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ino_PrepaidManufacturingExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Manufacturing Expenses, Current", "label": "Prepaid Manufacturing Expenses, Current", "terseLabel": "Prepaid manufacturing expenses" } } }, "localname": "PrepaidManufacturingExpensesCurrent", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings", "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings", "terseLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_ProceedsfromStockOptionandWarrantExercises": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Stock Option and Warrant Exercises", "label": "Proceeds from Stock Option and Warrant Exercises", "verboseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsfromStockOptionandWarrantExercises", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_PropertyPlantAndEquipmentDisposedOfBySale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Property, Plant and Equipment, Disposed Of By Sale", "label": "Property, Plant and Equipment, Disposed Of By Sale", "terseLabel": "Property, plant and equipment sold" } } }, "localname": "PropertyPlantAndEquipmentDisposedOfBySale", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ino_RangeOfExercisePricesFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices Five [Member]", "label": "Range of Exercise Prices Five [Member]", "terseLabel": "$12.01-$15.00" } } }, "localname": "RangeOfExercisePricesFiveMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RangeOfExercisePricesFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices Four [Member]", "label": "Range of Exercise Prices Four [Member]", "terseLabel": "$9.01-$12.00" } } }, "localname": "RangeOfExercisePricesFourMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RangeOfExercisePricesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices One [Member]", "label": "Range of Exercise Prices One [Member]", "terseLabel": "$1.56-$3.00" } } }, "localname": "RangeOfExercisePricesOneMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RangeOfExercisePricesSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices Five [Member]", "label": "Range of Exercise Prices Six [Member]", "terseLabel": "$15.01-$25.62" } } }, "localname": "RangeOfExercisePricesSixMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RangeOfExercisePricesThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices Three [Member]", "label": "Range of Exercise Prices Three [Member]", "terseLabel": "$6.01-$9.00" } } }, "localname": "RangeOfExercisePricesThreeMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RangeOfExercisePricesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of Exercise Prices Two [Member]", "label": "Range of Exercise Prices Two [Member]", "terseLabel": "$3.01-$6.00" } } }, "localname": "RangeOfExercisePricesTwoMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ino_RestructuringAndRelatedCostExpectedAnnualSavings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Cost, Expected Annual Savings", "label": "Restructuring and Related Cost, Expected Annual Savings", "terseLabel": "Expected annual savings" } } }, "localname": "RestructuringAndRelatedCostExpectedAnnualSavings", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ino_SARSCoV2COVID19VaccineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S A R S Co V2 C O V I D19 Vaccine", "label": "S A R S Co V2 C O V I D19 Vaccine [Member]", "terseLabel": "COVID19 Vaccine" } } }, "localname": "SARSCoV2COVID19VaccineMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage", "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage", "terseLabel": "Sales Agents will be entitled to compensation" } } }, "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "ino_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Agreement [Member]", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_SanDiegoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Diego, California [Member]", "label": "San Diego, California [Member]", "terseLabel": "San Diego, California" } } }, "localname": "SanDiegoCaliforniaMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Prepaid Expenses And Other Current Assets", "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]", "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]", "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]", "terseLabel": "Schedule Of Operating Loss And Tax Credit Carryforward Expirations" } } }, "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ino_SeriesA2OnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A-2 One Preferred Stock", "label": "Series A-2 One Preferred Stock [Member]", "terseLabel": "Series A-2 One Preferred Stock" } } }, "localname": "SeriesA2OnePreferredStockMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "domainItemType" }, "ino_SeriesAOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A One Preferred Stock [Member]", "label": "Series A One Preferred Stock [Member]", "terseLabel": "Series A-1 Preferred Stock" } } }, "localname": "SeriesAOnePreferredStockMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_ServiceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service Based Restricted Stock Units", "label": "Service Based Restricted Stock Units [Member]", "terseLabel": "Service-based restricted stock units" } } }, "localname": "ServiceBasedRestrictedStockUnitsMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security", "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security", "negatedTerseLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)" } } }, "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash", "terseLabel": "Awards settled in cash, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.", "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term", "verboseLabel": "Contractual year term of incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, remaining contractual term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized", "terseLabel": "Increase in number of shares authorized (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "terseLabel": "Number of options expected to vest (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number", "terseLabel": "RSU's expected to vest (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment", "label": "Stock Purchase Agreement, Commitment Of Additional Investment", "terseLabel": "Stock purchase agreement, commitment of additional investment" } } }, "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_StockSaleAgreementAggregateNumberofSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued", "label": "Stock Sale Agreement, Aggregate Number of Shares Issued", "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)" } } }, "localname": "StockSaleAgreementAggregateNumberofSharesIssued", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock", "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock", "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock" } } }, "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_StockSaleAgreementWeightedAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Sale Agreement Weighted Average Price Per Share", "label": "Stock Sale Agreement, Weighted Average Price Per Share", "terseLabel": "Sales made at a weighted average price (in dollars per share)" } } }, "localname": "StockSaleAgreementWeightedAveragePricePerShare", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ino_StockSalesAgreementMaximumAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Sales Agreement, Maximum Authorized Amount", "label": "Stock Sales Agreement, Maximum Authorized Amount", "terseLabel": "Common stock aggregate offering price" } } }, "localname": "StockSalesAgreementMaximumAuthorizedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_StockSalesAgreementRemainingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Sales Agreement, Remaining Authorized Amount", "label": "Stock Sales Agreement, Remaining Authorized Amount", "terseLabel": "Remaining authorized amount" } } }, "localname": "StockSalesAgreementRemainingAuthorizedAmount", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxBenefitsExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Benefits Expired", "label": "Tax Benefits Expired", "terseLabel": "Tax benefits expired" } } }, "localname": "TaxBenefitsExpired", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardCarryforwardIndefinitely": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 5.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Carryforward Indefinitely", "label": "Tax Credit Carryforward, Carryforward Indefinitely", "terseLabel": "Indefinite" } } }, "localname": "TaxCreditCarryforwardCarryforwardIndefinitely", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardExpiringInFourYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 3.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Expiring in Four Years", "label": "Tax Credit Carryforward, Expiring in Four Years", "terseLabel": "2025" } } }, "localname": "TaxCreditCarryforwardExpiringInFourYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardExpiringInSixYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 6.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Expiring in Six Years", "label": "Tax Credit Carryforward, Expiring in Six Years", "terseLabel": "2027 and thereafter" } } }, "localname": "TaxCreditCarryforwardExpiringInSixYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardExpiringInThreeYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 2.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Expiring in Three Years", "label": "Tax Credit Carryforward, Expiring in Three Years", "terseLabel": "2024" } } }, "localname": "TaxCreditCarryforwardExpiringInThreeYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardExpiringinFiveYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 4.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Expiring in Five Years", "label": "Tax Credit Carryforward, Expiring in Five Years", "terseLabel": "2026" } } }, "localname": "TaxCreditCarryforwardExpiringinFiveYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TaxCreditCarryforwardExpiringinTwoYears": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": 1.0, "parentTag": "us-gaap_TaxCreditCarryforwardAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward, Expiring in Two Years", "label": "Tax Credit Carryforward, Expiring in Two Years", "terseLabel": "2023" } } }, "localname": "TaxCreditCarryforwardExpiringinTwoYears", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "monetaryItemType" }, "ino_TheWistarInstituteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Wistar Institute [Member]", "label": "The Wistar Institute [Member]", "terseLabel": "The Wistar Institute" } } }, "localname": "TheWistarInstituteMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ino_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten Public Offering", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Increase (Decrease) In Other", "label": "Unrecognized Tax Benefits, Increase (Decrease) In Other", "terseLabel": "Other" } } }, "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseInOther", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "ino_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net amount of current assets and current liabilities.", "label": "Working Capital", "verboseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.inovio.com/20221231", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r288", "r289", "r425", "r454", "r780", "r782" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r238", "r294", "r301", "r307", "r374", "r546", "r547", "r548", "r572", "r573", "r602", "r605", "r607", "r608", "r658" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r238", "r294", "r301", "r307", "r374", "r546", "r547", "r548", "r572", "r573", "r602", "r605", "r607", "r608", "r658" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r238", "r294", "r301", "r307", "r374", "r546", "r547", "r548", "r572", "r573", "r602", "r605", "r607", "r608", "r658" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r351", "r799", "r879", "r932" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r406", "r407", "r408", "r409", "r512", "r700", "r736", "r773", "r774", "r796", "r807", "r817", "r876", "r922", "r923", "r924", "r925", "r926", "r927" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r406", "r407", "r408", "r409", "r512", "r700", "r736", "r773", "r774", "r796", "r807", "r817", "r876", "r922", "r923", "r924", "r925", "r926", "r927" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r351", "r799", "r879", "r932" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Name of Major Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r349", "r702", "r797", "r816", "r871", "r872", "r879", "r931" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r349", "r702", "r797", "r816", "r871", "r872", "r879", "r931" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r406", "r407", "r408", "r409", "r494", "r512", "r540", "r541", "r542", "r676", "r700", "r736", "r773", "r774", "r796", "r807", "r817", "r869", "r876", "r923", "r924", "r925", "r926", "r927" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r406", "r407", "r408", "r409", "r494", "r512", "r540", "r541", "r542", "r676", "r700", "r736", "r773", "r774", "r796", "r807", "r817", "r869", "r876", "r923", "r924", "r925", "r926", "r927" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r772", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r772", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r288", "r289", "r425", "r454", "r781", "r782" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r513", "r855" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r307", "r513", "r829", "r855" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r307", "r513", "r829", "r830", "r855" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r859", "r918" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]", "verboseLabel": "Title of Individual with Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r773", "r774", "r922", "r924", "r927" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average Useful Life (Yrs)" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r295", "r296", "r297", "r358", "r359", "r371", "r372", "r373", "r374", "r375", "r376", "r546", "r547", "r548", "r572", "r573", "r582", "r583", "r584", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r640", "r641", "r644", "r645", "r646", "r655", "r656", "r657", "r658", "r659", "r660", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r854" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Accounts payable and accrued liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": { "auth_ref": [ "r202", "r224" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable, Trade", "terseLabel": "Accounts Payable, Trade" } } }, "localname": "AccountsPayableTradeCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r767" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r728", "r766" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/FixedAssetsDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r188", "r190", "r220", "r255", "r850" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r188", "r190", "r255", "r850" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable from affiliated entities" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r17", "r779" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued Salaries, Current" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r96", "r246" ], "calculation": { "http://www.inovio.com/role/FixedAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated Depreciation and Amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r29", "r30", "r31", "r256", "r729", "r744", "r748" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r31", "r161", "r660", "r739", "r740", "r839", "r840", "r841", "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r9", "r815" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "negatedLabel": "Additional paid-in capital", "negatedTerseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r546", "r547", "r548", "r851", "r852", "r853", "r914" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r295", "r296", "r297", "r298", "r307", "r358", "r359", "r371", "r372", "r373", "r374", "r375", "r376", "r546", "r547", "r548", "r570", "r571", "r572", "r573", "r582", "r583", "r584", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r640", "r641", "r644", "r645", "r646", "r647", "r655", "r656", "r657", "r658", "r659", "r660", "r704", "r705", "r706", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r140", "r141", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r257", "r356", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r53", "r83", "r89" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Total antidilutive securities (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r193", "r216", "r250", "r284", "r333", "r343", "r347", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r591", "r595", "r618", "r815", "r874", "r875", "r920" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r242", "r259", "r284", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r591", "r595", "r618", "r815", "r874", "r875", "r920" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r174" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r74" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Gross\u00a0Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r75" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross\u00a0Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r361", "r383" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r73", "r360", "r383", "r721" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair\u00a0Market\u00a0Value", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Liquidity" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r57", "r58", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Amounts accrued for purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r55", "r244", "r777" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r838" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents, and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r50", "r55", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r50", "r182" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r45" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "negatedTerseLabel": "Decrease in cash resulting from the deconsolidation of Geneos" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r252", "r253", "r254", "r284", "r310", "r311", "r313", "r315", "r319", "r320", "r370", "r411", "r414", "r415", "r416", "r420", "r421", "r452", "r453", "r456", "r460", "r468", "r618", "r775", "r828", "r846", "r856" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r585", "r586", "r589" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r203", "r222" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r100", "r404", "r405", "r768", "r873" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r851", "r852", "r914" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r815" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, value, issued", "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December\u00a031, 2022 and 217,382,887 at December\u00a031, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r32", "r263", "r265", "r273", "r724", "r732" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r154", "r155", "r170", "r263", "r265", "r272", "r723", "r731" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Comprehensive loss attributable to non-controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r153", "r170", "r263", "r265", "r271", "r722", "r730" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r66", "r67", "r179", "r180", "r351", "r767" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r66", "r67", "r179", "r180", "r351", "r749", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r66", "r67", "r179", "r180", "r351", "r767", "r933" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r212", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r66", "r67", "r179", "r180", "r351" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "%\u00a0of\u00a0Total Revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r66", "r67", "r179", "r180", "r351", "r767" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r158", "r783" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities (VIE)" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r470", "r471", "r490" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r470", "r471", "r490" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "verboseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized from deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r3", "r196", "r217" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r104", "r422", "r423", "r434", "r435", "r436", "r440", "r441", "r442", "r443", "r444", "r791", "r792", "r793", "r794", "r795" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r881" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "verboseLabel": "Convertible Debt Securities" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule Of Convertible Debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r452", "r453", "r456" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "verboseLabel": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r6", "r7", "r114", "r117", "r463" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostMaintenance": { "auth_ref": [ "r842" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.", "label": "Cost, Maintenance", "terseLabel": "Annual maintenance" } } }, "localname": "CostMaintenance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r65", "r351" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r57", "r59" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r108", "r282", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r438", "r445", "r446", "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r194", "r196", "r214", "r290", "r422", "r423", "r424", "r425", "r426", "r428", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r643", "r791", "r792", "r793", "r794", "r795", "r847" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r105", "r424" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r20", "r114", "r117", "r119", "r424" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt instrument, convertible, conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Debt instrument, convertible, threshold consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Debt instrument, convertible, threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r184", "r186", "r422", "r643", "r792", "r793" ], "calculation": { "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "netLabel": "Principal amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r19", "r184", "r450", "r643" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r423" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt interest based on the fixed rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r290", "r422", "r423", "r424", "r425", "r426", "r428", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r643", "r791", "r792", "r793", "r794", "r795", "r847" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt instrument, redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r21", "r114", "r118", "r119", "r120", "r183", "r184", "r186", "r211", "r290", "r422", "r423", "r424", "r425", "r426", "r428", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r447", "r643", "r791", "r792", "r793", "r794", "r795", "r847" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r183", "r186", "r877" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "terseLabel": "Debt securities, available-for-sale, realized gain" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Debt securities, available-for-sale, realized gain" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r364", "r384" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of securities in a gross unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r163" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedLabel": "Gain on deconsolidation of Geneos", "terseLabel": "Gain on deconsolidation of Geneos" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": { "auth_ref": [ "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.", "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount", "terseLabel": "Remeasurement of Geneos Series A-1 preferred stock" } } }, "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r185", "r877" ], "calculation": { "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance cost", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r195", "r213", "r564" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r553", "r554" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "verboseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r565" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred tax assets, gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Capitalized research expense" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInvestments": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Assets, Investments", "terseLabel": "Investment in affiliated entity" } } }, "localname": "DeferredTaxAssetsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r910" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "NOL carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]", "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.", "label": "Deferred Tax Assets, Other Tax Carryforwards", "terseLabel": "Research and development and other tax credits" } } }, "localname": "DeferredTaxAssetsOtherTaxCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Fixed assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]", "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r566" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r143", "r910" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r149", "r911" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Company's contribution to 401(k) plan" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/A401kPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Maximum annual contribution per employee, percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/A401kPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/A401kPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r53", "r94" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r489", "r797", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r14", "r413", "r414", "r415", "r419", "r420", "r421", "r664", "r850" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r201", "r225", "r413", "r414", "r415", "r419", "r420", "r421", "r664", "r850" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r274", "r299", "r300", "r301", "r302", "r303", "r308", "r310", "r313", "r314", "r315", "r317", "r608", "r609", "r725", "r733", "r786" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r274", "r299", "r300", "r301", "r302", "r303", "r310", "r313", "r314", "r315", "r317", "r608", "r609", "r725", "r733", "r786" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r631" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "auth_ref": [ "r913" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r545" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r113", "r238", "r267", "r268", "r269", "r291", "r292", "r293", "r296", "r304", "r306", "r318", "r374", "r469", "r546", "r547", "r548", "r572", "r573", "r607", "r632", "r633", "r634", "r635", "r636", "r637", "r660", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Percentage of ownership" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r77", "r334", "r831" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Investment in Geneos" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r49", "r79", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule Of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r251", "r617", "r778" ], "calculation": { "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Investments in affiliated entity" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "auth_ref": [ "r251", "r617" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Investments in affiliated entity" } } }, "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r734", "r863" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Net unrealized loss on available-for-sale equity securities", "negatedTerseLabel": "Net unrealized loss (gain) on available-for-sale equity securities", "terseLabel": "Net unrealized (loss) gain on available-for-sale equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r832" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Estimated Insurance Recoveries" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r174", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r436", "r496", "r497", "r498", "r499", "r500", "r501", "r612", "r673", "r674", "r675", "r792", "r793", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r611", "r612", "r613", "r614", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Short-term Investments and Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r436", "r496", "r501", "r612", "r673", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1", "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r436", "r496", "r501", "r612", "r674", "r792", "r793", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r436", "r496", "r497", "r498", "r499", "r500", "r501", "r612", "r675", "r792", "r793", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r436", "r496", "r497", "r498", "r499", "r500", "r501", "r673", "r674", "r675", "r792", "r793", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r362", "r363", "r378", "r379", "r380", "r381", "r382", "r385", "r386", "r387", "r447", "r466", "r597", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r789", "r860", "r861", "r862", "r942", "r943", "r944", "r945", "r946", "r947", "r948" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "verboseLabel": "Eligible Item or Group for Fair Value Option [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life", "verboseLabel": "Useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r248", "r396" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": { "order": 2.0, "parentTag": "ino_GoodwillAndIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r90" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r90" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "verboseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r90" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r90" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r90" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r394", "r395", "r396", "r397", "r703", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r88", "r707" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r84", "r87" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r88", "r703" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": 2.0, "parentTag": "ino_GoodwillAndIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite lived intangible assets, net", "totalLabel": "Intangible assets, net book value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails", "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "verboseLabel": "Indefinite lived:" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r627", "r628", "r629", "r630" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Unrealized transaction (gain) loss on foreign-currency denominated debt" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Office furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r845" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedLabel": "Share of net loss in Geneos" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "auth_ref": [ "r53" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) included in earnings for investments classified as other.", "label": "Gain (Loss) on Sale of Other Investments", "negatedTerseLabel": "Loss on short-term investments" } } }, "localname": "GainLossOnSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r53", "r106", "r107" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain (loss) on extinguishment of convertible bonds and senior notes", "terseLabel": "Gain (loss) on extinguishment of convertible bonds and senior notes" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r247", "r388", "r720", "r790", "r815", "r867", "r868" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": 1.0, "parentTag": "ino_GoodwillAndIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "totalLabel": "Goodwill, net book value", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r81", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Valuation of Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r390", "r392", "r790" ], "calculation": { "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_Goodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r53", "r389", "r391", "r393", "r790" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r515", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r515", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivable": { "auth_ref": [ "r835" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.", "label": "Grants Receivable", "terseLabel": "Grants receivable" } } }, "localname": "GrantsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r53", "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r93", "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r285", "r576" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S. Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r33", "r191", "r205", "r228", "r333", "r342", "r346", "r348", "r726", "r788" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before share in net loss of Geneos" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r285", "r576" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r333", "r342", "r346", "r348", "r788" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before share in net loss of Geneos" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r34", "r53", "r77", "r204", "r226", "r331" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Share in net loss of Geneos", "terseLabel": "Share in net loss of Geneos", "verboseLabel": "Share in current and accumulated net loss of Geneos" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r398", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r286", "r557", "r562", "r568", "r574", "r577", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r287", "r305", "r306", "r332", "r555", "r575", "r578", "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r266", "r551", "r552", "r562", "r563", "r567", "r569" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 7.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r550", "r556" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 8.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Change in tax rates" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 5.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign tax rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r556" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 2.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Benefit from income taxes at statutory rates" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 9.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 4.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 11.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income tax, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r908" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": { "order": 1.0, "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses, including from affiliated entities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, including from affiliated entities" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r701", "r844" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue, including from affiliated entity" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r844" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease) in Derivative Liabilities", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]", "verboseLabel": "Definite lived:" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r82", "r86" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "verboseLabel": "Schedule of intangible assets by major asset class" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r185", "r207", "r270", "r330", "r642" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r40", "r442", "r451", "r794", "r795" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense, debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r37" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r275", "r279", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r40" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of (discounts) premiums on investments" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r229", "r753" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment Owned, Balance, Shares", "terseLabel": "Number of shares owned (in shares)" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r369", "r930" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Short Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r750", "r751", "r752", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r750", "r751", "r752", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r76", "r192", "r208", "r231", "r776" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Short-term Investments and Fair Value Measurements" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r653", "r814" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r917" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule Of Maturities Of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total remaining lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r917" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r654" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r916" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating lease, remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r284", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r592", "r595", "r596", "r618", "r787", "r874", "r920", "r921" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r197", "r219", "r815", "r848", "r864", "r915" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r243", "r284", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r592", "r595", "r596", "r618", "r815", "r874", "r920", "r921" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r880" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Revenue under collaborative research and development arrangements" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "verboseLabel": "Licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r23", "r870" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Accrued litigation settlement" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Amount paid to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r196", "r217", "r435", "r449", "r792", "r793" ], "calculation": { "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r102", "r290", "r440" ], "calculation": { "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r102", "r290", "r440" ], "calculation": { "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r21", "r103" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r406", "r407", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimate of cash settlement" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails", "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r121", "r156", "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Dissolution of majority-owned subsidiary VGX Animal Health, Inc." } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r26", "r38", "r152", "r162" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": { "auth_ref": [ "r881" ], "lang": { "en-us": { "role": { "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).", "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]", "terseLabel": "U.S. agency mortgage-backed securities" } } }, "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r321", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "The Company" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/TheCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r278" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r278" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r50", "r51", "r54" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r35", "r54", "r206", "r227", "r241", "r262", "r264", "r269", "r284", "r295", "r299", "r300", "r301", "r302", "r305", "r306", "r312", "r333", "r342", "r346", "r348", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r609", "r618", "r788", "r874" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss from operations", "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r159", "r169", "r262", "r264", "r305", "r306", "r841" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r62", "r236", "r237", "r238", "r239", "r240", "r294", "r295", "r296", "r297", "r298", "r301", "r307", "r317", "r358", "r359", "r371", "r372", "r373", "r374", "r375", "r376", "r546", "r547", "r548", "r570", "r571", "r572", "r573", "r582", "r583", "r584", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r640", "r641", "r644", "r645", "r646", "r647", "r655", "r656", "r657", "r658", "r659", "r660", "r704", "r705", "r706", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements - Recently Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "auth_ref": [ "r122", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "negatedTerseLabel": "Deconsolidation of Geneos" } } }, "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r122", "r156", "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Acquisition of non-controlling interest in Geneos, net" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r151", "r469", "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r858" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Research and development equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r333", "r342", "r346", "r348", "r788" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r649" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r649" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: current portion", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails", "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r649" ], "calculation": { "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "netLabel": "Long-term operating lease liabilities", "verboseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails", "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r648" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r845" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r652", "r814" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r651", "r814" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r147" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Geneos Therapeutics, Inc." } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r202", "r224" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r249" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r27" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation", "verboseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r260", "r261" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized (loss) gain on short-term investments, net of tax", "verboseLabel": "Unrealized loss on short-term investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Certain Balance Sheet Items" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "verboseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r836", "r866" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r43" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "negatedTerseLabel": "Investment in Geneos", "terseLabel": "Payments to acquire additional interest in subsidiaries" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r44" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of capital assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r45" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r494", "r495", "r501", "r502", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r514", "r806" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "401(k) Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/A401kPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r452" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r452" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r7", "r815" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2022 and 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r838" ], "calculation": { "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails", "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r200", "r223", "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "terseLabel": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r46" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r843" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Commissions and other estimated offering expenses" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r48" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Acquisition of non-controlling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r47" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from Geneos issuance of note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "auth_ref": [ "r276", "r367" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Proceeds from sale of investment of GeneOne" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-Term Investments", "verboseLabel": "Proceeds from sale of or maturity of investments" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r46", "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r241", "r262", "r264", "r277", "r284", "r295", "r305", "r306", "r333", "r342", "r346", "r348", "r370", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r590", "r593", "r594", "r609", "r618", "r726", "r788", "r812", "r813", "r841", "r874" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss attributable to common stockholders" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r99", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Disposals", "terseLabel": "Property, plant and equipment disposed of" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r95", "r245" ], "calculation": { "http://www.inovio.com/role/FixedAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r97", "r221", "r727", "r815" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.inovio.com/role/FixedAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Net Book Value", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other Types [Member]", "terseLabel": "Computer equipment and other" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r97", "r769", "r770" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule Of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant, and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r503", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Due from (to) Related Party [Abstract]", "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Operating expenses related to affiliated entity" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r503", "r663", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r919" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r661", "r662", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r142", "r232", "r928" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Performance-based restricted stock units", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r399", "r401", "r402", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected charge" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Number of positions reduced" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Number of positions reduced (in percent)" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r121", "r218", "r743", "r748", "r815" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r238", "r291", "r292", "r293", "r296", "r304", "r306", "r374", "r546", "r547", "r548", "r572", "r573", "r607", "r739", "r741" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r328", "r329", "r341", "r344", "r345", "r349", "r350", "r351", "r488", "r489", "r702" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from collaborative arrangements and other contracts, including affiliated entity" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r351", "r857" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer Benchmark" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r493", "r784" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition and Concentration of Credit Risk" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r37", "r230", "r413", "r414", "r415", "r419", "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "verboseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule Of Accounts Payable And Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "verboseLabel": "Summary Of Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r912" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Revenue From External Customers" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r849" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule Of Components Of Pretax Loss From Operations" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "verboseLabel": "Summary Of Intangible Assets By Major Asset Class" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule Of Maturities Of Long-Term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/FixedAssetsDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r515", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule Of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r125", "r131", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule Of Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r109", "r111", "r112", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r252", "r253", "r254", "r319", "r452", "r453", "r454", "r456", "r460", "r466", "r468", "r796", "r828", "r846" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r6", "r7", "r8", "r110", "r111", "r112", "r114", "r115", "r116", "r118", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "verboseLabel": "Summary Of Preferred Stock Authorized, Issued And Outstanding" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r811", "r909" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule Of Unrecognized Tax Benefits Rollforward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r833", "r834", "r878" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock", "verboseLabel": "Series\u00a0C Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r52" ], "calculation": { "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Non-cash stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r808" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)", "verboseLabel": "Vesting period of incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r126", "r128" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "terseLabel": "Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r536" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, exercises in period, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "terseLabel": "Options, expirations in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r888" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r888" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "verboseLabel": "Number of options outstanding to purchase common stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]", "verboseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options, expirations in period, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, lower range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, upper range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Nonemployee" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Aggregate intrinsic value of unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r809" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Award exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value for options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise\u00a0price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life (in Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r198", "r199", "r215", "r837" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r61", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r252", "r253", "r254", "r284", "r310", "r311", "r313", "r315", "r319", "r320", "r370", "r411", "r414", "r415", "r416", "r420", "r421", "r452", "r453", "r456", "r460", "r468", "r618", "r775", "r828", "r846", "r856" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails", "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r113", "r238", "r267", "r268", "r269", "r291", "r292", "r293", "r296", "r304", "r306", "r318", "r374", "r469", "r546", "r547", "r548", "r572", "r573", "r607", "r632", "r633", "r634", "r635", "r636", "r637", "r660", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.inovio.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r291", "r292", "r293", "r318", "r702" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets", "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows", "http://www.inovio.com/role/ConsolidatedStatementsofOperations", "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r113", "r114", "r121", "r439" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of preferred stock/senior notes to common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r8", "r113", "r121" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r113", "r121" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r113", "r121", "r526" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r113", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of preferred stock/senior notes to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r25", "r113", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Carrying value of december 2019 bonds" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r8", "r113", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock for cash, net of financing costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r121", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r72", "r815", "r848", "r864", "r915" ], "calculation": { "http://www.inovio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r151", "r152", "r168", "r238", "r239", "r268", "r291", "r292", "r293", "r296", "r304", "r374", "r469", "r546", "r547", "r548", "r572", "r573", "r607", "r632", "r633", "r637", "r660", "r740", "r741", "r848", "r864", "r915" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r123", "r283", "r453", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r465", "r467", "r469", "r598" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r638", "r668" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r638", "r668" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r638", "r668" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r638", "r668" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r667", "r669" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/StockholdersEquityNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r147" ], "calculation": { "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward amount", "totalLabel": "Total" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails", "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r233", "r234", "r235", "r354", "r355", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r362", "r363", "r447", "r466", "r597", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r860", "r861", "r862", "r942", "r943", "r944", "r945", "r946", "r947", "r948" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]", "verboseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r295", "r296", "r297", "r298", "r307", "r358", "r359", "r371", "r372", "r373", "r374", "r375", "r376", "r546", "r547", "r548", "r570", "r571", "r572", "r573", "r582", "r583", "r584", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r640", "r641", "r644", "r645", "r646", "r647", "r655", "r656", "r657", "r658", "r659", "r660", "r704", "r705", "r706", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails", "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r912" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/CollaborativeAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. treasury securities" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r785", "r804", "r806", "r929" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized loss on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r549", "r558" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of the year", "periodStartLabel": "Balance at beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r559" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Increases (decreases) related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases (decreases) related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r68", "r69", "r70", "r322", "r323", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r309", "r315" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r308", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.inovio.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r818": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r819": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r821": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r822": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "https://asc.fasb.org/subtopic&trid=2229187", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 99 0001055726-23-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001055726-23-000010-xbrl.zip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